WO2023057598A1 - Methods involving bacterial strain replacement - Google Patents
Methods involving bacterial strain replacement Download PDFInfo
- Publication number
- WO2023057598A1 WO2023057598A1 PCT/EP2022/077865 EP2022077865W WO2023057598A1 WO 2023057598 A1 WO2023057598 A1 WO 2023057598A1 EP 2022077865 W EP2022077865 W EP 2022077865W WO 2023057598 A1 WO2023057598 A1 WO 2023057598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacterial strain
- engineered
- gene
- molecule
- subject
- Prior art date
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 439
- 238000000034 method Methods 0.000 title claims abstract description 89
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 378
- 230000008901 benefit Effects 0.000 claims abstract description 131
- 230000002860 competitive effect Effects 0.000 claims abstract description 121
- 230000009931 harmful effect Effects 0.000 claims abstract description 34
- 230000002829 reductive effect Effects 0.000 claims abstract description 16
- 230000009286 beneficial effect Effects 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 98
- 235000015097 nutrients Nutrition 0.000 claims description 82
- 150000007523 nucleic acids Chemical class 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- 108010062877 Bacteriocins Proteins 0.000 claims description 59
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 150000001720 carbohydrates Chemical class 0.000 claims description 53
- -1 ulvan Polymers 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 49
- 208000035475 disorder Diseases 0.000 claims description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 241000894006 Bacteria Species 0.000 claims description 46
- 229920001542 oligosaccharide Polymers 0.000 claims description 45
- 150000002482 oligosaccharides Chemical class 0.000 claims description 45
- 239000003242 anti bacterial agent Substances 0.000 claims description 42
- 235000013336 milk Nutrition 0.000 claims description 34
- 210000004080 milk Anatomy 0.000 claims description 34
- 239000008267 milk Substances 0.000 claims description 33
- 241001220441 Bacteroides plebeius Species 0.000 claims description 30
- 241000894007 species Species 0.000 claims description 30
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 230000009467 reduction Effects 0.000 claims description 21
- RJTOFDPWCJDYFZ-UHFFFAOYSA-N lacto-N-triose Natural products CC(=O)NC1C(O)C(O)C(CO)OC1OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O RJTOFDPWCJDYFZ-UHFFFAOYSA-N 0.000 claims description 15
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims description 14
- 229920001715 Porphyran Polymers 0.000 claims description 11
- HMQPEDMEOBLSQB-RCBHQUQDSA-N beta-D-Galp-(1->3)-alpha-D-GlcpNAc Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HMQPEDMEOBLSQB-RCBHQUQDSA-N 0.000 claims description 11
- 230000004060 metabolic process Effects 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 229930191176 lacto-N-biose Natural products 0.000 claims description 10
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 9
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 9
- 235000020256 human milk Nutrition 0.000 claims description 9
- 210000004251 human milk Anatomy 0.000 claims description 9
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000008676 import Effects 0.000 claims description 7
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 7
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 7
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 150000004804 polysaccharides Chemical class 0.000 claims description 7
- 229920001221 xylan Polymers 0.000 claims description 7
- 150000004823 xylans Chemical class 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- 101150105849 H5 gene Proteins 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 5
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 5
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims description 5
- 229920000855 Fucoidan Polymers 0.000 claims description 5
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 5
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 5
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 5
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 5
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 4
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims description 4
- MKNNYTWMAUAKMA-FHHHURIISA-N (2s,4s,5r,6r)-5-acetamido-2-[(2s,3r,4s,5s,6r)-2-[(2r,3s,4r,5r)-5-amino-1,2,4-trihydroxy-6-oxohexan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](N)C=O)O[C@H](CO)[C@@H]1O MKNNYTWMAUAKMA-FHHHURIISA-N 0.000 claims description 4
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 4
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 4
- FNCPZGGSTQEGGK-DRSOAOOLSA-N 3'-Sialyl-3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 FNCPZGGSTQEGGK-DRSOAOOLSA-N 0.000 claims description 4
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- 229920001543 Laminarin Polymers 0.000 claims description 4
- 239000005717 Laminarin Substances 0.000 claims description 4
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 4
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- RPSBVJXBTXEJJG-LURNZOHQSA-N alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)O1 RPSBVJXBTXEJJG-LURNZOHQSA-N 0.000 claims description 4
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 4
- 102000038379 digestive enzymes Human genes 0.000 claims description 4
- 108091007734 digestive enzymes Proteins 0.000 claims description 4
- 102000002464 Galactosidases Human genes 0.000 claims description 3
- 108010093031 Galactosidases Proteins 0.000 claims description 3
- 102000005262 Sulfatase Human genes 0.000 claims description 3
- 108060007951 sulfatase Proteins 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 description 60
- 239000000203 mixture Substances 0.000 description 56
- 235000014633 carbohydrates Nutrition 0.000 description 39
- 244000005700 microbiome Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 31
- 239000000304 virulence factor Substances 0.000 description 29
- 230000007923 virulence factor Effects 0.000 description 29
- 239000003814 drug Substances 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 26
- 108090000790 Enzymes Proteins 0.000 description 26
- 229940088598 enzyme Drugs 0.000 description 26
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 25
- 229940079593 drug Drugs 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 239000003053 toxin Substances 0.000 description 24
- 231100000765 toxin Toxicity 0.000 description 24
- 108700012359 toxins Proteins 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 24
- 241000588724 Escherichia coli Species 0.000 description 23
- 239000002537 cosmetic Substances 0.000 description 23
- 108010005774 beta-Galactosidase Proteins 0.000 description 17
- 241000956551 Bacteroides faecis Species 0.000 description 16
- 108010004171 colibactin Proteins 0.000 description 16
- ZWKHDAZPVITMAI-ROUUACIJSA-N colibactin Chemical compound C[C@H]1CCC(=N1)C1=C(CC(=O)NCC(=O)c2csc(n2)C(=O)C(=O)c2csc(CNC(=O)CC3=C(C(=O)NC33CC3)C3=N[C@@H](C)CC3)n2)C2(CC2)NC1=O ZWKHDAZPVITMAI-ROUUACIJSA-N 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 102100026189 Beta-galactosidase Human genes 0.000 description 14
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000606125 Bacteroides Species 0.000 description 11
- 241000606124 Bacteroides fragilis Species 0.000 description 11
- 101000958741 Homo sapiens Myosin-6 Proteins 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 11
- 102000056087 human MYH6 Human genes 0.000 description 11
- 241000194032 Enterococcus faecalis Species 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 229940032049 enterococcus faecalis Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 8
- 241000186427 Cutibacterium acnes Species 0.000 description 8
- 241000588722 Escherichia Species 0.000 description 8
- 241000385060 Prevotella copri Species 0.000 description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 8
- 230000001738 genotoxic effect Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 244000005709 gut microbiome Species 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 241001515965 unidentified phage Species 0.000 description 8
- CTBBEXWJRAPJIZ-VHPBLNRZSA-N (1S,2S,3S,6R,8R,9S,10R)-2-benzoyl-1,3,8,10-tetrahydroxy-9-(4-methoxy-6-oxopyran-2-yl)-5-oxatricyclo[4.3.1.03,8]decan-4-one Chemical compound O1C(=O)C=C(OC)C=C1[C@H]1[C@]([C@@H]2O)(O)[C@H](C(=O)C=3C=CC=CC=3)[C@@]3(O)C(=O)O[C@@H]2C[C@]31O CTBBEXWJRAPJIZ-VHPBLNRZSA-N 0.000 description 7
- 241000193163 Clostridioides difficile Species 0.000 description 7
- CTBBEXWJRAPJIZ-UHFFFAOYSA-N Enterocin Natural products O1C(=O)C=C(OC)C=C1C1C(C2O)(O)C(C(=O)C=3C=CC=CC=3)C3(O)C(=O)OC2CC31O CTBBEXWJRAPJIZ-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108010046504 Type IV Secretion Systems Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000003278 mimic effect Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 244000005714 skin microbiome Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000588626 Acinetobacter baumannii Species 0.000 description 6
- 241000193738 Bacillus anthracis Species 0.000 description 6
- 241000606215 Bacteroides vulgatus Species 0.000 description 6
- 241001657508 Eggerthella lenta Species 0.000 description 6
- 241000194031 Enterococcus faecium Species 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 6
- 241000186394 Eubacterium Species 0.000 description 6
- 241000605986 Fusobacterium nucleatum Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000590002 Helicobacter pylori Species 0.000 description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241000736262 Microbiota Species 0.000 description 6
- 241000605947 Roseburia Species 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 229940037467 helicobacter pylori Drugs 0.000 description 6
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 6
- 108010079904 microcin Proteins 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 5
- 241000193403 Clostridium Species 0.000 description 5
- 241000158508 Corynebacterium amycolatum Species 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 240000001929 Lactobacillus brevis Species 0.000 description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 241000398180 Roseburia intestinalis Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940065181 bacillus anthracis Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108010086913 mundticin Proteins 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 241001113610 Actinomyces massiliensis Species 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241001135228 Bacteroides ovatus Species 0.000 description 4
- 241000123777 Blautia obeum Species 0.000 description 4
- 241000193470 Clostridium sporogenes Species 0.000 description 4
- 241000589602 Francisella tularensis Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 4
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 4
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 241001464887 Parvimonas micra Species 0.000 description 4
- 108010080032 Pediocins Proteins 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 241000605894 Porphyromonas Species 0.000 description 4
- 241000186336 Pseudopropionibacterium propionicum Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000193985 Streptococcus agalactiae Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 241000607479 Yersinia pestis Species 0.000 description 4
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000002662 enteric coated tablet Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940118764 francisella tularensis Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000009117 preventive therapy Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229960001940 sulfasalazine Drugs 0.000 description 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 3
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 3
- 241000606750 Actinobacillus Species 0.000 description 3
- 241000511582 Actinomyces meyeri Species 0.000 description 3
- 241000186045 Actinomyces naeslundii Species 0.000 description 3
- 241000186066 Actinomyces odontolyticus Species 0.000 description 3
- 241001464907 Anaerococcus hydrogenalis Species 0.000 description 3
- 241001464890 Anaerococcus prevotii Species 0.000 description 3
- 108010037833 Bacterial Adhesins Proteins 0.000 description 3
- 241001105998 Bacteroides dorei Species 0.000 description 3
- 241000204294 Bacteroides stercoris Species 0.000 description 3
- 241000606219 Bacteroides uniformis Species 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000589876 Campylobacter Species 0.000 description 3
- 241000678016 Cloacibacterium normanense Species 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 241000928573 Cutibacterium Species 0.000 description 3
- 101001023124 Drosophila melanogaster Myosin heavy chain, non-muscle Proteins 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- 241000588697 Enterobacter cloacae Species 0.000 description 3
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 3
- 241000192016 Finegoldia magna Species 0.000 description 3
- 241000605909 Fusobacterium Species 0.000 description 3
- 241000192128 Gammaproteobacteria Species 0.000 description 3
- 241000207201 Gardnerella vaginalis Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000588749 Klebsiella oxytoca Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 241001324870 Lactobacillus iners Species 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241000186781 Listeria Species 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000191938 Micrococcus luteus Species 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241000606210 Parabacteroides distasonis Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000530062 Peptoniphilus harei Species 0.000 description 3
- 241001135213 Porphyromonas endodontalis Species 0.000 description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 description 3
- 241000605861 Prevotella Species 0.000 description 3
- 241000938719 Prevotella baroniae Species 0.000 description 3
- 241001135215 Prevotella bivia Species 0.000 description 3
- 241001135221 Prevotella intermedia Species 0.000 description 3
- 241001135223 Prevotella melaninogenica Species 0.000 description 3
- 241001141020 Prevotella micans Species 0.000 description 3
- 241001135225 Prevotella nigrescens Species 0.000 description 3
- 241001135264 Prevotella veroralis Species 0.000 description 3
- 241000186429 Propionibacterium Species 0.000 description 3
- 241001464976 Propionimicrobium lymphophilum Species 0.000 description 3
- 241000589776 Pseudomonas putida Species 0.000 description 3
- 108010025955 Pyocins Proteins 0.000 description 3
- 241001394655 Roseburia inulinivorans Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241001138501 Salmonella enterica Species 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 241000607760 Shigella sonnei Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000960363 Streptococcus infantis Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 241000194025 Streptococcus oralis Species 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 241001135235 Tannerella forsythia Species 0.000 description 3
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 3
- 241000589892 Treponema denticola Species 0.000 description 3
- 241001467018 Typhis Species 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 241001085082 Varibaculum cambriense Species 0.000 description 3
- 241001531188 [Eubacterium] rectale Species 0.000 description 3
- 241001464867 [Ruminococcus] gnavus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 231100000024 genotoxic Toxicity 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 108010066097 lactococcin A Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229940051921 muramidase Drugs 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940115939 shigella sonnei Drugs 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229960005053 tinidazole Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 2
- IXXFZUPTQVDPPK-ZAWHAJPISA-N (1r,2r,4r,6r,7r,8r,10s,13r,14s)-17-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-7-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-10-fluoro-6-methoxy-2,4,6,8,10,14-hexamethyl-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tet Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@](C)(F)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3N=NC(=C3)C=3C=C(N)C=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IXXFZUPTQVDPPK-ZAWHAJPISA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
- IBZYPBGPOGJMBF-UHFFFAOYSA-N 3,6 anhydrogalactose Natural products CCC=CCC1C(CC(=O)NC(C(C)CC)C(O)=O)CCC1=O IBZYPBGPOGJMBF-UHFFFAOYSA-N 0.000 description 2
- WZYRMLAWNVOIEX-BGPJRJDNSA-N 3,6-anhydro-D-galactose Chemical compound O=C[C@H](O)[C@H]1OC[C@@H](O)[C@@H]1O WZYRMLAWNVOIEX-BGPJRJDNSA-N 0.000 description 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 2
- 241000122229 Acinetobacter johnsonii Species 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 241000933025 Actinomyces europaeus Species 0.000 description 2
- 241000544634 Actinomyces graevenitzii Species 0.000 description 2
- 241000186041 Actinomyces israelii Species 0.000 description 2
- 241001464988 Actinomyces neuii Species 0.000 description 2
- 241000900275 Actinomyces turicensis Species 0.000 description 2
- 241000609850 Actinotignum schaalii Species 0.000 description 2
- 241000005140 Aerococcus christensenii Species 0.000 description 2
- 241000193795 Aerococcus urinae Species 0.000 description 2
- 241000891830 Aeromicrobium massiliense Species 0.000 description 2
- 241001245632 Aeromonas encheleia Species 0.000 description 2
- 241001580959 Alistipes finegoldii Species 0.000 description 2
- 241001041927 Alloscardovia omnicolens Species 0.000 description 2
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001464884 Anaerococcus lactolyticus Species 0.000 description 2
- 241000962510 Anaerococcus murdochii Species 0.000 description 2
- 241001464864 Anaerococcus vaginalis Species 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 241001222025 Aquabacterium parvum Species 0.000 description 2
- 241000863009 Archangium gephyra Species 0.000 description 2
- 241001313491 Asticcacaulis excentricus Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000193838 Atopobium parvulum Species 0.000 description 2
- 241000193836 Atopobium rimae Species 0.000 description 2
- 241001633064 Atopobium vaginae Species 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 241000194106 Bacillus mycoides Species 0.000 description 2
- 241000194103 Bacillus pumilus Species 0.000 description 2
- 241000193388 Bacillus thuringiensis Species 0.000 description 2
- 241001122266 Bacteroides nordii Species 0.000 description 2
- 241001122267 Bacteroides salyersiae Species 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- 241000115153 Bacteroides xylanisolvens Species 0.000 description 2
- 241000606660 Bartonella Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241000186020 Bifidobacterium dentium Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 2
- 241001495172 Bilophila wadsworthia Species 0.000 description 2
- 241000194002 Blautia hansenii Species 0.000 description 2
- 241000520742 Blautia hydrogenotrophica Species 0.000 description 2
- 241001464894 Blautia producta Species 0.000 description 2
- 241001038648 Blautia wexlerae Species 0.000 description 2
- 241000589174 Bradyrhizobium japonicum Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- 241000692373 Brevibacterium paucivorans Species 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 2
- 241000589873 Campylobacter concisus Species 0.000 description 2
- 241000606208 Campylobacter gracilis Species 0.000 description 2
- 241001290832 Campylobacter hominis Species 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 241000606177 Campylobacter ureolyticus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 241000190885 Capnocytophaga ochracea Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000207210 Cardiobacterium hominis Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000159549 Catonella morbi Species 0.000 description 2
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 241000588919 Citrobacter freundii Species 0.000 description 2
- 241000920610 Citrobacter youngae Species 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010073254 Colicins Proteins 0.000 description 2
- 241001262170 Collinsella aerofaciens Species 0.000 description 2
- 241001453268 Comamonas terrigena Species 0.000 description 2
- 241001517050 Corynebacterium accolens Species 0.000 description 2
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 2
- 241000520076 Corynebacterium coyleae Species 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241001517041 Corynebacterium jeikeium Species 0.000 description 2
- 241000334646 Corynebacterium kroppenstedtii Species 0.000 description 2
- 241000334665 Corynebacterium lipophiloflavum Species 0.000 description 2
- 241001518260 Corynebacterium minutissimum Species 0.000 description 2
- 241000577797 Corynebacterium mucifaciens Species 0.000 description 2
- 241000353352 Corynebacterium pyruviciproducens Species 0.000 description 2
- 241000334675 Corynebacterium singulare Species 0.000 description 2
- 241001518263 Corynebacterium tuberculostearicum Species 0.000 description 2
- 241000186245 Corynebacterium xerosis Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 241000990232 Curtobacterium flaccumfaciens pv. flaccumfaciens Species 0.000 description 2
- 241000625997 Cutibacterium acnes subsp. acnes Species 0.000 description 2
- 241001464974 Cutibacterium avidum Species 0.000 description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 241001508479 Dermabacter hominis Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000205644 Devosia riboflavina Species 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 241001624700 Dialister invisus Species 0.000 description 2
- 241000982523 Dialister micraerophilus Species 0.000 description 2
- 241000966565 Dialister propionicifaciens Species 0.000 description 2
- 241000659005 Dietzia timorensis Species 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001647151 Dokdonella koreensis Species 0.000 description 2
- 241000016537 Dorea longicatena Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000588878 Eikenella corrodens Species 0.000 description 2
- 241000291067 Enhydrobacter aerosaccus Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000881810 Enterobacter asburiae Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241001522957 Enterococcus casseliflavus Species 0.000 description 2
- 241000520130 Enterococcus durans Species 0.000 description 2
- 241000556426 Erwinia rhapontici Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000701838 Escherichia virus N4 Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241001608234 Faecalibacterium Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 241001134569 Flavonifractor plautii Species 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- 108090000717 Fragilysin Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
- 241000605908 Fusobacterium gonidiaformans Species 0.000 description 2
- 241000605994 Fusobacterium periodonticum Species 0.000 description 2
- 241000193814 Gemella haemolysans Species 0.000 description 2
- 241001657446 Gemella sanguinis Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001660000 Gordonia polyisoprenivorans Species 0.000 description 2
- 241000978170 Granulicatella elegans Species 0.000 description 2
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 2
- 241000588729 Hafnia alvei Species 0.000 description 2
- 241001148477 Halomonas meridiana Species 0.000 description 2
- 241000186399 Holdemanella biformis Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001674997 Hungatella hathewayi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000037075 Intestinibacter bartlettii Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- 241001393959 Jonquetella anthropi Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241001180676 Lachnoanaerobaculum saburreum Species 0.000 description 2
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 description 2
- 241000218492 Lactobacillus crispatus Species 0.000 description 2
- 241001134659 Lactobacillus curvatus Species 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241000186685 Lactobacillus hilgardii Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241000316280 Lactobacillus ultunensis Species 0.000 description 2
- 241000186783 Lactobacillus vaginalis Species 0.000 description 2
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 2
- 241000123728 Leptotrichia buccalis Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000192003 Leuconostoc carnosum Species 0.000 description 2
- 241001468192 Leuconostoc citreum Species 0.000 description 2
- 241000192129 Leuconostoc lactis Species 0.000 description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 108090000988 Lysostaphin Proteins 0.000 description 2
- 241001046559 Marvinbryantia Species 0.000 description 2
- 241000425724 Marvinbryantia formatexigens Species 0.000 description 2
- 241000215495 Massilia timonae Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 241001328156 Microbacterium hydrothermale Species 0.000 description 2
- 241001467566 Microbacterium lacticum Species 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000897456 Microvirga aerilata Species 0.000 description 2
- 241000579746 Microvirgula aerodenitrificans Species 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 241001494429 Mogibacterium timidum Species 0.000 description 2
- 241000588772 Morganella morganii Species 0.000 description 2
- 241000373884 Murdochiella asaccharolytica Species 0.000 description 2
- 241000761550 Mycobacterium conceptionense Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 108010088346 NVP PDF 713 Proteins 0.000 description 2
- 241000732090 Negativicoccus succinicivorans Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241001136170 Neisseria subflava Species 0.000 description 2
- 241000905447 Nevskia ramosa Species 0.000 description 2
- 241001391497 Nitriliruptor alkaliphilus Species 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 241001435548 Novosphingobium lindaniclasticum Species 0.000 description 2
- 241001135232 Odoribacter splanchnicus Species 0.000 description 2
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 2
- 241000927555 Olsenella uli Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- 241000204306 Parabacteroides merdae Species 0.000 description 2
- 241001326098 Paracoccus yeei Species 0.000 description 2
- 241000941395 Pararheinheimera texasensis Species 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 241000122116 Parvimonas Species 0.000 description 2
- 241000191998 Pediococcus acidilactici Species 0.000 description 2
- 241000206590 Peptococcus niger Species 0.000 description 2
- 241000962519 Peptoniphilus gorbachii Species 0.000 description 2
- 241001464881 Peptoniphilus lacrimalis Species 0.000 description 2
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 2
- 241000684246 Peptostreptococcus stomatis Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 2
- 241000302292 Porphyromonas bennonis Species 0.000 description 2
- 241001635667 Porphyromonas somerae Species 0.000 description 2
- 241000770209 Porphyromonas uenonis Species 0.000 description 2
- 241001135217 Prevotella buccae Species 0.000 description 2
- 241001135206 Prevotella buccalis Species 0.000 description 2
- 241001135208 Prevotella corporis Species 0.000 description 2
- 241000509620 Prevotella dentalis Species 0.000 description 2
- 241001135209 Prevotella denticola Species 0.000 description 2
- 241000495654 Prevotella jejuni Species 0.000 description 2
- 241001135262 Prevotella oris Species 0.000 description 2
- 241000665168 Prevotella pleuritidis Species 0.000 description 2
- 241000331195 Prevotella salivae Species 0.000 description 2
- 241000331194 Prevotella shahii Species 0.000 description 2
- 241001430102 Prevotella stercorea Species 0.000 description 2
- 241000530934 Prevotella timonensis Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 241000043392 Providencia rustigianii Species 0.000 description 2
- 241001528479 Pseudoflavonifractor capillosus Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241001515920 Pseudomonas koreensis Species 0.000 description 2
- 241000204709 Pseudomonas mucidolens Species 0.000 description 2
- 241000589630 Pseudomonas pseudoalcaligenes Species 0.000 description 2
- 241001555430 Psychrobacter okhotskensis Species 0.000 description 2
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 description 2
- 241000589625 Ralstonia pickettii Species 0.000 description 2
- 241001148115 Rhizobium etli Species 0.000 description 2
- 241001639233 Rhizobium vignae Species 0.000 description 2
- 241000187694 Rhodococcus fascians Species 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000026500 Roseateles aquatilis Species 0.000 description 2
- 241000157939 Rothia mucilaginosa Species 0.000 description 2
- 241000123753 Ruminococcus bromii Species 0.000 description 2
- 108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 101100465903 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psp3 gene Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- 241001657517 Slackia exigua Species 0.000 description 2
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 2
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 2
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 2
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 2
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 2
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 2
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 2
- 241000123706 Sneathia sanguinegens Species 0.000 description 2
- 241000947298 Sphingobium amiense Species 0.000 description 2
- 241000328432 Sphingobium japonicum Species 0.000 description 2
- 241000721363 Sphingomonas dokdonensis Species 0.000 description 2
- 241000774445 Sphingomonas fonticola Species 0.000 description 2
- 241000850749 Sphingomonas hankookensis Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241001147687 Staphylococcus auricularis Species 0.000 description 2
- 241001582999 Staphylococcus nepalensis Species 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 241001607911 Stenotrophomonas rhizophila Species 0.000 description 2
- 241000194008 Streptococcus anginosus Species 0.000 description 2
- 241000176094 Streptococcus australis Species 0.000 description 2
- 241000191981 Streptococcus cristatus Species 0.000 description 2
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 2
- 241000194049 Streptococcus equinus Species 0.000 description 2
- 241000194026 Streptococcus gordonii Species 0.000 description 2
- 241000194046 Streptococcus intermedius Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241001617354 Streptococcus lutetiensis Species 0.000 description 2
- 241001134658 Streptococcus mitis Species 0.000 description 2
- 241000193991 Streptococcus parasanguinis Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241000194024 Streptococcus salivarius Species 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 2
- 241000123713 Sutterella wadsworthensis Species 0.000 description 2
- 241000192584 Synechocystis Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 241001147840 Turicella otitidis Species 0.000 description 2
- 241001678097 Turicibacter sanguinis Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 241000202921 Ureaplasma urealyticum Species 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 101800000970 Vacuolating cytotoxin Proteins 0.000 description 2
- 241001533207 Veillonella atypica Species 0.000 description 2
- 241001533204 Veillonella dispar Species 0.000 description 2
- 241001148135 Veillonella parvula Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 2
- 241000204291 [Bacteroides] coagulans Species 0.000 description 2
- 241000186569 [Clostridium] leptum Species 0.000 description 2
- 241001531273 [Eubacterium] eligens Species 0.000 description 2
- 241000498616 [Eubacterium] saphenum Species 0.000 description 2
- 241001531189 [Eubacterium] siraeum Species 0.000 description 2
- 241001282046 [Eubacterium] sulci Species 0.000 description 2
- 241001464870 [Ruminococcus] torques Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 2
- LKOHREGGXUJGKC-NTQZDHPLSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-NTQZDHPLSA-N 0.000 description 2
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 description 2
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960004191 artemisinin Drugs 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 229940097012 bacillus thuringiensis Drugs 0.000 description 2
- 230000001420 bacteriolytic effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- PDWGIAAFQACISG-QZBWVFMZSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PDWGIAAFQACISG-QZBWVFMZSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000003876 biosurfactant Substances 0.000 description 2
- 229960000503 bisacodyl Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960005495 cefotetan Drugs 0.000 description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 2
- 229950002020 clemizole Drugs 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960004287 clofazimine Drugs 0.000 description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960003572 cyclobenzaprine Drugs 0.000 description 2
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- FCIROHDMPFOSFG-LAVSNGQLSA-N disialyllacto-N-tetraose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]3[C@@H]([C@@H](O)C(O)O[C@@H]3CO)O)O[C@H](CO)[C@@H]2O)O)O1 FCIROHDMPFOSFG-LAVSNGQLSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical group C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
- 229960003337 entacapone Drugs 0.000 description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960000628 fidaxomicin Drugs 0.000 description 2
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 2
- 101150043770 fimA gene Proteins 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229930193965 lacto-N-fucopentaose Natural products 0.000 description 2
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 2
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 108010042648 lactocin Proteins 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 229940041028 lincosamides Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 229960001977 loracarbef Drugs 0.000 description 2
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 2
- 229960000589 loxapine succinate Drugs 0.000 description 2
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960001962 mefloquine Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229960004011 methenamine Drugs 0.000 description 2
- XJAJBFWPYSQCKP-UHFFFAOYSA-N methyl 2-(6,7-dimethyl-3-oxo-4h-quinoxalin-2-yl)-4-(4-methoxy-2-nitroanilino)-3,4-dioxobutanoate Chemical compound N=1C2=CC(C)=C(C)C=C2NC(=O)C=1C(C(=O)OC)C(=O)C(=O)NC1=CC=C(OC)C=C1[N+]([O-])=O XJAJBFWPYSQCKP-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- 229950009116 mevastatin Drugs 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229940076266 morganella morganii Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- DVOUJRUFCBNRQW-UHFFFAOYSA-N mucoxin Chemical compound O1C(C(O)CCCCCCCCCCCCCCCCC)CC(O)C1C1OC(C(O)CCCCCC=2C(OC(C)C=2)=O)CC1 DVOUJRUFCBNRQW-UHFFFAOYSA-N 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 229960000210 nalidixic acid Drugs 0.000 description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229960005425 nitrendipine Drugs 0.000 description 2
- 229960000564 nitrofurantoin Drugs 0.000 description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 108010000785 non-ribosomal peptide synthase Proteins 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 229960001199 olmesartan medoxomil Drugs 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229960000986 oxetacaine Drugs 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical group CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229960001057 paliperidone Drugs 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 108010049023 pediocin PA-1 Proteins 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229960001181 phenazopyridine Drugs 0.000 description 2
- 101150014100 pilA gene Proteins 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 108010035592 piscicolin 126 Proteins 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960002262 profenamine Drugs 0.000 description 2
- CDOZDBSBBXSXLB-UHFFFAOYSA-N profenamine Chemical compound C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 CDOZDBSBBXSXLB-UHFFFAOYSA-N 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- ABBQGOCHXSPKHJ-WUKNDPDISA-N prontosil Chemical compound NC1=CC(N)=CC=C1\N=N\C1=CC=C(S(N)(=O)=O)C=C1 ABBQGOCHXSPKHJ-WUKNDPDISA-N 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- NYBZAGXTZXPYND-GBIKHYSHSA-N pyochelin I Chemical compound S1C[C@@H](C(O)=O)N(C)[C@H]1[C@@H]1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-GBIKHYSHSA-N 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229960000885 rifabutin Drugs 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 108010027327 sakacin A Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229950008588 solithromycin Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 229940115921 streptococcus equinus Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 108010045452 sublancin 168 Proteins 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960004673 sulfadoxine Drugs 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960003250 telithromycin Drugs 0.000 description 2
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- 229950008375 tenatoprazole Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 108010067167 thuricin Proteins 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- YOTBLRKYLWEPOA-UHFFFAOYSA-N trifucosyllacto-n-hexaose Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(COC4C(C(OC5C(C(O)C(O)C(C)O5)O)C(OC5C(C(O)C(O)C(CO)O5)O)C(CO)O4)NC(C)=O)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O YOTBLRKYLWEPOA-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- WEYVVCKOOFYHRW-SFHVURJKSA-N (+)-usnic acid Chemical compound O=C([C@@]12C)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-SFHVURJKSA-N 0.000 description 1
- KGAGLTSPYLYTGL-UHFFFAOYSA-N (+)-usnic acid Natural products COc1c(O)c(C)c(O)c2c1OC3=CC(=C(C(=O)C)C(=O)C23C)O KGAGLTSPYLYTGL-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- DEEOVDONDDERBX-MUDWFXPSSA-N (2S)-6-amino-2-[[(1S,4R,10S,19S,22S,25S,28S,31S,34R,37S,43S,46S,47S,50R,53S,56S,62S)-50-amino-43-(2-amino-2-oxoethyl)-56-(3-amino-3-oxopropyl)-10-benzyl-37-(carboxymethyl)-31-(hydroxymethyl)-28-(1H-indol-3-ylmethyl)-47,62-dimethyl-7-methylidene-22-(2-methylpropyl)-2,5,8,11,14,20,23,26,29,32,35,38,41,44,51,54,57-heptadecaoxo-53-propan-2-yl-48,60,63-trithia-3,6,9,12,15,21,24,27,30,33,36,39,42,45,52,55,58-heptadecazatetracyclo[32.24.3.34,25.015,19]tetrahexacontane-46-carbonyl]amino]hexanoic acid Chemical compound CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)C(=C)NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CO)C(=O)N[C@H]1CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CS[C@@H](C)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC1=O)C(=O)N[C@@H](CCCCN)C(O)=O)C(C)C)C(=O)N2 DEEOVDONDDERBX-MUDWFXPSSA-N 0.000 description 1
- MXABZXILAJGOTL-AUYMZICSSA-N (2S)-N-[(2S)-1-[(2S)-1-[(2S,3S)-1-[(2S)-1-[2-[(2S)-1,3-dihydroxy-1-[(E)-1-hydroxy-1-[(2S,3S)-1-hydroxy-3-methyl-1-[[(2Z,6S,9S,12R)-5,8,11-trihydroxy-9-(2-methylpropyl)-6-propan-2-yl-1-thia-4,7,10-triazacyclotrideca-2,4,7,10-tetraen-12-yl]imino]pentan-2-yl]iminobut-2-en-2-yl]iminopropan-2-yl]imino-2-hydroxyethyl]imino-1,5-dihydroxy-5-iminopentan-2-yl]imino-1-hydroxy-3-methylpentan-2-yl]imino-1-hydroxy-3-methylbutan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[[(2S)-1-[(Z)-2-[[(2S)-2-(dimethylamino)-1-hydroxypropylidene]amino]but-2-enoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1-hydroxypropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1-hydroxypropylidene]amino]pentanediimidic acid Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@@H](\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)[C@H](C)\N=C(/O)[C@@H](\N=C(/O)\C(=C\C)\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)\C(=C\C)\N=C(/O)[C@H](C)\N=C(/O)[C@@H]1CCCN1C(=O)\C(=C\C)\N=C(/O)[C@H](C)N(C)C)C(C)C)C(C)C)C(\O)=N\[C@@H](CCC(O)=N)C(\O)=N\C\C(O)=N\[C@@H](CO)C(\O)=N\C(=C\C)\C(\O)=N\[C@@H]([C@@H](C)CC)C(\O)=N\[C@H]1CS\C=C/N=C(O)\[C@@H](\N=C(O)/[C@H](CC(C)C)\N=C1\O)C(C)C MXABZXILAJGOTL-AUYMZICSSA-N 0.000 description 1
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- AYCMYBACERJYNY-HIFRSBDPSA-N (2s)-n-(5-fluoro-1-hydroxypyridin-2-ylidene)-1-[(2r)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide Chemical compound CCCC[C@H](CN(O)C=O)C(=O)N1CCC[C@H]1C(=O)N=C1N(O)C=C(F)C=C1 AYCMYBACERJYNY-HIFRSBDPSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- HBJOXQRURQPDEX-MHXMMLMNSA-N (2s,4r)-n-[(1s,2s)-2-chloro-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-ethylpiperidine-2-carboxamide Chemical compound C1[C@H](CC)CCN[C@@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 HBJOXQRURQPDEX-MHXMMLMNSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- UJAOSPFULOFZRR-UHFFFAOYSA-N (4-acetamidophenyl) acetate Chemical compound CC(=O)NC1=CC=C(OC(C)=O)C=C1 UJAOSPFULOFZRR-UHFFFAOYSA-N 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- HBUJYEUPIIJJOS-PBHICJAKSA-N (5r)-3-[4-[1-[(2s)-2,3-dihydroxypropanoyl]-3,6-dihydro-2h-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one Chemical compound C1N(C(=O)[C@@H](O)CO)CCC(C=2C(=CC(=CC=2F)N2C(O[C@@H](COC3=NOC=C3)C2)=O)F)=C1 HBUJYEUPIIJJOS-PBHICJAKSA-N 0.000 description 1
- MMQXRUYUBYWTDP-KEIGCJKLSA-N (5s,6r,7r)-3-(acetyloxymethyl)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-5,8-dioxo-5$l^{4}-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2[C@@H]1[S@](CC(COC(C)=O)=C2C(O)=O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MMQXRUYUBYWTDP-KEIGCJKLSA-N 0.000 description 1
- FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 1
- YBHZVPYSEUQIII-DYJQDLSISA-N (6r,7r)-3-(acetyloxymethyl)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 YBHZVPYSEUQIII-DYJQDLSISA-N 0.000 description 1
- OCLRGULJISNUQS-OXQOHEQNSA-N (6r,7r)-3-(acetyloxymethyl)-7-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl OCLRGULJISNUQS-OXQOHEQNSA-N 0.000 description 1
- LHNIIDJCEODSHA-OQRUQETBSA-N (6r,7r)-3-[(e)-2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)\C=C\C=1C(=CC(=CC=1)[N+]([O-])=O)[N+]([O-])=O)C(=O)CC1=CC=CS1 LHNIIDJCEODSHA-OQRUQETBSA-N 0.000 description 1
- QFTZCQVZVRVDTD-DNVCBOLYSA-N (6r,7r)-3-methyl-8-oxo-7-[[2-[4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)C)C(O)=O)C(=O)CC(C=C1)=CC=C1C1=NCCCN1 QFTZCQVZVRVDTD-DNVCBOLYSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- RULITNAIJFZYLO-UEKVPHQBSA-N (6r,7r)-7-[[(2r)-2-amino-2-(3-chloro-4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C(Cl)=C1 RULITNAIJFZYLO-UEKVPHQBSA-N 0.000 description 1
- SBUCDZYLTRYMFG-PBFPGSCMSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](N)C=3C=CC(O)=CC=3)[C@H]2SC1 SBUCDZYLTRYMFG-PBFPGSCMSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- VDFFPBOAOLQAJV-SUYBPPKGSA-N (6r,7r)-7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 VDFFPBOAOLQAJV-SUYBPPKGSA-N 0.000 description 1
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 1
- CUCFRCCRYQDMNM-PXIRVSTKSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-5-yl)-2-(2-oxopyrrolidin-3-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1C(N)=NC=C1C(\C(=O)N[C@@H]1C(N2C(=C(C[N+]=3C=CC=CC=3)CS[C@@H]21)C([O-])=O)=O)=N\OC1C(=O)NCC1 CUCFRCCRYQDMNM-PXIRVSTKSA-N 0.000 description 1
- JXHWKLWIYBATLL-GMIKGCRTSA-N (6r,7r)-7-[[2-[(z)-2-cyanoethenyl]sulfanylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CS\C=C/C#N)[C@H]2SC1 JXHWKLWIYBATLL-GMIKGCRTSA-N 0.000 description 1
- UQWYUAURRDNBKR-BXUZGUMPSA-N (6r,7r)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-3-(1h-1,2,4-triazol-5-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NC=NN1 UQWYUAURRDNBKR-BXUZGUMPSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 1
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- VNJHUUNVDMYCRH-UHFFFAOYSA-N 1,1-diphenyl-3-piperidin-1-ylpropan-1-ol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 VNJHUUNVDMYCRH-UHFFFAOYSA-N 0.000 description 1
- DJHHDLMTUOLVHY-UHFFFAOYSA-N 1,2,3,4-tetrachlorodibenzodioxine Chemical compound C1=CC=C2OC3=C(Cl)C(Cl)=C(Cl)C(Cl)=C3OC2=C1 DJHHDLMTUOLVHY-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- LXBIFEVIBLOUGU-FSIIMWSLSA-N 1-Deoxymannojirimycin Natural products OC[C@@H]1NC[C@@H](O)[C@H](O)[C@H]1O LXBIFEVIBLOUGU-FSIIMWSLSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- GNUXVOXXWGNPIV-UHFFFAOYSA-N 1-methyl-5-[[methyl(1-phenylpropan-2-yl)amino]methyl]-2-phenyl-4-propan-2-yl-3-pyrazolone Chemical compound CN1N(C=2C=CC=CC=2)C(=O)C(C(C)C)=C1CN(C)C(C)CC1=CC=CC=C1 GNUXVOXXWGNPIV-UHFFFAOYSA-N 0.000 description 1
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- ODUOJXZPIYUATO-UHFFFAOYSA-N 2-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]acetic acid (phenylmethyl) ester Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 description 1
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical compound CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- 101710113919 3,4-dihydroxyphenylacetaldehyde synthase 2 Proteins 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- QAIRPCMWTLMPCW-UHFFFAOYSA-N 4-bromo-2,6-diethylpyridine Chemical compound CCC1=CC(Br)=CC(CC)=N1 QAIRPCMWTLMPCW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 108091000044 4-hydroxy-tetrahydrodipicolinate synthase Proteins 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- HWJPWWYTGBZDEG-UHFFFAOYSA-N 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine Chemical compound C=12C=CC(C3CC3)OC2=C(OC)C(OC)=CC=1CC1=CN=C(N)N=C1N HWJPWWYTGBZDEG-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- UBHSARJULCDNFC-UHFFFAOYSA-N 5-benzyl-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole;naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 UBHSARJULCDNFC-UHFFFAOYSA-N 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- FVNFBBAOMBJTST-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FVNFBBAOMBJTST-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 241000201856 Abiotrophia defectiva Species 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241001430193 Absiella dolichum Species 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241001420322 Acetanaerobacterium Species 0.000 description 1
- 241001430271 Acetitomaculum Species 0.000 description 1
- 241001495178 Acetivibrio Species 0.000 description 1
- 241001446817 Acetobacter farinalis Species 0.000 description 1
- 241000776559 Acetobacter malorum Species 0.000 description 1
- 241001497697 Acetobacter orleanensis Species 0.000 description 1
- 241001671687 Acetobacter sicerae Species 0.000 description 1
- 241000245942 Acetomicrobium Species 0.000 description 1
- 241001584692 Acetomicrobium hydrogeniformans Species 0.000 description 1
- 101000818123 Acholeplasma phage L2 Uncharacterized 17.2 kDa protein Proteins 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000581737 Achromobacter anxifer Species 0.000 description 1
- 241001453369 Achromobacter denitrificans Species 0.000 description 1
- 241001480821 Achromobacter marplatensis Species 0.000 description 1
- 241001611468 Achromobacter spanius Species 0.000 description 1
- 241000604451 Acidaminococcus Species 0.000 description 1
- 241000604450 Acidaminococcus fermentans Species 0.000 description 1
- 241001116699 Acidaminococcus intestini Species 0.000 description 1
- 241000093740 Acidaminococcus sp. Species 0.000 description 1
- 241001468099 Acidocella aminolytica Species 0.000 description 1
- 241001453304 Acidovorax konjaci Species 0.000 description 1
- 241001648893 Acidovorax radicis Species 0.000 description 1
- 241001430401 Acinetobacter antiviralis Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000998457 Acinetobacter guangdongensis Species 0.000 description 1
- 241000122230 Acinetobacter junii Species 0.000 description 1
- 241000930987 Acinetobacter parvus Species 0.000 description 1
- 241000122231 Acinetobacter radioresistens Species 0.000 description 1
- 241000271152 Acinetobacter soli Species 0.000 description 1
- 241001221084 Acinetobacter variabilis Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000606730 Actinobacillus capsulatus Species 0.000 description 1
- 241001164718 Actinobaculum massiliense Species 0.000 description 1
- 241000201754 Actinomadura citrea Species 0.000 description 1
- 241000201753 Actinomadura coerulea Species 0.000 description 1
- 241000157192 Actinomadura fibrosa Species 0.000 description 1
- 241000201769 Actinomadura fulvescens Species 0.000 description 1
- 241001553041 Actinomadura jiaoheensis Species 0.000 description 1
- 241000201781 Actinomadura luteofluorescens Species 0.000 description 1
- 241000934313 Actinomadura mexicana Species 0.000 description 1
- 241000936961 Actinomadura nitritigenes Species 0.000 description 1
- 241000201778 Actinomadura verrucosospora Species 0.000 description 1
- 241000157200 Actinomadura yumaensis Species 0.000 description 1
- 241001061295 Actinomyces cardiffensis Species 0.000 description 1
- 241000423324 Actinomyces dentalis Species 0.000 description 1
- 241000511654 Actinomyces gerencseriae Species 0.000 description 1
- 241000501351 Actinomyces haliotis Species 0.000 description 1
- 241000132732 Actinomyces johnsonii Species 0.000 description 1
- 241001147826 Actinomyces neuii subsp. anitratus Species 0.000 description 1
- 241000132734 Actinomyces oris Species 0.000 description 1
- 241000900280 Actinomyces radingae Species 0.000 description 1
- 241001478947 Actinomyces urogenitalis Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 241000864819 Actinomycetospora atypica Species 0.000 description 1
- 241000557576 Actinomycetospora corticicola Species 0.000 description 1
- 241000769682 Actinomycetospora rhizophila Species 0.000 description 1
- 241000414984 Actinomycetospora rishiriensis Species 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000466670 Adlercreutzia Species 0.000 description 1
- 241000452716 Adlercreutzia equolifaciens Species 0.000 description 1
- 241000193792 Aerococcus viridans Species 0.000 description 1
- 241000203710 Aeromicrobium Species 0.000 description 1
- 241001017251 Aeromicrobium flavum Species 0.000 description 1
- 241000156875 Aeromicrobium tamlense Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241001602154 Aeromonas australiensis Species 0.000 description 1
- 241001506298 Aeromonas bestiarum Species 0.000 description 1
- 241000383177 Aeromonas bivalvium Species 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607513 Aeromonas eucrenophila Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241001486715 Aeromonas hydrophila subsp. hydrophila Species 0.000 description 1
- 241001676222 Aeromonas piscicola Species 0.000 description 1
- 241001223881 Aeromonas popoffii Species 0.000 description 1
- 241001571014 Aeromonas rivuli Species 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- 241000382429 Aeromonas salmonicida subsp. pectinolytica Species 0.000 description 1
- 241001599567 Aeromonas salmonicida subsp. smithia Species 0.000 description 1
- 241000317507 Aeromonas virus Aeh1 Species 0.000 description 1
- 241001537480 Afipia massiliensis Species 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001024600 Aggregatibacter Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 241000606828 Aggregatibacter aphrophilus Species 0.000 description 1
- 241000606806 Aggregatibacter segnis Species 0.000 description 1
- 241000321222 Agrobacterium larrymoorei Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241001660822 Agrococcus baldri Species 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 108010041525 Alanine racemase Proteins 0.000 description 1
- 241000610026 Albibacter methylovorans Species 0.000 description 1
- 241001453371 Alcaligenes faecalis subsp. faecalis Species 0.000 description 1
- 102100026609 Aldehyde dehydrogenase family 3 member B1 Human genes 0.000 description 1
- 101710130543 Aldehyde dehydrogenase family 3 member B1 Proteins 0.000 description 1
- 241000538014 Algoriphagus aquatilis Species 0.000 description 1
- 241000577542 Algoriphagus ratkowskyi Species 0.000 description 1
- 241000706408 Aliagarivorans Species 0.000 description 1
- 241000836860 Aliagarivorans marinus Species 0.000 description 1
- 241001387768 Aliidiomarina maris Species 0.000 description 1
- 241001600138 Aliivibrio wodanis Species 0.000 description 1
- 241000701474 Alistipes Species 0.000 description 1
- 241000801627 Alistipes indistinctus Species 0.000 description 1
- 241000039830 Alistipes inops Species 0.000 description 1
- 241000030713 Alistipes onderdonkii Species 0.000 description 1
- 241001135230 Alistipes putredinis Species 0.000 description 1
- 241000623794 Alistipes senegalensis Species 0.000 description 1
- 241000030716 Alistipes shahii Species 0.000 description 1
- 241000937487 Alistipes timonensis Species 0.000 description 1
- 241000422407 Alkalibacterium olivapovliticus Species 0.000 description 1
- 241001377934 Alkalibacterium pelagium Species 0.000 description 1
- 241000186032 Alloiococcus otitis Species 0.000 description 1
- 241000913130 Alloprevotella rava Species 0.000 description 1
- 241001288806 Alloprevotella tannerae Species 0.000 description 1
- 241001041926 Alloscardovia Species 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 241000670857 Alsobacter metallidurans Species 0.000 description 1
- 241001400751 Altererythrobacter epoxidivorans Species 0.000 description 1
- 241000577584 Amaricoccus kaplicensis Species 0.000 description 1
- 241000577583 Amaricoccus veronensis Species 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 241001646017 Aminobacter aganoensis Species 0.000 description 1
- 241001628727 Aminobacter ciceronei Species 0.000 description 1
- 241000938042 Aminobacter lissarensis Species 0.000 description 1
- 241001646015 Aminobacter niigataensis Species 0.000 description 1
- 241000936844 Ammoniphilus oxalaticus Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000322020 Amnibacterium kyonggiense Species 0.000 description 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 description 1
- 241000379991 Anaerococcus Species 0.000 description 1
- 241000581897 Anaerococcus obesiensis Species 0.000 description 1
- 241000530054 Anaerococcus octavius Species 0.000 description 1
- 241000623797 Anaerococcus senegalensis Species 0.000 description 1
- 241001464898 Anaerococcus tetradius Species 0.000 description 1
- 241001424158 Anaerocolumna jejuensis Species 0.000 description 1
- 241000511612 Anaerofilum Species 0.000 description 1
- 241000079561 Anaerofustis Species 0.000 description 1
- 241001580965 Anaerofustis stercorihominis Species 0.000 description 1
- 241000025434 Anaeroglobus geminatus Species 0.000 description 1
- 241001629581 Anaerosinus Species 0.000 description 1
- 241001227086 Anaerostipes Species 0.000 description 1
- 241001505572 Anaerostipes caccae Species 0.000 description 1
- 241001584951 Anaerostipes hadrus Species 0.000 description 1
- 241001013579 Anaerotruncus Species 0.000 description 1
- 241000428313 Anaerotruncus colihominis Species 0.000 description 1
- 241001558988 Anaerovorax Species 0.000 description 1
- 241000259848 Ancylobacter polymorphus Species 0.000 description 1
- 241000555286 Aneurinibacillus Species 0.000 description 1
- 241000193741 Aneurinibacillus aneurinilyticus Species 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
- 241001664320 Anoxybacillus flavithermus subsp. yunnanensis Species 0.000 description 1
- 241001626810 Anoxybacillus pushchinoensis Species 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241001222027 Aquabacterium citratiphilum Species 0.000 description 1
- 241000962826 Aquabacterium olei Species 0.000 description 1
- 241000825857 Aquamicrobium aerolatum Species 0.000 description 1
- 241000848220 Aquincola tertiaricarbonis Species 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000900277 Arcanobacterium phocae Species 0.000 description 1
- 241001647017 Archangium minus Species 0.000 description 1
- 241001647019 Archangium violaceum Species 0.000 description 1
- 241000044133 Arcobacter venerupis Species 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 241000332481 Arsenicicoccus bolidensis Species 0.000 description 1
- 241000706992 Arthrobacter russicus Species 0.000 description 1
- 101100162206 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflJ gene Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 241000612630 Atopobium deltae Species 0.000 description 1
- 241000193815 Atopobium minutum Species 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000100277 Aureimonas altamirensis Species 0.000 description 1
- 241001259676 Aureimonas rubiginis Species 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000606591 Avibacterium gallinarum Species 0.000 description 1
- 241001312731 Azospira oryzae Species 0.000 description 1
- 241000825537 Azospirillum oryzae Species 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- 241001260372 Bacillus acidicola Species 0.000 description 1
- 241000193410 Bacillus atrophaeus Species 0.000 description 1
- 241001409534 Bacillus australimaris Species 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000678616 Bacillus coahuilensis Species 0.000 description 1
- 241000223006 Bacillus drentensis Species 0.000 description 1
- 241000193414 Bacillus fastidiosus Species 0.000 description 1
- 241001219268 Bacillus gaemokensis Species 0.000 description 1
- 241001032451 Bacillus indicus Species 0.000 description 1
- 241000867095 Bacillus lehensis Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000956037 Bacillus massilioanorexius Species 0.000 description 1
- 241000581937 Bacillus massiliosenegalensis Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000193398 Bacillus methanolicus Species 0.000 description 1
- 241000587861 Bacillus oceanisediminis Species 0.000 description 1
- 241001536371 Bacillus oleronius Species 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000025050 Bacillus rhizosphaerae Species 0.000 description 1
- 241000835167 Bacillus safensis Species 0.000 description 1
- 241000040345 Bacillus shackletonii Species 0.000 description 1
- 241000193400 Bacillus simplex Species 0.000 description 1
- 241000193399 Bacillus smithii Species 0.000 description 1
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 description 1
- 241000202341 Bacillus sporothermodurans Species 0.000 description 1
- 108700016166 Bacillus subtilis sboA Proteins 0.000 description 1
- 241000957580 Bacillus timonensis Species 0.000 description 1
- 241001249119 Bacillus vallismortis Species 0.000 description 1
- 241000602824 Bacillus wakoensis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101710083600 Bacteriocin E50-52 Proteins 0.000 description 1
- 241000604983 Bacteriovorax stolpii Species 0.000 description 1
- 241001674039 Bacteroides acidifaciens Species 0.000 description 1
- 241000168635 Bacteroides barnesiae Species 0.000 description 1
- 241000217846 Bacteroides caccae Species 0.000 description 1
- 241001032450 Bacteroides cellulosilyticus Species 0.000 description 1
- 241000801600 Bacteroides clarus Species 0.000 description 1
- 241001220439 Bacteroides coprocola Species 0.000 description 1
- 241000545821 Bacteroides coprophilus Species 0.000 description 1
- 241001135322 Bacteroides eggerthii Species 0.000 description 1
- 241000402140 Bacteroides finegoldii Species 0.000 description 1
- 241000801629 Bacteroides fluxus Species 0.000 description 1
- 241000168642 Bacteroides gallinarum Species 0.000 description 1
- 241000047484 Bacteroides intestinalis Species 0.000 description 1
- 241000801630 Bacteroides oleiciplenus Species 0.000 description 1
- 241000168636 Bacteroides salanitronis Species 0.000 description 1
- 241001135233 Bacteroides zoogleoformans Species 0.000 description 1
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 description 1
- 241000944683 Bandara Species 0.000 description 1
- 241000927512 Barnesiella Species 0.000 description 1
- 241000260432 Barnesiella intestinihominis Species 0.000 description 1
- 241000927510 Barnesiella viscericola Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000606108 Bartonella quintana Species 0.000 description 1
- 241000053357 Bavariicoccus Species 0.000 description 1
- 241000186553 Bavariicoccus seileri Species 0.000 description 1
- 241000604931 Bdellovibrio bacteriovorus Species 0.000 description 1
- 241000774461 Bdellovibrio exovorus Species 0.000 description 1
- 241001459701 Belnapia moabensis Species 0.000 description 1
- 241000029422 Belnapia soli Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000884531 Bhargavaea cecembensis Species 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241001312346 Bifidobacterium gallicum Species 0.000 description 1
- 241000042873 Bifidobacterium scardovii Species 0.000 description 1
- 241001495171 Bilophila Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241001202853 Blautia Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 241000335561 Blautia faecis Species 0.000 description 1
- 241000028537 Blautia luti Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 241001019268 Bosea lathyri Species 0.000 description 1
- 241000519601 Bosea thiooxidans Species 0.000 description 1
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
- 241000157894 Brachybacterium faecium Species 0.000 description 1
- 241000719298 Brachybacterium fresconis Species 0.000 description 1
- 241001640686 Brachybacterium muris Species 0.000 description 1
- 241001135754 Brachymonas Species 0.000 description 1
- 241000550899 Brachymonas chironomi Species 0.000 description 1
- 241000758110 Bradyrhizobium huanghuaihaiense Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241001373046 Brevibacterium ammoniilyticum Species 0.000 description 1
- 241001467572 Brevibacterium casei Species 0.000 description 1
- 241000186162 Brevibacterium epidermidis Species 0.000 description 1
- 241001430355 Brevibacterium iodinum Species 0.000 description 1
- 241001533533 Brevibacterium luteolum Species 0.000 description 1
- 241000520039 Brevibacterium mcbrellneri Species 0.000 description 1
- 241000520042 Brevibacterium otitidis Species 0.000 description 1
- 241000360938 Brevibacterium pityocampae Species 0.000 description 1
- 241000617516 Brevibacterium sanguinis Species 0.000 description 1
- 241000957581 Brevibacterium senegalense Species 0.000 description 1
- 241001008278 Brevundimonas albigilva Species 0.000 description 1
- 241001261629 Brevundimonas aurantiaca Species 0.000 description 1
- 241000589539 Brevundimonas diminuta Species 0.000 description 1
- 241001261628 Brevundimonas intermedia Species 0.000 description 1
- 241001423733 Brevundimonas vancanneytii Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001509299 Brucella canis Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 241000249957 Bulleidia extructa Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241000283588 Burkholderia diffusa Species 0.000 description 1
- 241001247370 Burkholderia virus Bcep781 Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241001622816 Buttiauxella gaviniae Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241001557932 Butyricicoccus Species 0.000 description 1
- 241000301580 Butyricicoccus pullicaecorum Species 0.000 description 1
- 241001216243 Butyricimonas Species 0.000 description 1
- 241000132393 Butyricimonas virosa Species 0.000 description 1
- 241000605902 Butyrivibrio Species 0.000 description 1
- 241000193174 Butyrivibrio crossotus Species 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- JSWKNDSDVHJUKY-MNVIWFPGSA-N CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC(=O)[C@@H]3CS[C@@H](C)[C@@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H]4NC(=O)[C@@H]([NH3+])CS[C@H]4C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)NC([C@H](C)S\C=C/NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC([O-])=O)C(=O)N2 Chemical compound CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC(=O)[C@@H]3CS[C@@H](C)[C@@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H]4NC(=O)[C@@H]([NH3+])CS[C@H]4C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)NC([C@H](C)S\C=C/NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC([O-])=O)C(=O)N2 JSWKNDSDVHJUKY-MNVIWFPGSA-N 0.000 description 1
- 241000003078 Caballeronia choica Species 0.000 description 1
- 241000821172 Caballeronia cordobensis Species 0.000 description 1
- 241000866631 Caballeronia glathei Species 0.000 description 1
- 241000003076 Caballeronia humi Species 0.000 description 1
- 241001488042 Caballeronia sordidicola Species 0.000 description 1
- 241000039258 Caballeronia terrestris Species 0.000 description 1
- 241000393956 Caballeronia udeis Species 0.000 description 1
- 241000040127 Caenimonas terrae Species 0.000 description 1
- 101100436077 Caenorhabditis elegans asm-1 gene Proteins 0.000 description 1
- 241000178335 Caldicellulosiruptor saccharolyticus Species 0.000 description 1
- 241000126081 Caldicoprobacter Species 0.000 description 1
- 241000316922 Caldicoprobacter faecalis Species 0.000 description 1
- 241000952606 Caldimonas taiwanensis Species 0.000 description 1
- 241001048927 Calidifontibacter indicus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 241000589992 Campylobacter showae Species 0.000 description 1
- 241000589990 Campylobacter sputorum Species 0.000 description 1
- 241001135528 Campylobacter upsaliensis Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000386787 Candidatus Peptoniphilus massiliensis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000190888 Capnocytophaga gingivalis Species 0.000 description 1
- 241000014851 Capnocytophaga leadbetteri Species 0.000 description 1
- 241000190882 Capnocytophaga sputigena Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- UKXFZNMZXWBSGH-UHFFFAOYSA-N Carbomycin A Natural products COC1C(OC2OC(C)C(OC3CC(C)(O)C(OC(=O)CC(C)C)C(C)O3)C(C2O)N(C)C)C(CC=O)CC(C)C(=O)C=CC4OC4CC(C)OC(=O)CC1C(=O)C UKXFZNMZXWBSGH-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001466752 Cardiobacterium valvarum Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000206593 Carnobacterium divergens Species 0.000 description 1
- 101000715434 Carnobacterium maltaromaticum Bacteriocin carnobacteriocin B2 Proteins 0.000 description 1
- 241000946390 Catenibacterium Species 0.000 description 1
- 241001443867 Catenibacterium mitsuokai Species 0.000 description 1
- 241000983334 Caulobacter henricii Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000446212 Cavicella subterranea Species 0.000 description 1
- 241000046135 Cedecea Species 0.000 description 1
- 241000046143 Cedecea davisae Species 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 241000186321 Cellulomonas Species 0.000 description 1
- 241000936108 Cellulomonas massiliensis Species 0.000 description 1
- 241000631018 Cellulomonas xylanilytica Species 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 241001047426 Cellvibrio vulgaris Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 241001051186 Cetobacterium Species 0.000 description 1
- 241001139343 Cetobacterium somerae Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000971747 Chitinimonas taiwanensis Species 0.000 description 1
- 241001218142 Chitinophaga dinghuensis Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000007190 Chlamydia Infections Diseases 0.000 description 1
- 241001647373 Chlamydia abortus Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001647025 Chondromyces robustus Species 0.000 description 1
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000611330 Chryseobacterium Species 0.000 description 1
- 241000764913 Chryseobacterium aquaticum Species 0.000 description 1
- 241000770195 Chryseobacterium arachidis Species 0.000 description 1
- 241001442200 Chryseobacterium daecheongense Species 0.000 description 1
- 241000661459 Chryseobacterium formosense Species 0.000 description 1
- 241000589593 Chryseobacterium gleum Species 0.000 description 1
- 241000724079 Chryseobacterium greenlandense Species 0.000 description 1
- 241000448657 Chryseobacterium jejuense Species 0.000 description 1
- 241000340909 Chryseobacterium piscium Species 0.000 description 1
- 241000677832 Chryseobacterium rigui Species 0.000 description 1
- 241000733063 Chryseobacterium sediminis Species 0.000 description 1
- 241000612644 Chryseobacterium solani Species 0.000 description 1
- 241001448919 Chryseobacterium taklimakanense Species 0.000 description 1
- 241001006014 Chryseobacterium tructae Species 0.000 description 1
- 241000142268 Chryseobacterium ureilyticum Species 0.000 description 1
- 241000025049 Chryseobacterium vietnamense Species 0.000 description 1
- 241000770194 Chryseobacterium zeae Species 0.000 description 1
- 241000147251 Chryseomicrobium aureum Species 0.000 description 1
- 241000580513 Citrobacter braakii Species 0.000 description 1
- 241000627108 Citrobacter pasteurii Species 0.000 description 1
- 241000873310 Citrobacter sp. Species 0.000 description 1
- 241000390531 Cloacibacillus Species 0.000 description 1
- 241000390547 Cloacibacillus evryensis Species 0.000 description 1
- 241000501350 Cloacibacterium haliotis Species 0.000 description 1
- 108010090591 Cloacin Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000904825 Clostridiales bacterium Species 0.000 description 1
- 241000064585 Clostridioides Species 0.000 description 1
- 241001318998 Clostridium boliviensis Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000779795 Clostridium cavendishii Species 0.000 description 1
- 241000788977 Clostridium colicanis Species 0.000 description 1
- 241000982978 Clostridium polyendosporum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000192020 Clostridium ventriculi Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 241001464956 Collinsella Species 0.000 description 1
- 241001330547 Collinsella intestinalis Species 0.000 description 1
- 241001330548 Collinsella stercoris Species 0.000 description 1
- 241000801626 Collinsella tanakaei Species 0.000 description 1
- 241000235863 Comamonas denitrificans Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241001443882 Coprobacillus Species 0.000 description 1
- 241001443880 Coprobacillus cateniformis Species 0.000 description 1
- 241000503641 Coprobacter Species 0.000 description 1
- 241001592881 Coprobacter fastidiosus Species 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- 241000220677 Coprococcus catus Species 0.000 description 1
- 241000949098 Coprococcus comes Species 0.000 description 1
- 241001464949 Coprococcus eutactus Species 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241001288679 Corynebacterium afermentans subsp. lipophilum Species 0.000 description 1
- 241000353681 Corynebacterium appendicis Species 0.000 description 1
- 241000427397 Corynebacterium aurimucosum Species 0.000 description 1
- 241000880909 Corynebacterium durum Species 0.000 description 1
- 241000521406 Corynebacterium freiburgense Species 0.000 description 1
- 241001117273 Corynebacterium glaucum Species 0.000 description 1
- 241001533284 Corynebacterium glucuronolyticum Species 0.000 description 1
- 241000399083 Corynebacterium glyciniphilum Species 0.000 description 1
- 241000024402 Corynebacterium imitans Species 0.000 description 1
- 241000393344 Corynebacterium massiliense Species 0.000 description 1
- 241000334674 Corynebacterium mastitidis Species 0.000 description 1
- 241000158496 Corynebacterium matruchotii Species 0.000 description 1
- 241001186315 Corynebacterium mustelae Species 0.000 description 1
- 241001518268 Corynebacterium mycetoides Species 0.000 description 1
- 241000959710 Corynebacterium nuruki Species 0.000 description 1
- 241001522132 Corynebacterium pseudodiphtheriticum Species 0.000 description 1
- 241001518270 Corynebacterium pseudogenitalium Species 0.000 description 1
- 241001313296 Corynebacterium simulans Species 0.000 description 1
- 241000297296 Corynebacterium sputi Species 0.000 description 1
- 241000158523 Corynebacterium striatum Species 0.000 description 1
- 241001182439 Corynebacterium suicordis Species 0.000 description 1
- 241000334945 Corynebacterium sundsvallense Species 0.000 description 1
- 241000586985 Corynebacterium ureicelerivorans Species 0.000 description 1
- 241000186244 Corynebacterium variabile Species 0.000 description 1
- 241000567111 Couchioplanes caeruleus subsp. caeruleus Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000134744 Cryobacterium psychrophilum Species 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- 241001140814 Cupriavidus nantongensis Species 0.000 description 1
- 241001528539 Cupriavidus necator Species 0.000 description 1
- 241000278502 Cupriavidus pampae Species 0.000 description 1
- 241000861157 Cupriavidus yeoncheonensis Species 0.000 description 1
- 241001617017 Curtobacterium herbarum Species 0.000 description 1
- 241000625996 Cutibacterium acnes subsp. elongatum Species 0.000 description 1
- 241001464975 Cutibacterium granulosum Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 241000604760 Cytophaga xylanolytica Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 241001245600 Dechloromonas agitata Species 0.000 description 1
- 241000565686 Dehalobacter Species 0.000 description 1
- 241000105169 Deinococcus actinosclerus Species 0.000 description 1
- 241000987160 Deinococcus antarcticus Species 0.000 description 1
- 241000940696 Deinococcus caeni Species 0.000 description 1
- 241001316802 Deinococcus ficus Species 0.000 description 1
- 241000959949 Deinococcus geothermalis Species 0.000 description 1
- 241000192091 Deinococcus radiodurans Species 0.000 description 1
- 241001453175 Deinococcus radiophilus Species 0.000 description 1
- 241000405753 Deinococcus wulumuqiensis Species 0.000 description 1
- 241000828346 Deinococcus xinjiangensis Species 0.000 description 1
- 241001051769 Delftia tsuruhatensis Species 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 241001508502 Dermabacter Species 0.000 description 1
- 241000844900 Dermabacter vaginalis Species 0.000 description 1
- 241000191949 Dermacoccus nishinomiyaensis Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241001635321 Desemzia incerta Species 0.000 description 1
- 241000163651 Desertibacter roseus Species 0.000 description 1
- 241001509319 Desulfitobacterium Species 0.000 description 1
- 241000228124 Desulfitobacterium hafniense Species 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 241000605739 Desulfovibrio desulfuricans Species 0.000 description 1
- 241000168528 Desulfovibrio fairfieldensis Species 0.000 description 1
- 241000604463 Desulfovibrio piger Species 0.000 description 1
- 241000894473 Devosia epidermidihirudinis Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001535083 Dialister Species 0.000 description 1
- 241001535058 Dialister pneumosintes Species 0.000 description 1
- 241000260433 Dialister succinatiphilus Species 0.000 description 1
- 241000551220 Diaphorobacter oryzae Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000588700 Dickeya chrysanthemi Species 0.000 description 1
- 101100447194 Dictyostelium discoideum fslA gene Proteins 0.000 description 1
- 101100452790 Dictyostelium discoideum ireA gene Proteins 0.000 description 1
- 101100465553 Dictyostelium discoideum psmB6 gene Proteins 0.000 description 1
- 241001263137 Dielma Species 0.000 description 1
- 241000995910 Dielma fastidiosa Species 0.000 description 1
- 241000446110 Dietzia aurantiaca Species 0.000 description 1
- 241000647360 Dietzia cercidiphylli Species 0.000 description 1
- 241000993423 Dietzia psychralcaliphila Species 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 241001147753 Dolosigranulum pigrum Species 0.000 description 1
- 241001143779 Dorea Species 0.000 description 1
- 241001531200 Dorea formicigenerans Species 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- 101100116914 Drosophila melanogaster shv gene Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000024397 Dysgonomonas Species 0.000 description 1
- 241000190581 Dysgonomonas capnocytophagoides Species 0.000 description 1
- 241000024398 Dysgonomonas gadei Species 0.000 description 1
- 241000365095 Dysgonomonas mossii Species 0.000 description 1
- 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- 241001657509 Eggerthella Species 0.000 description 1
- 241001430190 Eggerthia catenaformis Species 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000605312 Ehrlichia canis Species 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241001438871 Eisenbergiella Species 0.000 description 1
- 241001438869 Eisenbergiella tayi Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000706975 Elizabethkingia miricola Species 0.000 description 1
- 241000482503 Elstera litoralis Species 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 241000589586 Empedobacter brevis Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241001262771 Enorma Species 0.000 description 1
- 241001262770 Enorma massiliensis Species 0.000 description 1
- 241001528536 Ensifer adhaerens Species 0.000 description 1
- 241000982938 Enterobacter cancerogenus Species 0.000 description 1
- 241000962426 Enterobacter xiangfangensis Species 0.000 description 1
- 101000830026 Enterobacteria phage T4 Baseplate hub assembly protein gp28 Proteins 0.000 description 1
- 101000925646 Enterobacteria phage T4 Endolysin Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000032329 Enterococcus aquimarinus Species 0.000 description 1
- 241001468179 Enterococcus avium Species 0.000 description 1
- 108700031577 Enterococcus bacA Proteins 0.000 description 1
- 241000194030 Enterococcus gallinarum Species 0.000 description 1
- 241000194029 Enterococcus hirae Species 0.000 description 1
- 241001235140 Enterococcus malodoratus Species 0.000 description 1
- 241000750231 Enterococcus olivae Species 0.000 description 1
- 241000178338 Enterococcus pseudoavium Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000223163 Enterococcus viikkiensis Species 0.000 description 1
- 241000962428 Enterococcus xiangfangensis Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241001130498 Enterovibrio Species 0.000 description 1
- 241000345266 Enterovibrio nigricans Species 0.000 description 1
- GDSYPXWUHMRTHT-UHFFFAOYSA-N Epidermin Natural products N#CCC(C)(C)OC1OC(CO)C(O)C(O)C1O GDSYPXWUHMRTHT-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000556430 Erwinia persicina Species 0.000 description 1
- 241000318001 Erwinia toletana Species 0.000 description 1
- 241000089032 Erysipelatoclostridium Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 101100218161 Escherichia coli (strain K12) atpG gene Proteins 0.000 description 1
- 101100053236 Escherichia coli (strain K12) ymcE gene Proteins 0.000 description 1
- 101001018328 Escherichia coli Bacteriocin microcin B17 Proteins 0.000 description 1
- 101100434464 Escherichia coli afaD gene Proteins 0.000 description 1
- 101100186924 Escherichia coli neuC gene Proteins 0.000 description 1
- 101100242761 Escherichia coli papGI gene Proteins 0.000 description 1
- 101100242764 Escherichia coli papGIII gene Proteins 0.000 description 1
- 241000588720 Escherichia fergusonii Species 0.000 description 1
- 101000653449 Escherichia phage Mu Probable terminase, large subunit gp28 Proteins 0.000 description 1
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 description 1
- 241000488157 Escherichia sp. Species 0.000 description 1
- 241000702192 Escherichia virus P2 Species 0.000 description 1
- 241001350695 Ethanoligenens Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000186398 Eubacterium limosum Species 0.000 description 1
- 241001531190 Eubacterium ramulus Species 0.000 description 1
- 241001531192 Eubacterium ventriosum Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001468125 Exiguobacterium Species 0.000 description 1
- 241000131747 Exiguobacterium acetylicum Species 0.000 description 1
- 241000433468 Exiguobacterium marinum Species 0.000 description 1
- 241000670472 Exiguobacterium mexicanum Species 0.000 description 1
- 241000430983 Exiguobacterium undae Species 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 241000978172 Facklamia ignava Species 0.000 description 1
- 241000005566 Facklamia tabacinasalis Species 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241000986153 Faecalitalea Species 0.000 description 1
- 241001531275 Faecalitalea cylindroides Species 0.000 description 1
- 241001081557 Falsirhodobacter halotolerans Species 0.000 description 1
- 241000178316 Ferrimonas Species 0.000 description 1
- 241000178317 Ferrimonas balearica Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001282092 Filifactor alocis Species 0.000 description 1
- 241001617393 Finegoldia Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000660874 Flavobacterium araucananum Species 0.000 description 1
- 241001496083 Flavobacterium cutihirudinis Species 0.000 description 1
- 241001040742 Flavobacterium daejeonense Species 0.000 description 1
- 241000053194 Flavobacterium frigidimaris Species 0.000 description 1
- 241001405264 Flavobacterium lindanitolerans Species 0.000 description 1
- 241000425486 Flavobacterium resistens Species 0.000 description 1
- 241000662772 Flavonifractor Species 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- KBHMEHLJSZMEMI-UHFFFAOYSA-N Formycin A Natural products N1N=C2C(N)=NC=NC2=C1C1OC(CO)C(O)C1O KBHMEHLJSZMEMI-UHFFFAOYSA-N 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000404565 Friedmanniella capsulata Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000412001 Fusicatenibacter Species 0.000 description 1
- 241001365051 Fusicatenibacter saccharivorans Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000605956 Fusobacterium mortiferum Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241001291922 Fusobacterium nucleatum subsp. polymorphum Species 0.000 description 1
- 241000959640 Fusobacterium sp. Species 0.000 description 1
- 241000605991 Fusobacterium ulcerans Species 0.000 description 1
- 241000605975 Fusobacterium varium Species 0.000 description 1
- 101710090046 Galactose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102100036291 Galactose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- 241000012732 Gallibacterium Species 0.000 description 1
- 241000606562 Gallibacterium anatis Species 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 241000316301 Gemella asaccharolytica Species 0.000 description 1
- 241001657443 Gemella bergeri Species 0.000 description 1
- 241001147749 Gemella morbillorum Species 0.000 description 1
- 241001609640 Gemella palaticanis Species 0.000 description 1
- 241001185600 Gemmiger Species 0.000 description 1
- 241001223495 Gemmiger formicilis Species 0.000 description 1
- 241000538032 Gemmobacter aquaticus Species 0.000 description 1
- 241001666152 Gemmobacter caeni Species 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 241001468249 Geobacillus thermocatenulatus Species 0.000 description 1
- 241000010919 Geobacter grbiciae Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 241001518243 Gluconobacter frateurii Species 0.000 description 1
- 241001403124 Gluconobacter thailandicus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241001656677 Gordonia alkanivorans Species 0.000 description 1
- 241000481836 Gordonia jinhuaensis Species 0.000 description 1
- 241000277327 Gordonia kroppenstedtii Species 0.000 description 1
- 241001520576 Gordonibacter Species 0.000 description 1
- 241001486261 Gordonibacter pamelaeae Species 0.000 description 1
- 241000695160 Gracilibacter Species 0.000 description 1
- 241000201858 Granulicatella adiacens Species 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000329524 Guggenheimella Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606788 Haemophilus haemolyticus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606822 Haemophilus parahaemolyticus Species 0.000 description 1
- 101000818121 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 18.2 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 241000819598 Haemophilus sputorum Species 0.000 description 1
- 241000588731 Hafnia Species 0.000 description 1
- 101100500479 Hafnia alvei eaeA gene Proteins 0.000 description 1
- 241001299659 Halomonas aquamarina Species 0.000 description 1
- 241000202379 Halomonas axialensis Species 0.000 description 1
- 241000832341 Halomonas olivaria Species 0.000 description 1
- 241000011155 Halomonas phoceae Species 0.000 description 1
- 241000507035 Halomonas songnenensis Species 0.000 description 1
- 241000202383 Halomonas sulfidaeris Species 0.000 description 1
- 241000169168 Halomonas venusta Species 0.000 description 1
- 241001430375 Halovibrio variabilis Species 0.000 description 1
- 101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
- 241001503513 Helicobacter bilis Species 0.000 description 1
- 241000543133 Helicobacter canadensis Species 0.000 description 1
- 241001148144 Helicobacter canis Species 0.000 description 1
- 241000590014 Helicobacter cinaedi Species 0.000 description 1
- 241000944308 Helicobacter macacae Species 0.000 description 1
- 241000368554 Helicobacter pametensis Species 0.000 description 1
- 241001495141 Helicobacter pullorum Species 0.000 description 1
- 241000610768 Helicobacter rodentium Species 0.000 description 1
- 241000027130 Helicobacter winghamensis Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000605016 Herbaspirillum Species 0.000 description 1
- 241001538178 Herbaspirillum chlorophenolicum Species 0.000 description 1
- 241000318924 Herbaspirillum frisingense Species 0.000 description 1
- 241000685544 Herbaspirillum hiltneri Species 0.000 description 1
- 241000586217 Herbaspirillum huttiense subsp. putei Species 0.000 description 1
- 241001572155 Herbaspirillum lusitanum Species 0.000 description 1
- 241000605014 Herbaspirillum seropedicae Species 0.000 description 1
- 241000908273 Herminiimonas fonticola Species 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000863028 Herpetosiphon aurantiacus Species 0.000 description 1
- 241000972946 Hespellia Species 0.000 description 1
- 241000986152 Holdemanella Species 0.000 description 1
- 241000862469 Holdemania Species 0.000 description 1
- 241000862470 Holdemania filiformis Species 0.000 description 1
- 241000956013 Holdemania massiliensis Species 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 101000664600 Homo sapiens Tripartite motif-containing protein 3 Proteins 0.000 description 1
- 101000667110 Homo sapiens Vacuolar protein sorting-associated protein 13B Proteins 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 241001304190 Hungatella Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 241001001088 Hydrocarboniphaga effusa Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000922465 Hydrogenophaga intermedia Species 0.000 description 1
- 241000216646 Hydrogenophaga pseudoflava Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 241000089024 Intestinibacter Species 0.000 description 1
- 241000616258 Intestinimonas Species 0.000 description 1
- 241000946243 Intestinimonas butyriciproducens Species 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- PJLVTVAIERNDEQ-BTJKTKAUSA-N Irsogladine maleate Chemical compound OC(=O)\C=C/C(O)=O.NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 PJLVTVAIERNDEQ-BTJKTKAUSA-N 0.000 description 1
- MIFYHUACUWQUKT-UHFFFAOYSA-N Isopenicillin N Natural products OC(=O)C1C(C)(C)SC2C(NC(=O)CCCC(N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-UHFFFAOYSA-N 0.000 description 1
- 241001332926 Janibacter anophelis Species 0.000 description 1
- 241001447546 Janibacter hoylei Species 0.000 description 1
- 241001328186 Janibacter indicus Species 0.000 description 1
- 241000520766 Janibacter limosus Species 0.000 description 1
- 241000052871 Janibacter melonis Species 0.000 description 1
- 241001148466 Janthinobacterium lividum Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001632260 Jeotgalicoccus halophilus Species 0.000 description 1
- 241000957262 Kaistia geumhonensis Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241000589015 Kingella denitrificans Species 0.000 description 1
- 241000589012 Kingella oralis Species 0.000 description 1
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- 101000790842 Klebsiella pneumoniae Uncharacterized 65.4 kDa protein in cps region Proteins 0.000 description 1
- 101100123074 Klebsiella pneumoniae pulC gene Proteins 0.000 description 1
- 241000409087 Knoellia aerolata Species 0.000 description 1
- 241000704959 Knoellia locipacati Species 0.000 description 1
- 241000281703 Kocuria atrinae Species 0.000 description 1
- 241000052872 Kocuria carniphila Species 0.000 description 1
- 241001524190 Kocuria kristinae Species 0.000 description 1
- 241001237849 Kocuria palustris Species 0.000 description 1
- 241000559104 Kocuria turfanensis Species 0.000 description 1
- 241001477369 Kosakonia sacchari Species 0.000 description 1
- 241000186809 Kurthia Species 0.000 description 1
- 241000957589 Kurthia massiliensis Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- 241001233595 Lachnobacterium Species 0.000 description 1
- 241001134638 Lachnospira Species 0.000 description 1
- 241001134642 Lachnospira pectinoschiza Species 0.000 description 1
- 241001647783 Lactobacillus amylolyticus Species 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 241000316282 Lactobacillus antri Species 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001061980 Lactobacillus coleohominis Species 0.000 description 1
- 241001640457 Lactobacillus intestinalis Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241000316281 Lactobacillus kalixensis Species 0.000 description 1
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 description 1
- 241001108870 Lactobacillus kimchicus Species 0.000 description 1
- 241000674808 Lactobacillus kitasatonis Species 0.000 description 1
- 241000590413 Lactobacillus modestisalitolerans Species 0.000 description 1
- 241000394636 Lactobacillus mucosae Species 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 241000216456 Lactobacillus panis Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 244000150562 Lactobacillus plantarum subsp argentoratensis Species 0.000 description 1
- 235000002054 Lactobacillus plantarum subsp argentoratensis Nutrition 0.000 description 1
- 241001495404 Lactobacillus pontis Species 0.000 description 1
- 241000186870 Lactobacillus ruminis Species 0.000 description 1
- 108700009548 Lactobacillus sakacin P Proteins 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000617441 Lactobacillus xiangfangensis Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000194039 Lactococcus piscium Species 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000591943 Lapillicoccus jejuensis Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000217863 Lautropia mirabilis Species 0.000 description 1
- 241001398471 Lechevalieria roselyniae Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000307152 Legionella beliardensis Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000921781 Lentzea albida Species 0.000 description 1
- 241000111815 Lentzea californiensis Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001135196 Leptospira noguchii Species 0.000 description 1
- 241001135198 Leptospira santarosai Species 0.000 description 1
- 241001135200 Leptospira weilii Species 0.000 description 1
- 241000029613 Leptotrichia goodfellowii Species 0.000 description 1
- 241000029588 Leptotrichia hofstadii Species 0.000 description 1
- 241000495747 Leptotrichia hongkongensis Species 0.000 description 1
- 241000029603 Leptotrichia shahii Species 0.000 description 1
- 241001558986 Leptotrichia trevisanii Species 0.000 description 1
- 241000029590 Leptotrichia wadei Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001376276 Leuconostoc garlicum Species 0.000 description 1
- 241000201465 Leuconostoc gelidum subsp. gasicomitatum Species 0.000 description 1
- 241000406209 Leuconostoc mesenteroides subsp. suionicum Species 0.000 description 1
- 241001468196 Leuconostoc pseudomesenteroides Species 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 101710170970 Leukotoxin Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000186806 Listeria grayi Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102100040323 Low molecular weight phosphotyrosine protein phosphatase Human genes 0.000 description 1
- 101710186835 Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000774295 Luteimonas aestuarii Species 0.000 description 1
- 241001523608 Luteimonas terricola Species 0.000 description 1
- 241001134775 Lysinibacillus fusiformis Species 0.000 description 1
- 241000054611 Lysinimonas kribbensis Species 0.000 description 1
- 241001660189 Lysobacter antibioticus Species 0.000 description 1
- 241000096994 Lysobacter koreensis Species 0.000 description 1
- 241000645501 Lysobacter oryzae Species 0.000 description 1
- 241000073336 Lysobacter spongiicola Species 0.000 description 1
- 241000161438 Lysobacter xinjiangensis Species 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 241000973043 Macrococcus caseolyticus Species 0.000 description 1
- 241000732352 Mageeibacillus indolicus Species 0.000 description 1
- 241001485605 Magnetospirillum moscoviense Species 0.000 description 1
- 102100038560 Maleylacetoacetate isomerase Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- 241001672246 Mannheimia granulomatis Species 0.000 description 1
- 241000329447 Maribacter orientalis Species 0.000 description 1
- 241000551564 Marinomonas alcarazii Species 0.000 description 1
- 241000777733 Marinomonas primoryensis Species 0.000 description 1
- 241000320425 Marinomonas protea Species 0.000 description 1
- 241001611002 Marinospirillum insulare Species 0.000 description 1
- 241000539923 Marmoricola pocheonensis Species 0.000 description 1
- 241001485736 Marmoricola scoriae Species 0.000 description 1
- 241000825080 Massilia alkalitolerans Species 0.000 description 1
- 241000130161 Massilia aurea Species 0.000 description 1
- 241001571406 Massilia jejuensis Species 0.000 description 1
- 241000630906 Massilia kyonggiensis Species 0.000 description 1
- 241001616286 Massilia plicata Species 0.000 description 1
- 241000043362 Megamonas Species 0.000 description 1
- 241000096799 Megamonas funiformis Species 0.000 description 1
- 241000043361 Megamonas hypermegale Species 0.000 description 1
- 241000550893 Megamonas rupellensis Species 0.000 description 1
- 241000604449 Megasphaera Species 0.000 description 1
- 241000604448 Megasphaera elsdenii Species 0.000 description 1
- 241001116693 Megasphaera micronuciformis Species 0.000 description 1
- 241000508289 Meiothermus silvanus Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001420150 Mesorhizobium acaciae Species 0.000 description 1
- 241001235187 Mesorhizobium amorphae Species 0.000 description 1
- 241000108789 Mesorhizobium qingshengii Species 0.000 description 1
- 241001001996 Mesorhizobium shonense Species 0.000 description 1
- 241001657039 Metakosakonia massiliensis Species 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000202987 Methanobrevibacter Species 0.000 description 1
- 241000202985 Methanobrevibacter smithii Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000821682 Methylobacterium dankookense Species 0.000 description 1
- 241001000998 Methylobacterium goesingense Species 0.000 description 1
- 241000515912 Methylobacterium haplocladii Species 0.000 description 1
- 241001287913 Methylobacterium isbiliense Species 0.000 description 1
- 241000481564 Methylobacterium jeotgali Species 0.000 description 1
- 241000647037 Methylobacterium oxalidis Species 0.000 description 1
- 241001391199 Methylobacterium platani Species 0.000 description 1
- 241001587143 Methylobacterium pseudosasicola Species 0.000 description 1
- 241001430258 Methylobacterium radiotolerans Species 0.000 description 1
- 241001148213 Methylobacterium zatmanii Species 0.000 description 1
- 241000028786 Methylotenera versatilis Species 0.000 description 1
- 241000198658 Methyloversatilis universalis Species 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- LWYXFDXUMVEZKS-ZVFOLQIPSA-N Methysergide maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 LWYXFDXUMVEZKS-ZVFOLQIPSA-N 0.000 description 1
- FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 241001492499 Microbacterium foliorum Species 0.000 description 1
- 241000758252 Microbacterium halophilum Species 0.000 description 1
- 241001508001 Microbacterium laevaniformans Species 0.000 description 1
- 241001633954 Microbacterium oxydans Species 0.000 description 1
- 241000856710 Microbacterium paludicola Species 0.000 description 1
- 241001612332 Microbacterium petrolearium Species 0.000 description 1
- 241000558600 Microbacterium phyllosphaerae Species 0.000 description 1
- 241000024401 Microbacterium resistens Species 0.000 description 1
- 241001670074 Micrococcus antarcticus Species 0.000 description 1
- 241000796259 Micrococcus cohnii Species 0.000 description 1
- 241000515012 Micrococcus flavus Species 0.000 description 1
- 241000191951 Micrococcus lylae Species 0.000 description 1
- 241001216465 Micrococcus terreus Species 0.000 description 1
- 241000461040 Microlunatus aurantiacus Species 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 241000953488 Micromonospora chaiyaphumensis Species 0.000 description 1
- 241000187724 Micromonospora chalcea Species 0.000 description 1
- 241000218948 Micromonospora citrea Species 0.000 description 1
- 241001101918 Micromonospora coxensis Species 0.000 description 1
- 241000218951 Micromonospora echinofusca Species 0.000 description 1
- 241000218932 Micromonospora halophytica Species 0.000 description 1
- 241000783771 Micromonospora kangleipakensis Species 0.000 description 1
- 241001306665 Micromonospora nigra Species 0.000 description 1
- 241000218939 Micromonospora purpureochromogenes Species 0.000 description 1
- 241000916488 Micromonospora rhizosphaerae Species 0.000 description 1
- 241000811661 Micromonospora saelicesensis Species 0.000 description 1
- 241001275805 Micropruina glycogenica Species 0.000 description 1
- 241000973922 Microterricola viridarii Species 0.000 description 1
- 241001112069 Microvirga subterranea Species 0.000 description 1
- 241000053504 Microvirga vignae Species 0.000 description 1
- 241000362874 Microvirga zambiensis Species 0.000 description 1
- 241000579763 Microvirgula Species 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 241000509624 Mitsuokella Species 0.000 description 1
- 241001123604 Mitsuokella jalaludinii Species 0.000 description 1
- 241000509622 Mitsuokella multacida Species 0.000 description 1
- 241000203734 Mobiluncus curtisii Species 0.000 description 1
- 241000203732 Mobiluncus mulieris Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241001522189 Mollicutes bacterium Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 241000178985 Moorella Species 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 241001478301 Moraxella atlantae Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241001478294 Moraxella osloensis Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241001052646 Morganella morganii subsp. morganii Species 0.000 description 1
- 241001491473 Morganella psychrotolerans Species 0.000 description 1
- 241000098695 Moryella Species 0.000 description 1
- 241000115065 Moryella indoligenes Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000420724 Murimonas Species 0.000 description 1
- 241000151756 Murimonas intestini Species 0.000 description 1
- 101100434972 Mus musculus Ankrd17 gene Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000957223 Mycobacterium alvei Species 0.000 description 1
- 241000187474 Mycobacterium asiaticum Species 0.000 description 1
- 241000178954 Mycobacterium avium subsp. silvaticum Species 0.000 description 1
- 241000187913 Mycobacterium chubuense Species 0.000 description 1
- 241000419175 Mycobacterium colombiense Species 0.000 description 1
- 241000559497 Mycobacterium crocinum Species 0.000 description 1
- 241000187911 Mycobacterium farcinogenes Species 0.000 description 1
- 241001295730 Mycobacterium fortuitum subsp. fortuitum Species 0.000 description 1
- 241000187470 Mycobacterium gadium Species 0.000 description 1
- 241000936963 Mycobacterium goodii Species 0.000 description 1
- 241001644172 Mycobacterium holsaticum Species 0.000 description 1
- 241000437390 Mycobacterium insubricum Species 0.000 description 1
- 241001166087 Mycobacterium iranicum Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000755466 Mycobacterium llatzerense Species 0.000 description 1
- 241001280523 Mycobacterium longobardum Species 0.000 description 1
- 241000187469 Mycobacterium neoaurum Species 0.000 description 1
- 241001316374 Mycobacterium neworleansense Species 0.000 description 1
- 241000187918 Mycobacterium obuense Species 0.000 description 1
- 241000168058 Mycobacterium peregrinum Species 0.000 description 1
- 241001027257 Mycobacterium saopaulense Species 0.000 description 1
- 241000409180 Mycobacterium septicum Species 0.000 description 1
- 241000024083 Mycobacterium setense Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 241001313484 Mycoplasma alvi Species 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000202962 Mycoplasma muris Species 0.000 description 1
- 241000202936 Mycoplasma mycoides Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 241000202889 Mycoplasma salivarium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 1
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 1
- GWBPFRGXNGPPMF-UHFFFAOYSA-N N-[4-[(4-nitrophenyl)sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1 GWBPFRGXNGPPMF-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- KEECCEWTUVWFCV-UHFFFAOYSA-N N-acetylprocainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1 KEECCEWTUVWFCV-UHFFFAOYSA-N 0.000 description 1
- AAKDPDFZMNYDLR-UHFFFAOYSA-N N-methyl deoxynojirimycin Natural products CN1CC(O)C(O)C(O)C1CO AAKDPDFZMNYDLR-UHFFFAOYSA-N 0.000 description 1
- AAKDPDFZMNYDLR-XZBKPIIZSA-N N-methyl-1-deoxynojirimycin Chemical compound CN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO AAKDPDFZMNYDLR-XZBKPIIZSA-N 0.000 description 1
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241000109432 Neisseria bacilliformis Species 0.000 description 1
- 241001478320 Neisseria flava Species 0.000 description 1
- 241000588674 Neisseria macacae Species 0.000 description 1
- 241000588659 Neisseria mucosa Species 0.000 description 1
- 241001294835 Neisseria oralis Species 0.000 description 1
- 241000588645 Neisseria sicca Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- QSDSSSQWVNLFIG-UHFFFAOYSA-N Neosporin Natural products CC(O)CC1=C(OC)C(=O)C2=CC(O)=C3OCOC4=C(O)C=C5C6=C4C3=C2C1=C6C(CC(C)O)=C(OC)C5=O QSDSSSQWVNLFIG-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241001628296 Nesterenkonia lacusekhoensis Species 0.000 description 1
- 241000502729 Nesterenkonia rhizosphaerae Species 0.000 description 1
- 206010029229 Neuralgic amyotrophy Diseases 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 101100204282 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Asm-1 gene Proteins 0.000 description 1
- 241000477554 Nevskia persephonica Species 0.000 description 1
- 241001036973 Nevskia soli Species 0.000 description 1
- 241001267412 Niabella yanshanensis Species 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 229930184499 Nikkomycin Natural products 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 241000339046 Nitriliruptor Species 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 241001207691 Niveibacterium umoris Species 0.000 description 1
- 241001221853 Nocardia lijiangensis Species 0.000 description 1
- 241000793348 Nocardia niwae Species 0.000 description 1
- 241001405616 Nocardia thailandica Species 0.000 description 1
- 241000054677 Nocardioides agariphilus Species 0.000 description 1
- 241000054649 Nocardioides dilutus Species 0.000 description 1
- 241001347700 Nocardioides ganghwensis Species 0.000 description 1
- 241000918143 Nocardioides hwasunensis Species 0.000 description 1
- 241001276405 Nocardioides nanhaiensis Species 0.000 description 1
- 241000054626 Nocardioides sediminis Species 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 241000297280 Nosocomiicoccus ampullae Species 0.000 description 1
- 101000801048 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Monocarboxylate 2-oxoacid-binding periplasmic protein all3028 Proteins 0.000 description 1
- 241001446789 Noviherbaspirillum malthae Species 0.000 description 1
- 241000936329 Noviherbaspirillum massiliense Species 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 241001049695 Novosphingobium barchaimii Species 0.000 description 1
- 241001405239 Novosphingobium mathurense Species 0.000 description 1
- 241001292297 Novosphingobium rosa Species 0.000 description 1
- CQSRTOJJBONKMC-VHEBQXMUSA-N OC(=O)CNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)CNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O CQSRTOJJBONKMC-VHEBQXMUSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007684 Occupational Stress Diseases 0.000 description 1
- 241001072230 Oceanobacillus Species 0.000 description 1
- 241000937421 Oceanobacillus massiliensis Species 0.000 description 1
- 241001051694 Ochrobactrum pseudogrignonense Species 0.000 description 1
- 241001188758 Ochrobactrum rhizosphaerae Species 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000785902 Odoribacter Species 0.000 description 1
- 241000801628 Odoribacter laneus Species 0.000 description 1
- 241000192134 Oenococcus oeni Species 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 241000293016 Oligella urethralis Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 101000781204 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 36.6 kDa protein Proteins 0.000 description 1
- 241000089925 Oribacterium Species 0.000 description 1
- 241000572528 Ornithinimicrobium Species 0.000 description 1
- 241001230978 Ornithinimicrobium tianjinense Species 0.000 description 1
- 241001135630 Ornithobacterium Species 0.000 description 1
- 241001135620 Ornithobacterium rhinotracheale Species 0.000 description 1
- 241000484779 Oryzobacter terrae Species 0.000 description 1
- 241000976434 Ottowia beijingensis Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000982691 Oxalicibacterium solurbis Species 0.000 description 1
- 241000605937 Oxalobacter Species 0.000 description 1
- 241000605936 Oxalobacter formigenes Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000178986 Oxobacter Species 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000930790 Paenalcaligenes suwonensis Species 0.000 description 1
- 241000157908 Paenarthrobacter aurescens Species 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241000694866 Paenibacillus agaridevorans Species 0.000 description 1
- 241000193411 Paenibacillus amylolyticus Species 0.000 description 1
- 241000708785 Paenibacillus barengoltzii Species 0.000 description 1
- 241001337872 Paenibacillus chitinolyticus Species 0.000 description 1
- 241000974611 Paenibacillus humicus Species 0.000 description 1
- 241000194109 Paenibacillus lautus Species 0.000 description 1
- 241001175671 Paenibacillus motobuensis Species 0.000 description 1
- 241000193397 Paenibacillus pabuli Species 0.000 description 1
- 241001610657 Paenibacillus pasadenensis Species 0.000 description 1
- 241000495407 Paenibacillus phoenicis Species 0.000 description 1
- 241000636058 Paenibacillus pini Species 0.000 description 1
- 241000937418 Paenibacillus senegalensis Species 0.000 description 1
- 241000178958 Paenibacillus validus Species 0.000 description 1
- 241001097592 Paenibacillus xylanexedens Species 0.000 description 1
- 241000193465 Paeniclostridium sordellii Species 0.000 description 1
- 241001459592 Paenisporosarcina quisquiliarum Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000573660 Paludibacterium yongneupense Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241000556405 Pantoea cypripedii Species 0.000 description 1
- 241001446614 Papillibacter Species 0.000 description 1
- 241000160321 Parabacteroides Species 0.000 description 1
- 241000030714 Parabacteroides goldsteinii Species 0.000 description 1
- 241001216709 Parabacteroides gordonii Species 0.000 description 1
- 241000543747 Parabacteroides johnsonii Species 0.000 description 1
- 241001384049 Paraburkholderia aspalathi Species 0.000 description 1
- 241001135514 Paraburkholderia caryophylli Species 0.000 description 1
- 241000930992 Paraburkholderia fungorum Species 0.000 description 1
- 241000147274 Paraburkholderia insulsa Species 0.000 description 1
- 241000866634 Paraburkholderia phenazinium Species 0.000 description 1
- 241000037463 Paraburkholderia phytofirmans Species 0.000 description 1
- 241000261185 Paraburkholderia rhynchosiae Species 0.000 description 1
- 241000428237 Paraburkholderia terricola Species 0.000 description 1
- 241001509383 Paraburkholderia xenovorans Species 0.000 description 1
- 241001478308 Paracoccus alcaliphilus Species 0.000 description 1
- 241000678566 Paracoccus angustae Species 0.000 description 1
- 241001478302 Paracoccus kocurii Species 0.000 description 1
- 241001214926 Paracoccus laeviglucosivorans Species 0.000 description 1
- 241001309443 Paracoccus sediminis Species 0.000 description 1
- 241001638605 Paracoccus sphaerophysae Species 0.000 description 1
- 241000193390 Parageobacillus thermoglucosidasius Species 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 241001267970 Paraprevotella Species 0.000 description 1
- 241000789906 Paraprevotella xylaniphila Species 0.000 description 1
- 241000425482 Pararheinheimera soli Species 0.000 description 1
- 241000571310 Pararheinheimera tangshanensis Species 0.000 description 1
- 241000384679 Pararheinheimera tilapiae Species 0.000 description 1
- 241000046935 Parastreptomyces abscessus Species 0.000 description 1
- 241001267951 Parasutterella Species 0.000 description 1
- 241000260425 Parasutterella excrementihominis Species 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 241001190874 Parviterribacter multiflagellatus Species 0.000 description 1
- 241000517603 Patulibacter ginsengiterrae Species 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 241000556402 Pectobacterium betavasculorum Species 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 101100082836 Pediococcus acidilactici pedC gene Proteins 0.000 description 1
- 241001331797 Pediococcus ethanolidurans Species 0.000 description 1
- 241001550219 Pedobacter alluvionis Species 0.000 description 1
- 241001042951 Pedobacter aquatilis Species 0.000 description 1
- 241001429261 Pedobacter ginsengisoli Species 0.000 description 1
- 241000833549 Pedobacter wanjuense Species 0.000 description 1
- 241001273631 Pedobacter xixiisoli Species 0.000 description 1
- 241000026497 Pelomonas aquatica Species 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- XVASOOUVMJAZNJ-MBNYWOFBSA-N Penicillin K Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CCCCCCC)[C@H]21 XVASOOUVMJAZNJ-MBNYWOFBSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 208000022034 Penile disease Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241001607889 Peptoclostridium Species 0.000 description 1
- 241000351207 Peptoniphilus Species 0.000 description 1
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 1
- 241001607074 Peptoniphilus coxii Species 0.000 description 1
- 241001464878 Peptoniphilus indolicus Species 0.000 description 1
- 241000374258 Peptoniphilus koenoeneniae Species 0.000 description 1
- 241001262774 Peptoniphilus obesi Species 0.000 description 1
- 241000937477 Peptoniphilus senegalensis Species 0.000 description 1
- 241001515696 Peptoniphilus timonensis Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108010093184 Pesticin Proteins 0.000 description 1
- 241001464921 Phascolarctobacterium Species 0.000 description 1
- 241001464924 Phascolarctobacterium faecium Species 0.000 description 1
- 241000801571 Phascolarctobacterium succinatutens Species 0.000 description 1
- 241000409524 Phenylobacterium haematophilum Species 0.000 description 1
- 241000200127 Phenylobacterium kunshanense Species 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 241000607602 Photobacterium angustum Species 0.000 description 1
- 241000078170 Photobacterium frigidiphilum Species 0.000 description 1
- 241000607565 Photobacterium phosphoreum Species 0.000 description 1
- ZQLBCAUKNYXILZ-UGKGYDQZSA-N Piericidin A Natural products COc1nc(CC=C(/C)C=CCC(=C[C@H](C)[C@@H](O)C(=CC)C)C)c(C)c(O)c1OC ZQLBCAUKNYXILZ-UGKGYDQZSA-N 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 241000881813 Pluralibacter gergoviae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000715525 Polymorphobacter multimanifer Species 0.000 description 1
- 241000400657 Polymorphospora rubra Species 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000060255 Porphyrobacter colymbi Species 0.000 description 1
- 241000134844 Porphyromonas catoniae Species 0.000 description 1
- 241000095441 Porphyromonas gingivicanis Species 0.000 description 1
- 241000041193 Porphyromonas pogonae Species 0.000 description 1
- 241000828389 Povalibacter uvarum Species 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 241001041813 Prevotella amnii Species 0.000 description 1
- 241000326476 Prevotella aurantiaca Species 0.000 description 1
- 241000987248 Prevotella bergensis Species 0.000 description 1
- 241001147550 Prevotella colorans Species 0.000 description 1
- 241001135219 Prevotella disiens Species 0.000 description 1
- 241001288803 Prevotella enoeca Species 0.000 description 1
- 241001482483 Prevotella histicola Species 0.000 description 1
- 241000605951 Prevotella loescheii Species 0.000 description 1
- 241000124542 Prevotella maculosa Species 0.000 description 1
- 241001141018 Prevotella marshii Species 0.000 description 1
- 241000782070 Prevotella multiformis Species 0.000 description 1
- 241001221454 Prevotella multisaccharivorax Species 0.000 description 1
- 241001365165 Prevotella nanceiensis Species 0.000 description 1
- 241001135261 Prevotella oralis Species 0.000 description 1
- 241001135263 Prevotella oulorum Species 0.000 description 1
- 241000864367 Prevotella pallens Species 0.000 description 1
- 241000605860 Prevotella ruminicola Species 0.000 description 1
- 241001116196 Prevotella saccharolytica Species 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 241000519651 Propionibacterium acidifaciens Species 0.000 description 1
- 241001171103 Propionimicrobium Species 0.000 description 1
- 241000042965 Propionispira arcuata Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241001472782 Proteus penneri Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000576783 Providencia alcalifaciens Species 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- PWNMXPDKBYZCOO-UHFFFAOYSA-N Prulifloxacin Chemical compound C1=C2N3C(C)SC3=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1CC=1OC(=O)OC=1C PWNMXPDKBYZCOO-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000032921 Pseudaeromonas sharmana Species 0.000 description 1
- 241000750264 Pseudoalteromonas agarivorans Species 0.000 description 1
- 241000589515 Pseudoalteromonas atlantica Species 0.000 description 1
- 241000396463 Pseudoalteromonas paragorgicola Species 0.000 description 1
- 241000202386 Pseudobutyrivibrio Species 0.000 description 1
- 241000422592 Pseudoclavibacter alba Species 0.000 description 1
- 241000422214 Pseudoclavibacter bifida Species 0.000 description 1
- 241000280572 Pseudoflavonifractor Species 0.000 description 1
- 241000282184 Pseudokineococcus lusitanus Species 0.000 description 1
- 241000028636 Pseudomonas abietaniphila Species 0.000 description 1
- 101100280248 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) exoS gene Proteins 0.000 description 1
- 101100135758 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) pchB gene Proteins 0.000 description 1
- 241000218934 Pseudomonas amygdali Species 0.000 description 1
- 241000520871 Pseudomonas asplenii Species 0.000 description 1
- 241001636080 Pseudomonas asuensis Species 0.000 description 1
- 241000218935 Pseudomonas azotoformans Species 0.000 description 1
- 241000521394 Pseudomonas benzenivorans Species 0.000 description 1
- 241000007104 Pseudomonas cannabina Species 0.000 description 1
- 241000286467 Pseudomonas chengduensis Species 0.000 description 1
- 241001646398 Pseudomonas chlororaphis Species 0.000 description 1
- 241001144911 Pseudomonas congelans Species 0.000 description 1
- 241000425890 Pseudomonas costantinii Species 0.000 description 1
- 241000121962 Pseudomonas cuatrocienegasensis Species 0.000 description 1
- 241000520898 Pseudomonas ficuserectae Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241001497665 Pseudomonas frederiksbergensis Species 0.000 description 1
- 241000218899 Pseudomonas fulva Species 0.000 description 1
- 241000042121 Pseudomonas graminis Species 0.000 description 1
- 241001300822 Pseudomonas jessenii Species 0.000 description 1
- 241001288557 Pseudomonas kunmingensis Species 0.000 description 1
- 241000999303 Pseudomonas lutea Species 0.000 description 1
- 241000218905 Pseudomonas luteola Species 0.000 description 1
- 241000394642 Pseudomonas marginalis pv. marginalis Species 0.000 description 1
- 241000589781 Pseudomonas oleovorans Species 0.000 description 1
- 241001291513 Pseudomonas orientalis Species 0.000 description 1
- 241000954716 Pseudomonas panacis Species 0.000 description 1
- 241001223182 Pseudomonas plecoglossicida Species 0.000 description 1
- 241001144909 Pseudomonas poae Species 0.000 description 1
- 241000530526 Pseudomonas psychrophila Species 0.000 description 1
- 101100385759 Pseudomonas putida pchC gene Proteins 0.000 description 1
- 241000897024 Pseudomonas reinekei Species 0.000 description 1
- 241001598355 Pseudomonas rhizosphaerae Species 0.000 description 1
- 241001458752 Pseudomonas seleniipraecipitans Species 0.000 description 1
- 241000218902 Pseudomonas synxantha Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 241001148199 Pseudomonas tolaasii Species 0.000 description 1
- 241001515941 Pseudomonas umsongensis Species 0.000 description 1
- 241000507051 Pseudomonas zhaodongensis Species 0.000 description 1
- 241001276367 Pseudonocardia alaniniphila Species 0.000 description 1
- 241000023238 Pseudonocardia ammonioxydans Species 0.000 description 1
- 241000204087 Pseudonocardia autotrophica Species 0.000 description 1
- 241000321851 Pseudonocardia benzenivorans Species 0.000 description 1
- 241001464398 Pseudonocardia kongjuensis Species 0.000 description 1
- 241000592984 Pseudonocardia yunnanensis Species 0.000 description 1
- 241000184247 Pseudoramibacter Species 0.000 description 1
- 241000147355 Pseudorhodoferax soli Species 0.000 description 1
- 241000417023 Pseudorhodoplanes sinuspersici Species 0.000 description 1
- 241000096317 Pseudoxanthomonas daejeonensis Species 0.000 description 1
- 241001405237 Pseudoxanthomonas indica Species 0.000 description 1
- 241000794756 Pseudoxanthomonas kaohsiungensis Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241001048588 Psychrobacter aquaticus Species 0.000 description 1
- 241000355705 Psychrobacter arcticus Species 0.000 description 1
- 241000950687 Psychrobacter celer Species 0.000 description 1
- 241001674581 Psychrobacter marincola Species 0.000 description 1
- 241000769123 Psychrobacter nivimaris Species 0.000 description 1
- 241000496279 Psychrobacter piscatorii Species 0.000 description 1
- 241000331165 Psychrobacter pulmonis Species 0.000 description 1
- 241001642682 Psychrobacter sanguinis Species 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- NYBZAGXTZXPYND-UHFFFAOYSA-N Pyochelin I Natural products S1CC(C(O)=O)N(C)C1C1N=C(C=2C(=CC=CC=2)O)SC1 NYBZAGXTZXPYND-UHFFFAOYSA-N 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 241001148023 Pyrococcus abyssi Species 0.000 description 1
- 101100169519 Pyrococcus abyssi (strain GE5 / Orsay) dapAL gene Proteins 0.000 description 1
- 241001478271 Rahnella aquatilis Species 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- 241000316322 Ramlibacter ginsenosidimutans Species 0.000 description 1
- 241000588746 Raoultella planticola Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 241000948188 Rheinheimera Species 0.000 description 1
- 241000976133 Rheinheimera aquimaris Species 0.000 description 1
- 241000182435 Rheinheimera japonica Species 0.000 description 1
- 241001207704 Rheinheimera muenzenbergensis Species 0.000 description 1
- 241001502333 Rheinheimera perlucida Species 0.000 description 1
- 241000022649 Rhizobacter dauci Species 0.000 description 1
- 241000563500 Rhizobium alamii Species 0.000 description 1
- 241000677747 Rhizobium alvei Species 0.000 description 1
- 241000682559 Rhizobium azibense Species 0.000 description 1
- 241000703606 Rhizobium binae Species 0.000 description 1
- 241000972381 Rhizobium daejeonense Species 0.000 description 1
- 241001269866 Rhizobium endophyticum Species 0.000 description 1
- 241001206173 Rhizobium fabae Species 0.000 description 1
- 241000820597 Rhizobium freirei Species 0.000 description 1
- 241000556551 Rhizobium gallicum Species 0.000 description 1
- 241000043559 Rhizobium loessense Species 0.000 description 1
- 101100327931 Rhizobium meliloti (strain 1021) chvG gene Proteins 0.000 description 1
- 241000758566 Rhizobium rhizoryzae Species 0.000 description 1
- 241001353184 Rhizobium soli Species 0.000 description 1
- 241001159582 Rhizobium sophoriradicis Species 0.000 description 1
- 241000765952 Rhizobium taibaishanense Species 0.000 description 1
- 241001132465 Rhizobium vallis Species 0.000 description 1
- 241000185992 Rhizobium viscosum Species 0.000 description 1
- 241000861993 Rhizobium yanglingense Species 0.000 description 1
- 241001587027 Rhodanobacter glycinis Species 0.000 description 1
- 241001464946 Rhodobacter veldkampii Species 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000706991 Rhodococcus baikonurensis Species 0.000 description 1
- 241001380797 Rhodococcus enclensis Species 0.000 description 1
- 241001671945 Rhodoferax saidenbachensis Species 0.000 description 1
- 241000190950 Rhodopseudomonas palustris Species 0.000 description 1
- 241000123818 Rhodovarius lipocyclicus Species 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 241000606716 Rickettsia canadensis Species 0.000 description 1
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 description 1
- 241000303241 Rickettsia heilongjiangensis Species 0.000 description 1
- 241001523686 Rickettsia honei Species 0.000 description 1
- 241001506408 Rickettsia raoultii Species 0.000 description 1
- 241001478225 Riemerella Species 0.000 description 1
- 241001478126 Riemerella columbina Species 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000046381 Rivicola pingtungensis Species 0.000 description 1
- JPRXYLQNJJVCMZ-UHFFFAOYSA-N Rizatriptan benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1.C1=C2C(CC[NH+](C)C)=CNC2=CC=C1CN1C=NC=N1 JPRXYLQNJJVCMZ-UHFFFAOYSA-N 0.000 description 1
- 241001135520 Robbsia andropogonis Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000040577 Romboutsia Species 0.000 description 1
- 241000186567 Romboutsia lituseburensis Species 0.000 description 1
- 241000872831 Roseburia faecis Species 0.000 description 1
- 241000494079 Rosenbergiella nectarea Species 0.000 description 1
- 241000772704 Roseomonas aerilata Species 0.000 description 1
- 241000130158 Roseomonas aquatica Species 0.000 description 1
- 241001227620 Roseomonas mucosa Species 0.000 description 1
- 241001506688 Roseomonas rosea Species 0.000 description 1
- 241001353161 Roseomonas vinacea Species 0.000 description 1
- 241000706990 Rothia aeria Species 0.000 description 1
- 241000428493 Rothia amarae Species 0.000 description 1
- 241000203719 Rothia dentocariosa Species 0.000 description 1
- 241001383836 Rothia endophytica Species 0.000 description 1
- 241001671680 Rothia nasimurium Species 0.000 description 1
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 1
- 241000309188 Rubellimicrobium mesophilum Species 0.000 description 1
- 241001338712 Rubellimicrobium roseum Species 0.000 description 1
- 241000281537 Rubrobacter bracarensis Species 0.000 description 1
- 241000090565 Rudaea cellulosilytica Species 0.000 description 1
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 241000062639 Ruminococcus bicirculans Species 0.000 description 1
- 241000123754 Ruminococcus callidus Species 0.000 description 1
- 241000061145 Ruminococcus champanellensis Species 0.000 description 1
- 241000291327 Ruminococcus faecis Species 0.000 description 1
- 241000202356 Ruminococcus lactaris Species 0.000 description 1
- 241000134861 Ruminococcus sp. Species 0.000 description 1
- 241000357493 Runella zeae Species 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 241001134661 Saccharopolyspora rectivirgula Species 0.000 description 1
- ACQJWVPNGVNRCD-UHFFFAOYSA-N Sakacin A Chemical compound CC(C)(C)N(C)C(=O)NC(C)NC(=O)C(N)CC(O)=O ACQJWVPNGVNRCD-UHFFFAOYSA-N 0.000 description 1
- VMETVXNVLXCEFC-UHFFFAOYSA-N Sakacin P Chemical compound NC(=O)C(=O)C(C)NC(=O)OC(C)(C)C VMETVXNVLXCEFC-UHFFFAOYSA-N 0.000 description 1
- 241001255100 Salinicoccus qingdaonensis Species 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607358 Salmonella enterica subsp. salamae Species 0.000 description 1
- 241000869103 Sanguibacter keddieii Species 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 241000585143 Scardovia wiggsiae Species 0.000 description 1
- 241000989219 Sediminibacterium ginsengisoli Species 0.000 description 1
- 241001378703 Sediminibacterium salmoneum Species 0.000 description 1
- 241001136691 Seinonella Species 0.000 description 1
- 241000605036 Selenomonas Species 0.000 description 1
- 241000913117 Selenomonas artemidis Species 0.000 description 1
- 241001017228 Selenomonas bovis Species 0.000 description 1
- 241000951718 Selenomonas infelix Species 0.000 description 1
- 241000951712 Selenomonas noxia Species 0.000 description 1
- 241000985259 Selenomonas sputigena Species 0.000 description 1
- 241000093136 Sellimonas Species 0.000 description 1
- 241001601862 Sellimonas intestinalis Species 0.000 description 1
- 241001258888 Senegalimassilia Species 0.000 description 1
- 241001258865 Senegalimassilia anaerobia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000758275 Serratia myotis Species 0.000 description 1
- 241000758272 Serratia vespertilionis Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000631389 Shewanella aestuarii Species 0.000 description 1
- 241001518135 Shewanella algae Species 0.000 description 1
- 241000865982 Shewanella amazonensis Species 0.000 description 1
- 241001388028 Shewanella decolorationis Species 0.000 description 1
- 241001223867 Shewanella oneidensis Species 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 241000607766 Shigella boydii Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 241000763413 Shuttleworthia Species 0.000 description 1
- 241000763410 Shuttleworthia satelles Species 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 241000863010 Simonsiella muelleri Species 0.000 description 1
- 241001468009 Sinorhizobium americanum Species 0.000 description 1
- 241000702202 Siphoviridae Species 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000863350 Skermanella aerolata Species 0.000 description 1
- 241001182517 Skermanella stibiiresistens Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241001657520 Slackia Species 0.000 description 1
- 241000801625 Slackia piriformis Species 0.000 description 1
- 101710142606 Sliding clamp Proteins 0.000 description 1
- 241001133484 Smaragdicoccus niigatensis Species 0.000 description 1
- 241001115883 Sneathia amnii Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001429400 Solirubrobacter soli Species 0.000 description 1
- 241001464874 Solobacterium moorei Species 0.000 description 1
- 241000862997 Sorangium cellulosum Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000954524 Sphingobacterium caeni Species 0.000 description 1
- 241000115839 Sphingobacterium daejeonense Species 0.000 description 1
- 241001573261 Sphingobacterium hotanense Species 0.000 description 1
- 241000125346 Sphingobacterium kyonggiense Species 0.000 description 1
- 241001136276 Sphingobacterium multivorum Species 0.000 description 1
- 241000431171 Sphingobacterium nematocida Species 0.000 description 1
- 241000589595 Sphingobacterium spiritivorum Species 0.000 description 1
- 241000068334 Sphingobium baderi Species 0.000 description 1
- 241000044146 Sphingobium barthaii Species 0.000 description 1
- 241000203415 Sphingobium chlorophenolicum Species 0.000 description 1
- 241000674904 Sphingobium cupriresistens Species 0.000 description 1
- 241001433455 Sphingobium czechense Species 0.000 description 1
- 241000374964 Sphingobium fuliginis Species 0.000 description 1
- 241000328430 Sphingobium indicum Species 0.000 description 1
- 241001044382 Sphingobium lactosutens Species 0.000 description 1
- 241000804709 Sphingobium subterraneum Species 0.000 description 1
- 241000736091 Sphingobium yanoikuyae Species 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 241000675921 Sphingomonas abaci Species 0.000 description 1
- 241000774311 Sphingomonas aestuarii Species 0.000 description 1
- 241001353988 Sphingomonas canadensis Species 0.000 description 1
- 241000506857 Sphingomonas daechungensis Species 0.000 description 1
- 241000611852 Sphingomonas echinoides Species 0.000 description 1
- 241001643155 Sphingomonas formosensis Species 0.000 description 1
- 241000344853 Sphingomonas koreensis Species 0.000 description 1
- 241001520498 Sphingomonas kyeonggiensis Species 0.000 description 1
- 241001641240 Sphingomonas laterariae Species 0.000 description 1
- 241000101519 Sphingomonas mucosissima Species 0.000 description 1
- 241000874774 Sphingomonas oligophenolica Species 0.000 description 1
- 241000989603 Sphingomonas pseudosanguinis Species 0.000 description 1
- 241000541937 Sphingomonas sediminicola Species 0.000 description 1
- 241000321601 Sphingomonas wittichii Species 0.000 description 1
- 241000714805 Sphingomonas yantingensis Species 0.000 description 1
- 241001220764 Sphingomonas yunnanensis Species 0.000 description 1
- 241001052481 Sphingopyxis chilensis Species 0.000 description 1
- 241000462028 Sphingopyxis fribergensis Species 0.000 description 1
- 241000112734 Sphingopyxis granuli Species 0.000 description 1
- 241000084840 Sphingopyxis indica Species 0.000 description 1
- 241000720921 Sphingopyxis witflariensis Species 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 241000870209 Spirosoma rigui Species 0.000 description 1
- 241000823036 Sporacetigenium mesophilum Species 0.000 description 1
- 241000168515 Sporobacter Species 0.000 description 1
- 241001446760 Sporobacterium Species 0.000 description 1
- 241001660858 Sporocytophaga myxococcoides Species 0.000 description 1
- 241000196330 Sporosarcina aquimarina Species 0.000 description 1
- 241000458595 Staphylococcus agnetis Species 0.000 description 1
- 101000794214 Staphylococcus aureus Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 1
- 241001147736 Staphylococcus capitis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241001301565 Staphylococcus hominis subsp. novobiosepticus Species 0.000 description 1
- 241000147121 Staphylococcus lentus Species 0.000 description 1
- 241000681475 Staphylococcus pettenkoferi Species 0.000 description 1
- 241000794282 Staphylococcus pseudintermedius Species 0.000 description 1
- 241001327113 Staphylococcus saprophyticus subsp. bovis Species 0.000 description 1
- 241000192099 Staphylococcus schleiferi Species 0.000 description 1
- 241001327099 Staphylococcus sciuri subsp. carnaticus Species 0.000 description 1
- 241000967959 Staphylococcus simiae Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000192086 Staphylococcus warneri Species 0.000 description 1
- 241000191973 Staphylococcus xylosus Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000097009 Stenotrophomonas koreensis Species 0.000 description 1
- 241001324998 Stenoxybacter acetivorans Species 0.000 description 1
- 229930190931 Stigmatellin Natural products 0.000 description 1
- UZHDGDDPOPDJGM-UHFFFAOYSA-N Stigmatellin A Natural products COC1=CC(OC)=C2C(=O)C(C)=C(CCC(C)C(OC)C(C)C(C=CC=CC(C)=CC)OC)OC2=C1O UZHDGDDPOPDJGM-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000114471 Streptococcus caballi Species 0.000 description 1
- 241000194007 Streptococcus canis Species 0.000 description 1
- 241001364812 Streptococcus castoreus Species 0.000 description 1
- 241001472859 Streptococcus didelphis Species 0.000 description 1
- 241000194050 Streptococcus ferus Species 0.000 description 1
- 241001288016 Streptococcus gallolyticus Species 0.000 description 1
- 241000114457 Streptococcus henryi Species 0.000 description 1
- 241001345024 Streptococcus hyovaginalis Species 0.000 description 1
- 241001473878 Streptococcus infantarius Species 0.000 description 1
- 241000134187 Streptococcus marimammalium Species 0.000 description 1
- 241000573651 Streptococcus merionis Species 0.000 description 1
- 101001138042 Streptococcus mutans Lantibiotic mutacin-1140 Proteins 0.000 description 1
- 241001635315 Streptococcus ovis Species 0.000 description 1
- 241000252846 Streptococcus phocae Species 0.000 description 1
- 241000814304 Streptococcus plurextorum Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000313511 Streptococcus porci Species 0.000 description 1
- 241001403829 Streptococcus pseudopneumoniae Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 241000555264 Streptococcus thoraltensis Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 241000187759 Streptomyces albus Species 0.000 description 1
- 241000541532 Streptomyces caeruleatus Species 0.000 description 1
- 241000813864 Streptomyces canarius Species 0.000 description 1
- 241000593950 Streptomyces canus Species 0.000 description 1
- 241000970295 Streptomyces capoamus Species 0.000 description 1
- 241000946917 Streptomyces griseorubiginosus Species 0.000 description 1
- 241000288063 Streptomyces iconiensis Species 0.000 description 1
- 241000187413 Streptomyces olivaceoviridis Species 0.000 description 1
- 241001234887 Streptomyces panaciradicis Species 0.000 description 1
- 241000719745 Streptomyces phaechromogenes Species 0.000 description 1
- 241000946810 Streptomyces phaeopurpureus Species 0.000 description 1
- 241000946783 Streptomyces pseudovenezuelae Species 0.000 description 1
- 241000946782 Streptomyces resistomycificus Species 0.000 description 1
- 241001218904 Streptomyces yanglinensis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001136694 Subdoligranulum Species 0.000 description 1
- 241001580973 Subdoligranulum variabile Species 0.000 description 1
- 241000956269 Succinatimonas Species 0.000 description 1
- 241000801622 Succinatimonas hippei Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000123710 Sutterella Species 0.000 description 1
- 241000096798 Sutterella parvirubra Species 0.000 description 1
- 241001656784 Syntrophococcus Species 0.000 description 1
- 241000909294 Tabrizicola aquatica Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241000530408 Tahibacter caeni Species 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 241001398939 Tepidicella xavieri Species 0.000 description 1
- 241001199727 Tepidimonas fonticaldi Species 0.000 description 1
- 241000520170 Terracoccus luteus Species 0.000 description 1
- 241001611469 Terrahaemophilus aromaticivorans Species 0.000 description 1
- 241000089063 Terrisporobacter Species 0.000 description 1
- 241001509489 Terrisporobacter glycolicus Species 0.000 description 1
- 241000186582 Terrisporobacter mayombei Species 0.000 description 1
- 241000946898 Tessaracoccus flavescens Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241000322298 Thalassobacillus Species 0.000 description 1
- 241000495343 Thalassobacillus devorans Species 0.000 description 1
- 101000666752 Theionarchaea archaeon (strain DG-70-1) NAD(+) hydrolase TcpA Proteins 0.000 description 1
- 241001291204 Thermobacillus Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 241000078442 Tianweitania sediminis Species 0.000 description 1
- 241000936345 Timonella Species 0.000 description 1
- 241000936343 Timonella senegalensis Species 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100033055 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 241000611736 Treponema amylovorum Species 0.000 description 1
- 241000520888 Treponema lecithinolyticum Species 0.000 description 1
- 241000498553 Treponema maltophilum Species 0.000 description 1
- 241000593416 Treponema medium Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000988897 Treponema parvum Species 0.000 description 1
- 241000984746 Treponema vincentii Species 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- FSRLGULMGJGKGI-BTJKTKAUSA-N Trimebutine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 FSRLGULMGJGKGI-BTJKTKAUSA-N 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 102100038798 Tripartite motif-containing protein 3 Human genes 0.000 description 1
- 241000609534 Trueperella bernardiae Species 0.000 description 1
- 241000204063 Tsukamurella paurometabola Species 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 241001425419 Turicibacter Species 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 241001147795 Tyzzerella nexilis Species 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- HMQPEDMEOBLSQB-UHFFFAOYSA-N UNPD117640 Natural products CC(=O)NC1C(O)OC(CO)C(O)C1OC1C(O)C(O)C(O)C(CO)O1 HMQPEDMEOBLSQB-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 241000600185 Undibacterium oligocarboniphilum Species 0.000 description 1
- 241000638635 Undibacterium squillarum Species 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000935255 Ureaplasma parvum Species 0.000 description 1
- 241000207192 Vagococcus salmoninarum Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241001085041 Varibaculum Species 0.000 description 1
- 241000408516 Variovorax guangxiensis Species 0.000 description 1
- 241001478284 Variovorax paradoxus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 241001116698 Veillonella montpellierensis Species 0.000 description 1
- 241000607296 Vibrio cincinnatiensis Species 0.000 description 1
- 241001135144 Vibrio metschnikovii Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241001659629 Virgibacillus Species 0.000 description 1
- 241001659625 Virgibacillus proomii Species 0.000 description 1
- 241000862002 Virgibacillus salexigens Species 0.000 description 1
- 241000065508 Viridibacillus arenosi Species 0.000 description 1
- 241000065502 Viridibacillus arvi Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 241001207692 Vogesella alkaliphila Species 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 241000975185 Weissella cibaria Species 0.000 description 1
- 241000192133 Weissella paramesenteroides Species 0.000 description 1
- 241000010758 Weissella soli Species 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000865160 Xanthobacter tagetidis Species 0.000 description 1
- 241000567083 Xanthomonas arboricola Species 0.000 description 1
- 241000520892 Xanthomonas axonopodis Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 241000566992 Xanthomonas cassavae Species 0.000 description 1
- 241000566981 Xanthomonas cucurbitae Species 0.000 description 1
- 241001559599 Xanthomonas cynarae Species 0.000 description 1
- 241000815873 Xanthomonas euvesicatoria Species 0.000 description 1
- 241000231754 Xanthomonas fragariae Species 0.000 description 1
- 241000293040 Xanthomonas gardneri Species 0.000 description 1
- 241000411046 Xanthomonas perforans Species 0.000 description 1
- 241000566994 Xanthomonas pisi Species 0.000 description 1
- 241000520894 Xanthomonas populi Species 0.000 description 1
- 241000566997 Xanthomonas vasicola Species 0.000 description 1
- 241000567019 Xanthomonas vesicatoria Species 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 241000772777 Xenophilus aerolatus Species 0.000 description 1
- 241000521067 Xenophilus arseniciresistens Species 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 101100395365 Yersinia enterocolitica serotype O:8 / biotype 1B (strain NCTC 13174 / 8081) irp2 gene Proteins 0.000 description 1
- 101100053619 Yersinia enterocolitica yscF gene Proteins 0.000 description 1
- 241001321500 Yersinia nurmii Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241001643985 Yimella lutea Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 241001047078 Zobellia laminariae Species 0.000 description 1
- 241000156025 Zoogloea caeni Species 0.000 description 1
- 241000589153 Zoogloea ramigera Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2r,3s,4r,5r,6r)-6-[[(3as,7r,7as)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3s)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 241000514948 [Bacteroides] pectinophilus Species 0.000 description 1
- 241000342876 [Clostridium] asparagiforme Species 0.000 description 1
- 241001246487 [Clostridium] bolteae Species 0.000 description 1
- 241000030487 [Clostridium] hiranonis Species 0.000 description 1
- 241000030493 [Clostridium] hylemonae Species 0.000 description 1
- 241001656805 [Clostridium] methylpentosum Species 0.000 description 1
- 241001147801 [Clostridium] scindens Species 0.000 description 1
- 241001147796 [Clostridium] spiroforme Species 0.000 description 1
- 241000193450 [Clostridium] symbiosum Species 0.000 description 1
- 241000215449 [Clostridium] viride Species 0.000 description 1
- 241001494424 [Eubacterium] brachy Species 0.000 description 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 1
- 241000557616 [Eubacterium] infirmum Species 0.000 description 1
- 241001494431 [Eubacterium] nodatum Species 0.000 description 1
- 241001531183 [Eubacterium] yurii Species 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 241001670036 [Pseudomonas] cissicola Species 0.000 description 1
- 101150116772 aatA gene Proteins 0.000 description 1
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
- 229960000531 abacavir sulfate Drugs 0.000 description 1
- PENDGIOBPJLVBT-HMMOOPTJSA-N abt-773 Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(C)OC\C=C\C=1C=C2C=CC=CC2=NC=1)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O PENDGIOBPJLVBT-HMMOOPTJSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- 229950005879 acecainide Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229950008644 adicillin Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- BHAYDBSYOBONRV-IUYQGCFVSA-N alafosfalin Chemical compound C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O BHAYDBSYOBONRV-IUYQGCFVSA-N 0.000 description 1
- 229960000919 alatrofloxacin Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 239000006672 alkalibacterium olivapovliticus Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229950008560 almecillin Drugs 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229940044726 anaerococcus tetradius Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 108010055869 ancovenin Proteins 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229960003420 antazoline phosphate Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- 101150015540 apxIIC gene Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- VLAXZGHHBIJLAD-UHFFFAOYSA-N arsphenamine Chemical compound [Cl-].[Cl-].C1=C(O)C([NH3+])=CC([As]=[As]C=2C=C([NH3+])C(O)=CC=2)=C1 VLAXZGHHBIJLAD-UHFFFAOYSA-N 0.000 description 1
- 229940003446 arsphenamine Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 101150005925 aspC gene Proteins 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 108010050826 aureocin A70 Proteins 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960002617 azatadine maleate Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229950000805 balofloxacin Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 229940092523 bartonella quintana Drugs 0.000 description 1
- 108010060301 bavaricin A Proteins 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 101150009149 bfpA gene Proteins 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 229960005400 bisoprolol fumarate Drugs 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 108010089737 brochocin C Proteins 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- YFLRYAVDPKONNX-UHFFFAOYSA-N buramate Chemical compound OCCOC(=O)NCC1=CC=CC=C1 YFLRYAVDPKONNX-UHFFFAOYSA-N 0.000 description 1
- 229950009824 buramate Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- PWPDEXVGKDEKTE-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate Chemical compound O.OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 PWPDEXVGKDEKTE-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004587 carisoprodol Drugs 0.000 description 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
- 108010041442 carotovoricin Proteins 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960003972 cefacetrile Drugs 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950005258 cefalonium Drugs 0.000 description 1
- GOFCPYKUMJBHBH-RHSMWYFYSA-N cefaloram Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CC=C1 GOFCPYKUMJBHBH-RHSMWYFYSA-N 0.000 description 1
- 229950001373 cefaloram Drugs 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229950000042 cefaparole Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229950004359 cefazaflur Drugs 0.000 description 1
- HGXLJRWXCXSEJO-GMSGAONNSA-N cefazaflur Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CSC(F)(F)F)[C@H]2SC1 HGXLJRWXCXSEJO-GMSGAONNSA-N 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001817 cefbuperazone Drugs 0.000 description 1
- SMSRCGPDNDCXFR-CYWZMYCQSA-N cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 description 1
- 229950002706 cefcanel Drugs 0.000 description 1
- 229960002966 cefcapene Drugs 0.000 description 1
- HJJRIJDTIPFROI-NVKITGPLSA-N cefcapene Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 HJJRIJDTIPFROI-NVKITGPLSA-N 0.000 description 1
- JUVHVMCKLDZLGN-TVNFHGJBSA-N cefclidin Chemical compound N([C@@H]1C(N2C(=C(C[N+]34CCC(CC3)(CC4)C(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 JUVHVMCKLDZLGN-TVNFHGJBSA-N 0.000 description 1
- 229950006550 cefdaloxime Drugs 0.000 description 1
- HOGISBSFFHDTRM-GHXIOONMSA-N cefdaloxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/O)\C1=CSC(N)=N1 HOGISBSFFHDTRM-GHXIOONMSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- 229950007281 cefedrolor Drugs 0.000 description 1
- 229950009347 cefempidone Drugs 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-O cefepime(1+) Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-O 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229950003098 cefetrizole Drugs 0.000 description 1
- 229950007546 cefivitril Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- XAKKNLNAJBNLPC-MAYKBZFQSA-N cefluprenam Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 description 1
- 229950001334 cefluprenam Drugs 0.000 description 1
- 229950008727 cefmatilen Drugs 0.000 description 1
- UEQVTKSAEXANEZ-YCRCPZNHSA-N cefmatilen Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(SCSC4=NNN=C4)CS[C@@H]32)C(O)=O)=O)=C1 UEQVTKSAEXANEZ-YCRCPZNHSA-N 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229950001580 cefoselis Drugs 0.000 description 1
- ZINFAXPQMLDEEJ-GFVOIPPFSA-N cefoselis Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO ZINFAXPQMLDEEJ-GFVOIPPFSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960003391 cefovecin Drugs 0.000 description 1
- ZJGQFXVQDVCVOK-MSUXKOGISA-N cefovecin Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1[C@@H]1CCCO1 ZJGQFXVQDVCVOK-MSUXKOGISA-N 0.000 description 1
- 229950002823 cefoxazole Drugs 0.000 description 1
- 229960002642 cefozopran Drugs 0.000 description 1
- QDUIJCOKQCCXQY-WHJQOFBOSA-N cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 description 1
- LNZMRLHZGOBKAN-KAWPREARSA-N cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 1
- 229950004036 cefpimizole Drugs 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229950009592 cefquinome Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229950003685 cefrotil Drugs 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- OFKRKCHCYWQZLY-XHBSWPGZSA-N cefsumide Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC(NS(C)(=O)=O)=C1 OFKRKCHCYWQZLY-XHBSWPGZSA-N 0.000 description 1
- 229950010594 cefsumide Drugs 0.000 description 1
- 229940036735 ceftaroline Drugs 0.000 description 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- 229960004366 ceftezole Drugs 0.000 description 1
- DZMVCVMFETWNIU-LDYMZIIASA-N ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- WJXAHFZIHLTPFR-JLRJEBFFSA-N ceftiolene Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C\SC1=NNC(=O)C(=O)N1CC=O WJXAHFZIHLTPFR-JLRJEBFFSA-N 0.000 description 1
- 229950008880 ceftiolene Drugs 0.000 description 1
- 229950007152 ceftioxide Drugs 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 description 1
- 229950004259 ceftobiprole Drugs 0.000 description 1
- 229960002405 ceftolozane Drugs 0.000 description 1
- JHFNIHVVXRKLEF-DCZLAGFPSA-N ceftolozane Chemical compound CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C(=N/OC(C)(C)C([O-])=O)\C=3N=C(N)SN=3)[C@H]2SC1 JHFNIHVVXRKLEF-DCZLAGFPSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229950010799 cefuracetime Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 description 1
- 229950000807 cefuzonam Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008618 cell wall macromolecule catabolic process Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- 229950010329 cethromycin Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- CYETUYYEVKNSHZ-LGOOQLFJSA-N chembl1200498 Chemical compound CS(O)(=O)=O.C([C@@H]1[C@H]([C@@H]1C1)NC(=O)[C@H](C)NC(=O)[C@@H](N)C)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F CYETUYYEVKNSHZ-LGOOQLFJSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- RKLXDNHNLPUQRB-TVJUEJKUSA-N chembl564271 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]2C(C)SC[C@H](N[C@@H](CC(N)=O)C(=O)NC(=O)[C@@H](NC2=O)CSC1C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NC(=O)C(=C\C)/NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)[C@H]3N[C@@H](CC(C)C)C(=O)NC(=O)C(=C)NC(=O)CC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C5=CC=CC=C5NC=4)CSC3)C(O)=O)C(C)SC2)C(C)C)C(C)SC1)C1=CC=CC=C1 RKLXDNHNLPUQRB-TVJUEJKUSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
- 229960002810 chlormezanone Drugs 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 108010063293 cinnamycin Proteins 0.000 description 1
- QJDWKBINWOWJNZ-OURZNGJWSA-N cinnamycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CNCCCC[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CS[C@H]4C)C(=O)N[C@@H](CS[C@H]2C)C(=O)N3)NC1=O)[C@@H](O)C(O)=O)C(O)=O QJDWKBINWOWJNZ-OURZNGJWSA-N 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960000584 citalopram hydrobromide Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960005098 clidinium bromide Drugs 0.000 description 1
- GKEGFOKQMZHVOW-KUTGSRRKSA-M clidinium bromide Chemical compound [Br-].C1([C@H]2CC[N@+](CC2)(C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 GKEGFOKQMZHVOW-KUTGSRRKSA-M 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- LOHQECMUTAPWAC-UHFFFAOYSA-N coagulin Natural products C1C(C)=C(CO)C(=O)OC1C1(C)C(C2(C)CCC3C4(C(=O)CC=CC4=CCC43)C)(O)CCC24O1 LOHQECMUTAPWAC-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- WTIJXIZOODAMJT-DHFGXMAYSA-N coumermycin A1 Chemical compound O([C@@H]1[C@H](C(O[C@@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-DHFGXMAYSA-N 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 101150112550 csgA gene Proteins 0.000 description 1
- 101150055700 csgB gene Proteins 0.000 description 1
- 101150095724 csgC gene Proteins 0.000 description 1
- 101150031345 csgD gene Proteins 0.000 description 1
- 101150101046 csgE gene Proteins 0.000 description 1
- 101150044423 csgF gene Proteins 0.000 description 1
- 101150099331 csgG gene Proteins 0.000 description 1
- 101150028842 ctxA gene Proteins 0.000 description 1
- 101150087320 ctxB gene Proteins 0.000 description 1
- 101150096136 cyaC gene Proteins 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960004951 dabigatran etexilate mesylate Drugs 0.000 description 1
- XETBXHPXHHOLOE-UHFFFAOYSA-N dabigatran etexilate methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C(\N)=N/C(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C XETBXHPXHHOLOE-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- 108700009376 dalbavancin Proteins 0.000 description 1
- 229960002615 dalfopristin Drugs 0.000 description 1
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 1
- 108700028430 dalfopristin Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- KSRLIXGNPXAZHD-UHFFFAOYSA-M dantrolene sodium (anhydrous) Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1C=NN1C(=O)[N-]C(=O)C1 KSRLIXGNPXAZHD-UHFFFAOYSA-M 0.000 description 1
- 101150011371 dapA gene Proteins 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 229960002287 darifenacin hydrobromide Drugs 0.000 description 1
- UQAVIASOPREUIT-VQIWEWKSSA-N darifenacin hydrobromide Chemical compound Br.C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 UQAVIASOPREUIT-VQIWEWKSSA-N 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- 229950006412 delafloxacin Drugs 0.000 description 1
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960004981 desvenlafaxine succinate Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229950004220 diacetamate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960001863 disopyramide phosphate Drugs 0.000 description 1
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 108010005174 divercin V41 Proteins 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960000220 doxazosin mesylate Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 108010046161 drug combination polymyxin B neomycin sulfate bacitracin zinc Proteins 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 108010025837 duramycin B Proteins 0.000 description 1
- 108010025839 duramycin C Proteins 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 101150107911 eae gene Proteins 0.000 description 1
- 229940051998 ehrlichia canis Drugs 0.000 description 1
- UTINOWOSWSPFLJ-FSRHSHDFSA-N eletriptan hydrobromide Chemical compound Br.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 UTINOWOSWSPFLJ-FSRHSHDFSA-N 0.000 description 1
- 229960003470 eletriptan hydrobromide Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 101150094741 eltB gene Proteins 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 108010005965 endoglycoceramidase Proteins 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 108010049056 enterocin A Proteins 0.000 description 1
- 108010018853 enterocin BC25 Proteins 0.000 description 1
- 108010004819 enterocin CRL35 Proteins 0.000 description 1
- 108010047973 enterocin P Proteins 0.000 description 1
- 108010075883 enterocin SE-K4 Proteins 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 108010079222 epicidin 280 Proteins 0.000 description 1
- 229960002457 epicillin Drugs 0.000 description 1
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 description 1
- 108010064962 epidermin Proteins 0.000 description 1
- CXTXHTVXPMOOSW-JUEJINBGSA-N epidermin Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@H](C(N\C=C/SC2)=O)CSC1)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 CXTXHTVXPMOOSW-JUEJINBGSA-N 0.000 description 1
- 108010044807 epilancin K7 Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 101150055072 epsA gene Proteins 0.000 description 1
- YREISLCRUMOYAY-IIPCNOPRSA-N ergometrine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 YREISLCRUMOYAY-IIPCNOPRSA-N 0.000 description 1
- 229940030804 ergonovine maleate Drugs 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 101150055155 espA gene Proteins 0.000 description 1
- 101150006505 estA gene Proteins 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 101150115756 exoT gene Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 229950009324 famprofazone Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960002912 fenspiride Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 101150028805 fimF gene Proteins 0.000 description 1
- 101150015947 fimH gene Proteins 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- LZLGHWHSUZVUFZ-HZPDHXFCSA-N folerogenin Chemical compound C1([C@@H]2[C@H](O)C(=O)C3=C(O)C=C(C=C3O2)OC)=CC=C(O)C=C1 LZLGHWHSUZVUFZ-HZPDHXFCSA-N 0.000 description 1
- KBHMEHLJSZMEMI-KSYZLYKTSA-N formycin A Chemical compound N=1NC=2C(N)=NC=NC=2C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KBHMEHLJSZMEMI-KSYZLYKTSA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 101150002737 fyuA gene Proteins 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 108010047651 gallidermin Proteins 0.000 description 1
- AHMZTHYNOXWCBS-PCUVAHMGSA-N gallidermin Chemical compound C([C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C\C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](C(N/C=C/SC2)=O)CSC1)=O)=O)C1=CC=CC=C1 AHMZTHYNOXWCBS-PCUVAHMGSA-N 0.000 description 1
- 108010070411 gardimycin Proteins 0.000 description 1
- LAWKVNVCUPIOMG-HWWYPGLISA-N gardimycin Chemical compound C1=CC=C2C(C[C@H](C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@H](CC)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(O)=O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](C)NC(=O)[C@@H](CC)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)N)[C@@H](C)CC)C(C)C)=CNC2=C1 LAWKVNVCUPIOMG-HWWYPGLISA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 108010020998 gassericin A Proteins 0.000 description 1
- 108700034506 gassericin S Proteins 0.000 description 1
- 108010020991 gassericin T Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000002302 glucosamines Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 108010059016 helveticin J Proteins 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 229930193320 herbimycin Natural products 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- DXQWPBNWAKTXPF-UHFFFAOYSA-M hexadecyl(trimethyl)azanium;octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC[N+](C)(C)C DXQWPBNWAKTXPF-UHFFFAOYSA-M 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 108010083434 hiracin JM79 Proteins 0.000 description 1
- 101150039987 hlyC gene Proteins 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 229960001925 iclaprim Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012770 industrial material Substances 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 229950008410 ipsalazide Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229950010984 irsogladine Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229950007634 kitasamycin Drugs 0.000 description 1
- 101150023351 kpsE gene Proteins 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 108010093128 lactacin F Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010087689 lacticin 481 Proteins 0.000 description 1
- QCQYVCMYGCHVMR-UHFFFAOYSA-N lacto-N-biose I Natural products CC(=O)NC(C=O)C(C(O)C(O)CO)OC1OC(CO)C(O)C(O)C1O QCQYVCMYGCHVMR-UHFFFAOYSA-N 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000006356 lactobacillus kefiranofaciens Substances 0.000 description 1
- 108010062224 lactocin S Proteins 0.000 description 1
- 108010074479 lactococcin 972 Proteins 0.000 description 1
- 108010066379 lactococcin G Proteins 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- BBMULGJBVDDDNI-UHFFFAOYSA-N lasalocid A Natural products C=1C=C(C)C(O)=C(C(O)=O)C=1CCC(C)C(O)C(C)C(=O)C(CC)C(C(C1)C)OC1(CC)C1CCC(O)(CC)C(C)O1 BBMULGJBVDDDNI-UHFFFAOYSA-N 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 108010065723 leucocin B-Ta11a Proteins 0.000 description 1
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 108010047534 linocin Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 108010061634 listeriocin 743A Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 101150099153 malX gene Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 108010035293 maleylacetoacetate isomerase Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- VSKYMPAGYGCTFA-PQAXMVAFSA-N mature microcin B18 zwitterion Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@H](Cc1cnc[nH]1)\N=C(/O)[C@H](CO)\N=C(/O)C\N=C(/O)c1coc(C\N=C(/O)C\N=C(/O)c2coc(C\N=C(/O)C\N=C(/O)[C@H](CC(O)=N)\N=C(/O)C\N=C(/O)C\N=C(/O)c3coc(n3)-c3csc(C\N=C(/O)[C@H](CC(O)=N)\N=C(/O)[C@H](CO)\N=C(/O)c4csc(C\N=C(/O)C\N=C(/O)c5csc(C\N=C(/O)C\N=C(/O)C\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)C\N=C(/O)C\N=C(/O)c6csc(n6)-c6coc(C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)[C@@H](\N=C(/O)C\N=C(/O)[C@@H](N)C(C)C)[C@@H](C)CC)n6)n5)n4)n3)n2)n1)C(O)=O VSKYMPAGYGCTFA-PQAXMVAFSA-N 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 108010067215 mersacidin Proteins 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 229960003806 metampicillin Drugs 0.000 description 1
- FZECHKJQHUVANE-MCYUEQNJSA-N metampicillin Chemical compound C1([C@@H](N=C)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 FZECHKJQHUVANE-MCYUEQNJSA-N 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- IWDBEHWZGDSFHR-BTJKTKAUSA-N methiothepin maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 IWDBEHWZGDSFHR-BTJKTKAUSA-N 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960004377 methysergide maleate Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960003738 meticrane Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 108010001459 microcin H47 Proteins 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 108010021550 millericin B Proteins 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 108010093400 mutacin I Proteins 0.000 description 1
- 108010004592 mutacin II Proteins 0.000 description 1
- 108010004659 mutacin IV Proteins 0.000 description 1
- SUJOIPVTNUVDCB-UHFFFAOYSA-N mutactin Natural products CC1=CC(O)=C2C(=O)CC(O)CC2=C1C1=CC(O)=CC(=O)O1 SUJOIPVTNUVDCB-UHFFFAOYSA-N 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229940052683 nafronyloxalate Drugs 0.000 description 1
- 229950005705 naftopidil Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960000751 nefopam Drugs 0.000 description 1
- 229960002353 nemonoxacin Drugs 0.000 description 1
- AVPQPGFLVZTJOR-RYUDHWBXSA-N nemonoxacin Chemical compound COC1=C(N2C[C@@H](N)C[C@H](C)C2)C=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 AVPQPGFLVZTJOR-RYUDHWBXSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- WWJFFVUVFNBJTN-UHFFFAOYSA-N neopolyoxin C Natural products C=1C=C(O)C=NC=1C(O)C(C)C(N)C(=O)NC(C(O)=O)C(C(C1O)O)OC1N1C=CC(=O)NC1=O WWJFFVUVFNBJTN-UHFFFAOYSA-N 0.000 description 1
- 229940049337 neosporin Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229960001499 neostigmine bromide Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- WWJFFVUVFNBJTN-VHDFTHOZSA-N nikkomycin Z Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)[C@H](NC(=O)[C@@H](N)[C@H](C)[C@H](O)C=2N=CC(O)=CC=2)C(O)=O)C=CC(=O)NC1=O WWJFFVUVFNBJTN-VHDFTHOZSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 108010074461 nisin A Proteins 0.000 description 1
- 108700042622 nisin Z Proteins 0.000 description 1
- OUBCNLGXQFSTLU-UHFFFAOYSA-N nitisinone Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C1C(=O)CCCC1=O OUBCNLGXQFSTLU-UHFFFAOYSA-N 0.000 description 1
- 229960001721 nitisinone Drugs 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001607 oritavancin Drugs 0.000 description 1
- 108010006945 oritavancin Proteins 0.000 description 1
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 description 1
- MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 description 1
- 229960001687 orphenadrine citrate Drugs 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 229960002016 oxybutynin chloride Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 101150061305 papC gene Proteins 0.000 description 1
- 101150040891 papGII gene Proteins 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- 101150098891 pchA gene Proteins 0.000 description 1
- 101150075787 pchD gene Proteins 0.000 description 1
- 101150020987 pchE gene Proteins 0.000 description 1
- 101150084964 pchF gene Proteins 0.000 description 1
- 108010026249 pediocin A Proteins 0.000 description 1
- 108010074593 pediocin SJ-1 Proteins 0.000 description 1
- FLTWKHKMXZLDNR-CVMNUACMSA-N pediocin ach Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)OC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1N=CN=C1)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)C1C=NC=N1 FLTWKHKMXZLDNR-CVMNUACMSA-N 0.000 description 1
- ZRUMXHGBGLWVDT-SJMRFLIKSA-N pediocin pa 1 Chemical compound C([C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@H](CC=2NC=NC=2)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(O)=O)C1=CN=CN1 ZRUMXHGBGLWVDT-SJMRFLIKSA-N 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 239000004466 pelleted feed Substances 0.000 description 1
- FEDSNBHHWZEYTP-ZFQYHYQMSA-N penbutolol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 FEDSNBHHWZEYTP-ZFQYHYQMSA-N 0.000 description 1
- 229960004493 penbutolol sulfate Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 1
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000081 peptide deformylase inhibitor Substances 0.000 description 1
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
- 229960001511 pergolide mesylate Drugs 0.000 description 1
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
- 229960000769 periciazine Drugs 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 229960003929 perindopril erbumine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical class OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 229960001163 pidotimod Drugs 0.000 description 1
- BBLGCDSLCDDALX-LKGBESRRSA-N piericidin A Chemical compound COC=1NC(C\C=C(/C)C\C=C\C(\C)=C\[C@@H](C)[C@@H](O)C(\C)=C\C)=C(C)C(=O)C=1OC BBLGCDSLCDDALX-LKGBESRRSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229960001635 pirlimycin Drugs 0.000 description 1
- 229960004444 piromidic acid Drugs 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 229960003296 pitavastatin calcium Drugs 0.000 description 1
- 229960003342 pivampicillin Drugs 0.000 description 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 1
- 108010011394 plantaricin 423 Proteins 0.000 description 1
- 108010010610 plantaricin C Proteins 0.000 description 1
- CSOMAHTTWTVBFL-OFBLZTNGSA-N platensimycin Chemical compound C([C@]1([C@@H]2[C@@H]3C[C@@H]4C[C@@]2(C=CC1=O)C[C@@]4(O3)C)C)CC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-OFBLZTNGSA-N 0.000 description 1
- CSOMAHTTWTVBFL-UHFFFAOYSA-N platensimycin Natural products O1C2(C)CC3(C=CC4=O)CC2CC1C3C4(C)CCC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229930001118 polyketide hybrid Natural products 0.000 description 1
- 125000003308 polyketide hybrid group Chemical group 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 108010046630 polymyxin B drug combination bacitracin Proteins 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940103255 polysporin Drugs 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229950004447 posizolid Drugs 0.000 description 1
- LLLCSBYSPJHDJX-UHFFFAOYSA-M potassium;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O LLLCSBYSPJHDJX-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960003195 pridinol Drugs 0.000 description 1
- 229960005462 primaquine phosphate Drugs 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055009 propionibacterium avidum Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 229960001224 prulifloxacin Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 101150069622 pvdA gene Proteins 0.000 description 1
- 101150024179 pvdQ gene Proteins 0.000 description 1
- 108010025281 pyoverdin Proteins 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- 229960002281 racecadotril Drugs 0.000 description 1
- 108700040249 racecadotril Proteins 0.000 description 1
- 229950009965 radezolid Drugs 0.000 description 1
- BTTNOGHPGJANSW-IBGZPJMESA-N radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1
- 229960001150 ramelteon Drugs 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000213 ranolazine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004323 rivastigmine tartrate Drugs 0.000 description 1
- 229960004789 rizatriptan benzoate Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- 229960003889 rosoxacin Drugs 0.000 description 1
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 229960004796 rosuvastatin calcium Drugs 0.000 description 1
- 229960003287 roxatidine acetate Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 102220135950 rs143613534 Human genes 0.000 description 1
- 102220026969 rs63751070 Human genes 0.000 description 1
- 229960004062 rufloxacin Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000012233 scrotal disease Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- VBKBDLMWICBSCY-UHFFFAOYSA-N serinyl-aspartate Chemical compound OCC(N)C(=O)NC(C(O)=O)CC(O)=O VBKBDLMWICBSCY-UHFFFAOYSA-N 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960001368 solifenacin succinate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 108010037687 staphylococcin Proteins 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 229940037648 staphylococcus simulans Drugs 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- UZHDGDDPOPDJGM-CVOZLMQJSA-N stigmatellin A Chemical compound COC1=CC(OC)=C2C(=O)C(C)=C(CC[C@H](C)[C@H](OC)[C@H](C)[C@H](\C=C\C=C\C(\C)=C\C)OC)OC2=C1O UZHDGDDPOPDJGM-CVOZLMQJSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 108010075242 streptolysin S Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 108010082567 subtilin Proteins 0.000 description 1
- NRQODXJXWWUXFE-LYQFAKRDSA-N subtilosin a Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]1N(C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)O)[C@@H](C)CC)C(C)C)CCC1 NRQODXJXWWUXFE-LYQFAKRDSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960000468 sulfalene Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960004936 sulfamethoxypyridazine Drugs 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- 229960001363 sulfamoxole Drugs 0.000 description 1
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229950004215 sulfanitran Drugs 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960001975 sulfisomidine Drugs 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 108010006247 sulfoxide reductase Proteins 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960000658 sumatriptan succinate Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 101150065777 tcpN gene Proteins 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960004354 tegaserod maleate Drugs 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 108010041283 teixobactin Proteins 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 108010051977 thermophilin 13 Proteins 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 101150072314 thyA gene Proteins 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 1
- 229960004885 tiamulin Drugs 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 101150104391 traT gene Proteins 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- 229960005345 trimebutine Drugs 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
- 229960004161 trimethobenzamide Drugs 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 229960002835 trimipramine maleate Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- ICTZCAHDGHPRQR-UHFFFAOYSA-N usnic acid Natural products OC1=C(C)C(O)=C(C(C)=O)C2=C1C1(C)C(O)=C(C(=O)C)C(=O)C=C1O2 ICTZCAHDGHPRQR-UHFFFAOYSA-N 0.000 description 1
- WEYVVCKOOFYHRW-UHFFFAOYSA-N usninic acid Natural products CC12C(=O)C(C(=O)C)=C(O)C=C1OC1=C2C(O)=C(C)C(O)=C1C(C)=O WEYVVCKOOFYHRW-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 108010005406 variacin Proteins 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003740 vilazodone Drugs 0.000 description 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 101150099695 vps11 gene Proteins 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229950005850 zabofloxacin Drugs 0.000 description 1
- ZNPOCLHDJCAZAH-UCQKPKSFSA-N zabofloxacin Chemical compound CO\N=C1\CN(C=2C(=CC=3C(=O)C(C(O)=O)=CN(C=3N=2)C2CC2)F)CC11CNC1 ZNPOCLHDJCAZAH-UCQKPKSFSA-N 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 1
- 229960004487 ziprasidone mesylate Drugs 0.000 description 1
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01178—Beta-porphyranase (3.2.1.178)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01025—Tyrosine decarboxylase (4.1.1.25)
Definitions
- the present invention concerns methods for reducing, in a subject or environment, the level of bacteria-produced molecules which are harmful and/or not beneficial to said subject or environment.
- Microbiomes in particular within subjects, are constituted of numerous bacterial species that are most of the time beneficial to the subjects.
- association studies in humans and rodents have also shown disease-related dysbiosis across a wide spectrum of common chronic disorders, including atherosclerosis, metabolic disorders, asthma, and autism spectrum disorder. Some of these observations have been combined with experimental studies, prospective studies, or both to identify putative microbiota-derived molecular mediators of pathogenic mechanisms. More particularly, some commensal bacteria, in particular some commensal bacterial species or subpopulations of bacterial strains, can produce molecules that are or become harmful for a subject.
- One strategy can be to selectively remove these harmful molecule-producing bacteria.
- selectively removing a specific commensal bacterial strain can be damaging for the subject since it frees a niche in the microbiome which can be occupied by opportunistic pathogenic bacteria.
- commensals are often providing benefits to the host, and removing them will likely be detrimental to the host.
- the inventors are proposing herein an innovative strategy which is to use a bacterial strain from the same species as the harmful molecule-producing strain but which does not produce said harmful molecule, and conferring to said strain a competitive advantage, so that it can compete with the harmful molecule-producing strain and even outcompete or replace it, thereby reducing the level of the harmful molecule in the subject down to a value which is not detrimental anymore for the subject.
- the level of the harmful molecule is selectively reduced without the formation of any empty niche, and it is even possible to maintain the production of other molecules from the harmful molecule-producing strain which could be beneficial by using an engineered strain which only differs from the harmful-molecule producing strain by the absence of production of the harmful molecule and its additional competitive advantage provided by genetic engineering methods.
- the resulting B. thetaiotaomicron strain engineered to be able to metabolize porphyran, was not able to outcompete a corresponding wildtype B. thetaiotaomicron strain, naturally unable to metabolize porphyran.
- the present invention arises from the unexpected finding by the inventors that it is possible to actually reduce the level of a harmful molecule by using a bacterial strain, which does not produce the harmful molecule, and which is engineered to have a competitive advantage over the harmful molecule-producing strain, said competitive advantage being for example advantage in interference competition or the capacity or an improved capacity of importing and metabolizing oligosaccharides, in particular human milk oligosaccharide. Thereby, an actual therapeutic effect can be obtained when administering said engineered strain.
- the present invention thus concerns a method for reducing, in a subject or in a environment, the level of a molecule produced by at least one target bacterial strain which is harmful and/or not beneficial to said subject or environment, said method comprising: administering to the subject or providing the environment with an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target bacterial strain(s), wherein said engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s), and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the level of the molecule produced by the target bacterial strain(s) is reduced in the subject or environment.
- said heterologous gene or gene set providing a competitive advantage is from another species than the engineered bacterial strain.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene involved in the import and/or metabolism of a nutrient source.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a transporter of a nutrient source.
- said nutrient source is a milk oligosaccharide, more particularly a human milk oligosaccharide.
- said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
- said milk oligosaccharide is selected from the group consisting of lacto-N-biose, lacto-N-triose, N-acetyllactosamime, lacto-N-neotriose, lacto-N- tetraose, lacto-N-neotetraose, fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2’-fucosyllactose, 3’-sialyllactosamine, 3’-fucosyllactose, 3’-sialyl-3-fucosyllactose, 3’-sialyllactose, 6’-sialyllactosamine, 6’-sialyllactose, difucosyllactoase
- said milk oligosaccharide is a modified, recombinant or synthetic milk oligosaccharide.
- said milk oligosaccharide is obtained from human milk.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene of the H5 gene cluster from Bifidobacterium longum subsp. infantis.
- said nutrient source is a rare carbohydrate. In a more particular embodiment, less than 50% of other bacterial cells in the subject utilize said rare carbohydrate as a nutrient source.
- said rare carbohydrate is a polysaccharide.
- said rare carbohydrate is a sulfated carbohydrate.
- said rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans and any combination thereof.
- said rare carbohydrate is selected from the group consisting of porphyran, agarose, carrageenan, ulvan, xylan and any combination thereof.
- said rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
- said rare carbohydrate is a sulfated polygalactan.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene selected from the group consisting of genes encoding porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding protein(s) which sequence(s) is(are) at least 80% identical to at least one of BACPLE 1683-1706 from the Bacteroides plebeius genome.
- said heterologous or engineered gene set providing a competitive advantage comprises at least two, three, four, five or six genes.
- the nutrient source cannot be utilized as a nutrient source by the engineered bacterial strain in the absence of the heterologous or engineered gene or gene set providing a competitive advantage.
- the nutrient source is utilized as a nutrient source more efficiently by the engineered bacterial strain in the presence of the heterologous or engineered gene or gene set providing a competitive advantage than in the absence thereof.
- the method further comprises administering the nutrient source to the subject or providing the environment with the nutrient source.
- the reduction of the level of the molecule produced by the target bacterial strain(s) is only due to the administration of said engineered bacterial strain.
- no antibacterial agent is administered to the subject.
- an antibacterial agent is administered to the subject.
- the engineered bacterial strain further produces an antibacterial agent to which the engineered bacterial strain is resistant, but to which the target bacterial strain(s) is sensitive. In a more particular embodiment, the engineered bacterial strain further produces an antibacterial agent to which the engineered bacterial strain is resistant, but to which the target bacterial strain(s) and other bacteria from the subject are sensitive.
- the antibacterial agent is a bacteriocin.
- the engineered bacterial strain produces multiple antibacterial agents, at least one, two, three, four, five or more antibacterial agents.
- the produced molecule is expressed, secreted and/or displayed by the target bacterial strain(s).
- said engineered bacterial strain does not naturally produce the molecule produced by the target bacterial strain(s).
- said engineered bacterial strain has been engineered to not produce the molecule produced by the target bacterial strain(s).
- said engineered bacterial strain has been engineered to produce a non-harmful mutant or variant of the molecule produced by the target bacterial strain(s).
- the engineered bacterial strain produces a variant or a mutant of the molecule produced by the target bacterial strain(s), thereby reducing the level, in the subject or environment, of the molecule produced by the target bacterial strain(s), in particular reducing the ratio of the level, in the subject or environment, of the molecule produced by the target bacterial strain(s) to the level, in the subject or environment, of a variant or mutant of said molecule.
- the engineered bacterial strain neither produces the molecule produced by the target bacterial strain(s), nor any variant or any mutant of the molecule produced by the target bacterial strain(s).
- the present invention also concerns a method for preventing and/or treating, in a subject, a disease, disorder or condition associated to at least one target molecule-producing bacterial strain, said method comprising: administering to the subject a therapeutically efficient amount of an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce the molecule(s) produced by the target bacterial strain(s) which is involved in said disease or disorder, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the disease, disorder or condition is prevented and/or treated in the subject.
- said molecule is a molecule able to induce or sustain an autoimmune reaction in the host.
- said molecule is a peptide that mimics a human autoantigen.
- said molecule is a virulence factor.
- said molecule is a molecule encoded by an antibiotic resistance gene.
- said molecule is a molecule which induces or can induce inflammation in a subject.
- said molecule is a molecule that modulates or can modulate a neurodegenerative disease.
- said engineered bacterial strain does not naturally produce said molecule.
- said engineered bacterial strain has been engineered to not produce said molecule.
- said engineered bacterial strain has been engineered to produce a mutant or variant of said molecule, in particular a non-harmful mutant or variant of said molecule.
- an engineered bacterial strain comprising a heterologous or engineered gene or gene set providing a competitive advantage over target bacterial strain(s) is used.
- the term “engineered” means that the bacterial cell of the invention has been modified by standard molecular biology techniques, typically to introduce the indicated heterologous gene or gene set or to modify the indicated gene or gene set, for example by transformation of the cell with a plasmid, by conjugation, by transduction of the cell with a bacteriophage, or by any suitable technique enabling introducing or modifying a nucleic acid sequence into a bacterial cell.
- engineering of a bacterial strain implies a deliberate action to introduce or modify a nucleic acid sequence and does not cover introduction or modification of a nucleic acid sequence through natural evolution of the bacterial strain.
- the bacteria of the invention can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
- transformation chemical transformation or ultrasound transformation
- transduction using for example optionally engineered bacteriophages, or packaged phagemids technologies
- conjugation or electroporation.
- said heterologous gene or gene set providing a competitive advantage has been incorporated into the bacterial cell’s chromosomal or extrachromosomal expression system, or as extrachromosomal expression system, by genetic engineering techniques known in the art.
- said bacteria can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
- engineered gene or gene set is meant herein a gene or gene set, autologous to said bacterial strain, but which has been modified by standard molecular biology techniques, typically to introduce a mutation in the sequence of said autologous gene or gene set, in such a way that the expression of the gene or gene set or the activity of the protein encoded by said gene or gene set is modified.
- engineering of a gene or gene set implies a deliberate action to introduce a modification in the nucleic acid sequence and does not cover mutation of a nucleic acid sequence through natural evolution of the bacterial strain.
- Said engineered gene or gene set may be any piece of a gene such as a portion of an open reading frame of a gene, or a sequence involved in the regulation of the expression of a gene such as a promoter, an operator, a terminator.
- a nucleic acid encoding a transcription factor a nucleic acid encoding a repressor, a nucleic acid encoding an activator, or a nucleic acid encoding an inducer.
- said engineered gene or gene set providing a competitive advantage has been modified into the bacterial cell’s chromosomal or extrachromosomal expression system, by genetic engineering techniques known in the art.
- said bacteria can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
- said heterologous or engineered gene or gene set providing a competitive advantage is or is engineered to be under the control of a high expression promoter.
- said heterologous or engineered gene or gene set providing a competitive advantage is under the control of an inducible promoter, constitutive promoter, native promoter (e.g., native to the bacterial strain), heterologous promoter, or a promoter associated with said heterologous gene in its native form.
- said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source, as defined below
- said heterologous or engineered gene or gene set providing a competitive advantage is or is engineered to be under the control of a promoter which is induced in the presence of a nutrient source.
- said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source, as defined below, the expression of said heterologous or engineered gene or gene set providing a competitive advantage is increased in the presence of a nutrient source.
- said heterologous or engineered gene or gene set providing a competitive advantage is under the control of a burden-sensing promoter. More particularly, when said engineered bacterial strain produces a mutant or variant of said molecule produced by the target bacterial strain(s), as defined below, synthesis of said mutant or variant may confer a burden and/or fitness cost on said engineered bacterial strain. In such embodiment, expression of said heterologous or engineered gene or gene set providing a competitive advantage can be up-regulated when said burden-sensing promoter is induced by said burden and/or fitness cost relative to a basal level expression of said heterologous or engineered gene or gene set when said burden-sensing promoter is not induced.
- said engineered bacterial strain further comprises an essential gene operably linked to a burden-sensing promoter, wherein expression of said heterologous or engineered gene or gene set providing a competitive advantage and/or, when said engineered bacterial strain produces a mutant or variant of said molecule produced by the target bacterial strain(s), as defined below, synthesis of said mutant or variant, confer a burden and/or fitness cost on said strain, and wherein expression of said essential gene is up-regulated when said burden-sensing promoter is induced by said burden and/or fitness cost relative to a basal level expression of said essential gene when said burden-sensing promoter is not induced.
- burden-sensing promoters are typically disclosed in international application WO2021/160854.
- burden-sensing promoters include a o factor regulated promoter, such as o 32 , o B and o s factor regulated promoters, a ribosomal RNA promoter, an HAC1 -upregulated promoter comprising a UPR element, and a DNA-damage sensing promoter.
- said heterologous or engineered gene or gene set providing a competitive advantage is chromosomally integrated upstream of an autologous essential gene, in particular as part of a single operon including said autologous essential gene. Such a location of the heterologous or engineered gene is advantageous to prevent loss of function of the heterologous or engineered gene.
- the downstream autologous essential gene will not be expressed anymore, and the engineered bacterial strain will die.
- said gene or gene set encoding said mutant or variant is chromosomally integrated upstream of a heterologous or engineered gene providing a competitive advantage, in particular as part of a single operon including said heterologous or engineered gene providing a competitive advantage.
- a location of the gene or gene set encoding said mutant or variant is advantageous to prevent loss of function of the gene or gene set.
- the engineered bacterial strain used in the context of the invention can be obtained from any suitable bacterial strain.
- the engineered bacterial strain is obtained from an autologous strain, i.e. a strain isolated from the subject to be treated.
- the engineered bacterial strain is obtained from a non-autologous strain, i.e. a strain which was not isolated from the subject to be treated.
- a “bacterial strain” refers to a genetic variant or subtype within a bacterial species. Therefore, a bacterial strain more particularly refers to a bacterium which remains genetically unchanged when grown or multiplied. The multiplicity of identical bacteria are included.
- a bacterial strain is typically obtained from the isolation of a clone, which can give birth to a population of cells obtained from a single bacterial cell or colony.
- Examples of bacterial strains include, without limitation, strains from bacteria of the genus Acinetobacter spp., Actinobacillus spp., Actinobacter spp., Actinomyces spp., Aeromonas spp., Bacillus spp., Bacteroides spp., Bartonella spp., Bifidobacterium spp., Bartonella spp., Bordetella spp., Borrelia spp., Brevibacterium spp., Brucelia spp., Brucella spp., Campylobacter spp., Chlamydia spp., Chlamydophilia spp., Citrobacter spp., Clostridium spp., Corynebacterium spp., Cutibacterium spp., Ehrlichia spp., Enterobacter spp., Enterococcus
- bacterial strains used in the context of the invention are anaerobic bacterial strains (e.g., cells that do not require oxygen for growth).
- Anaerobic bacterial strains include facultative anaerobic strains such as, but not limited to, Escherichia coll, Shewanella oneidensi, Gardnerella vaginalis and Listeria.
- Anaerobic bacterial strains also include obligate anaerobic strains such as, for example, Bacteroides, Clostridium, Cutibacterium, Propionibacterium, Fusobacterium and Porphyromonas species.
- anaerobic bacteria are most commonly found in the gastrointestinal tract.
- the engineered bacterial strains are thus obtained from bacteria most commonly found in the gastrointestinal tract.
- the bacterial strains are, without limitation, Actinobacillus actinobycetemcomitans, Actinobacter baumanii, Actinomyces israelii, Aeromonas caviae, Aeromonas hydrophila, Bacillus anthracis, Bacillus cereus, Bacillus coagulans, Bacillus liquefaciens, Bacillus megaterium, Bacillus popillae, Bacillus subtilis, Bacillus thuringiensis, Bacteroides distasonis, Bacteroides faecis, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bartonella henselae, Bartonella Quintana, Bordetella pertussis, Borrelia afzelii, Borrelia burgdorferi, Borrelia garinii, Borrelia recurrentis, Brevibacterium lactofermentum,
- the bacterial strains are, without limitation, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Achromobacter, Acidaminococcus, Acinetobacter, Actinobacillus, Actinomyces, Adlercreutzia, Aeromicrobium, Aggregatibacter, Akkermansia, Aliagarivorans, Alistipes, Alloscardovia, Anaerobacter, Anaerobaculum, Anaerococcus, Anaerofilum, Anaerofustis, Anaerosinus, Anaerostipes, Anaerotruncus, Anaerovorax, Aneurinibacillus, Bacillus, Bacteroides, Barnesiella, Bavariicoccus, Bifidobacterium, Bilophila, Blautia, Brachymonas, Brevibacterium, Bryantella, Butyricicoccus, Butyri vibrio, Butyricimonas, Cal
- the bacteria strains are, without limitation, Achromobacter xylosoxidans, Acidaminococcus fermentans, Acidaminococcus intestini, Acidaminococcus sp., Acinetobacter baumannii, Acinetobacter junii, Acinetobacter Iwoffii, Actinobacillus capsulatus, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces radingae, Adlercreutzia equolifaciens, Aeromicrobium massiliense, Aggregatibacter actinomycetemcomitans, Akkermansia muciniphila, Aliagarivorans marinus, Alistipes finegoldii, Alistipes indistinctus, Alistipes inops, Alistipes onderdonkii, Alistipes putredinis, Alistipes sene
- the bacteria strains are those commonly found on the skin microbiota and are without limitation Abiotrophia defectiva, Acetobacter farinalis, Acetobacter malorum, Acetobacter orleanensis, Acetobacter sicerae, Achromobacter anxifer, Achromobacter denitrificans, Achromobacter marplatensis, Achromobacter spanius, Achromobacter xylosoxidans subsp.
- Actinomyces odontolyticus Actinomyces oris, Actinomyces turicensis, Actinomycetospora atypica, Actinomycetospora corticicola, Actinomycetospora rhizophila, Actinomycetospora rishiriensis, Actinotignum schaalii, Aerococcus christensenii, Aerococcus urinae, Aeromicrobium flavum, Aeromicrobium massiliense, Aeromicrobium tamlense, Aeromonas australiensis, Aeromonas bestiarum, Aeromonas bivalvium, Aeromonas encheleia, Aeromonas eucrenophila, Aeromonas hydrophila subsp.
- Aeromonas piscicola Aeromonas popoffii
- Aeromonas rivuli Aeromonas salmonicida subsp. pectinolytica
- Aeromonas salmonicida subsp. smithia Aeromonas sharmana
- Aggregatibacter aphrophilus Aggregatibacter segnis
- Agrococcus baldri Albibacter methylovorans
- Corynebacterium ammoniagenes Corynebacterium amycolatum, Corynebacterium aurimucosum, Corynebacterium coyleae, Corynebacterium durum, Corynebacterium grisburgense, Corynebacterium glaucum, Corynebacterium glyciniphilum, Corynebacterium imitans, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium massiliense, Corynebacterium mastitidis, Corynebacterium matruchotii, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium mustelae, Corynebacterium mycetoides, Corynebacterium pyruviciproducens, Corynebacterium simulans, Corynebacterium simulans
- Lactobacillus iners Lactobacillus modestisalitolerans
- Lactobacillus plantarum subsp. argentoratensis Lactobacillus xiang
- Lactococcus lactis subsp. lactis Lactococcus lactis subsp.
- lactis Lactococcus piscium, Lapillicoccus jejuensis, Lautropia mirabilis, Lechevalieria roselyniae, Legionella beliardensis, Lentzea albida, Lentzea californiensis, Leptotrichia buccalis, Leptotrichia goodfellowii, Leptotrichia hofstadii, Leptotrichia hongkongensis, Leptotrichia shahii, Leptotrichia trevisanii, Leptotrichia wadei, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc gelidum subsp.
- Propionibacterium acnes subsp. acnes Propionibacterium acnes subsp. elongatum, Propionibacterium granulosum, Propionimicrobium lymphophilum, Propionispira arcuata, Proteus vulgaris, Providencia rustigianii, Pseudoalteromonas agarivorans, Pseudoalteromonas atlantica, Pseudoalteromonas paragorgicola, Pseudokineococcus lusitanus, Pseudomonas aeruginosa, Pseudomonas asplenii, Pseudomonas asuensis, Pseudomonas benzenivorans, Pseudomonas cannabina, Pseudomonas chengduensis, Pseudomonas cissicola, Pseudomon
- Streptococcus agalactiae Streptococcus canis, Streptococcus cristatus, Streptococcus gordonii, Streptococcus infantis, Streptococcus intermedius, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus sanguinis, Streptomyces caeruleatus, Streptomyces canarius, Streptomyces capoamus, Streptomyces ciscaucasicus, Streptomyces griseorubiginosus, Streptomyces iconiensis, Streptomyces olivaceoviridis, Streptomyces panaciradicis, Streptomyces phaeopur
- the bacteria strains are those commonly found in the vaginal microbiota and are, without limitation, Acinetobacter antiviralis, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Actinobaculum massiliense, Actinobaculum schaalii, Actinomyces europaeus, Actinomyces graevenitzii, Actinomyces israelii, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces turicensis, Actinomyces urogenitalis, Actinomyces viscosus, Aerococcus christensenii, Aerococcus urinae, Aerococcus viridans, Aeromonas encheleia, Aeromonas salmonicida, Afip
- the engineered bacterial strain of the invention is obtained from a Bacteroides bacterial strain, in particular from a Bacteroides thetaiotaomicron and/or a Bacteroides faecis strain.
- the engineered bacterial strain of the invention is obtained from a strain of a bacterial species selected from the group consisting of Escherichia coli, Bacteroides fragilis, Enterococcus faecalis, Yersinia pestis, Francisella tularensis, Bacillus anthracis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enterica Typhi, Fusobacterium nucleatum, Bacteroides fragilis, Cutibacterium acnes and Helicobacter pylori.
- Escherichia coli Bacteroides fragilis, Enterococcus faecalis, Yersinia pestis, Francisella tularensis, Bacillus anthracis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enterica Typhi, Fusobacterium nucleat
- the engineered bacterial strain of the invention is obtained from a Propionibacterium propionicum, Corynebacterium amycolatum, Actinomyces massiliensis or Bacteroides thetaiotaomicron strain.
- the engineered bacterial strain of the invention is obtained from a strain of a bacterial species from the Firmicutes phylum.
- the engineered bacterial strain of the invention is obtained from a Roseburia intestinalis strain.
- the engineered bacterial strain of the invention is obtained from a Prevotella copri strain.
- the engineered bacterial strain of the invention is obtained from a Eggerthella lenta strain.
- the engineered bacterial strain of the invention is obtained from a Enterococcus faecalis, Enterococcus faecium or Lactobacillus brevis strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Clostridium sporogenes strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Escherichia co// strain or from a strain of a Gammaproteobacteria. In another embodiment, the engineered bacterial strain of the invention is obtained from a Prevotella copri or Bacteroides vulgatus strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a C. difficile strain.
- the engineered bacterial strain is a Gram positive bacterial strain. In an alternative embodiment, the engineered bacterial strain is a Gram negative bacterial strain.
- the engineered bacterial strain is not a Bacteroides strain. Heterologous or engineered gene or gene set providing a competitive advantage
- the engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over target bacterial strain(s).
- competitive advantage of the engineered bacterial strain over target bacterial strain(s) is meant herein an advantage in the interaction between the engineered bacterial strain and target bacterial strain(s) within a community, typically within a microbiome.
- Examples of competitive advantages include a fitness advantage wherein the engineered bacterial strain is better suited to conquer a specific niche in the microbiome, an advantage in interference competition wherein the engineered bacterial strain can typically produce antagonists (such as toxins, biosurfactants, bacteriocins, volatiles or antibiotics) against other members of the microbiome or wherein the engineered bacterial strain can typically be resistant to administered antagonists (such as toxins, biosurfactants, bacteriocins, volatiles or antibiotics) to which other members of the microbiome are sensitive, or an advantage in exploitation competition wherein the engineered bacterial strain exploits more efficiently the growth substrates available to the community, more particularly a metabolic advantage wherein the engineered bacterial strain metabolizes more efficiently some growth substrates available to the community.
- antagonists such as toxins, biosurfactants, bacteriocins, volatiles or antibiotics
- the engineered bacterial strain can typically be resistant to administered antagonists (such as toxins, biosurfactants, bacteriocins, volatile
- said competitive advantage is a metabolic advantage.
- said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source.
- gene or gene set involved in the import of a nutrient source is meant herein a gene or set of genes encoding a molecule enabling directly and/or indirectly the active transport of the nutrient source from the extracellular medium into the cytoplasm.
- gene or gene set involved in the metabolism of a nutrient source is meant herein a gene or set of genes encoding a molecule enabling, intracellularly and/or extracellularly after secretion in the extracellular medium or in the periplasm, the degradation of the nutrient source.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a transporter of a nutrient source.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding an intracellular or extracellular enzyme involved in the degradation of the nutrient source.
- said heterologous or engineered gene set providing a competitive advantage comprises a gene encoding a transporter of a nutrient source and a gene encoding an intracellular enzyme involved in the degradation of the nutrient source.
- said heterologous gene or gene set providing a competitive advantage is from another species than the engineered bacterial strain.
- said nutrient source is a rare carbohydrate.
- IR carbohydrate is meant herein a carbohydrate that is utilized, as a nutrient source, by less than 50% e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1 %, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1 %, less than 0.03%, less than 0.01 %, less than 0.003%, less than 0.001 %, less than 0.0001 %, or none) of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome (i.e., cells “other” than the engineered bacterial strain of the invention, e.g., cells of the resident population prior to administration).
- a rare carbohydrate is one that can be utilized, as a nutrient source, by less than 50% e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1 %, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1 %, less than 0.03%, less than 0.01 %, less than 0.003%, less than 0.001 %, less than 0.0001 %, or none) of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
- the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 20% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
- the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 5% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
- the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 2% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 0.5% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
- the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by none of the other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
- the rare carbohydrate is a polysaccharide.
- the rare carbohydrate is a sulfated carbohydrate.
- the rare carbohydrate is selected from the group consisting of porphyran, ulvan, carrageenan, fucoidan and any combination thereof.
- the rare carbohydrate is a marine carbohydrate.
- marine carbohydrates include but are not limited to: porphyran, agarose, agaropectin, carrageenan, ulvan, alginate, fucoidan, laminarin, and marine microbe exopolysaccharides.
- the rare carbohydrate of interest is selected from porphyran and agarose.
- the rare carbohydrate is porphyran.
- the rare carbohydrate is agarose.
- said rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans (such as carrageenan and agarose), porphyran, ulvan, xylan and any combination thereof.
- the rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
- the rare carbohydrate is a carbohydrate that contains a glycosidic linkage selected from the group consisting of p-d-galactopyranose to a-l-galactopyranose-6- sulfate, p-d-galactopyranose to 3,6-anhydro-a-l-galactopyranose.
- the rare carbohydrate is a sulfated polygalactan.
- one or more of the galactose residues of the sulfated polygalactan can be a 3,6- anhydro-galactose (e.g., in some embodiments joined by alternating a-1 ,3 and p-1 ,4-glycosidic linkage).
- one or more of the galactopyranose residues of the sulfated polygalactan can be modified by one or more ester sulfates.
- one or more of the galactose residues of the sulfated polygalactan is a 3,6-anhydro-galactose (e.g., in some embodiments joined by alternating a-1 ,3 and p-1 ,4-glycosidic linkage); and one or more of the galactopyranose residues of the sulfated polygalactan is modified by one or more ester sulfates.
- the heterologous or engineered gene or gene set providing a competitive advantage can be or comprise a gene selected from the group consisting of genes encoding porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a porphyranase (e.g., one from GH family 86 (GH86)).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding an agarase (e.g., one from GH family 86 (GH86)).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1706 from the Bacteroides plebeius genome (or homologs thereof) (see, e.g., Table 1).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) and BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1699 from the B.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1688-1706 from the B. plebeius genome (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acid(s) encoding BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acid(s) encoding BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acid(s) encoding BACPLE 1683-1687 and BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome (or homologs thereof).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity ⁇ e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1706 from the B. plebeius genome (see, e.g., Table 1 ).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 from the B. plebeius genome.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1700-1706 from the B. plebeius genome.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity ⁇ e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) and/or at least one of BACPLE 1700-1706 from the B. plebeius genome.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity ⁇ e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1699 from the B. plebeius genome.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity ⁇ e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1688-1706 from the B.
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome.
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome.
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 and/or at least one of BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome.
- sequence identity e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity
- Table 1 SEQ ID NOs. and annotations for proteins encoded by B. plebeius genome (BACPLE 1669-1706)
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 28-34 (or homologs thereof).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof) and SEQ ID NOs: 28-34 (or homologs thereof).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-27 (or homologs thereof).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 18-34 (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 28-34 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 14-17 and SEQ ID NOs: 28-34 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof).
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-34.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that have 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 28-34.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 and/or at least one of SEQ ID NOs: 28-34.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-27.
- the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 18-34.
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21.
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 28-34 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21 .
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 and/or at least one of SEQ ID NOs: 28-34 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21 .
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding (i) at least one protein of sequence selected from SEQ ID NOs: 19, 21 and 22 (or a homolog(s) thereof); (ii) at least one protein of sequence selected from SEQ ID NOs: 26 and 33 (or a homolog(s) thereof); and (iii) at least one protein of sequence selected from SEQ ID NOs: 25 and 32 (or a homolog(s) thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding proteins of sequences SEQ ID NOs: 19, 21-22, 25, 26, and 32-33 (or homologs thereof).
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding (i) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 19, 21 and 22; (ii) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 26 and 33; and (iii) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 25 and 32.
- sequence identity e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity
- the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding proteins having respectively 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with SEQ ID NOs: 19, 21-22, 25, 26, and 32-33.
- the heterologous or engineered gene set providing a competitive advantage comprises at least 3 genes (e.g., at least 4, at least 5, at least 6, at least 8 genes, at least 10 genes, at least 12 genes, at least 15 genes, or at least 20 genes). In a particular embodiment, the heterologous or engineered gene set providing a competitive advantage comprises at least six genes.
- the heterologous or engineered gene set providing a competitive advantage comprises 3 to 30 genes (e.g., 5-30, 3-25, 3-20, 3-15, 3-10, 3-8, 5-25, 5-20, 5-15, 5-10, 5-8, 8-30, 8-25, 8-20, 8-15, 10-30, 10-25, 10-20, 10-15, 12-30, 12- 25, 12-20, 15-30, 15-25, 20-30, or 20-25 genes).
- the heterologous or engineered gene set providing a competitive advantage comprises 3 to 10 genes. Oligosaccharides
- said nutrient source is an oligosaccharide, more particularly a milk oligosaccharide.
- said milk oligosaccharide can be from any mammalian milk source such as human, bovine, pig, rabbit, goat, sheep or camel milk.
- said rare carbohydrate is a mammalian milk oligosaccharide (MMO).
- said rare carbohydrate is a human milk oligosaccharide (HMO).
- oligosaccharide refers broadly to a carbohydrate having 3-20 sugar residues or degrees of polymerization from any source.
- MMO include individual structures synthesized to produce carbohydrate structures known to be in a mammalian milk including milk from human, bovine, equine, porcine, goat, camel, water buffalo, and sheep. It refers broadly to those indigestible glycans, sometimes referred to as “dietary fiber”, or the carbohydrate polymers that are not hydrolyzed by the endogenous mammalian enzymes in the digestive tract (e.g., the small intestine) of the mammal.
- Mammalian milks contain a significant quantity of MMO that are not usable directly as an energy source for the milk-fed mammal but may be usable by microorganisms in the gut of that mammal.
- the core structures of HMO consist of lactose at the reducing ends elongated by [3-1 -3- linked lacto-N-biose I (LNB, Gal -3GlcNAc) and/or [3-1 -3/6-linked N-acetyllactosamine (LacNAc, Gaipi -4GlcNAc). These core structures can be further elongated with residues of galactose (Gal), N-acetylglucosamine (GIcNAc), N-acetylneuraminic acid (Neu5Ac) and decorated with fucose or sialic acid (see Ninonuevo et al. (2006) J Agric Food Chem 54:7471 -7480).
- the combinatorial effect of elongation, fucosylation and sialylation produces a heterogenous mix of short-chain, long-chain and branched structures with more than 200 distinct HMO types identified to date (Kirmiz etal. (2016) Annu Rev Food Sci Technol 9:429).
- the type 1 tetrasaccharide Lacto- N-tetraose is one of the most highly abundant oligosaccharides in breast milk and together with its isomer Lacto-N-neotetraose (LNnT) and derivatives comprise up to 70% of the total amount of HMO (Ninonuevo et al. (2006) J Agric Food Chem 54:7471 -7480).
- MMO particularly comprises lacto-N-biose (LNB), lacto-N-triose (LNT), at least one oligosaccharide having a Type I core, at least one oligosaccharide having a Type II core, and/or combinations thereof.
- LNB lacto-N-biose
- LNT lacto-N-triose
- Type I or type II may be isomers of each other.
- MMO typically includes one or more of lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-neotriose, lacto-N- tetraose (LNT), lacto-N-neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'- fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'-fucosyllactose (3FL), 3'-sialyl-3- fucosyllactose(3S3FL), 3 '-sialyllactose (3SL), 6'-sialyll
- TTLNH trifucosyllacto-N-hexaose
- LNH lacto-N-hexaose
- LNFPIII lacto-N-fucopentaose III
- MFLNHIII monofucosylated lacto-N-Hexose III
- MFLNHIII Monofucosylmonosialyllacto-N- hexose
- said milk oligosaccharide is selected from the group consisting of lacto-N-biose, lacto-N-triose, N-acetyllactosamime, lacto-N-neotriose, lacto-N-tetraose, lacto- N-neotetraose, fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2’-fucosyllactose, 3’-sialyllactosamine, 3’-fucosyllactose, 3’-sialyl-3- fucosyllactose, 3’-sialyllactose, 6’-sialyllactosamine, 6’-sialyllactose, difucosyllactoase, lac
- said milk oligosaccharide is selected from the group consisting of lacto-N-biose, N-acetyllactosamine, and combinations thereof.
- said milk oligosaccharide is 2'-fucosyllactose (2FL).
- said milk oligosaccharide is selected from lacto-N- triose, lacto-N-neotetrose and combinations thereof.
- said milk oligosaccharide is a modified, recombinant or synthetic milk oligosaccharide.
- Modified, recombinant or synthetic milk oligosaccharides can be obtained by any method well-known from the skilled person, in particular by chemical synthesis (as disclosed for example in Bandara etal. (2020) Org Biomol Chem 18(9) :1747-1753), biological synthesis or engineering or by fermentation (as disclosed for example in PCT application WO2015/197082).
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises at least one gene of the H5 gene cluster, in particular at least one gene of a functional H5 gene cluster, from Bifidobacterium longum subsp. infantis.
- a “functional H5 gene cluster” refers to a cluster of genes in Bifidobacterium responsible for the uptake and metabolism of human milk oligosaccharides containing LNB.
- a functional H5 cluster typically comprises Blon_2175, Blon_2176 and Blon_2177.
- the H5 gene cluster typically comprises the following genes: Blon_2171 (which typically encodes a UDP-glucose 4-epimerase, typically a protein of sequence SEQ ID NO: 35), Blon_2173 (which typically encodes an aminoglycoside phosphotransferase, typically a protein of sequence SEQ ID NO: 36), Blon_2174 (which typically encodes a protein of sequence SEQ ID NO: 37), Blon_2175 (which typically encodes a binding-protein-dependent transport systems inner membrane component, typically a protein of sequence SEQ ID NO: 38), Blon_2176 (which typically encodes a binding-protein-dependent transport systems inner membrane component, typically a protein of sequence SEQ ID NO: 39), Blon_2177 (which typically encodes an extracellular solute-binding protein, family 1 , typically a protein of sequence SEQ ID NO: 40), and galT (galactose- 1 -phosphate uridylyltransferase, typically of sequence SEQ ID NO: 41
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene selected from the group consisting of sequences encoding (i) a protein of sequence SEQ ID NO: 35 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 35, (ii) a protein of sequence SEQ ID NO: 36 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 36, (iii) a protein of sequence SEQ ID NO: 35 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 9
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises at least one gene of a Roseburia HMO utilization loci, as defined in Pichler et al. (2020). Nat Commun 11 :3285, in particular a Roseburia GH136 gene, a Roseburia GH112 and/or a Roseburia ABC transporter gene.
- said heterologous or engineered gene or gene set providing a competitive advantage is or comprises at least one gene of an Eubacterium HMO loci, as defined in Pichler et al. (2020). Nat Commun 11 :3285, in particular an Eubacterium GH136 gene, an Eubacterium GH112 and/or an Eubacterium ABC transporter gene.
- the percent identity is calculated in relation to polymers (e.g., polynucleotide or polypeptide) whose sequences have been aligned.
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
- the percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11 -17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol.
- the nutrient source cannot be utilized as a nutrient source by the engineered bacterial strain in the absence of the heterologous or engineered gene or gene set providing a competitive advantage.
- the nutrient source is utilized as a nutrient source more efficiently by the engineered bacterial strain in the presence of the heterologous or engineered gene or gene set providing a competitive advantage than in the absence thereof.
- the engineered bacterial strain is able to use the nutrient source in the absence of the heterologous or engineered gene or gene set, but the presence of the heterologous or engineered gene or gene set enables the engineered bacterial strain to use the nutrient source more efficiently, for example by providing a gene that can ensure the transport of the nutrient source before it is metabolized by the bacterial strain.
- the method further comprises administering the nutrient source, as defined above, to the subject, or providing the environment with the nutrient source, as defined above.
- said nutrient source is not used in its natural context.
- the nutrient source is HMO as defined above, the subject is an adult. Indeed, as well-known from the skilled person, HMO are generally not eaten or drunk by adults.
- said engineered bacterial strain and said nutrient source are administered or provided either together or separately.
- the nutrient source may be provided as a solution and the engineered bacterial strain may be provided in dry form or as an enteric-coated tablet or capsule.
- a composition comprising both the engineered bacterial strain and the nutrient source, for example in the form of a non-aqueous liquid or gel composition or in dry form or as an enteric-coated tablet or capsule, can be administered or provided.
- the nutrient source may be provided in dry form or as an enteric-coated tablet or capsule and the engineered bacterial strain may be provided in a separate dry form or as an enteric-coated tablet or capsule.
- the nutrient source can be administered or provided prior to the administration or provision of the engineered bacterial strain, or the nutrient source can be administered or provided contemporaneously with the administration or provision of the engineered bacterial strain, and/or the nutrient source can be administered or provided after the administration or provision of the engineered bacterial strain.
- the nutrient source is administered contemporaneously with the administration of the engineered bacterial strain and further administered after the administration of the engineered bacterial strain.
- said competitive advantage is or further includes an advantage in interference competition, in particular in intraspecies direct competition, wherein the engineered bacterial strain can typically produce antibacterials against other members of the microbiome, in particular against the target bacterial strain(s), as defined below, or wherein the engineered bacterial strain can typically be resistant to administered antibacterials to which other members of the microbiome, in particular the target bacterial strain(s), are sensitive.
- said competitive advantage is provided or further provided by the production of one or more bacteriocins, as defined below, by said engineered bacterial strain.
- the engineered bacterial strain thus comprises or further comprises a heterologous or engineered gene or gene set involved in intraspecies direct competition, more particularly a heterologous or engineered gene or gene set involved in the expression or synthesis of an antibacterial agent, in particular as defined in the section “Reduction of the level of a molecule produced by at least one target bacterial strain’’ below, more particularly an antibacterial agent to which the engineered bacterial strain is resistant and the target bacterial strain(s) is sensitive, more particularly a heterologous or engineered gene or gene set involved in the expression or synthesis of one or more bacteriocins.
- said engineered bacterial strain does not comprise any antibiotic-resistance gene or marker.
- said engineered bacterial strain is auxotrophic.
- said engineered bacterial strain comprises an auxotrophic selection marker such as air (alanine racemase), thyA (Thymidylate synthase), dapA (4-hydroxy- tetrahydrodipicolinate synthase).
- said engineered bacterial strain is auxotrophic to the nutrient source as defined above.
- said engineered bacterial strain further comprises a nucleic acid, in particular a heterologous or engineered nucleic acid, involved in the expression of a molecule of interest, in particular a molecule of interest having a beneficial effect, as defined above, for the subject or environment, or for the subject’s or environment’s microbiome.
- a nucleic acid in particular a heterologous or engineered nucleic acid, involved in the expression of a molecule of interest, in particular a molecule of interest having a beneficial effect, as defined above, for the subject or environment, or for the subject’s or environment’s microbiome.
- the method of the invention further includes administering to the subject or providing to the environment a prebiotic.
- Prebiotics include, but are not limited to, amino acids, biotin, fructo-oligosaccharide, galacto-oligosaccharides, hemicelluloses (e.g., arabinoxylan, xylan, xyloglucan, and glucomannan), inulin, chitin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, gums (e.g., guar gum, gum arabic and carrageenan), oligofructose, oligodextrose, tagatose, resistant maltodextrins (e.g., resistant starch), trans- galactooligosaccharide, pectins (e.g., homogalacturonan, citrus pectin, apple pectin, and rhamnogalacturonan-l), dietary fibers (e.g., soy fiber, sugarbeet fiber, pect fiber
- said prebiotic is not the nutrient source as defined above.
- molecule is meant herein any type of molecule which can be directly or indirectly produced by a bacteria, such as nucleic acids, peptides, polypeptides, proteins, carbohydrates, lipids, small compounds, metabolites, organic acids, alcohols, etc..
- said molecule is a peptide, polypeptide or protein.
- molecule which is harmful and/or not beneficial to a subject is meant herein a molecule which (i) is directly or indirectly involved in the triggering and/or the maintenance of a disease, disorder, condition or unesthetic effect in any subject, (ii) is directly or indirectly involved in the triggering and/or the maintenance of a disease, disorder, condition, or unesthetic effect in a subject displaying specific features, (iii) directly or indirectly leads to the maintenance or growth of microorganisms that are associated with a disease, disorder, condition or unesthetic effect in a subject and/or (iv) does not directly or indirectly produce a beneficial effect to a subject compared to a mutant or variant thereof.
- said beneficial effect can be of any type such as stimulating the immune system, breaking down potentially toxic compounds, synthesizing certain vitamins and/or amino acids, or protecting from pathogenic organisms.
- produced molecule is meant herein a molecule which is expressed, secreted, displayed or produced by said target bacterial strain(s).
- said produced molecule can be expressed by a gene or set of genes comprised by said target bacterial strain(s), and then be secreted, membrane displayed or kept intracellularly by said target bacterial strain(s).
- the target bacterial strain(s) is a bacterial strain as defined in the section “Bacterial strain” above, provided that said engineered bacterial strain and said target bacterial strain(s) are from the same species.
- said target bacterial strain(s) is a commensal bacterial strain.
- said target bacterial strain(s) is a pathogenic bacterial strain.
- the target bacterial strain(s) is a Bacteroides bacterial strain, in particular a Bacteroides thetaiotaomicron and/or a Bacteroides faecis strain.
- the target bacterial strain(s) is a strain of a bacterial species selected from the group consisting of Escherichia coll, Bacteroides fragilis, Enterococcus faecalis, Yersinia pestis, Francisella tularensis, Bacillus anthracis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enterica Typhi, Fusobacterium nucleatum, Bacteroides fragilis, Cutibacterium acnes and Helicobacter pylori.
- the target bacterial strain(s) is a Propionibacterium propionicum, Corynebacterium amycolatum, Actinomyces massiliensis or Bacteroides thetaiotaomicron strain.
- the target bacterial strain(s) is a strain of a bacterial species from the Firmicutes phylum.
- the target bacterial strain(s) is a Roseburia intestinalis strain.
- the target bacterial strain(s) is a Prevotella copri strain.
- the target bacterial strain(s) is a Eggerthella lenta strain.
- the target bacterial strain(s) is a Enterococcus faecalis, Enterococcus faecium or Lactobacillus brevis strain. In another embodiment, the target bacterial strain(s) is a Clostridium sporogenes strain. In another embodiment, the target bacterial strain(s) is a Escherichia coli strain or a strain of a Gammaproteobacteria. In another embodiment, the target bacterial strain(s) is a Prevotella copri or Bacteroides vulgatus strain. In another embodiment, the target bacterial strain(s) is a C. difficile strain.
- level is meant herein the amount or concentration of said specific produced molecule in the subject or in the environment. As will be understood by the skilled person, depending on the fact that said produced molecule is secreted, displayed or remained intracellular in said target bacterial strain(s), the level of said produced molecule will be determined either in the subject or environment, or in the subject’s or environment’s microbiome hosting the target bacterial strain(s).
- reduction of the level of the produced molecule is meant herein a decrease in the level of the produced molecule after the engineered bacterial strain is administered or provided, or engineered in-situ, compared to the level of said produced molecule in the absence of any administration or provision of said engineered bacterial strain.
- the reduction of the level of the produced molecule refers to a decrease in the ratio of the level of the produced molecule to the level of a mutant or variant of said produced molecule.
- the reduction of the level of the produced molecule applies to the specific molecule produced by the target bacterial strain(s), and does not encompass any mutant or variant of said produced molecule. However, in some embodiments the level of any mutant or variant of said produced molecule may further be reduced by the methods of the invention.
- variant or mutant of the produced molecule is meant herein a modified version of the produced molecule, compared to the version produced by the target bacterial strain(s).
- said variant or mutant of the produced molecule does not have the same direct or indirect effect on the subject, the environment or other microorganisms present in the subject or environment, and/or the same activity as the version of the molecule produced by the target bacterial strain(s).
- said variant or mutant of the produced molecule is not directly nor indirectly harmful to the subject or to the environment.
- the reduction of the level of the produced molecule is a statistically significant decrease in the level of the produced molecule or a statistically significant decrease in the ratio of the level of the produced molecule to the level of a mutant or variant of said produced molecule.
- said reduction of the level of the produced molecule is observed 30 min after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source, in particular 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, or 1 month after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source.
- said reduction of the level of the produced molecule is maintained (not necessarily at the same level) for 30 min after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source, in particular for 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source.
- said reduction of the level of the produced molecule is maintained (not necessarily at the same level) for the whole period during which the engineered bacterial strain and/or the nutrient source is administered, in particular is regularly administered.
- the reduction of the level of the produced molecule by administration of the engineered bacterial strain is due to the transient or permanent, partial or total replacement of the target bacterial strain(s) producing said produced molecule, by the engineered bacterial strain which does not produce said molecule, thanks to the competitive advantage of the engineered bacterial strain over the target bacterial strain(s).
- the reduction of the level of the molecule produced by the target bacterial strain(s) is due only to the administration of said engineered bacterial strain.
- the reduction of the level of molecule produced by the target bacterial strain(s) is not mediated by another administered additional element, such as an element degrading or sequestering said molecule, an element modifying the target bacterial strain(s) in such a way that the molecule is no longer produced or is produced in a mutant or variant version, or an element that kills or reduces the growth the target bacterial strain(s).
- no antibacterial agent is administered to the subject.
- antibacterial agent is meant an agent that either kills or inhibits the growth of a bacteria.
- antibacterial agents include antibiotics, bacteriocins, endolysins, bacteriolytic enzymes, phages (in particular prophages or filamentous phages), toxins, polypeptides having a/p-type SASP activity, nucleases, molecules involved in type Vl-secretion system (T6SS)-mediated effector translocation, molecules involved in type Ill-secretion system (T3SS), molecules involved in type IV-secretion system (T4SS), molecules involved in contactdependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz), molecules involved in microcin proximity-dependent inhibition (MccPDI) and any combination thereof.
- antibiotics antibiotics
- bacteriocins endolysins
- phages in particular prophages or filamentous phages
- toxins polypeptides having a/p-type SASP activity
- nucleases molecules involved in type Vl-secretion system (T6SS)
- said antibacterial agent is a combination of a contactdependent antibacterial agent such as molecules involved in type Vl-secretion system (T6SS)- mediated effector translocation, molecules involved in type Ill-secretion system (T3SS), molecules involved in type IV-secretion system (T4SS), molecules involved in contact-dependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz) or molecules involved in microcin proximity-dependent inhibition (MccPDI), and of a contact-independent antibacterial agent such as antibiotics or bacteriocins.
- a contactdependent antibacterial agent such as molecules involved in type Vl-secretion system (T6SS)- mediated effector translocation, molecules involved in type Ill-secretion system (T3SS), molecules involved in type IV-secretion system (T4SS), molecules involved in contact-dependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz) or molecules involved in microcin proximity-dependent
- the antibiotic is selected from the group consisting of penicillins such as penicillin G, penicillin K, penicillin N, penicillin O, penicillin V, methicillin, benzylpenicillin, nafcillin, oxacillin, cioxacillin, dicloxacillin, ampicillin, amoxicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, epicillin, carbenicillin, ticarcillin, temocillin, mezlocillin, and piperacillin; cephalosporins such as cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cef
- antibacterial agents include azaserine, bestatin, D-cycloserine, 1 ,10- phenanthroline, 6-diazo-5-oxo-L-norleucine, L-alanyl-L-1 -aminoethyl-phosphonic acid; aureolic acids such as chromomycin A3, mithramycin A and mitomycin C C; coumarin-glycosides such as novobiocin; diphenyl ether derivatives such as irgasan; epipolythiodixopiperazines such as gliotoxin from Gliocladium fimbriatum; cerulenin; glucosamines such as 1 -deoxymannojirimycin, 1 -deoxynojirimycin and N-methyl-1 -deoxynojirimycin; indole derivatives such as staurosporine; diaminopyrimidines such as iclaprim (AR-100); macro
- cytochalasin B and cytochalasin D emetine and ionomycin
- antiseptic agents such as chlorhexidine, phenol derivatives (e.g. thymol and triclosan), quaternary ammonium compounds (e.g. benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, cetrimonium bromide, cetrimonium chloride and cetrimonium stearate), octenidine dihydrochloride, and terpenes (e.g. terpinen-4-ol).
- phenol derivatives e.g. thymol and triclosan
- quaternary ammonium compounds e.g. benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, cetrimonium bromide, cetrimonium chloride and cetrimonium stearate
- octenidine dihydrochloride e.g.
- the level of the molecule produced by the target bacterial strain(s) may be reduced or further reduced by the administration of the engineered bacterial strain by using an engineered bacterial strain, as defined above, which is able or further able to kill or inhibit the growth of said target bacterial strain(s).
- the engineered bacterial strain produces or further produces an antibacterial agent, as defined above, to which the engineered bacterial strain is resistant to, but to which the target bacterial strain(s) is sensitive to.
- the engineered bacterial strain produces or further produces an antibacterial agent, as defined above, to which the engineered bacterial strain is resistant, but to which the target bacterial strain(s) and other bacteria from the subject are sensitive.
- the antibacterial agent can be for example a bacteriocin or an endolysin.
- antibacterial agents include bacteriolytic enzymes, phages (in particular prophages or filamentous phages), toxins, polypeptides having a/p-type SASP activity, nucleases, molecules involved in type Vl-secretion system (T6SS)-mediated effector translocation, molecules involved in type Ill-secretion system (T3SS), molecules involved in type IV-secretion system (T4SS), molecules involved in contact-dependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz), molecules involved in microcin proximity-dependent inhibition (MccPDI) and any combination thereof.
- bacteriocin is meant herein a proteinaceous or peptidic toxin produced by bacteria to inhibit the growth of other bacterial strain(s).
- Bacteriocins are categorized in several ways, including producing strain, common resistance mechanisms, and mechanism of killing. Such bacteriocins have been described from gram negative bacteria (e.g. microcins, colicin-like bacteriocins and tailocins) and from gram positive bacteria (e.g. Class I, Class II, Class III or Class IV bacteriocins).
- gram negative bacteria e.g. microcins, colicin-like bacteriocins and tailocins
- gram positive bacteria e.g. Class I, Class II, Class III or Class IV bacteriocins.
- said at least one bacteriocin is selected from the group consisting of microcins, colicin-like bacteriocins, tailocins, Class I, Class II, Class III and Class IV bacteriocins.
- microcins is meant herein very small bacteriocins, composed of relatively few amino acids, and typically including microcin V (MccV) produced by Escherichia coli and subtilosin A produced by Bacillus subtilis.
- microcins examples include MccB17, MccC, MccD93, MccJ25, MccL, MccV, MccS, MccE492, MccM, MccH47, Mccl47, MccN and MccPDI.
- colicin-like bacteriocin or “CLBs” is meant herein bacteriocins found in Gramnegative bacteria, which are modular proteins between 20 and 90 kDa in size and often consist of a receptor binding domain, a translocation domain and a cytotoxic domain.
- CLBs typically include colicins, in particular colicins A, B, D, K, E1 , E2, E3, E4, E5, E6, E7, E8, E9, la, lb, M, N, S4, II, Y, 5, 10; klebicins, in particular klebicins A, B, C, CCL, D, KpneA, KaerA, KoxyY, Kvarla, Kpnela, KaerM, KpneM (or Kpne CHS1 10), KpneM2 (or Kpne e1602) and KvarM (or Kvar 6A2); alveicins, in particular alveicins A and B; marcescins, in particular marcescins A, B and 28B; S-type pyocins, in particular pyocins S1 , S2, S3, S5, S4, AP41 ; cloacins, in particular cloacin DF13; and pestici
- tailocin is meant herein a multisubunit bacteriocin that resembles bacteriophage tails.
- Examples of tailocins typically include F-type and R-type pyocins, carotovoricin, xenorhabdicin, and maltocin.
- Class I bacteriocin refers to small peptide inhibitors which include nisin and other lantibiotics.
- Class I bacteriocins typically include type A lantibiotics such as nisin A, nisin Z, bisin, subtilin, epidermin, gallidermin, mutacin II, mutacin I, mutacin III, pep5, epicidin 280, epilancin K7, lacticin 481 , lacticin 3147, cytolysin, staphylococcin C55, salvaricin A, lactocin S, streptococcin A-FF2, sublancin 168, carnocin U149, variacin 8 and cypemycin; and type B lantibiotics such as mersacidin, actagardine, duramycin B, duramycin C, cinnamycin, ancovenin, and plantaricin C.
- Class II bacteriocin refers to small ( ⁇ 10 kDa) heat-stable bacteriocins, subdivided into five subclasses: the class Ila bacteriocins (pediocin-like bacteriocins), which correspond to the largest subgroup and contain an N-terminal consensus sequence across this group and a C-terminal region responsible for species-specific activity, causing cell-leakage by permeabilizing the target cell wall; the class lib bacteriocins (two-peptide bacteriocins) which require two different peptides for activity; the class lie bacteriocins which encompass cyclic peptides, in which the N-terminal and C-terminal regions are covalently linked; the class lid bacteriocins which cover single-peptide bacteriocins, which are not post- translationally modified and do not show the pediocin-like signature; and the class lie bacteriocins
- class Ila bacteriocins typically include pediocin, pediocin A, pediocin AcH, pediocin PA-1 , pediocin PP-1 , pediocin SJ-1 , prepediocin AcH, prepediocin PA-1 , mesentericin Y105, mesentericin 52A, carnobacteriocin B2, carnobacteriocin BM1 , sakacin A, sakacin G, sakacin P, sakacin X, enterocin A, enterocin BC25, enterocin P, enterocin P-like, enterocin CRL35, enterocin HF, enterocin SE-K4, leucocin A, leucocin B-Ta11 a, leucocin C, leucocin C- TA33a, curvacin A, listeriocin
- class lib bacteriocins typically include enterocin C, enterocin 1071 , gassericin T, gassericin S, lactococcin G, lactococcin Q, plantaricin E/F, plantaricin J/K, plantaricin S, plantaricin NC8, lactacin F, brochocin-C, thermophilin 13, ABP-118, salivaricin P, mutacin IV and lactocin 705.
- class lie bacteriocins typically include enterocin AS-48, lactocyclicin Q, garvicin ML, gassericin A, acidocin B and butyrovibriocin AR10.
- class lid bacteriocins typically include aureocin A53, garvicin A, laterosporulinl O, lactococcin A, lactococcin 972, lacticin Q, carnobacteriocin XY, leucocin B, thuricin S, thuricin-17 and bactofensin A.
- class lie bacteriocins typically include aureocin A70.
- Class III bacteriocin refers to large (>10 kDa), heat-labile protein bacteriocins. This class is subdivided in two subclasses: subclass Illa (bacteriolysins) and subclass 11 lb.
- Subclass Illa comprises those peptides that kill bacterial cells by cell wall degradation, thus causing cell lysis, and typically include Lysostaphin.
- Subclass II lb in contrast, comprises those peptides that do not cause cell lysis, killing the target cells by disrupting plasma membrane potential.
- class III bacteriocins typically include Lysostaphin, enterolysin A, helveticin V-1829, helveticin J, caseicin 80, lactacin A, lactacin B, zoocin A, millericin B, linocin M18 and acidophilus A.
- Class IV bacteriocin refers to complex bacteriocins containing lipid or carbohydrate moieties.
- classes IV bacteriocins typically include sublancin 168, glycocin F, ASM1 , enterocin 96 and enterocin F4-9.
- the bacteriocin is a bacteroidetocin, as disclosed for example in Coyne et al. (2019) Nat. Commun. 10:3460.
- endolysin or “lysin” is meant herein enzymes used by bacteriophages at the end of their replication cycle to degrade the peptidoglycan of the bacterial host from within, resulting in cell lysis and release of progeny virions. They are typically either P(1 ,4)-glycosylases (lysozymes), transglycosylases, amidases or endopeptidases.
- endolysins typically include PhiV10p30, STM0907.Fels0, epsilon15p25, YuA20, ORF23, BcepMu22, F1 16p62, STM2715.S.Fels2, gp76, SPSV3_gp23, phi32_17, HK022p54, HK97p58, HK620p36, VIP0007, Sf6p62, R (SfVp40), gp22, Nazgul38, K (P2p09), K (Wphi09), rv5_gp085, EpJS98_gp116, gp3.5 (from 13A phage), gp3.5 (from BAM phage), gp3.5 (from ECODS1 phage), CKV1 F_gp16, T3p18, gh-1 p12, gp3.5 (from K1 1 phage), ORF12, Bcep43-27, Bcep781 -27,
- coli phage N4 endolysins of the phage LUZ24, gp61 muramidase, STM0016 endolysin, PSP3 endolysin, phiKZgp144, ELgp188, Salmonella endolysin, Enterobacteria phage T4 endolysin, Acinetobacter baumanii endolysin, E. coli phage KIF endolysin, OBPgpLYS, PSP3 Salmonella endolysin (PSP3gp1 ), E. coli phage P2 endolysin (P2gp9), Salmonella typhimurium phage muramidase STMOO16, E.
- endolysins also include endolysins disclosed in Fernandez- Ruiz et al. (2016) Front. Microbiol. 9:1033.
- said antibacterial agent is produced from a gene or set of genes derived from a bacterium which is from the same species as the engineered bacterial strain. In another particular embodiment, said antibacterial agent is produced from a gene or set of genes derived from a bacterium which is from a different species than the engineered bacterial strain.
- said engineered bacterial strain produces several antibacterial agents targeting different bacterial strains or different bacterial species.
- said engineered bacterial strain produces at least one antibacterial agent targeting a bacterial strain from the same species as the engineered bacterial strain, and at least one different antibacterial agent targeting a bacterial species from another species than the engineered bacterial strain.
- said engineered bacterial strain further comprises a gene or gene set conferring resistance to said antibacterial agent, in particular to said bacteriocin, type Vl-secretion system (T6SS) or antibiotic.
- said antibacterial agent is a nuclease or a toxin
- said antibacterial agent is produced in the target bacterial strain after conjugation.
- said engineered bacterial strain is able to transduce, in the target bacterial strain, a plasmid encoding an antibacterial agent, as defined above.
- the engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s).
- the engineered bacterial strain may produce a variant or a mutant, as defined above, of the molecule produced by the target bacterial strain(s), in particular a non-harmful variant or mutant of the molecule produced by the target bacterial strain(s), thereby reducing the level, in the subject, of the molecule produced by the target bacterial strain(s), in particular reducing the ratio of the level, in the subject, of the molecule produced by the target bacterial strain(s) to the level, in the subject, of a mutant or variant of the molecule produced by the target bacterial strain(s).
- the engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s) and does not produce either any variant or any mutant thereof, thereby reducing the level, in the subject, of the molecule produced by the target bacterial strain(s).
- said engineered bacterial strain does not naturally produce the molecule produced by the target bacterial strain(s).
- the engineered bacterial strain has not been engineered to not produce said molecule.
- the engineered bacterial strain is obtained from a bacterial strain, which, naturally, without any genetic engineering, does not produce said molecule.
- the engineered bacterial strain can naturally produce a mutant or variant, as defined above, in particular a non-harmful mutant or variant, of the molecule produced by the target bacterial strain(s).
- said engineered bacterial strain has been engineered to not produce the molecule produced by the target bacterial strain(s).
- the engineered bacterial strain is both engineered to comprise the heterologous or engineered gene or gene set providing a competitive advantage, and to not produce the molecule produced by the target bacterial strain(s).
- the engineered bacterial strain can have been engineered to produce a mutant or variant, as defined above, in particular a non-harmful mutant or variant, of the molecule produced by the target bacterial strain(s).
- the engineered bacterial strain can have been engineered to not produce neither said molecule produced by the target bacterial strain(s) nor any variant or any mutant thereof.
- the bacterial strain used in the context of the invention is engineered in situ.
- the method can alternatively comprise: administering to the subject or providing to the environment a bacterial delivery vehicle for delivery into a bacterial strain of interest, wherein said bacterial strain of interest and said target bacterial strain are from the same species, wherein said bacterial delivery vehicle comprises:
- (A) (a1) a heterologous gene or gene set providing a competitive advantage, as defined above, to the bacterial strain of interest over the target bacterial strain, or
- (a2) a nucleic acid encoding a gene editing enzyme/system designed to modify the genome of said bacterial strain of interest so that said bacterial strain of interest has a competitive advantage, as defined above, over the target bacterial strain, and
- a gene editing enzyme/system designed to modify the genome of said bacterial strain of interest so that said bacterial strain of interest does not produce said molecule produced by the target bacterial strain, as defined above, wherein said gene editing enzyme/system does not lead to the death of the bacterial strain of interest, whereby said bacterial strain of interest is engineered in situ to not produce said molecule produced by the target bacterial strain and to have a competitive advantage over the target bacterial strain, and where
- bacterial delivery vehicle is meant herein any mean that allows the transfer of a payload into a bacterium.
- delivery vehicle encompassed by the present invention including, without limitation, bacteriophage scaffold, virus scaffold, chemical based delivery vehicle (e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes), proteinbased or peptide-based delivery vehicle, lipid-based delivery vehicle, nanoparticle-based delivery vehicles, non-chemical-based delivery vehicles (e.g., transformation, electroporation, sonoporation, optical transfection), particle-based delivery vehicles (e.g., gene gun, magnetofection, impalefection, particle bombardment, cell-penetrating peptides) or donor bacteria (conjugation).
- chemical based delivery vehicle e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes
- proteinbased or peptide-based delivery vehicle e.g., lipid-based delivery vehicle, nanoparticle-based delivery vehicles, non-chemical-based delivery vehicles (e.g., transformation, electrop
- the delivery vehicle can refer to a bacteriophage derived scaffold and can be obtained from a natural, evolved or engineered capsid.
- the delivery vehicle is the payload as bacteria are naturally competent to take up a payload from the environment on their own.
- said bacterial delivery vehicle is a packaged phagemid, said heterologous genes and/or nucleic acids being located on the phagemid.
- the present invention also concerns a method for preventing and/or treating, in a subject, a disease, disorder or condition directly or indirectly associated to at least one target moleculeproducing bacterial strain, said method comprising administering to the subject a therapeutically efficient amount of an engineered bacterial strain, as defined above, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is involved directly or indirectly in said disease, disorder or condition, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the disease, disorder or condition is prevented and/or treated in the subject.
- the present invention also concerns an engineered bacterial strain, as defined above, for use for preventing and/or treating, in a subject, a disease, disorder or condition directly or indirectly associated to at least one target molecule-producing bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is directly or indirectly involved in said disease, disorder or condition, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species.
- the present invention further concerns the use of an engineered bacterial strain, as defined above, for the manufacture of a medicament intended for the prevention and/or the treatment of a disease, disorder or condition directly or indirectly associated to at least one target molecule-producing bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is directly or indirectly involved in said disease, disorder or condition, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species.
- treating means reversing, alleviating, or inhibiting the progress of the disease, disorder or condition to which such term applies, or one or more symptoms of such disease, disorder or condition.
- prevention refers to any indicia of success in protecting a subject or patient (e.g. a subject or patient at risk of developing a disease, disorder or condition) from developing, contracting, or having a disease, disorder or condition, including preventing one or more symptoms of a disease, disorder or condition or diminishing the occurrence, severity, or duration of any symptoms of a disease, disorder or condition following administration of the engineered bacterial strain as described herein.
- a "therapeutically effective amount" of an engineered bacterial strain of the invention is meant a sufficient amount of the engineered bacterial strain to treat or prevent a specific disease, disorder or condition, to contribute to the treatment of a specific disease, disorder or condition, or to avoid side effects of a treatment of a specific disease, disorder or condition, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the engineered bacterial strain of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disease, disorder or condition being treating and the severity of the disease, disorder or condition, activity of the specific engineered bacterial strain employed, the specific combinations employed, the age, body weight, general health, sex and diet of the subject, the time of administration, route of administration and rate of excretion of the specific engineered bacterial strains employed, the duration of the treatment, drugs used in combination or coincidental with the specific engineered bacterial strains employed, and like factors well known in the medical arts.
- a “disease, disorder or condition directly or indirectly associated to at least one target molecule-producing bacterial strain” is disease, disorder or condition directly or indirectly associated to at least one bacterial strain because of the production by said bacterial strain(s) of at least one given molecule.
- the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for the onset and/or the maintenance and/or the progression and/or the worsening of said disease, disorder or condition. In another particular embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for specific symptoms associated with said disease, disorder or condition.
- the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for a lack of efficiency of therapeutic and/or prophylactic therapies against said disease, disorder or condition.
- the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for such a lack of efficiency by direct interaction with said therapeutic and/or prophylactic therapy, for example by quenching, binding, neutralizing, and/or degrading the active molecule of the therapy.
- the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for such a lack of efficiency by indirect interaction with said therapeutic and/or prophylactic therapy, for example by interacting with the cells targeted by the therapy and making them non- or less responsive to the therapy.
- the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for specific side effects of therapeutic and/or prophylactic therapies against a disease, disorder or condition.
- said molecule(s) is a toxin.
- said molecule(s) may be an exotoxin or an endotoxin. Exotoxins are generated and actively secreted; endotoxins remain part of the bacteria. The response to a bacterial toxin can involve severe inflammation and can lead to sepsis.
- toxins include Colibactin of E. coli, Toxin A and other enzymes (e.g., hemolysin, leukotoxin, exfoliative toxin, enterotoxin, and toxic-shock syndrome toxin-1 (TSST-1 )) from Staphylococcus aureus (typically as described in Tam and Torres, Microbiol Spectr.
- Colibactin of E. coli Toxin A and other enzymes (e.g., hemolysin, leukotoxin, exfoliative toxin, enterotoxin, and toxic-shock syndrome toxin-1 (TSST-1 )) from Staphylococcus aureus (typically as described in Tam and Torres, Microbiol Spectr.
- colibactin is meant herein a secondary metabolite synthetized by the clbA-S genes present in the 54-kb pathogenicity pks island, a genetic island encoding a non-ribosomal peptide synthetase-polyketide synthase (NRPS-PKS) assembly line in Enterobacteriaceae.
- Colibactin is typically produced as a prodrug moiety that is exported in the periplasm by the efflux pump ClbM and then hydrolyzed by the periplasmic membrane-bound ClbP protein with a peptidase activity, which releases the active colibactin.
- said method is for treating and/or preventing colorectal cancer, and said molecule is fragilysin, in particular produced by Enterotoxigenic Bacteroides fragilis (ETBF).
- EBF Enterotoxigenic Bacteroides fragilis
- said method is for treating and/or preventing colorectal cancer, and said molecule is colibactin, in particular produced by Enterococcus faecalis and/or E. coli.
- said molecule(s) is a virulence factor.
- a virulence factor can be any substance produced by a pathogen that alters hostpathogen interaction by increasing the degree of damage done to the host. Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche in the host, to evade the host's immune response, to facilitate entry to and egress from host cells, to obtain nutrition from the host, or to inhibit other physiological processes in the host. Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, scavenging factors and factors that promote biofilm formation. [0221] Examples of virulence factors include virulence factors encoded by the following E.
- said molecule is a molecule encoded by a Cutibacterium acnes porphyrins gene, a CAMP-factor (CAMP1 , CAMP2, CAMP3, CAMP4), Hyaluronate lyase (HYL-IB/II, HYL-IA), Lipases (GehA, GehB), Haemolysins, Sialidases, Endoglycoceramidases, Endo-B-N-acetylglucosaminidase, Dermatan sulphate adhesin (DsA1 , DsA2), Proline-Threonine Repeats (PTRs) or in any virulence factors included on the acne associated genomic loci 1 , 2, 3(plasmid), 4 such as a tight adhesion locus (tad), Streptolysin S-associated genes (sag), nonribosomal peptide synthetases (NRPS) as described in To
- said molecule is cytotoxin-associated antigen A (CagA) and/or vacuolating cytotoxin (VacA), preferably produced by Helicobacter pylori.
- CagA cytotoxin-associated antigen A
- VacA vacuolating cytotoxin
- said molecule(s) is a bacterial mimic peptide.
- bacterial mimic peptide is meant herein a peptide produced by a bacterium or part of a protein or polypeptide produced by a bacterium, which mimics the structure, sequence, and/or function of a subject’s peptide or of a part of a subject’s protein or polypeptide.
- the bacterial mimic peptide has homology, in particular 80% homology, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology, with a subject’s peptide or a part of a subject’s protein or polypeptide.
- homologous amino acid sequence is partially or completely identical.
- the homologous amino acid sequence has 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% sequence similarity or identity to the amino acid sequence of reference.
- percent homology between two sequences is equivalent to the percent identity, as defined above, between the two sequences.
- said bacterial mimic peptide is associated with an autoimmune disease.
- said bacterial mimic peptide is one of those mentioned in Negi et al. (2017) PLoS ONE 12(7): e018051 , in particular one of those disclosed in S1 Table of Negi et al.
- said bacterial mimic peptide is produced by a target Proteobacteria or Firmicutes bacterial strain.
- said bacterial mimic peptide is one of the 24 gut bacterial peptides identified by Negi et al. with homology to four human peptides from Low molecular weight phosphotyrosine protein phosphatase, Aldehyde dehydrogenase family 3 member B1 , Maleylacetoacetate isomerase and Uracil-DNA glycosylase.
- said molecule is the Ro60 protein produced by human commensal bacteria comprising a Ro60 ortholog gene, in particular by Propionibacterium propionicum, Corynebacterium amycolatum, Actinomyces massiliensis and/or Bacteroides thetaiotaomicron.
- said molecule(s) is a molecule able to induce or sustain or worsen an autoimmune reaction in the host.
- said molecule(s) is a peptide that mimics a human autoantigen.
- said molecule is a beta-galactosidase produced by Bacteroides faecis and/or Bacteroides thetaiotaomicron bacterial strains.
- said molecule is a peptide, produced by human commensal bacteria in particular by bacteria of the Firmicutes phylum, that mimics insulin B 9-25, a self-epitope involved in type 1 diabetes (Garcia et al. Peripheral tolerance to insulin is encoded by mimicry in the microbiome. Biorxiv 2019.12.18.881433 (2019) doi:10.1 101/2019.12.18.881433) and which is typically encoded by a gene which is part of the transketolase N superfamily.
- said molecule is a peptide, produced by Roseburia intestinalis, that mimics the epitope of the autoantigen p2-glycoprotein I (P2GPI), a self-epitope involved in antiphospholipid syndrome (APS) (Ruff et al. (2019) Cell Host Microbe 26, 100-1 13. e8).
- P2GPI autoantigen p2-glycoprotein I
- APS antiphospholipid syndrome
- said molecule in particular in a method for treating and/or preventing rheumatoid arthritis, is a Prevotella cop/7-produced peptide exhibiting high homology with autoantigens of rheumatoid arthritis patients.
- said molecule(s) is a bacterial enzyme.
- said molecule(s) is a bacterial enzyme targeting a drug administered to the subject to treat and/or prevent a disease, disorder or condition.
- a “bacterial enzyme targeting a drug” encompasses both an enzyme leading to the elimination of the drug and an enzyme involved in the more general evolution of the drug activity in the subject once administered to said subject.
- Said given drug may be selected from the group consisting of Nicardipine- HCI, Risperidone, Tolcapone, Azathioprine, Entacapone, Exemestane, Nimodipine, Capsaicin, Dexamethasone, Ethacrynic Acid, Rifampin (Rifampicin), Sulindac, Vorinostat, Dolasetron, Mycophenolate Mofetil, Zidovudine (3'-Azido-3'-Deoxythymidine), Allopurinol, Betamethasone, Bisacodyl, Estradiol, Famciclovir, Flutamide, Hydrocortisone, Hydrocortisone Acetate, Methylprednisolone, Metronidazole, Nabumetone, Pantoprazole, Prednisolone, Progesterone, Prednisone, Spironolactone, Sulfasalazine, Tinidazole, Fluox
- Said given drug may further be selected from the group consisting of abacavir sulfate, acebutolol, acecainide, alfuzosin, almotriptan, alprenolol, amantadine, aminoglutethimide, amisulpride, anagrelide, anastrozole, antazoline phosphate, apomorphine, artemisinin, atenolol, atorvastatin calcium, azatadine maleate, bambuterol, Benazepril, benzbromarone, benzthiazide, betamethasone acetate, betamethasone valerate, betaxalol, bezafibrate, bicalutamide, biperiden, bisacodyl, bisoprolol fumarate, bromocriptine mesylate, budesonide, bupropion, buramate, buspirone, camylofine dihydrochloride, cape
- said molecule(s) is selected from the bacterial enzymes having oxidation, deamination, isomerization, esterification, condensation, reduction, hydrolysis and/or rearrangement activities.
- said molecule(s) is selected from - glucuronidases, nitroreductases and sulfoxide reductases.
- said given drug is dantrolene, clonazepam, and/or nicardipine
- said molecule is an enzyme having nitro-reduction activity.
- said molecule is an enzyme having hydrolysis activity, in particular an enzyme hydrolysing the isoxazole moiety of risperidone.
- said molecule when said given drug is sulfasalazine, said molecule is an enzyme having azoreduction activity.
- said target bacterial strain producing said molecule being preferably Eggerthella lenta.
- said given drug is levodopa (L-DOPA), in particular in a subject suffering from Parkinson’s disease
- said molecule is tyrosine decarboxylase, preferably produced by Enterococcus faecalis, Enterococcus faecium and/or Lactobacillus brevis and/or dopamine dehydrolase, preferably produced by Eggerthella lenta.
- said given drug is levodopa (L-DOPA), in particular in a subject suffering from Parkinson’s disease
- said molecule is DHPAA synthase, preferably produced by Clostridium sporogenes.
- said molecule when said given drug is gemcitabine, said molecule is a cytidine deaminase, said target bacterial strain producing said molecule being preferably Escherichia coll and/or Gammaproteobacteria.
- said molecule is an enzyme converting prontosil into p-aminobenzenesulfonamide by azo-reduction.
- said given drug when said given drug is selected from sulfasalazine, ipsalazide and balsalazide, said molecule is an enzyme converting said drug into 5-aminosalicylic acid.
- said given drug is a non-steroidal anti-inflammatory drug
- said molecule is a p-glucuronidase
- said molecule is a bacterial enzyme involved in amino acid metabolism, preferably produced by Prevotella copri and/or Bacteroides vulgates.
- said molecule is a bacterial adhesin.
- said molecule is a bacterial adhesin involved in the adsorption of a given drug, administered to the subject to treat and/or prevent a disease, disorder or condition, to the target bacterial strain.
- said molecule when said given drug is L-DOPA, typically in a subject suffering from Parkinson’s disease, said molecule is a molecule involved in the adsorption of L- DOPA by Helicobacter pylori, typically a bacterial adhesin from H. pylori involved in said adsorption.
- said molecule(s) is a bacterial molecule competing with a given drug for a receptor of the subject’s cells.
- said given drug is acetaminophen
- said molecule is p- cresol produced by C. difficile or an enzyme involved in the production and/or secretion of p- cresol by C. difficile.
- said molecule(s) is a bacterial metabolite.
- said method is for preventing and/or treating liver disease, and said molecule(s) is selected from the group consisting of ethanol, ammonia and acetaldehyde.
- said method is for preventing and/or treating NAFLD and/or cardiovascular disease, and said molecule is a choline metabolite.
- said molecule is a bacterial antigen
- said method is for treating and/or preventing a disease selected from liver cirrhosis, hepatic encephalopathy, renal failure, autoimmune hepatitis, NAFLD and NASH.
- said molecule is not oxalate.
- said engineered bacterial strain does not naturally produce, as defined above, said molecule(s). In a particular embodiment, said engineered bacterial strain naturally produces a non-harmful mutant or variant of said molecule(s).
- said engineered bacterial strain has been engineered to not produce said molecule(s), as defined above. In an alternative embodiment, said engineered bacterial strain has been engineered to produce a non-harmful mutant or variant of said molecule(s).
- said engineered bacterial strain when said molecule is a peptide that mimics a human autoantigen, said engineered bacterial strain does not produce said peptide, or produces a variant or mutant of said peptide which does not show any homology or show less homology with said human autoantigen.
- examples of diseases, disorders or conditions to be treated or prevented by the method of the invention include a neurodegenerative disease or condition; a brain disease or condition; a CNS disease or condition; memory loss or impairment; a heart or cardiovascular disease or condition, such as heart attack, stroke or atrial fibrillation; a liver disease or condition; a kidney disease or condition, such as chronic kidney disease (CKD); a pancreas disease or condition; a lung disease or condition, such as cystic fibrosis or COPD; a gastrointestinal disease or condition; a throat or oral cavity disease or condition; an ocular disease or condition; a genital disease or condition, such as a vaginal, labial, penile or scrotal disease or condition; a sexually-transmissible disease or condition, such as gonorrhea, HIV infection, syphilis or chlamydia infection; an ear disease or condition; a skin disease or condition; a heart disease or condition; a nasal disease
- the neurodegenerative or CNS disease, disorder or condition is selected from the group consisting of Alzheimer disease, geriopsychosis, Down syndrome, Parkinson's disease, Creutzfeldt-Jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis and diabetic neuropathy.
- Autoimmune diseases that may be treated or prevented include Acute Disseminated Encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus (SLE), Lyme disease, Meniere’s disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis
- Inflammatory diseases that may be treated or prevented include Alzheimer disease, ankylosing spondylitis, arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), asthma, atherosclerosis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson's disease, and ulcerative colitis.
- arthritis osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis
- asthma atherosclerosis
- Crohn's disease colitis
- dermatitis dermatitis
- diverticulitis fibromyalgia
- hepatitis hepatitis
- IBS irritable bowel syndrome
- SLE systemic lupus erythematosus
- Parkinson's disease and ulcerative colitis
- the present invention also concerns a method for the cosmetic caring of a subject presenting unesthetic manifestation due to at least one target molecule-producing bacterial strain(s), said method comprising administering to the subject a cosmetically efficient amount of an engineered bacterial strain, as defined above, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is involved in said unesthetic manifestation, wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species.
- unesthetic manifestation is meant herein a non-pathological manifestation on a subject, in particular on the skin of a subject, of the effect of a molecule produced by a target bacterial strain(s) on the subject.
- examples of unesthetic manifestation include redness, feeling of heat or warmth, tension, tingling, stinging, tightness, pigment spots, burning sensation, itching sensation, tautness, visible squama, thickening of the skin, wrinkles, sagging skin, localized resistant fat, and/or cellulite appearance.
- the engineered bacterial strain of the invention is in a pharmaceutical, veterinary or cosmetic composition.
- composition according to the invention may further comprise a pharmaceutically acceptable excipient.
- pharmaceutically acceptable excipient is meant herein a non-pharmaceutically active additive used in the manufacture of a pharmaceutical composition, which allows the pharmaceutically active ingredient to be manufactured into a pharmaceutical formulation or a galenic formulation providing the necessary bioavailability of the medicament to the patient upon the administration of the pharmaceutical composition.
- the excipient is preferably compatible with the other ingredients of the composition and produces no adverse effect, allergic reaction or other undesirable reaction when it is administered to a human or an animal.
- the cosmetic composition according to the invention may further comprise a cosmetically acceptable excipient.
- a cosmetically acceptable excipient is meant herein a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a cosmetic composition or otherwise used as a vehicle, carrier, or diluents to facilitate administration of a cosmetically active ingredient and that is compatible therewith.
- a solid pharmaceutically or cosmetically acceptable vehicle or excipient may include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet- disintegrating agents.
- Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.
- the pharmaceutical, veterinary or cosmetic composition may be prepared as a sterile solid composition that may be suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
- the pharmaceutical, veterinary or cosmetic compositions of the invention may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monooleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.
- compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions.
- forms useful for enteral administration include sterile solutions, emulsions, and suspensions.
- the engineered bacterial strains according to the invention may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats.
- the liquid vehicle can contain other suitable pharmaceutical or cosmetic additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
- suitable examples of liquid vehicles for oral and enteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g.
- the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration.
- the liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
- the invention encompasses pharmaceutical, veterinary or cosmetic composition formulated for delayed or gradual enteric release.
- formulations or pharmaceutical preparations of the invention are formulated for delivery of the engineered bacterial strain into the distal small bowel and/or the colon.
- the formulation can allow the engineered bacterial strain to pass through stomach acid and pancreatic enzymes and bile, and reach undamaged to be viable in the distal small bowel and colon.
- the pharmaceutical, veterinary or cosmetic composition is micro- encapsulated, formed into tablets and/or placed into capsules, preferably enteric-coated capsules.
- the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release, using cellulose acetate (CA) and polyethylene glycol (PEG).
- the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using a hydroxypropylmethylcellulose (HPMC), a microcrystalline cellulose (MCC) and magnesium stearate.
- the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using e.g., a poly(meth)acrylate, e.g. a methacrylic acid copolymer B, a methyl methacrylate and/or a methacrylic acid ester, or a polyvinylpyrrolidone (PVP).
- a poly(meth)acrylate e.g. a methacrylic acid copolymer B, a methyl methacrylate and/or a methacrylic acid ester, or a polyvinylpyrrolidone (PVP).
- the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using a release-retarding matrix material such as: an acrylic polymer, a cellulose, a wax, a fatty acid, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, polyvinylpyrrolidone, a vinyl acetate copolymer, a vinyl alcohol copolymer, polyethylene oxide, an acrylic acid and methacrylic acid copolymer, a methyl methacrylate copolymer, an ethoxyethyl methacrylate polymer, a cyanoethyl methacrylate polymer, an aminoalkyl methacrylate copolymer, a poly(acrylic acid), a poly(methacrylic acid), a methacrylic acid alkylamide copolymer, a poly(methyl methacrylate), a poly(methacrylic acid anhydride), a methyl methacrylate polymer
- the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release as described in U.S. Pat. App. Pub. 20110218216, which describes an extended release pharmaceutical composition for oral administration, and uses a hydrophilic polymer, a hydrophobic material and a hydrophobic polymer or a mixture thereof, with a microenvironment pH modifier.
- the hydrophobic polymer can be ethylcellulose, cellulose acetate, cellulose propionate, cellulose butyrate, methacrylic acid-acrylic acid copolymers or a mixture thereof.
- the hydrophilic polymer can be polyvinylpyrrolidone, hydroxypropylcellulose, methylcellulose, hydroxypropylmethyl cellulose, polyethylene oxide, acrylic acid copolymers or a mixture thereof.
- the hydrophobic material can be a hydrogenated vegetable oil, hydrogenated castor oil, carnauba wax, candelilla wax, beeswax, paraffin wax, stearic acid, glyceryl behenate, cetyl alcohol, cetostearyl alcohol or and a mixture thereof.
- the microenvironment pH modifier can be an inorganic acid, an amino acid, an organic acid or a mixture thereof.
- the microenvironment pH modifier can be lauric acid, myristic acid, acetic acid, benzoic acid, palmitic acid, stearic acid, oxalic acid, malonic acid, succinic acid, adipic acid, sebacic acid, fumaric acid, maleic acid; glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, sodium dihydrogen citrate, gluconic acid, a salicylic acid, tosylic acid, mesylic acid or malic acid or a mixture thereof.
- the pharmaceutical, veterinary or cosmetic compositions are a powder that can be included into a tablet or a suppository.
- a formulation or pharmaceutical preparation of the invention can be a “powder for reconstitution” as a liquid to be drunk or otherwise administered.
- the pharmaceutical, veterinary or cosmetic compositions can be administered in a cream, gel, lotion, liquid, feed, or aerosol spray.
- Engineered bacterial strains may be immobilized onto appropriately sized polymeric beads so that the coated beads may be added to aerosols, creams, gels or liquids.
- the size of the polymeric beads may be from about 0.1 pm to 500 pm, for example 50 pm to 100 pm.
- the coated polymeric beads may be incorporated into animal feed, including pelleted feed and feed in any other format, incorporated into any other edible device used to present phage to the animals, added to water offered to animals in a bowl, presented to animals through water feeding systems.
- the compositions are used for treatment of surface wounds and other surface infections using creams, gels, aerosol sprays and the like.
- the pharmaceutical, veterinary or cosmetic compositions can be administered by inhalation, in the form of a suppository or pessary, topically (e.g., in the form of a lotion, solution, cream, ointment or dusting powder), epi- or transdermally (e.g., by use of a skin patch), orally (e.g., as a tablet, which may contain excipients such as starch or lactose), as a capsule, ovule, elixirs, solutions, or suspensions (each optionally containing flavoring, coloring agents and/or excipients), or they can be injected parenterally (e.g., intravenously, intramuscularly or subcutaneously).
- a suppository or pessary topically (e.g., in the form of a lotion, solution, cream, ointment or dusting powder), epi- or transdermally (e.g., by use of a skin patch), orally (e.g.,
- compositions may be used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.
- compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
- the pharmaceutical, veterinary or cosmetic compositions can also be dermally or transdermally administered.
- the pharmaceutical, veterinary or cosmetic composition can be combined with one or a combination of carriers, which can include but are not limited to, an aqueous liquid, an alcohol base liquid, a water soluble gel, a lotion, an ointment, a nonaqueous liquid base, a mineral oil base, a blend of mineral oil and petrolatum, lanolin, liposomes, proteins carriers such as serum albumin or gelatin, powdered cellulose carmel, and combinations thereof.
- a topical mode of delivery may include a smear, a spray, a bandage, a time-release patch, a liquid-absorbed wipe, and combinations thereof.
- the pharmaceutical, veterinary or cosmetic composition can be applied to a patch, wipe, bandage, etc., either directly or in a carrier(s).
- the patches, wipes, bandages, etc. may be damp or dry, wherein the engineered bacterial strain is in a lyophilized form on the patch.
- the carriers of topical compositions may comprise semi-solid and gel-like vehicles that include a polymer thickener, water, preservatives, active surfactants, or emulsifiers, antioxidants, sun screens, and a solvent or mixed solvent system.
- U.S. Pat. No. 5,863,560 discloses a number of different carrier combinations that can aid in the exposure of skin to a medicament, and its contents are incorporated herein.
- the pharmaceutical, veterinary or cosmetic composition is conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, or nebuliser with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3-heptafluoropropane, carbon dioxide, or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3-h
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the pressurized container, pump, spray, or nebuliser may contain a solution or suspension of the active compound, e.g., using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g., sorbitan trioleate.
- a lubricant e.g., sorbitan trioleate.
- Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the engineered bacterial strain of the invention and a suitable powder base such as lactose or starch.
- compositions of the invention can be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment, or dusting powder.
- Compositions of the invention may also be administered by the ocular route.
- the compositions of the invention can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride.
- they may be formulated in an ointment such as petrolatum.
- Dosages and desired drug concentrations of the pharmaceutical and veterinary composition compositions of the present invention may vary depending on the particular use. The determination of the appropriate dosage or route of administration is within the skill of an ordinary physician. Animal experiments can provide reliable guidance for the determination of effective doses in human therapy.
- the pharmaceutical, veterinary or cosmetic composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
- nasal sprays for transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used.
- the active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
- the method further comprises administering said nutrient source to the subject.
- the method of the invention can be applied to soil or water to eliminate a toxin or environmental contamination, such as in an industrial chemical spill or waste product.
- the method of the invention can also be applied to waste water or industrial waste or byproduct to decontaminate or detoxify the waste.
- the method of the invention can be applied to industrial or environmental material such as but not limited to agricultural or food production waste to produce or improve the production of a metabolic product.
- the subject according to the invention is an animal, preferably a mammal, even more preferably a human.
- the term "subject” can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep, donkeys, rabbits, ferrets, gerbils, hamsters, chinchillas, rats, mice, guinea pigs and non-human primates, among others, or non-mammals such as poultry, that are in need of treatment.
- the human subject according to the invention may be a human at the prenatal stage, a new-born, a child, an infant, an adolescent or an adult at any age.
- the subject has been diagnosed with, or is at risk of developing an infection, a disorder and/or a disease preferably due to or associated with a bacterium. Diagnostic methods of such infection, disorder and/or disease are well known by the man skilled in the art.
- the infection, disorder and/or disease presents a resistance to treatment, preferably the infection, disorder or disease presents an antibiotic resistance.
- the subject has never received any treatment prior to the administration of the engineered bacterial strain according to the invention.
- the subject has already received at least one line of treatment, preferably several lines of treatment, prior to the administration of the engineered bacterial strain according to the invention.
- the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day.
- the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day.
- the duration of treatment according to the invention is preferably comprised between 1 day and 20 weeks, more preferably between 1 day and 10 weeks, still more preferably between 1 day and 4 weeks, even more preferably between 1 day and 2 weeks. In a particular embodiment, the duration of the treatment is about 1 week. Alternatively, the treatment may last as long as the infection, disorder and/or disease persists.
- the duration of treatment according to the invention is comprised between 2 days and 20 weeks and involves (i) several successive administrations of the engineered bacterial strain and of the nutrient source, or (ii) a single administration of the engineered bacterial strain and several successive administrations of the nutrient source, or (iii) several successive administrations of the engineered bacterial strain and several successive administrations of the nutrient source, the administrations of the nutrient source being continued at least once after stopping administrations of the engineered bacterial strain.
- compositions comprising the engineered bacterial strain of the invention and/or the nutrient source, the route of administration and the dose of administration thereof can be adjusted by the man skilled in the art according to the type and severity of the infection, disease or disorder (e.g. depending on the bacteria species involved in the disease, disorder and/or infection and its localization in the patient’s or subject’s body), and to the patient or subject, in particular its age, weight, sex, and general physical condition.
- the amount of engineered bacterial strains according to the invention and/or the amount of nutrient source to be administered has to be determined by standard procedure well known by those of ordinary skills in the art.
- Physiological data of the patient or subject e.g. age, size, and weight
- the routes of administration have to be taken into account to determine the appropriate dosage, so as a therapeutically effective amount will be administered to the patient or subject.
- the total amount of engineered bacterial strain, for each administration may be comprised between 1 billion and 100 billion cfu of engineered bacteria, from 5 billion to 50 billion cfu, or from 10 billion to 25 billion cfu of engineered bacteria.
- the total amount of milk oligosaccharide, for each administration may be comprised between 4.5 and 18 g of milk oligosaccharide per day, in particular between 9 and 18 g of milk oligosaccharide per day.
- a cell includes a plurality of such cells (e.g., a population of such cells).
- a nucleic acid includes one or more of such nucleic acids.
- Example 1 Method to prevent colorectal cancer by decreasing the abundance of a toxinproducing bacterial population
- a personalized method to prevent colorectal cancer (CRC) initiation or progression associated with the presence of colibactin-producing E. coli by in-situ reduction or replacement of the resident colibactin-producing E. coli with an engineered and non toxigenic version of the patient’s E. co// strain is disclosed.
- E. coli are more frequently found in CRC biopsies than in healthy mucosa. Furthermore, the majority of mucosa-associated E. coli isolated from CRC harbors the pks genomic island (pks-i- E. coli) that is responsible for the synthesis of colibactin, a genotoxic compound. It has also been reported that transient contact of a few malignant cells with colibactin-producing E. co// increases tumor growth in a xenograft mouse model. In the present method, patients are screened for the presence of pks-i- E. coli. For positive patients, the pks+ strain is isolated and grown.
- pks genomic island pks-i- E. coli
- the strain is engineered to contain both an operon encoding for the internalization and metabolism of 2’FL and a very targeted genetic mutation in the ClbP gene leading to the inactivation of the genotoxic activity of the Colibactin toxin, but maintaining the antagonistic activity of the toxin.
- the single-amino acid mutations of the ClbP gene in pks-i- E. coli are a genetic modification selected from the group consisting of S95A, S95R and K98T.
- the engineered E. coli is grown in fermenters at high titers and a pharmaceutical composition comprising the engineered E. coli is prepared.
- the pharmaceutical composition is administered to human patients together with 2’FL to replace the resident E.
- Example 2 Method to stop the progression of myocarditis by replacement of an immunogenic-peptide producing bacterial population
- AIM Acute Inflammatory Myocarditis
- the preparation of the administered pharmaceutical composition is achieved by growing both strains separately in fermenters at high titers, followed by formulation into a single stable drug product or two separate stable drug products.
- the administration results in colonization of the patient gut by the engineered B. thetaiotaomicron and/or B. faecis strains in which the immunogenicity of a peptidic sequence within the beta-galactosidase is reduced, leading to significant reduction or even total replacement of the resident population of B. thetaiotaomicron, or B.
- Example 3 Replacement, in mice gut, of a B. thetaiotaomicron strain expressing a betagalactosidase protein with high homology to human MYH6 cardiac peptide by an engineered B. thetaiotaomicron strain expressing a beta-galactosidase protein with low homology to human MYH6 cardiac peptide and a competitive advantage
- mice comprising, in their gut, a B. thetaiotaomicron strain expressing a beta-galactosidase protein with high homology to human MYH6 cardiac peptide are used.
- An engineered B. thetaiotaomicron strain wherein the gene encoding beta-galactosidase has been inactivated is produced. Said strain is further engineered to be resistant to a specific antibiotic, which confers to this strain a competitive advantage over the B. thetaiotaomicron strain present in the mice gut.
- the engineered B. thetaiotaomicron strain is orally administered to the mice, together with the antibiotic, prior to or after the antibiotic.
- Example 4 Method to improve Levodopa therapy against Parkinson’s disease by decreasing the abundance of a drug-modifying bacterial population
- L-dopa The primary treatment for Parkinson’s disease is L-dopa, which is prescribed to manage motor symptoms that result from dopaminergic neuron loss in the substantia nigra. It has been shown that E. faecalis and E. faecium from the gut microbiome can metabolize L-dopa, reducing its availability and leading to side effects (Maini Rekdal et al. (2019) Science 364:eaau6323).
- a pharmaceutical composition is prepared that contain a strain of either E. faecalis or E. faecium or both, that have been engineered to contain both an operon encoding for the internalization and metabolism of 2’FL and a very targeted genetic mutation in the tyrDC gene or another gene from the highly conserved tyrDC operon, leading to the prevention of the L-dopa decarboxylation in the gut.
- the engineered E. faecium and/or E. faecalis are grown in fermenters at high titers and a pharmaceutical composition comprising the engineered E. faecium and/or E. faecalis is prepared.
- the pharmaceutical composition is administered to human patients together with 2’FL to reduce the colonization level of resident E. faecium or E. faecalis or both strains from the patient.
- the administration results in colonization of the patient gut by the engineered E. faecalis and/or E. faecium strain in which the catalytic activity of at least one of the four genes from the TyrDC operon has been inactivated, leading to significant reduction or even total replacement of the resident population of E.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention concerns a method for reducing, in a subject or in a environment, the level of a molecule produced by at least one target bacterial strain which is harmful and/or not beneficial to said subject or environment, said method comprising: administering to the subject or providing the environment with an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target bacterial strain(s), wherein said engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s), and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the level of the molecule produced by the target bacterial strain(s) is reduced in the subject or environment.
Description
METHODS INVOLVING BACTERIAL STRAIN REPLACEMENT
Field of the invention
[01] The present invention concerns methods for reducing, in a subject or environment, the level of bacteria-produced molecules which are harmful and/or not beneficial to said subject or environment.
Background
[02] Microbiomes, in particular within subjects, are constituted of numerous bacterial species that are most of the time beneficial to the subjects.
[03] This is the case of the intestinal microbiota, which play a critical role in many instances such as the maturation and continued education of the host immune response (Fulde etal. (2014) Immunol. Rev. 260:21-34); provide protection against pathogen overgrowth (Kamada et al. (2013) Nat. Immunol 14:685-690); influence host-cell proliferation (Ijssennagger et al. (2015) Proc. Natl. Acad. Sci. USA 112:10038-43) and vascularization (Reinhardt et al. (2012) Nature 483:627-631); regulate intestinal endocrine functions (Neuman et al. (2015) FEMS Miicrobiol. Rev. 39:509-521), neurologic signaling (Yano et al. (2015) Cell 161 :264-76), and bone density (Cho et al. (2012) Nature 488:621-6); provide a source of energy biogenesis (Canfora et al. (2015) Nat. Rev. Endocrinol. 11 :577-591) (5 to 10% of daily host energy requirements); biosynthesize vitamins (Yatsuenko et al. (2012) Nature 486:222-7), neurotransmitters (Yano et al. (2015) Cell 161 :264-76), and multiple other compounds with as yet unknown targets; metabolize bile salts (Devlin etal. (2015) Nat. Chem. Biol. 11 :685-690); react to or modify specific drugs; and eliminate exogenous toxins (Haiser etal. (2013) Science 341 :295-8).
[04] Similarly, human skin, lung and vagina are home to millions of bacteria that compose the skin microbiota, the lung microbiota and the vaginal microbiota. Similar to those in our gut, skin, lung and vaginal resident microorganisms have essential roles in the protection against invading pathogens (Scharschmidt et al. (2013) Drug Discov. Today Dis. Meeh. 10:e83-e89), the education of our immune system (Belkaid etal. (2014) Science 346:954-959) and the breakdown of natural products (Grice (2015) Genome Res. 25:1514-1520).
[05] However, association studies in humans and rodents have also shown disease-related dysbiosis across a wide spectrum of common chronic disorders, including atherosclerosis, metabolic disorders, asthma, and autism spectrum disorder. Some of these observations have been combined with experimental studies, prospective studies, or both to identify putative microbiota-derived molecular mediators of pathogenic mechanisms. More particularly, some commensal bacteria, in particular some commensal bacterial species or subpopulations of bacterial strains, can produce molecules that are or become harmful for a subject.
[06] Using antibiotics to eliminate these bacteria producing harmful molecules would be either very challenging or dangerous. Indeed, commensal bacteria are strongly engrafted in the host
microbiome and belong to a robust community of microorganisms. Having evolved in sometimes a symbiotic relationship, it has been demonstrated that antimicrobial treatment effects on commensal resident bacteria are often only transitory, i.e. the bacteria are repopulating their ecological niche after treatment, or even during treatment by becoming resistant to the treatment. On the other hand, large spectrum antibiotics can sometimes lead to the opposite effect, inducing dysbiosis which is damaging for the subject.
[07] One strategy can be to selectively remove these harmful molecule-producing bacteria. However, even selectively removing a specific commensal bacterial strain can be damaging for the subject since it frees a niche in the microbiome which can be occupied by opportunistic pathogenic bacteria. Moreover, commensals are often providing benefits to the host, and removing them will likely be detrimental to the host.
[08] There is thus a need for new solutions enabling the selective removal of deleterious genes from commensal bacteria while preserving the beneficial effects of the commensal bacteria and avoiding widespread microbiome dysbiosis or occupation of the corresponding niche by opportunistic pathogenic bacteria.
[09] The inventors are proposing herein an innovative strategy which is to use a bacterial strain from the same species as the harmful molecule-producing strain but which does not produce said harmful molecule, and conferring to said strain a competitive advantage, so that it can compete with the harmful molecule-producing strain and even outcompete or replace it, thereby reducing the level of the harmful molecule in the subject down to a value which is not detrimental anymore for the subject.
[010] In that way, the level of the harmful molecule is selectively reduced without the formation of any empty niche, and it is even possible to maintain the production of other molecules from the harmful molecule-producing strain which could be beneficial by using an engineered strain which only differs from the harmful-molecule producing strain by the absence of production of the harmful molecule and its additional competitive advantage provided by genetic engineering methods.
[011] In the international application WO2018/112194, it is suggested to replace a harmful version of a strain by a non-harmful version that can compete for limiting resources with the harmful strain. However, the replacement of one strain by another is only shown as being possible using a Bacteroides ovatus strain which is naturally able to consume a specific limiting resource, namely porphyran, i.e. which has not been modified to acquire a competitive advantage. The authors only showed in one specific species, namely Bacteroides thetaiotaomicron, that it was possible to transfer a gene set sufficient to confer the capacity to metabolize porphyran. However, this transfer was achieved with a very low efficiency rate, suggesting that obtaining such a transfer in other species would be challenging. Moreover, the resulting B. thetaiotaomicron strain, engineered to be able to metabolize porphyran, was not able
to outcompete a corresponding wildtype B. thetaiotaomicron strain, naturally unable to metabolize porphyran.
[012] There is thus a strong need for new solutions enabling reduction of the level of harmful molecules in a subject or an environment by selectively reducing the relative abundance of harmful molecule-producing bacteria from the microbiome to reach a level at which the harmful molecule is not detrimental anymore for the subject, while minimizing the impact on the rest of the microbiome and avoiding occupation of the corresponding niche by opportunistic pathogenic bacteria.
[013] The present invention meets this need.
[014] The present invention arises from the unexpected finding by the inventors that it is possible to actually reduce the level of a harmful molecule by using a bacterial strain, which does not produce the harmful molecule, and which is engineered to have a competitive advantage over the harmful molecule-producing strain, said competitive advantage being for example advantage in interference competition or the capacity or an improved capacity of importing and metabolizing oligosaccharides, in particular human milk oligosaccharide. Thereby, an actual therapeutic effect can be obtained when administering said engineered strain.
Summary of the invention
[015] The present invention thus concerns a method for reducing, in a subject or in a environment, the level of a molecule produced by at least one target bacterial strain which is harmful and/or not beneficial to said subject or environment, said method comprising: administering to the subject or providing the environment with an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target bacterial strain(s), wherein said engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s), and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the level of the molecule produced by the target bacterial strain(s) is reduced in the subject or environment.
[016] In a particular embodiment, said heterologous gene or gene set providing a competitive advantage is from another species than the engineered bacterial strain.
[017] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene involved in the import and/or metabolism of a nutrient source.
[018] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a transporter of a nutrient source.
[019] In a particular embodiment, said nutrient source is a milk oligosaccharide, more particularly a human milk oligosaccharide.
[020] In a particular embodiment, said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
[021] In a particular embodiment, said milk oligosaccharide is selected from the group consisting of lacto-N-biose, lacto-N-triose, N-acetyllactosamime, lacto-N-neotriose, lacto-N- tetraose, lacto-N-neotetraose, fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2’-fucosyllactose, 3’-sialyllactosamine, 3’-fucosyllactose, 3’-sialyl-3-fucosyllactose, 3’-sialyllactose, 6’-sialyllactosamine, 6’-sialyllactose, difucosyllactoase, lacto-N-fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, their derivatives and any combination thereof.
[022] In a particular embodiment, said milk oligosaccharide is a modified, recombinant or synthetic milk oligosaccharide.
[023] In another particular embodiment, said milk oligosaccharide is obtained from human milk. [024] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene of the H5 gene cluster from Bifidobacterium longum subsp. infantis.
[025] In a particular embodiment, said nutrient source is a rare carbohydrate. In a more particular embodiment, less than 50% of other bacterial cells in the subject utilize said rare carbohydrate as a nutrient source.
[026] In a particular embodiment, said rare carbohydrate is a polysaccharide.
[027] In another particular embodiment, said rare carbohydrate is a sulfated carbohydrate.
[028] In a particular embodiment, said rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans and any combination thereof.
[029] In a more particular embodiment, said rare carbohydrate is selected from the group consisting of porphyran, agarose, carrageenan, ulvan, xylan and any combination thereof.
[030] In a particular embodiment, said rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
[031] In a particular embodiment, said rare carbohydrate is a sulfated polygalactan.
[032] In a particular embodiment, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene selected from the group consisting of genes encoding porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
[033] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding protein(s) which sequence(s) is(are) at least 80% identical to at least one of BACPLE 1683-1706 from the Bacteroides plebeius genome.
[034] In a particular embodiment, said heterologous or engineered gene set providing a competitive advantage comprises at least two, three, four, five or six genes.
[035] In a particular embodiment, the nutrient source cannot be utilized as a nutrient source by the engineered bacterial strain in the absence of the heterologous or engineered gene or gene set providing a competitive advantage.
[036] In an alternative embodiment, the nutrient source is utilized as a nutrient source more efficiently by the engineered bacterial strain in the presence of the heterologous or engineered gene or gene set providing a competitive advantage than in the absence thereof.
[037] In a particular embodiment, the method further comprises administering the nutrient source to the subject or providing the environment with the nutrient source.
[038] In a particular embodiment, the reduction of the level of the molecule produced by the target bacterial strain(s) is only due to the administration of said engineered bacterial strain.
[039] In a more particular embodiment, no antibacterial agent is administered to the subject. In an alternative embodiment, an antibacterial agent is administered to the subject.
[040] In a particular embodiment, the engineered bacterial strain further produces an antibacterial agent to which the engineered bacterial strain is resistant, but to which the target bacterial strain(s) is sensitive. In a more particular embodiment, the engineered bacterial strain further produces an antibacterial agent to which the engineered bacterial strain is resistant, but to which the target bacterial strain(s) and other bacteria from the subject are sensitive.
[041] In a particular embodiment, the antibacterial agent is a bacteriocin.
[042] In a particular embodiment, the engineered bacterial strain produces multiple antibacterial agents, at least one, two, three, four, five or more antibacterial agents.
[043] In a particular embodiment, the produced molecule is expressed, secreted and/or displayed by the target bacterial strain(s).
[044] In a particular embodiment, said engineered bacterial strain does not naturally produce the molecule produced by the target bacterial strain(s). In an alternative embodiment, said engineered bacterial strain has been engineered to not produce the molecule produced by the target bacterial strain(s). In an alternative embodiment, said engineered bacterial strain has been engineered to produce a non-harmful mutant or variant of the molecule produced by the target bacterial strain(s).
[045] In a particular embodiment, the engineered bacterial strain produces a variant or a mutant of the molecule produced by the target bacterial strain(s), thereby reducing the level, in the subject or environment, of the molecule produced by the target bacterial strain(s), in particular reducing the ratio of the level, in the subject or environment, of the molecule produced by the target bacterial strain(s) to the level, in the subject or environment, of a variant or mutant of said molecule. In an alternative embodiment, the engineered bacterial strain neither produces the molecule produced by the target bacterial strain(s), nor any variant or any mutant of the molecule produced by the target bacterial strain(s).
[046] The present invention also concerns a method for preventing and/or treating, in a subject, a disease, disorder or condition associated to at least one target molecule-producing bacterial strain, said method comprising: administering to the subject a therapeutically efficient amount of an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce the molecule(s) produced by the target bacterial strain(s) which is involved in said disease or disorder, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the disease, disorder or condition is prevented and/or treated in the subject.
[047] In a particular embodiment, said molecule is a molecule able to induce or sustain an autoimmune reaction in the host.
[048] In a particular embodiment, said molecule is a peptide that mimics a human autoantigen.
[049] In a particular embodiment, said molecule is a virulence factor.
[050] In a particular embodiment, said molecule is a molecule encoded by an antibiotic resistance gene.
[051] In a particular embodiment, said molecule is a molecule which induces or can induce inflammation in a subject.
[052] In a particular embodiment, said molecule is a molecule that modulates or can modulate a neurodegenerative disease.
[053] In a particular embodiment, said engineered bacterial strain does not naturally produce said molecule.
[054] In an alternative embodiment, said engineered bacterial strain has been engineered to not produce said molecule.
[055] In an alternative embodiment, said engineered bacterial strain has been engineered to produce a mutant or variant of said molecule, in particular a non-harmful mutant or variant of said molecule.
Detailed description of the invention
Engineered bacterial strain with competitive advantage
[056] In the context of the invention, an engineered bacterial strain comprising a heterologous or engineered gene or gene set providing a competitive advantage over target bacterial strain(s) is used.
[057] As used herein, the term “engineered” means that the bacterial cell of the invention has been modified by standard molecular biology techniques, typically to introduce the indicated heterologous gene or gene set or to modify the indicated gene or gene set, for example by transformation of the cell with a plasmid, by conjugation, by transduction of the cell with a bacteriophage, or by any suitable technique enabling introducing or modifying a nucleic acid sequence into a bacterial cell. As will be understood by the skilled person, engineering of a bacterial strain implies a deliberate action to introduce or modify a nucleic acid sequence and does not cover introduction or modification of a nucleic acid sequence through natural evolution of the bacterial strain.
[058] For example, the bacteria of the invention can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
[059] Typically, said heterologous gene or gene set providing a competitive advantage has been incorporated into the bacterial cell’s chromosomal or extrachromosomal expression system, or as extrachromosomal expression system, by genetic engineering techniques known in the art. For example, said bacteria can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
[060] By “engineered gene or gene set” is meant herein a gene or gene set, autologous to said bacterial strain, but which has been modified by standard molecular biology techniques, typically to introduce a mutation in the sequence of said autologous gene or gene set, in such a way that the expression of the gene or gene set or the activity of the protein encoded by said gene or gene set is modified. As will be understood by the skilled person, engineering of a gene or gene set implies a deliberate action to introduce a modification in the nucleic acid sequence and does not cover mutation of a nucleic acid sequence through natural evolution of the bacterial strain.
[061] Said engineered gene or gene set may be any piece of a gene such as a portion of an open reading frame of a gene, or a sequence involved in the regulation of the expression of a gene such as a promoter, an operator, a terminator. In this specific context, it also encompasses a nucleic acid encoding a transcription factor, a nucleic acid encoding a repressor, a nucleic acid encoding an activator, or a nucleic acid encoding an inducer.
[062] Typically, said engineered gene or gene set providing a competitive advantage has been modified into the bacterial cell’s chromosomal or extrachromosomal expression system, by genetic engineering techniques known in the art. For example, said bacteria can be genetically engineered by transformation (chemical transformation or ultrasound transformation), transduction (using for example optionally engineered bacteriophages, or packaged phagemids technologies), conjugation, or electroporation.
[063] In some embodiments, said heterologous or engineered gene or gene set providing a competitive advantage is or is engineered to be under the control of a high expression promoter. In particular embodiments, said heterologous or engineered gene or gene set providing a competitive advantage is under the control of an inducible promoter, constitutive promoter, native promoter (e.g., native to the bacterial strain), heterologous promoter, or a promoter associated with said heterologous gene in its native form.
[064] In some embodiments, in particular when said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source, as defined below, said heterologous or engineered gene or gene set providing a competitive advantage is or is engineered to be under the control of a promoter which is induced in the presence of a nutrient source. More particularly, in some embodiments, in particular when said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source, as defined below, the expression of said heterologous or engineered gene or gene set providing a competitive advantage is increased in the presence of a nutrient source.
[065] In some embodiments, said heterologous or engineered gene or gene set providing a competitive advantage is under the control of a burden-sensing promoter. More particularly, when said engineered bacterial strain produces a mutant or variant of said molecule produced by the target bacterial strain(s), as defined below, synthesis of said mutant or variant may confer a burden and/or fitness cost on said engineered bacterial strain. In such embodiment, expression of said heterologous or engineered gene or gene set providing a competitive advantage can be up-regulated when said burden-sensing promoter is induced by said burden and/or fitness cost relative to a basal level expression of said heterologous or engineered gene or gene set when said burden-sensing promoter is not induced.
[066] In other embodiments, said engineered bacterial strain further comprises an essential gene operably linked to a burden-sensing promoter, wherein expression of said heterologous or engineered gene or gene set providing a competitive advantage and/or, when said engineered bacterial strain produces a mutant or variant of said molecule produced by the target bacterial strain(s), as defined below, synthesis of said mutant or variant, confer a burden and/or fitness cost on said strain, and wherein expression of said essential gene is up-regulated when said burden-sensing promoter is induced by said burden and/or fitness cost relative to a basal level expression of said essential gene when said burden-sensing promoter is not induced.
[067] Such burden-sensing promoters are typically disclosed in international application WO2021/160854.
[068] Examples of burden-sensing promoters include a o factor regulated promoter, such as o32, oB and os factor regulated promoters, a ribosomal RNA promoter, an HAC1 -upregulated promoter comprising a UPR element, and a DNA-damage sensing promoter.
[069] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is chromosomally integrated upstream of an autologous essential gene, in particular as part of a single operon including said autologous essential gene. Such a location of the heterologous or engineered gene is advantageous to prevent loss of function of the heterologous or engineered gene. Indeed, in case the heterologous or engineered gene is not expressed due to a frameshift mutation and/or a point mutation leading to a STOP codon occurring in the heterologous or engineered gene, the downstream autologous essential gene will not be expressed anymore, and the engineered bacterial strain will die.
[070] In a particular embodiment, when said engineered bacterial strain produces a mutant or variant of said molecule produced by the target bacterial strain(s), said gene or gene set encoding said mutant or variant is chromosomally integrated upstream of a heterologous or engineered gene providing a competitive advantage, in particular as part of a single operon including said heterologous or engineered gene providing a competitive advantage. Such a location of the gene or gene set encoding said mutant or variant is advantageous to prevent loss of function of the gene or gene set. Indeed, in case the gene or gene set encoding said mutant or variant is not expressed due to a frameshift mutation and/or a point mutation leading to a STOP codon occurring in the gene or gene set encoding said mutant or variant, the downstream heterologous or engineered gene providing a competitive advantage will not be expressed anymore, and the engineered bacterial strain will lose its competitive advantage.
Bacterial strain
[071] The engineered bacterial strain used in the context of the invention can be obtained from any suitable bacterial strain.
[072] In a particular embodiment, the engineered bacterial strain is obtained from an autologous strain, i.e. a strain isolated from the subject to be treated.
[073] In an alternative embodiment, the engineered bacterial strain is obtained from a non- autologous strain, i.e. a strain which was not isolated from the subject to be treated.
[074] As used herein, a “bacterial strain” refers to a genetic variant or subtype within a bacterial species. Therefore, a bacterial strain more particularly refers to a bacterium which remains genetically unchanged when grown or multiplied. The multiplicity of identical bacteria are included. A bacterial strain is typically obtained from the isolation of a clone, which can give birth to a population of cells obtained from a single bacterial cell or colony.
[075] Examples of bacterial strains include, without limitation, strains from bacteria of the genus Acinetobacter spp., Actinobacillus spp., Actinobacter spp., Actinomyces spp., Aeromonas spp., Bacillus spp., Bacteroides spp., Bartonella spp., Bifidobacterium spp., Bartonella spp., Bordetella spp., Borrelia spp., Brevibacterium spp., Brucelia spp., Brucella spp., Campylobacter spp., Chlamydia spp., Chlamydophilia spp., Citrobacter spp., Clostridium spp., Corynebacterium spp., Cutibacterium spp., Ehrlichia spp., Enterobacter spp., Enterococcus spp., Erysipelothrix spp., Escherichia spp., Francisella spp., Fusobacterium spp., Gardnerella spp., Haemophilus spp.,
Helicobacter spp., Hemophilus spp., Klebsiella spp., Lactobacillus spp., Lactococcus spp., Legionella spp., Leptospira spp., Leuconostoc spp., Listeria spp., Micrococcus spp., Morganella spp., Mycobacterium spp., Mycoplasma spp., Neisseria spp., Nocardia spp., Parvimonas spp., Porphyromonas spp., Prevotella spp., Propionibacterium spp., Pseudomonas spp., Pyrococcus spp., Rhodococcus spp., Rickettsia spp., Salmonella spp., Selnomonas spp., Serratia spp., Shigella spp., Staphylococcus spp., Streptococcus spp., Streptomyces spp., Synechocystis spp., Treponema spp., Ureaplasma spp., Vibrio spp., Yersinia spp., Zymonas spp., and a mixture thereof.
[076] In some embodiments, bacterial strains used in the context of the invention are anaerobic bacterial strains (e.g., cells that do not require oxygen for growth). Anaerobic bacterial strains include facultative anaerobic strains such as, but not limited to, Escherichia coll, Shewanella oneidensi, Gardnerella vaginalis and Listeria. Anaerobic bacterial strains also include obligate anaerobic strains such as, for example, Bacteroides, Clostridium, Cutibacterium, Propionibacterium, Fusobacterium and Porphyromonas species. In humans, anaerobic bacteria are most commonly found in the gastrointestinal tract. In some particular embodiments, the engineered bacterial strains are thus obtained from bacteria most commonly found in the gastrointestinal tract.
[077] In some embodiments, the bacterial strains are, without limitation, Actinobacillus actinobycetemcomitans, Actinobacter baumanii, Actinomyces israelii, Aeromonas caviae, Aeromonas hydrophila, Bacillus anthracis, Bacillus cereus, Bacillus coagulans, Bacillus liquefaciens, Bacillus megaterium, Bacillus popillae, Bacillus subtilis, Bacillus thuringiensis, Bacteroides distasonis, Bacteroides faecis, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bartonella henselae, Bartonella Quintana, Bordetella pertussis, Borrelia afzelii, Borrelia burgdorferi, Borrelia garinii, Borrelia recurrentis, Brevibacterium lactofermentum, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter coll, Campylobacter fetus, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Citrobacter freundii, Clostridium botulinum, Clostridium butyricum, Clostridium coccoides, Clostridium difficile, Clostridium leptum, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheria, Corynebacterium xerosis, Cutibacterium acnes (formerly Propionibacterium acnes), cyanobacteria, Ehrlichia canis, Ehrlichia chaffeensis, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coll, Francisella tularensis, Fusobacterium nucleatum, Gardnerella vaginalis, Haemophilus influenza, Helicobacter pylori, Klebsiella pneumoniae, Lactobacillus acidophilus, Lactobacillus easel, Lactobacillus hilgardii, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactococcus lactis, Legionella pneumophila, Leptospira interrogans, Leptospira noguchii, Leptospira santarosai, Leptospira weilii, Leuconostoc lactis, Leuconostoc oenos, Listeria monocytogenes, Micrococcus luteus, Morganella morganii, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma mycoides,
Mycoplasma pneumonia, Neisseria gonorrhoeae, Neisseria meningitides, Nocardia asteroids, Parvimonas micra, Porphyromonas endodontalis, Porphyromonas gingivalis, Prevotella intermedia, Prevotella nigrescens, Propionibacterium freudenreichii, Pseudomonas aeruginosa, Pyrococcus abyssi, Rickettsia rickettsia, Salmonella enteritidis, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Selenomonas nominantium, Selnomonas ruminatium, Serratia marcescens, Shigella dysenteriae, Shigella flexnerii, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus ferus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Streptomyces ghanaenis, Streptomyces phaechromogenes, Synechocystis strain PCC6803, Treponema denticola, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholera, Vibrio parahaemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Zymomonas mobilis, and a mixture thereof.
[078] In some embodiments, the bacterial strains are, without limitation, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Achromobacter, Acidaminococcus, Acinetobacter, Actinobacillus, Actinomyces, Adlercreutzia, Aeromicrobium, Aggregatibacter, Akkermansia, Aliagarivorans, Alistipes, Alloscardovia, Anaerobacter, Anaerobaculum, Anaerococcus, Anaerofilum, Anaerofustis, Anaerosinus, Anaerostipes, Anaerotruncus, Anaerovorax, Aneurinibacillus, Bacillus, Bacteroides, Barnesiella, Bavariicoccus, Bifidobacterium, Bilophila, Blautia, Brachymonas, Brevibacterium, Bryantella, Butyricicoccus, Butyri vibrio, Butyricimonas, Caldicoprobacter, Campylobacter, Capracoccus, Catenibacterium, Cedecea, Cellulomonas, Cetobacterium, Citrobacter, Cloacibacillus, Clostridiales, Clostridioides, Clostridium, Collinsella, Coprobacillus, Coprobacter, Coprococcus, Corynebacterium, Cutibacterium, Dehalobacter, Dermabacter, Desulfitobacterium, Desulfovibrio, Dialister, Dielma, Dorea, Dysgonomonas, Edwardsiella, Eggerthella, Eisenbergiella, Enorma, Enterobacter, Enterococcus, Enterovibrio, Erysipelatoclostridium, Escherichia, Ethanoligenens, Eubacterium, Exiguobacterium, Faecalibacterium, Faecalitalea, Ferrimonas, Finegoldia, Flavobacterium, Flavonifractor, Fusicatenibacter, Fusobacterium, Gallibacterium, Gemmiger, Gordonibacter, Gracilibacter, Guggenheimella, Hafnia, Helicobacter, Herbaspirillum, Hespellia, Holdemanella, Holdemania, Hungatella, Intestinibacter, Intestinimonas, Klebsiella, Kurthia, Lachnobacterium, Lachnospira, Lactobacillus, Leuconostoc, Listeria, Mannheimia, Marvinbryantia, Megamonas, Megasphaera, Methanobrevibacter, Micrococcus, Microvirgula, Mitsuokella, Mollicutes, Moryella, Murimonas, Neisseria, Nitriliruptor, Oceanobacillus, Odoribacter, Oribacterium, Ornithobacterium, Oxalobacter, Oxobacter, Paenibacillus, Papillibacter, Parabacteroides, Paraprevotella, Parasutterella, Parvimonas, Pediococcus, Peptoclostridium, Peptoniphilus, Phascolarctobacterium, Porphyromonas, Prevotella, Propionibacterium, Propionimicrobium, Proprionispira, Proteus, Providencia, Pseudobutyrivibrio, Pseudoflavonifractor, Pseudomonas, Pseudoramibacter, Ralstonia, Rheinheimera, Riemerella, Romboutsia, Roseburia, Ruminococcus, Sarcina, Seinonella, Sellimonas, Senegalimassilia, Shigella, Shuttleworthia,
Slackia, Sporobacter, Sporobacterium, Staphylococcus, Stenotrophomonas, Streptococcus, Streptomyces, Subdoligranulum, Succinatimonas, Sutterella, Syntrophococcus, Terrisporobacter, Thalassobacillus, Thermobacillus, Timonella, Treponema, Turibacter, Turicibacter, Varibaculum, Veillonella, Vibrio, Virgibacillus and/or Weisella.
[079] In other embodiments, the bacteria strains are, without limitation, Achromobacter xylosoxidans, Acidaminococcus fermentans, Acidaminococcus intestini, Acidaminococcus sp., Acinetobacter baumannii, Acinetobacter junii, Acinetobacter Iwoffii, Actinobacillus capsulatus, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces radingae, Adlercreutzia equolifaciens, Aeromicrobium massiliense, Aggregatibacter actinomycetemcomitans, Akkermansia muciniphila, Aliagarivorans marinus, Alistipes finegoldii, Alistipes indistinctus, Alistipes inops, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Alloscardovia omnicolens, Anaerobacter polyendosporus, Anaerobaculum hydrogeniformans, Anaerococcus hydrogenalis, Anaerococcus prevotii, Anaerococcus senegalensis, Anaerofustis stercorihominis, Anaerostipes caccae, Anaerostipes hadrus, Anaerotruncus colihominis, Aneurinibacillus aneurinilyticus, Bacillus licheniformis, Bacillus massilioanorexius, Bacillus massiliosenegalensis, Bacillus simplex, Bacillus smithii, Bacillus subtilis, Bacillus thuringiensis, Bacillus timonensis, Bacteroides acidifaciens, Bacteroides caccae, Bacteroides capillosus, Bacteroides cellulosilyticus, Bacteroides clarus, Bacteroides coprocola, Bacteroides coprophilus, Bacteroides dorei, Bacteroides eggerthii, Bacteroides faecis, Bacteroides finegoldii, Bacteroides fluxus, Bacteroides fragilis, Bacteroides gallinarum, Bacteroides intestinalis, Bacteroides nordii, Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides pectinophilus, Bacteroides plebeius, Bacteroides salanitronis, Bacteroides salyersiae, Bacteroides sp., Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Barnesiella intestinihominis, Bavariicoccus seileri, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium gallicum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium stercoris, Bilophila wadsworthia, Blautia faecis, Blautia hansenii, Blautia hydrogenotrophica, Blautia luti, Blautia obeum, Blautia producta, Blautia wexlerae, Brachymonas chironomi, Brevibacterium senegalense, Bryantella formatexigens, butyrate-producing bacterium, Butyricicoccus pullicaecorum, Butyricimonas virosa, Butyrivibrio crossotus, Butyrivibrio fibrisolvens, Caldicoprobacter faecalis, Campylobacter concisus, Campylobacter jejuni, Campylobacter upsaliensis, Catenibacterium mitsuokai, Cedecea davisae, Cellulomonas massiliensis, Cetobacterium somerae, Citrobacter braakii, Citrobacter freundii, Citrobacter pasteurii, Citrobacter sp., Citrobacter youngae, Cloacibacillus evryensis, Clostridiales bacterium, Clostridioides difficile, Clostridium asparagiforme, Clostridium bartlettii, Clostridium boliviensis, Clostridium bolteae, Clostridium hathewayi, Clostridium hiranonis, Clostridium hylemonae,
Clostridium leptum, Clostridium methylpentosum, Clostridium nexile, Clostridium orbiscindens, Clostridium ramosum, Clostridium scindens, Clostridium sp, Clostridium spiroforme, Clostridium sporogenes, Clostridium symbiosum, Collinsella aerofaciens, Collinsella intestinalis, Collinsella stercoris, Collinsella tanakaei, Coprobacillus cateniformis, Coprobacter fastidiosus, Coprococcus catus, Coprococcus comes, Coprococcus eutactus, Corynebacterium ammoniagenes, Corynebacterium amycolatum, Corynebacterium pseudodiphtheriticum, Cutibacterium acnes, Dermabacter hominis, Desulfitobacterium hafniense, Desulfovibrio fairfieldensis, Desulfovibrio piger, Dialister succinatiphilus, Dielma fastidiosa, Dorea formicigenerans, Dorea longicatena, Dysgonomonas capnocytophagoides, Dysgonomonas gadei, Dysgonomonas mossii, Edwardsiella tarda, Eggerthella lenta, Eisenbergiella tayi, Enorma massiliensis, Enterobacter aerogenes, Enterobacter asburiae, Enterobacter cancerogenus, Enterobacter cloacae, Enterobacter massiliensis, Enterococcus casseliflavus, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus sp., Enterovibrio nigricans, Erysipelatoclostridium ramosum, Escherichia coli, Escherichia sp., Eubacterium biforme, Eubacterium dolichum, Eubacterium hallii, Eubacterium limosum, Eubacterium ramulus, Eubacterium rectale, Eubacterium siraeum, Eubacterium ventriosum, Exiguobacterium marinum, Exiguobacterium undae, Faecalibacterium cf, Faecal i bacterium prausnitzii, Faecalitalea cylindroides, Ferrimonas balearica, Finegoldia magna, Flavobacterium daejeonense, Flavonifractor plautii, Fusicatenibacter saccharivorans, Fusobacterium gonidiaformans, Fusobacterium mortiferum, Fusobacterium necrophorum, Fusobacterium nucleatum, Fusobacterium periodonticum, Fusobacterium sp., Fusobacterium ulcerans, Fusobacterium varium, Gallibacterium anatis, Gemmiger formicilis, Gordonibacter pamelaeae, Hafnia alvei, Helicobacter bilis, Helicobacter bills, Helicobacter canadensis, Helicobacter canis, Helicobacter cinaedi, Helicobacter macacae, Helicobacter pametensis, Helicobacter pullorum, Helicobacter pylori, Helicobacter rodentium, Helicobacter winghamensis, Herbaspirillum massiliense, Holdemanella biformis, Holdemania filiformis, Holdemania massiliensis, Hungatella hathewayi, Intestinibacter bartlettii, Intestinimonas butyriciproducens, Klebsiella oxytoca, Klebsiella pneumoniae, Kurthia massiliensis, Lachnospira pectinoschiza, Lactobacillus acidophilus, Lactobacillus amylolyticus, Lactobacillus animalis, Lactobacillus antri, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus iners, Lactobacillus intestinalis, Lactobacillus johnsonii, Lactobacillus murinus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus plantarum subsp., Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus ruminis, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus ultunensis, Lactobacillus vaginalis, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Listeria grayi, Listeria innocua, Mannheimia granulomatis, Marvinbryantia formatexigens, Megamonas funiformis, Megamonas hypermegale, Methanobrevibacter smithii, Micrococcus luteus, Microvirgula
aerodenitrificans, Mitsuokella jalaludinii, Mitsuokella multacida, Mollicutes bacterium, Murimonas intestini, Neisseria macacae, Nitriliruptor alkaliphilus, Oceanobacillus massiliensis, Odoribacter laneus, Odoribacter splanchnicus, Ornithobacterium rhinotracheale, Oxalobacter formigenes, Paenibacillus barengoltzii, Paenibacillus chitinolyticus, Paenibacillus lautus, Paenibacillus motobuensis, Paenibacillus senegalensis, Paenisporosarcina quisquiliarum, Parabacteroides distasonis, Parabacteroides goldsteinii, Parabacteroides gordonii, Parabacteroides johnsonii, Parabacteroides merdae, Paraprevotella xylaniphila, Parasutterella excrementihominis, Parvimonas micra, Pediococcus acidilactici, Peptoclostridium difficile, Peptoniphilus harei, Peptoniphilus obesi, Peptoniphilus senegalensis, Peptoniphilus timonensis, Phascolarctobacterium succinatutens, Porphyromonas asaccharolytica, Porphyromonas uenonis, Prevotella baroniae, Prevotella bivia, Prevotella copri, Prevotella dentalis, Prevotella micans, Prevotella multisaccharivorax, Prevotella oralis, Prevotella salivae, Prevotella stercorea, Prevotella veroralis, Propionibacterium acnes, Propionibacterium avidum, Propionibacterium freudenreichii, Propionimicrobium lymphophilum, Proteus mirabilis, Proteus penneri ATCC, Providencia alcalifaciens, Providencia rettgeri, Providencia rustigianii, Providencia stuartii, Pseudoflavonifractor capillosus, Pseudomonas aeruginosa, Pseudomonas luteola, Ralstonia pickettii, Rheinheimera perlucida, Rheinheimera texasensis, Riemerella columbina, Romboutsia lituseburensis, Roseburia faecis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus bicirculans, Ruminococcus bromii, Ruminococcus callidus, Ruminococcus champanellensis, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus obeum, Ruminococcus sp., Ruminococcus torques, Sarcina ventriculi, Sellimonas intestinalis, Senegalimassilia anaerobia, Shigella sonnei, Slackia piriformis, Staphylococcus epidermidis, Staphylococcus lentus, Staphylococcus nepalensis, Staphylococcus pseudintermedius, Staphylococcus xylosus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus australis, Streptococcus caballi, Streptococcus castoreus, Streptococcus didelphis, Streptococcus equinus, Streptococcus gordonii, Streptococcus henryi, Streptococcus hyovaginalis, Streptococcus infantarius, Streptococcus infantis, Streptococcus lutetiensis, Streptococcus merionis, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus ovis, Streptococcus parasanguinis, Streptococcus plurextorum, Streptococcus porci, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sobrinus, Streptococcus thermophilus, Streptococcus thoraltensis, Streptomyces albus, Subdoligranulum variabile, Succinatimonas hippei, Sutterella parvirubra, Sutterella wadsworthensis, Terrisporobacter glycolicus, Terrisporobacter mayombei, Thalassobacillus devorans, Timonella senegalensis, Turicibacter sanguinis, Varibaculum cambriense, Veillonella atypica, Veillonella dispar, Veillonella parvula, Vibrio cincinnatiensis, Virgibacillus salexigens, and/or Weissella paramesenteroides.
[080] In other embodiments, the bacteria strains are those commonly found on the skin microbiota and are without limitation Abiotrophia defectiva, Acetobacter farinalis, Acetobacter
malorum, Acetobacter orleanensis, Acetobacter sicerae, Achromobacter anxifer, Achromobacter denitrificans, Achromobacter marplatensis, Achromobacter spanius, Achromobacter xylosoxidans subsp. xylosoxidans, Acidocella aminolytica, Acidovorax konjaci, Acidovorax radicis, Acinetobacter guangdongensis, Acinetobacter johnsonii, Acinetobacter parvus, Acinetobacter radioresistens, Acinetobacter soli, Acinetobacter variabilis, Actinomadura citrea, Actinomadura coerulea, Actinomadura fibrosa, Actinomadura fulvescens, Actinomadura jiaoheensis, Actinomadura luteofluorescens, Actinomadura mexicana, Actinomadura nitritigenes, Actinomadura verrucosospora, Actinomadura yumaensis, Actinomyces cardiffensis, Actinomyces dentalis, Actinomyces europaeus, Actinomyces gerencseriae, Actinomyces graevenitzii, Actinomyces haliotis, Actinomyces johnsonii, Actinomyces massiliensis, Actinomyces meyeri, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii subsp. anitratus, Actinomyces odontolyticus, Actinomyces oris, Actinomyces turicensis, Actinomycetospora atypica, Actinomycetospora corticicola, Actinomycetospora rhizophila, Actinomycetospora rishiriensis, Actinotignum schaalii, Aerococcus christensenii, Aerococcus urinae, Aeromicrobium flavum, Aeromicrobium massiliense, Aeromicrobium tamlense, Aeromonas australiensis, Aeromonas bestiarum, Aeromonas bivalvium, Aeromonas encheleia, Aeromonas eucrenophila, Aeromonas hydrophila subsp. hydrophila, Aeromonas piscicola, Aeromonas popoffii, Aeromonas rivuli, Aeromonas salmonicida subsp. pectinolytica, Aeromonas salmonicida subsp. smithia, Aeromonas sharmana, Aggregatibacter aphrophilus, Aggregatibacter segnis, Agrococcus baldri, Albibacter methylovorans, Alcaligenes faecalis subsp. faecalis, Algoriphagus ratkowskyi, Alkalibacterium olivapovliticus, Alkalibacterium pelagium, Alloprevotella rava, Alsobacter metallidurans, Amaricoccus kaplicensis, Amaricoccus veronensis, Aminobacter aganoensis, Aminobacter ciceronei, Aminobacter lissarensis, Aminobacter niigataensis, Anaerococcus hydrogenalis, Anaerococcus lactolyticus, Anaerococcus murdochii, Anaerococcus octavius, Anaerococcus prevotii, Anaerococcus vaginalis, Ancylobacter polymorphus, Anoxybacillus flavithermus subsp. yunnanensis, Aquabacterium citratiphilum, Aquabacterium olei, Aquabacterium parvum, Aquamicrobium aerolatum, Aquincola tertiaricarbonis, Archangium gephyra, Archangium gephyra, Archangium minus, Archangium violaceum, Arcobacter venerupis, Arsenicicoccus bolidensis, Arthrobacter russicus, Arthrobacter viscosus, Asticcacaulis excentricus, Atopobium deltae, Atopobium parvulum, Atopobium rimae, Atopobium vaginae, Aureimonas altamirensis, Aureimonas rubiginis, Azospira oryzae, Azospirillum oryzae, Bacillus anthracis, Bacillus australimaris, Bacillus circulans, Bacillus drentensis, Bacillus fastidiosus, Bacillus lehensis, Bacillus mycoides, Bacillus pseudomycoides, Bacillus pumilus, Bacillus oceanisediminis, Bacillus rhizosphaerae, Bacillus safensis, Bacillus vallismortis, Bacteriovorax stolpii, Bacteroides coagulans, Bacteroides dorei, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus, Bdellovibrio bacteriovorus, Bdellovibrio exovorus, Belnapia moabensis, Belnapia soli, Blautia hansenii, Blautia obeum, Blautia wexlerae, Bosea lathyri, Bosea
thiooxidans, Brachybacterium fresconis, Brachybacterium muris, Bradyrhizobium huanghuaihaiense, Bradyrhizobium japonicum, Brevibacterium ammoniilyticum, Brevibacterium casei, Brevibacterium epidermidis, Brevibacterium iodinum, Brevibacterium luteolum, Brevibacterium paucivorans, Brevibacterium pityocampae, Brevibacterium sanguinis, Brevundimonas albigilva, Brevundimonas aurantiaca, Brevundimonas diminuta, Brevundimonas intermedia, Brevundimonas vancanneytii, Burkholderia aspalathi, Burkholderia choica, Burkholderia cordobensis, Burkholderia diffusa, Burkholderia insulsa, Burkholderia rhynchosiae, Burkholderia terrestris, Burkholderia udeis, Buttiauxella gaviniae, Caenimonas terrae, Calidifontibacter indicus, Campylobacter concisus, Campylobacter gracilis, Campylobacter hominis, Campylobacter rectus, Campylobacter showae, Campylobacter ureolyticus, Capnocytophaga gingivalis, Capnocytophaga leadbetteri, Capnocytophaga ochracea, Capnocytophaga sputigena, Cardiobacterium hominis, Cardiobacterium valvarum, Carnobacterium divergens, Catonella morbi, Caulobacter henricii, Cavicella subterranea, Cellulomonas xylanilytica, Cellvibrio vulgaris, Chitinimonas taiwanensis, Chitinophaga dinghuensis, Chryseobacterium arachidis, Chryseobacterium daecheongense, Chryseobacterium formosense, Chryseobacterium gleum, Chryseobacterium greenlandense, Chryseobacterium indoIogenes, Chryseobacterium jejuense, Chryseobacterium piscium, Chryseobacterium rigui, Chryseobacterium sediminis, Chryseobacterium solani, Chryseobacterium taklimakanense, Chryseobacterium tructae, Chryseobacterium ureilyticum, Chryseobacterium vietnamense, Chryseobacterium zeae, Chryseomicrobium aureum, Cloacibacterium haliotis, Cloacibacterium normanense, Cloacibacterium normanense, Collinsella aerofaciens, Comamonas denitrificans, Comamonas terrigena, Corynebacterium accolens, Corynebacterium afermentans subsp. lipophilum, Corynebacterium ammoniagenes, Corynebacterium amycolatum, Corynebacterium aurimucosum, Corynebacterium coyleae, Corynebacterium durum, Corynebacterium freiburgense, Corynebacterium glaucum, Corynebacterium glyciniphilum, Corynebacterium imitans, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium massiliense, Corynebacterium mastitidis, Corynebacterium matruchotii, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium mustelae, Corynebacterium mycetoides, Corynebacterium pyruviciproducens, Corynebacterium simulans, Corynebacterium singulare, Corynebacterium sputi, Corynebacterium suicordis, Corynebacterium sundsvallense, Corynebacterium tuberculostearicum, Corynebacterium ureicelerivorans, Corynebacterium variabile, Couchioplanes caeruleus subsp. caeruleus, Cupriavidus metallidurans, Cupriavidus nantongensis, Cupriavidus necator, Cupriavidus pampae, Cupriavidus yeoncheonensis, Curtobacterium flaccumfaciens, Curtobacterium herbarum, Dechloromonas agitata, Deinococcus actinosclerus, Deinococcus antarcticus, Deinococcus caeni, Deinococcus ficus, Deinococcus geothermalis, Deinococcus radiodurans, Deinococcus wulumuqiensis, Deinococcus xinjiangensis, Dermabacter hominis, Dermabacter vaginalis, Dermacoccus
nishinomiyaensis, Desemzia incerta, Desertibacter roseus, Devosia epidermidihirudinis, Devosia riboflavina, Devosia riboflavina, Dialister invisus, Dialister micraerophilus, Dialister propionicifaciens, Diaphorobacter oryzae, Dietzia aurantiaca, Dietzia cercidiphylli, Dietzia psychralcaliphila, Dietzia timorensis, Dietzia timorensis, Dokdonella koreensis, Dokdonella koreensis, Dolosigranulum pigrum, Eikenella corrodens, Elizabethkingia miricola, Elstera litoralis, Empedobacter brevis, Enhydrobacter aerosaccus, Ensifer adhaerens, Ensifer americanus, Enterobacter xiangfangensis, Enterococcus aquimarinus, Enterococcus faecalis, Enterococcus malodoratus, Enterococcus olivae, Enterococcus pseudoavium, Enterococcus viikkiensis, Enterococcus xiangfangensis, Erwinia rhapontici, Eubacterium eligens, Eubacterium infirmum, Eubacterium rectale, Eubacterium saphenum, Eubacterium sulci, Exiguobacterium mexicanum, Facklamia tabacinasalis, Falsirhodobacter halotolerans, Finegoldia magna, Flavobacterium araucananum, Flavobacterium cutihirudinis, Flavobacterium frigidimaris, Flavobacterium lindanitolerans, Flavobacterium resistens, Friedmanniella capsulata, Fusobacterium nucleatum subsp. polymorphum, Gemella haemolysans, Gemella morbillorum, Gemella palaticanis, Gemella sanguinis, Gemmobacter aquaticus, Gemmobacter caeni, Gluconobacter frateurii, Gluconobacter thailandicus, Gordonia alkanivorans, Gordonia jinhuaensis, Gordonia kroppenstedtii, Gordonia polyisoprenivorans, Gordonia polyisoprenivorans, Granulicatella adiacens, Granulicatella elegans, Haemophilus parainfluenzae, Haemophilus sputorum, Halomonas aquamarina, Halomonas axialensis, Halomonas meridiana, Halomonas olivaria, Halomonas songnenensis, Halomonas sulfidaeris, Halomonas variabilis, Herbaspirillum chlorophenolicum, Herbaspirillum frisingense, Herbaspirillum hiltneri, Herbaspirillum huttiense subsp. putei, Herbaspirillum lusitanum, Herminiimonas fonticola, Herpetosiphon aurantiacus, Hydrocarboniphaga effusa, Hydrogenophaga intermedia, Hydrogenophaga pseudoflava, Idiomarina maris, Janibacter anophelis, Janibacter hoylei, Janibacter indicus, Janibacter limosus, Janibacter melonis, Jeotgalicoccus halophilus, Jonquetella anthropi, Kaistia geumhonensis, Kingella denitrificans, Kingella oralis, Klebsiella oxytoca, Knoellia aerolata, Knoellia locipacati, Kocuria atrinae, Kocuria carniphila, Kocuria kristinae, Kocuria palustris, Kocuria turfanensis, Kosakonia sacchari, Lachnoanaerobaculum saburreum, Lachnoanaerobaculum saburreum, Lactobacillus crispatus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus iners, Lactobacillus modestisalitolerans, Lactobacillus plantarum subsp. argentoratensis, Lactobacillus xiangfangensis, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. lactis, Lactococcus piscium, Lapillicoccus jejuensis, Lautropia mirabilis, Lechevalieria roselyniae, Legionella beliardensis, Lentzea albida, Lentzea californiensis, Leptotrichia buccalis, Leptotrichia goodfellowii, Leptotrichia hofstadii, Leptotrichia hongkongensis, Leptotrichia shahii, Leptotrichia trevisanii, Leptotrichia wadei, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc gelidum subsp. gasicomitatum, Leuconostoc mesenteroides subsp. suionicum, Luteimonas aestuarii, Luteimonas terricola, Lysinibacillus fusiformis, Lysobacter antibioticus, Lysobacter koreensis, Lysobacter oryzae, Lysobacter spongiicola, Lysobacter xinjiangensis, Macrococcus
caseolyticus, Magnetospirillum moscoviense, Marinomonas alcarazii, Marinomonas primoryensis, Marmoricola pocheonensis, Marmoricola scoriae, Massilia alkalitolerans, Massilia aurea, Massilia jejuensis, Massilia kyonggiensis, Massilia plicata, Massilia timonae, Megamonas rupellensis, Meiothermus silvanus, Mesorhizobium acaciae, Mesorhizobium qingshengii, Mesorhizobium shonense, Methylobacterium dankookense, Methylobacterium goesingense, Methylobacterium haplocladii, Methylobacterium isbiliense, Methylobacterium jeotgali, Methylobacterium oxalidis, Methylobacterium platani, Methylobacterium pseudosasicola, Methylobacterium zatmanii, Methyloversatilis universalis, Microbacterium foliorum, Microbacterium hydrothermale, Microbacterium hydrothermale, Microbacterium lacticum, Microbacterium lacticum, Microbacterium laevaniformans, Microbacterium oxydan, Microbacterium paludicola, Microbacterium petrolearium, Microbacterium phyllosphaerae, Microbacterium resistens, Micrococcus antarcticus, Micrococcus cohnii, Micrococcus flavus, Micrococcus lylae, Micrococcus terreus, Microlunatus aurantiacus, Micromonospora chaiyaphumensis, Micromonospora chalcea, Micromonospora citrea, Micromonospora coxensis, Micromonospora echinofusca, Micromonospora halophytica, Micromonospora kangleipakensis, Micromonospora maritime, Micromonospora nigra, Micromonospora purpureochromogene, Micromonospora rhizosphaerae, Micromonospora saelicesensis, Micropruina glycogenica, Microvirga aerilata, Microvirga aerilata, Microvirga subterranea, Microvirga vignae, Microvirga zambiensis, Microvirgula aerodenitrificans, Mogibacterium timidum, Moraxella atlantae, Moraxella catarrhalis, Morganella morganii subsp. morganii, Morganella psychrotolerans, Murdochiella asaccharolytica, Mycobacterium alvei, Mycobacterium asiaticum, Mycobacterium avium subsp. silvaticum, Mycobacterium chubuense, Mycobacterium colombiense, Mycobacterium conceptionense, Mycobacterium conceptionense, Mycobacterium crocinum, Mycobacterium farcinogenes, Mycobacterium fortuitum subsp. fortuitum, Mycobacterium gadium, Mycobacterium goodii, Mycobacterium holsaticum, Mycobacterium insubricum, Mycobacterium llatzerense, Mycobacterium iranicum, Mycobacterium longobardum, Mycobacterium neoaurum, Mycobacterium neworleansense, Mycobacterium obuense, Mycobacterium peregrinum, Mycobacterium saopaulense, Mycobacterium septicum, Mycobacterium setense, Mycobacterium smegmatis, Negativicoccus succinicivorans, Neisseria bacilliformis, Neisseria oralis, Neisseria sicca, Neisseria subflava, Nesterenkonia lacusekhoensis, Nesterenkonia rhizosphaerae, Nevskia persephonica, Nevskia ramosa, Niabella yanshanensis, Niveibacterium umoris, Nocardia lijiangensis, Nocardia niwae, Nocardia thailandica, Nocardioides agariphilus, Nocardioides dilutes, Nocardioides ganghwensis, Nocardioides hwasunensis, Nocardioides nanhaiensis, Nocardioides sediminis, Nosocomiicoccus ampullae, Noviherbaspirillum malthae, Novosphingobium barchaimii, Novosphingobium lindaniclasticum, Novosphingobium lindaniclasticum, Novosphingobium mathurense, Novosphingobium rosa, Ochrobactrum pseudogrignonense, Ochrobactrum rhizosphaerae, Olsenella uli, Ornithinimicrobium morale, Ornithinimicrobium tianjinense,
Oryzobacter terrae, Ottowia beijingensis, Oxalicibacterium solurbis, Paenalcaligenes suwonensis, Paenibacillus agaridevorans, Paenibacillus phoenicis, Paenibacillus xylanexedens, Pal udi bacterium yongneupense, Pantoea cypripedii, Parabacteroides distasonis, Paraburkholderia andropogonis, Paraburkholderia glathei, Paraburkholderia humi, Paraburkholderia phenazinium, Paraburkholderia phytofirmans, Paraburkholderia sordidicola, Paraburkholderia terricola, Paraburkholderia xenovorans, Paracoccus alcaliphilus, Paracoccus angustae, Paracoccus kocurii, Paracoccus laeviglucosivorans, Paracoccus sediminis, Paracoccus sphaerophysae, Paracoccus yeei, Parvimonas micra, Parviterribacter multiflagellatus, Patulibacter ginsengiterrae, Pedobacter aquatilis, Pedobacter ginsengisoli, Pedobacter xixiisoli, Peptococcus niger, Peptoniphilus coxii, Peptoniphilus gorbachii, Peptoniphilus harei, Peptoniphilus koenoeneniae, Peptoniphilus lacrimalis, Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Phascolarctobacterium faecium, Phenylobacterium haematophilum, Phenylobacterium kunshanense, Pluralibacter gergoviae, Polymorphobacter multimanifer, Polymorphospora rubra, Porphyrobacter colymbi, Porphyromonas bennonis, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas gingivicanis, Porphyromonas paster!, Porphyromonas pogonae, Porphyromonas somerae, Povalibacter uvarum, Prevotella aurantiaca, Prevotella baroniae, Prevotella bivia, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella corporis, Prevotella denticola, Prevotella enoeca, Prevotella histicola, Prevotella intermedia, Prevotella jejuni, Prevotella jejuni, Prevotella maculosa, Prevotella melaninogenica, Prevotella melaninogenica, Prevotella micans, Prevotella multiformis, Prevotella nanceiensis, Prevotella nigrescens, Prevotella oris, Prevotella oulorum, Prevotella pallens, Prevotella pleuritidis, Prevotella saccharolytica, Prevotella salivae, Prevotella shahii, Prevotella timonensis, Prevotella veroralis, Propionibacterium acidifaciens, Propionibacterium acnes subsp. acnes, Propionibacterium acnes subsp. acnes, Propionibacterium acnes subsp. elongatum, Propionibacterium granulosum, Propionimicrobium lymphophilum, Propionispira arcuata, Proteus vulgaris, Providencia rustigianii, Pseudoalteromonas agarivorans, Pseudoalteromonas atlantica, Pseudoalteromonas paragorgicola, Pseudokineococcus lusitanus, Pseudomonas aeruginosa, Pseudomonas asplenii, Pseudomonas asuensis, Pseudomonas benzenivorans, Pseudomonas cannabina, Pseudomonas chengduensis, Pseudomonas cissicola, Pseudomonas congelans, Pseudomonas costantinii, Pseudomonas ficuserectae, Pseudomonas frederiksbergensis, Pseudomonas graminis, Pseudomonas jessenii, Pseudomonas koreensis, Pseudomonas koreensis, Pseudomonas kunmingensis, Pseudomonas marginalis, Pseudomonas mucidolens, Pseudomonas panacis, Pseudomonas plecoglossicida, Pseudomonas poae, Pseudomonas pseudoalcaligenes, Pseudomonas putida, Pseudomonas reinekei, Pseudomonas rhizosphaerae, Pseudomonas seleniipraecipitans, Pseudomonas umsongensis, Pseudomonas zhaodongensis, Pseudonocardia alaniniphila, Pseudonocardia ammonioxydans, Pseudonocardia autotrophica, Pseudonocardia benzenivorans, Pseudonocardia kongjuensis,
Pseudonocardia yunnanensis, Pseudorhodoferax soli, Pseudorhodoplanes sinuspersici, Pseudoxanthomonas daejeonensis, Pseudoxanthomonas indica, Pseudoxanthomonas kaohsiungensis, Psychrobacter aquaticus, Psychrobacter arcticus, Psychrobacter celer, Psychrobacter marincola, Psychrobacter nivimaris, Psychrobacter okhotskensis, Psychrobacter okhotskensis, Psychrobacter piscatorii, Psychrobacter pulmonis, Psychrobacter sanguinis, Ramlibacter ginsenosidimutans, Rheinheimera aquimaris, Rheinheimera japonica, Rheinheimera muenzenbergensis, Rheinheimera soli, Rheinheimera tangshanensis, Rheinheimera texasensis, Rheinheimera tilapiae, Rhizobium alamii, Rhizobium alvei, Rhizobium azibense, Rhizobium binae, Rhizobium daejeonense, Rhizobium endophyticum, Rhizobium etli, Rhizobium fabae, Rhizobium freirei, Rhizobium gallicum, Rhizobium larrymoorei, Rhizobium loessense, Rhizobium rhizoryzae, Rhizobium soli, Rhizobium sophoriradicis, Rhizobium taibaishanense, Rhizobium vallis, Rhizobium vignae, Rhizobium vignae, Rhizobium yanglingense, Rhodanobacter glycinis, Rhodobacter veldkampii, Rhodococcus baikonurensis, Rhodococcus enclensis, Rhodococcus fascians, Rhodoferax saidenbachensis, Rhodovarius lipocyclicus, Rickettsia canadensis, Rickettsia heilongjiangensis, Rickettsia honei, Rickettsia raoultii, Rivicola pingtungensis, Roseateles aquatilis, Roseateles aquatilis, Roseburia inulinivorans, Rosenbergiella nectarea, Roseomonas aerilata, Roseomonas aquatica, Roseomonas mucosa, Roseomonas rosea, Roseomonas vinacea, Rothia aeria, Rothia amarae, Rothia dentocariosa, Rothia endophytica, Rothia mucilaginosa, Rothia nasimurium, Rubellimicrobium mesophilum, Rubellimicrobium roseum, Rubrobacter bracarensis, Rudaea cellulosilytica, Ruminococcus gnavus, Runella zeae, Saccharopolyspora rectivirgula, Salinicoccus qingdaonensis, Salmonella enterica subsp. salamae, Scardovia wiggsiae, Sediminibacterium ginsengisoli, Selenomonas artemidis, Selenomonas infelix, Selenomonas noxia, Selenomonas sputigena, Serratia ficaria, Serratia myotis, Serratia vespertilionis, Shewanella aestuarii, Shewanella decolorationis, Shuttleworthia satelles, Simonsiella muelleri, Skermanella aerolata, Skermanella stibiiresistens, Slackia exigua, Smaragdicoccus niigatensis, Sneathia sanguinegens, Solirubrobacter soli, Sphingobacterium caeni, Sphingobacterium daejeonense, Sphingobacterium hotanense, Sphingobacterium kyonggiense, Sphingobacterium multivorum, Sphingobacterium nematocida, Sphingobacterium spiritivorum, Sphingobium amiense, Sphingobium baderi, Sphingobium barthaii, Sphingobium chlorophenolicum, Sphingobium cupriresistens, Sphingobium czechense, Sphingobium fuliginis, Sphingobium indicum, Sphingobium japonicum, Sphingobium lactosutens, Sphingobium subterraneum, Sphingomonas dokdonensis, Sphingomonas abaci, Sphingomonas aestuarii, Sphingomonas canadensis, Sphingomonas daechungensis, Sphingomonas dokdonensis, Sphingomonas echinoides, Sphingomonas fonticola, Sphingomonas fonticola, Sphingomonas formosensis, Sphingomonas gel, Sphingomonas hankookensis, Sphingomonas hankookensis, Sphingomonas koreensis, Sphingomonas kyeonggiensis, Sphingomonas laterariae, Sphingomonas mucosissima, Sphingomonas oligophenolica, Sphingomonas pseudosanguinis,
Sphingomonas sediminicola, Sphingomonas yantingensis, Sphingomonas yunnanensis, Sphingopyxis chilensis, Sphingopyxis fribergensis, Sphingopyxis granuli, Sphingopyxis indica, Sphingopyxis witflariensis, Spirosoma rigui, Sporacetigenium mesophilum, Sporocytophaga myxococcoides, Staphylococcus agnetis, Staphylococcus aureus subsp. aureus, Staphylococcus auricularis, Staphylococcus epidermidis, Staphylococcus hominis subsp. novobiosepticus, Staphylococcus lugdunensis, Staphylococcus nepalensis, Staphylococcus pettenkoferi, Staphylococcus saprophyticus subsp. bovis, Staphylococcus sciuri subsp. carnaticus, Stenotrophomonas koreensis, Stenotrophomonas rhizophila, Stenotrophomonas rhizophila, Streptococcus agalactiae, Streptococcus canis, Streptococcus cristatus, Streptococcus gordonii, Streptococcus infantis, Streptococcus intermedius, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus sanguinis, Streptomyces caeruleatus, Streptomyces canarius, Streptomyces capoamus, Streptomyces ciscaucasicus, Streptomyces griseorubiginosus, Streptomyces iconiensis, Streptomyces olivaceoviridis, Streptomyces panaciradicis, Streptomyces phaeopurpureus, Streptomyces pseudovenezuelae, Streptomyces resistomycificus, Streptomyces yanglinensis, Tabrizicola aquatica, Tahibacter caeni, Tannerella forsythia, Tepidicella xavieri, Tepidimonas fonticaldi, Terracoccus luteus, Tessaracoccus flavescens, Therm us thermophilus, Tianweitania sediminis, Treponema amylovorum, Treponema denticola, Treponema lecithinolyticum, Treponema medium, Tsukamurella paurometabola, Turicella otitidis, Turicibacter sanguinis, Undibacterium oligocarboniphilum, Undibacterium squillarum, Vagococcus salmoninarum, Varibaculum cambriense, Variovorax guangxiensis, Vibrio metschnikovii, Vogesella alkaliphila, Xanthobacter tagetidis, Xanthomonas arboricola, Xanthomonas axonopodis, Xanthomonas cassavae, Xanthomonas cucurbitae, Xanthomonas cynarae, Xanthomonas euvesicatoria, Xanthomonas fragariae, Xanthomonas gardneri, Xanthomonas perforans, Xanthomonas pisi, Xanthomonas populi, Xanthomonas vasicola, Xenophilus aerolatus, Xenophilus arseniciresistens, Yersinia nurmii, Yimella lutea, Zimmermannella alba, Zimmermannella bifida and/or Zoogloea caeni.
[081] In other embodiments, the bacteria strains are those commonly found in the vaginal microbiota and are, without limitation, Acinetobacter antiviralis, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Actinobaculum massiliense, Actinobaculum schaalii, Actinomyces europaeus, Actinomyces graevenitzii, Actinomyces israelii, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces turicensis, Actinomyces urogenitalis, Actinomyces viscosus, Aerococcus christensenii, Aerococcus urinae, Aerococcus viridans, Aeromonas encheleia, Aeromonas salmonicida, Afipia massiliensis, Agrobacterium tumefaciens, Algoriphagus aquatilis, Aliivibrio wodanis, Alistipes finegoldii, Alloiococcus otitis, Alloprevotella tannerae, Alloscardovia omnicolens, Altererythrobacter epoxidivorans, Ammoniphilus oxalaticus, Amnibacterium kyonggiense, Anaerococcus hydrogenalis, Anaerococcus lactolyticus, Anaerococcus murdochii, Anaerococcus obesiensis, Anaerococcus prevotii, Anaerococcus tetradius, Anaerococcus
vaginalis, Anaeroglobus geminatus, Anoxybacillus pushchinoensis, Aquabacterium parvum, Arcanobacterium phocae, Arthrobacter aurescens, Asticcacaulis excentricus, Atopobium minutum, Atopobium parvulum, Atopobium rimae, Atopobium vaginae, Avibacterium gallinarum, Bacillus acidicola, Bacillus atrophaeus, Bacillus cereus, Bacillus cibi, Bacillus coahuilensis, Bacillus gaemokensis, Bacillus methanolicus, Bacillus oleronius, Bacillus pumilus, Bacillus shackletonii, Bacillus sporothermodurans, Bacillus subtilis, Bacillus wakoensis, Bacillus weihenstephanensis, Bacteroides barnesiae, Bacteroides coagulans, Bacteroides dorei, Bacteroides faecis, Bacteroides forsythus, Bacteroides fragilis, Bacteroides nordii, Bacteroides ovatus, Bacteroides salyersiae, Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Bacteroides zoogleoformans, Barnesiella viscericola, Bhargavaea cecembensis, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium dentium, Bifidobacterium longum subsp. infantis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium scardovii, Bilophila wadsworthia, Blautia hydrogenotrophica, Blautia obeum, Blautia producta, Brachybacterium faecium, Bradyrhizobium japonicum, Brevibacterium mcbrellneri, Brevibacterium otitidis, Brevibacterium paucivorans, Bulleidia extructa, Burkholderia fungorum, Burkholderia phenoliruptix, Caldicellulosiruptor saccharolyticus, Caldimonas taiwanensis, Campylobacter gracilis, Campylobacter hominis, Campylobacter sputorum, Campylobacter ureolyticus, Capnocytophaga ochracea, Cardiobacterium hominis, Catonella morbi, Chlamydia trachomatis, Chlamydophila abortus, Chondromyces robustus, Chryseobacterium aquaticum, Citrobacter youngae, Cloacibacterium normanense, Clostridium cavendishii, Clostridium colicanis, Clostridium jejuense, Clostridium perfringens, Clostridium ramosum, Clostridium sordellii, Clostridium viride, Comamonas terrigena, Corynebacterium accolens, Corynebacterium appendicis, Corynebacterium coyleae, Corynebacterium glucuronolyticum, Corynebacterium glutamicum, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium nuruki, Corynebacterium pseudogenitalium, Corynebacterium pyruviciproducens, Corynebacterium singulare, Corynebacterium striatum, Corynebacterium tuberculostearicum, Corynebacterium xerosis, Cryobacterium psychrophilum, Curtobacterium flaccumfaciens, Cutibacterium acnes, Cutibacterium avidum, Cytophaga xylanolytica, Deinococcus radiophilus, Delftia tsuruhatensis, Desulfovibrio desulfuricans, Dialister invisus, Dialister micraerophilus, Dialister pneumosintes, Dialister propionicifaciens, Dickeya chrysanthemi, Dorea longicatena, Eggerthella lenta, Eggerthia catenaformis, Eikenella corrodens, Enhydrobacter aerosaccus, Enterobacter asburiae, Enterobacter cloacae, Enterococcus avium, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus hirae, Erwinia persicina, Erwinia rhapontici, Erwinia toletana, Escherichia coll, Escherichia fergusonii, Eubacterium brachy, Eubacterium eligens, Eubacterium nodatum, Eubacterium rectale, Eubacterium saphenum, Eubacterium siraeum, Eubacterium sulci,
Eubacterium yurii, Exiguobacterium acetylicum, Facklamia ignava, Faecalibacterium prausnitzii, Filifactor alocis, Finegoldia magna, Fusobacterium gonidiaformans, Fusobacterium nucleatum, Fusobacterium periodonticum, Gardnerella vaginalis, Gemella asaccharolytica, Gemella bergeri, Gemella haemolysans, Gemella sanguinis, Geobacillus stearothermophilus, Geobacillus thermocatenulatus, Geobacillus thermoglucosidasius, Geobacter grbiciae, Granulicatella elegans, Haemophilus ducreyi, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus parainfluenzae, Hafnia alvei, Halomonas meridiana, Halomonas phoceae, Halomonas venusta, Herbaspirillum seropedicae, Janthinobacterium lividum, Jonquetella anthropi, Klebsiella granulomatis, Klebsiella oxytoca, Klebsiella pneumoniae, Lactobacillus acidophilus, Lactobacillus amylovorus, Lactobacillus brevis, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kimchicus, Lactobacillus kitasatonis, Lactobacillus mucosae, Lactobacillus panis, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus ultunensis, Lactobacillus vaginalis, Lactococcus lactis, Leptotrichia buccalis, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc garlicum, Leuconostoc lactis, Leuconostoc mesenteroides, Lysinimonas kribbensis, Mageeibacillus indolicus, Maribacter orientalis, Marinomonas protea, Marinospirillum insulare, Massilia timonae, Megasphaera elsdenii, Megasphaera micronuciformis, Mesorhizobium amorphae, Methylobacterium radiotolerans, Methylotenera versatilis, Microbacterium halophilum, Micrococcus luteus, Microterricola viridarii, Mobiluncus curtisii, Mobiluncus mulieris, Mogibacterium timidum, Moorella glycerin!, Moraxella osloensis, Morganella morganii, Moryella indoligenes, Murdochiella asaccharolytica, Mycoplasma alvi, Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma muris, Mycoplasma salivarium, Negativicoccus succinicivorans, Neisseria flava, Neisseria gonorrhoeae, Neisseria mucosa, Neisseria subflava, Nevskia ramosa, Nevskia soli, Nitriliruptor alkaliphilus, Odoribacter splanchnicus, Oligella urethralis, Olsenella uli, Paenibacillus amylolyticus, Paenibacillus humicus, Paenibacillus pabuli, Paenibacillus pasadenensis, Paenibacillus pini, Paenibacillus validus, Pantoea agglomerans, Parabacteroides merdae, Paraburkholderia caryophylli, Paracoccus yeei, Parastreptomyces abscessus, Parvimonas micra, Pectobacterium betavasculorum, Pectobacterium carotovorum, Pediococcus acidilactici, Pediococcus ethanolidurans, Pedobacter alluvionis, Pedobacter wanjuense, Pelomonas aquatica, Peptococcus niger, Peptoniphilus asaccharolyticus, Peptoniphilus gorbachii, Peptoniphilus harei, Peptoniphilus indolicus, Peptoniphilus lacrimalis, Peptoniphilus massiliensis, Peptostreptococcus anaerobius, Peptostreptococcus massiliae, Peptostreptococcus stomatis, Photobacterium angustum, Photobacterium frigidiphilum, Photobacterium phosphoreum, Porphyromonas asaccharolytica, Porphyromonas bennonis, Porphyromonas catoniae, Porphyromonas endodontalis, Porphyromonas gingivalis,
Porphyromonas somerae, Porphyromonas uenonis, Prevotella amnii, Prevotella baroniae, Prevotella bergensis, Prevotella bivia, Prevotella buccae, Prevotella buccalis, Prevotella colorans, Prevotella copri, Prevotella corporis, Prevotella dentalis, Prevotella denticola, Prevotella disiens, Prevotella intermedia, Prevotella loescheii, Prevotella marshii, Prevotella melaninogenica, Prevotella micans, Prevotella nigrescens, Prevotella oris, Prevotella pleuritidis, Prevotella ruminicola, Prevotella shahii, Prevotella stercorea, Prevotella timonensis, Prevotella veroralis, Propionimicrobium lymphophilum, Proteus mirabilis, Pseudomonas abietaniphila, Pseudomonas aeruginosa, Pseudomonas amygdali, Pseudomonas azotoformans, Pseudomonas chlororaphis, Pseudomonas cuatrocienegasensis, Pseudomonas fluorescens, Pseudomonas fulva, Pseudomonas lutea, Pseudomonas mucidolens, Pseudomonas oleovorans, Pseudomonas orientalis, Pseudomonas pseudoalcaligenes, Pseudomonas psychrophila, Pseudomonas putida, Pseudomonas synxantha, Pseudomonas syringae, Pseudomonas tolaasii, Pseudopropionibacterium propionicum, Rahnella aquatilis, Ralstonia pickettii, Ralstonia solanacearum, Raoultella planticola, Rhizobacter dauci, Rhizobium etli, Rhodococcus fascians, Rhodopseudomonas palustris, Roseburia intestinalis, Roseburia inulinivorans, Rothia mucilaginosa, Ruminococcus bromii, Ruminococcus gnavus, Ruminococcus torques, Sanguibacter keddieii, Sediminibacterium salmoneum, Selenomonas bovis, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Shewanella algae, Shewanella amazonensis, Shigella boydii, Shigella sonnei, Slackia exigua, Sneathia amnii, Sneathia sanguinegens, Solobacterium moorei, Sorangium cellulosum, Sphingobium amiense, Sphingobium japonicum, Sphingobium yanoikuyae, Sphingomonas wittichii, Sporosarcina aquimarina, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Staphylococcus schleiferi, Staphylococcus simiae, Staphylococcus simulans, Staphylococcus warneri, Stenotrophomonas maltophilia, Stenoxybacter acetivorans, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus australis, Streptococcus equinus, Streptococcus gallolyticus, Streptococcus infantis, Streptococcus intermedius, Streptococcus lutetiensis, Streptococcus marimammalium, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus phocae, Streptococcus pseudopneumoniae, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus thermophilus, Sutterella wadsworthensis, Tannerella forsythia, Terrahaemophilus aromaticivorans, Treponema denticola, Treponema maltophilum, Treponema parvum, Treponema vincentii, Trueperella bernardiae, Turicella otitidis, Ureaplasma parvum, Ureaplasma urealyticum, Varibaculum cambriense, Variovorax paradoxus, Veillonella atypica, Veillonella dispar, Veillonella montpellierensis, Veillonella parvula, Virgibacillus proomii, Viridibacillus arenosi, Viridibacillus arvi, Weissella cibaria, Weissella soli, Xanthomonas campestris, Xanthomonas vesicatoria, Zobellia laminariae and/or Zoogloea ramigera.
[082] In one embodiment, the engineered bacterial strain of the invention is obtained from a Bacteroides bacterial strain, in particular from a Bacteroides thetaiotaomicron and/or a Bacteroides faecis strain. In one embodiment, the engineered bacterial strain of the invention is obtained from a strain of a bacterial species selected from the group consisting of Escherichia coli, Bacteroides fragilis, Enterococcus faecalis, Yersinia pestis, Francisella tularensis, Bacillus anthracis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enterica Typhi, Fusobacterium nucleatum, Bacteroides fragilis, Cutibacterium acnes and Helicobacter pylori. In another embodiment, the engineered bacterial strain of the invention is obtained from a Propionibacterium propionicum, Corynebacterium amycolatum, Actinomyces massiliensis or Bacteroides thetaiotaomicron strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a strain of a bacterial species from the Firmicutes phylum. In another embodiment, the engineered bacterial strain of the invention is obtained from a Roseburia intestinalis strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Prevotella copri strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Eggerthella lenta strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Enterococcus faecalis, Enterococcus faecium or Lactobacillus brevis strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Clostridium sporogenes strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a Escherichia co// strain or from a strain of a Gammaproteobacteria. In another embodiment, the engineered bacterial strain of the invention is obtained from a Prevotella copri or Bacteroides vulgatus strain. In another embodiment, the engineered bacterial strain of the invention is obtained from a C. difficile strain.
[083] In a particular embodiment, the engineered bacterial strain is a Gram positive bacterial strain. In an alternative embodiment, the engineered bacterial strain is a Gram negative bacterial strain.
[084] In a particular embodiment, the engineered bacterial strain is not a Bacteroides strain. Heterologous or engineered gene or gene set providing a competitive advantage
[085] In the context of the invention, the engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over target bacterial strain(s). [086] By “competitive advantage” of the engineered bacterial strain over target bacterial strain(s) is meant herein an advantage in the interaction between the engineered bacterial strain and target bacterial strain(s) within a community, typically within a microbiome. Examples of competitive advantages include a fitness advantage wherein the engineered bacterial strain is better suited to conquer a specific niche in the microbiome, an advantage in interference competition wherein the engineered bacterial strain can typically produce antagonists (such as toxins, biosurfactants, bacteriocins, volatiles or antibiotics) against other members of the microbiome or wherein the engineered bacterial strain can typically be resistant to administered
antagonists (such as toxins, biosurfactants, bacteriocins, volatiles or antibiotics) to which other members of the microbiome are sensitive, or an advantage in exploitation competition wherein the engineered bacterial strain exploits more efficiently the growth substrates available to the community, more particularly a metabolic advantage wherein the engineered bacterial strain metabolizes more efficiently some growth substrates available to the community.
[087] In a particular embodiment, said competitive advantage is a metabolic advantage.
[088] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source.
[089] By “gene or gene set involved in the import of a nutrient source” is meant herein a gene or set of genes encoding a molecule enabling directly and/or indirectly the active transport of the nutrient source from the extracellular medium into the cytoplasm.
[090] By “gene or gene set involved in the metabolism of a nutrient source” is meant herein a gene or set of genes encoding a molecule enabling, intracellularly and/or extracellularly after secretion in the extracellular medium or in the periplasm, the degradation of the nutrient source. [091] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a transporter of a nutrient source.
[092] In a particular embodiment, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding an intracellular or extracellular enzyme involved in the degradation of the nutrient source.
[093] In a particularly preferred embodiment, said heterologous or engineered gene set providing a competitive advantage comprises a gene encoding a transporter of a nutrient source and a gene encoding an intracellular enzyme involved in the degradation of the nutrient source. [094] In a particular embodiment, said heterologous gene or gene set providing a competitive advantage is from another species than the engineered bacterial strain.
[095] In a particular embodiment, said nutrient source is a rare carbohydrate.
[096] By “rare” carbohydrate is meant herein a carbohydrate that is utilized, as a nutrient source, by less than 50% e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1 %, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1 %, less than 0.03%, less than 0.01 %, less than 0.003%, less than 0.001 %, less than 0.0001 %, or none) of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome (i.e., cells “other” than the engineered bacterial strain of the invention, e.g., cells of the resident population prior to administration). Thus, in some embodiments, a rare carbohydrate is one that can be utilized, as a nutrient source, by less than 50% e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 3%, less than 2%, less than 1 %, less than 0.5%, less than 0.3%, less than 0.2%, less than 0.1 %, less than 0.03%, less than 0.01 %, less
than 0.003%, less than 0.001 %, less than 0.0001 %, or none) of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some cases, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 20% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 5% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 2% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by less than 0.5% of other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome. In some embodiments, the rare carbohydrate is one that can be utilized or is utilized, as a nutrient source, by none of the other bacterial cells present in the subject or in the environment, in particular present in the microbiome of the subject, more particularly present in a particular microbiome of the subject such as the gut microbiome and/or the skin microbiome.
Polysaccharides
[097] In some embodiments, the rare carbohydrate is a polysaccharide.
[098] In some embodiments, the rare carbohydrate is a sulfated carbohydrate. In more particular embodiments, the rare carbohydrate is selected from the group consisting of porphyran, ulvan, carrageenan, fucoidan and any combination thereof.
[099] In some embodiments, the rare carbohydrate is a marine carbohydrate. Examples of marine carbohydrates include but are not limited to: porphyran, agarose, agaropectin, carrageenan, ulvan, alginate, fucoidan, laminarin, and marine microbe exopolysaccharides. In some embodiments, the rare carbohydrate of interest is selected from porphyran and agarose. In some embodiments, the rare carbohydrate is porphyran. In some embodiments, the rare carbohydrate is agarose.
[0100] In a particular embodiment, said rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans (such as carrageenan and agarose), porphyran, ulvan, xylan and any combination thereof.
[0101] In some embodiments, the rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
[0102] In some embodiments, the rare carbohydrate is a carbohydrate that contains a glycosidic linkage selected from the group consisting of p-d-galactopyranose to a-l-galactopyranose-6- sulfate, p-d-galactopyranose to 3,6-anhydro-a-l-galactopyranose.
[0103] In some embodiments, the rare carbohydrate is a sulfated polygalactan. In some such embodiments, one or more of the galactose residues of the sulfated polygalactan can be a 3,6- anhydro-galactose (e.g., in some embodiments joined by alternating a-1 ,3 and p-1 ,4-glycosidic linkage). In some embodiments, one or more of the galactopyranose residues of the sulfated polygalactan can be modified by one or more ester sulfates. In some embodiments, one or more of the galactose residues of the sulfated polygalactan is a 3,6-anhydro-galactose (e.g., in some embodiments joined by alternating a-1 ,3 and p-1 ,4-glycosidic linkage); and one or more of the galactopyranose residues of the sulfated polygalactan is modified by one or more ester sulfates. [0104] In a particular embodiment, when the nutrient source is as defined under the section “Polysaccharide” above, the heterologous or engineered gene or gene set providing a competitive advantage can be or comprise a gene selected from the group consisting of genes encoding porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
[0105] In a particular embodiment, when the nutrient source is as defined under the section “Polysaccharide” above, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a porphyranase (e.g., one from GH family 86 (GH86)). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding an agarase (e.g., one from GH family 86 (GH86)).
[0106] In a particular embodiment, when the nutrient source is as defined under the section “Polysaccharide” above, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1706 from the Bacteroides plebeius genome (or homologs thereof) (see, e.g., Table 1). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) and BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1683-1699 from the B. plebeius genome (or
homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding BACPLE 1688-1706 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acid(s) encoding BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acid(s) encoding BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome (or homologs thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acid(s) encoding BACPLE 1683-1687 and BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as nucleic acids encoding both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome (or homologs thereof).
[0107] As such, in some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity {e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1706 from the B. plebeius genome (see, e.g., Table 1 ). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1700-1706 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity {e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) and/or at least one of BACPLE 1700-1706 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity {e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1699 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity {e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1688-1706 from the B. plebeius genome. In
some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome. In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of BACPLE 1683-1687 and/or at least one of BACPLE 1700-1706 from the B. plebeius genome (or homologs thereof) as well as both porphyranases from within BACPLE 1688-1699 from the B. plebeius genome.
[0108] In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 28-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof) and SEQ ID NOs: 28-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set
providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 14-27 (or homologs thereof). In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein of sequence selected from SEQ ID NOs: 18-34 (or homologs thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 14-17 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 28-34 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding a protein of sequence selected from SEQ ID NOs: 14-17 and SEQ ID NOs: 28-34 (or homologs thereof) as well as both porphyranases from within SEQ ID NOs: 18-27 (or homologs thereof).
[0109] As such, in some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-34. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that have 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 28-34. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 and/or at least one of SEQ ID NOs: 28-34. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-27. In some embodiments, the heterologous or engineered gene or gene set providing a competitive advantage is or comprises nucleic acid(s) encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 18-34. In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least
one of SEQ ID NOs: 14-17 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21. In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 28-34 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21 . In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding protein(s) that has(ve) 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with at least one of SEQ ID NOs: 14-17 and/or at least one of SEQ ID NOs: 28-34 as well as both porphyranases set forth as SEQ ID NOs: 19 and 21 .
[0110] In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding (i) at least one protein of sequence selected from SEQ ID NOs: 19, 21 and 22 (or a homolog(s) thereof); (ii) at least one protein of sequence selected from SEQ ID NOs: 26 and 33 (or a homolog(s) thereof); and (iii) at least one protein of sequence selected from SEQ ID NOs: 25 and 32 (or a homolog(s) thereof). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding proteins of sequences SEQ ID NOs: 19, 21-22, 25, 26, and 32-33 (or homologs thereof).
[0111] In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding (i) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 19, 21 and 22; (ii) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 26 and 33; and (iii) at least one protein that has 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with any one of SEQ ID NOs: 25 and 32. In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises nucleic acids encoding proteins having respectively 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, or 100% sequence identity) with SEQ ID NOs: 19, 21-22, 25, 26, and 32-33.
[0112] In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises at least 3 genes (e.g., at least 4, at least 5, at least 6, at least 8 genes, at least 10 genes, at least 12 genes, at least 15 genes, or at least 20 genes). In a particular embodiment, the heterologous or engineered gene set providing a competitive advantage comprises at least six genes. In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises 3 to 30 genes (e.g., 5-30, 3-25, 3-20, 3-15, 3-10, 3-8, 5-25, 5-20, 5-15, 5-10, 5-8, 8-30, 8-25, 8-20, 8-15, 10-30, 10-25, 10-20, 10-15, 12-30, 12- 25, 12-20, 15-30, 15-25, 20-30, or 20-25 genes). In some embodiments, the heterologous or engineered gene set providing a competitive advantage comprises 3 to 10 genes.
Oligosaccharides
[0113] In a particular embodiment, said nutrient source is an oligosaccharide, more particularly a milk oligosaccharide. In a particular embodiment, said milk oligosaccharide can be from any mammalian milk source such as human, bovine, pig, rabbit, goat, sheep or camel milk. In a particular embodiment, said rare carbohydrate is a mammalian milk oligosaccharide (MMO). In a particular embodiment, said rare carbohydrate is a human milk oligosaccharide (HMO).
[0114] An “oligosaccharide,” as used herein, refers broadly to a carbohydrate having 3-20 sugar residues or degrees of polymerization from any source.
[0115] A “mammalian milk oligosaccharide” or “MMO”, as used herein, refers broadly to an oligosaccharide from mammalian milk, whether it is purified or enriched or detectable in a dairy product, as long as the oligosaccharide is not subject to metabolism by digestive enzymes expressed in the mammalian genome. Therefore, in a particular embodiment, said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
[0116] MMO include individual structures synthesized to produce carbohydrate structures known to be in a mammalian milk including milk from human, bovine, equine, porcine, goat, camel, water buffalo, and sheep. It refers broadly to those indigestible glycans, sometimes referred to as “dietary fiber”, or the carbohydrate polymers that are not hydrolyzed by the endogenous mammalian enzymes in the digestive tract (e.g., the small intestine) of the mammal. Mammalian milks contain a significant quantity of MMO that are not usable directly as an energy source for the milk-fed mammal but may be usable by microorganisms in the gut of that mammal.
[0117] The core structures of HMO consist of lactose at the reducing ends elongated by [3-1 -3- linked lacto-N-biose I (LNB, Gal -3GlcNAc) and/or [3-1 -3/6-linked N-acetyllactosamine (LacNAc, Gaipi -4GlcNAc). These core structures can be further elongated with residues of galactose (Gal), N-acetylglucosamine (GIcNAc), N-acetylneuraminic acid (Neu5Ac) and decorated with fucose or sialic acid (see Ninonuevo et al. (2006) J Agric Food Chem 54:7471 -7480). The combinatorial effect of elongation, fucosylation and sialylation produces a heterogenous mix of short-chain, long-chain and branched structures with more than 200 distinct HMO types identified to date (Kirmiz etal. (2018) Annu Rev Food Sci Technol 9:429). The type 1 tetrasaccharide Lacto- N-tetraose is one of the most highly abundant oligosaccharides in breast milk and together with its isomer Lacto-N-neotetraose (LNnT) and derivatives comprise up to 70% of the total amount of HMO (Ninonuevo et al. (2006) J Agric Food Chem 54:7471 -7480).
[0118] MMO particularly comprises lacto-N-biose (LNB), lacto-N-triose (LNT), at least one oligosaccharide having a Type I core, at least one oligosaccharide having a Type II core, and/or combinations thereof. Type I or type II may be isomers of each other. MMO typically includes one or more of lacto-N-biose (LNB), N-acetyl lactosamine, lacto-N-triose, lacto-N-neotriose, lacto-N- tetraose (LNT), lacto-N-neotetraose (LNnT), fucosyllactose (FL), lacto-N-fucopentaose (LNFP), lactodifucotetraose, (LDFT) sialyllactose (SL), disialyllacto-N-tetraose (DSLNT), 2'-
fucosyllactose (2FL), 3’-sialyllactosamine (3SLN), 3'-fucosyllactose (3FL), 3'-sialyl-3- fucosyllactose(3S3FL), 3 '-sialyllactose (3SL), 6'-sialyllactosamine (6SLN), 6'-sialyllactose (6SL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFPI), lacto-N-fucopentaose II (LNFPII), lacto- N-fucopentaose III (LNFPIII), lacto-N-fucopentaose V (LNFPV), sialyllacto-N-tetraose (SLNT), their derivatives, or combinations thereof. Other type II cores include but are not limited to trifucosyllacto-N-hexaose (TFLNH), LNnH, lacto-N-hexaose (LNH), lacto-N-fucopentaose III (LNFPIII), monofucosylated lacto-N-Hexose III (MFLNHIII), Monofucosylmonosialyllacto-N- hexose (MFMSLNH).
[0119] In a particular embodiment, said milk oligosaccharide is selected from the group consisting of lacto-N-biose, lacto-N-triose, N-acetyllactosamime, lacto-N-neotriose, lacto-N-tetraose, lacto- N-neotetraose, fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2’-fucosyllactose, 3’-sialyllactosamine, 3’-fucosyllactose, 3’-sialyl-3- fucosyllactose, 3’-sialyllactose, 6’-sialyllactosamine, 6’-sialyllactose, difucosyllactoase, lacto-N- fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, their derivatives and combinations thereof.
[0120] In a more particular embodiment, said milk oligosaccharide is selected from the group consisting of lacto-N-biose, N-acetyllactosamine, and combinations thereof.
[0121] In a more particular embodiment, said milk oligosaccharide is 2'-fucosyllactose (2FL).
[0122] In another particular embodiment, said milk oligosaccharide is selected from lacto-N- triose, lacto-N-neotetrose and combinations thereof.
[0123] In a particular embodiment, said milk oligosaccharide is a modified, recombinant or synthetic milk oligosaccharide.
[0124] Modified, recombinant or synthetic milk oligosaccharides can be obtained by any method well-known from the skilled person, in particular by chemical synthesis (as disclosed for example in Bandara etal. (2020) Org Biomol Chem 18(9) :1747-1753), biological synthesis or engineering or by fermentation (as disclosed for example in PCT application WO2015/197082).
[0125] It has been previously shown that the capacity of a bacterial strain to uptake and metabolize human milk oligosaccharides was linked to the presence, in its genome, of a functional H5 cluster.
[0126] Therefore, in some embodiments where the nutrient source is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises at least one gene of the H5 gene cluster, in particular at least one gene of a functional H5 gene cluster, from Bifidobacterium longum subsp. infantis.
[0127] As used herein, a “functional H5 gene cluster” refers to a cluster of genes in Bifidobacterium responsible for the uptake and metabolism of human milk oligosaccharides containing LNB. A functional H5 cluster typically comprises Blon_2175, Blon_2176 and Blon_2177. The H5 gene cluster typically comprises the following genes: Blon_2171 (which typically encodes a UDP-glucose 4-epimerase, typically a protein of sequence SEQ ID NO: 35),
Blon_2173 (which typically encodes an aminoglycoside phosphotransferase, typically a protein of sequence SEQ ID NO: 36), Blon_2174 (which typically encodes a protein of sequence SEQ ID NO: 37), Blon_2175 (which typically encodes a binding-protein-dependent transport systems inner membrane component, typically a protein of sequence SEQ ID NO: 38), Blon_2176 (which typically encodes a binding-protein-dependent transport systems inner membrane component, typically a protein of sequence SEQ ID NO: 39), Blon_2177 (which typically encodes an extracellular solute-binding protein, family 1 , typically a protein of sequence SEQ ID NO: 40), and galT (galactose- 1 -phosphate uridylyltransferase, typically of sequence SEQ ID NO: 41 ).
[0128] Therefore, in some embodiments where the nutrient source is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene selected from the group consisting of sequences encoding (i) a protein of sequence SEQ ID NO: 35 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 35, (ii) a protein of sequence SEQ ID NO: 36 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 36, (iii) a protein of sequence SEQ ID NO: 37 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 37, (iv) a protein of sequence SEQ ID NO: 38 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 38, (v) a protein of sequence SEQ ID NO: 39 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 39, (vi) a protein of sequence SEQ ID NO: 40 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 40, and (vii) a protein of sequence SEQ ID NO: 41 or having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.9% or more, or 100% sequence identity) with SEQ ID NO: 41 .
[0129] It has also been shown that the capacity of a bacterial Roseburia or Eubacterium strain to uptake and metabolize human milk oligosaccharides, and that this capacity was linked to the presence, in its genome, of a HMO utilization loci, defined by the co-occurrence of GH136 and GH112 genes and the presence of an ABC transporter gene (Pichler et al. (2020). Nat Commun 11 :3285).
[0130] Therefore, in some embodiments where the nutrient source is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set providing a
competitive advantage is or comprises at least one gene of a Roseburia HMO utilization loci, as defined in Pichler et al. (2020). Nat Commun 11 :3285, in particular a Roseburia GH136 gene, a Roseburia GH112 and/or a Roseburia ABC transporter gene.
[0131] In other embodiments where the nutrient source is as defined under the section “Oligosaccharide” above, said heterologous or engineered gene or gene set providing a competitive advantage is or comprises at least one gene of an Eubacterium HMO loci, as defined in Pichler et al. (2020). Nat Commun 11 :3285, in particular an Eubacterium GH136 gene, an Eubacterium GH112 and/or an Eubacterium ABC transporter gene.
[0132] As used herein, the percent identity is calculated in relation to polymers (e.g., polynucleotide or polypeptide) whose sequences have been aligned. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology=# of identical positions/total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
[0133] The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11 -17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a BLOSUM62 matrix, a BLOSUM30 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1 , 2, 3, 4, 5, or 6. In a specific embodiment the BLOSUM30 matrix is used with gap open penalty of 12 and gap extension penalty of 4.
[0134] In a particular embodiment, the nutrient source cannot be utilized as a nutrient source by the engineered bacterial strain in the absence of the heterologous or engineered gene or gene set providing a competitive advantage.
[0135] In an alternative embodiment, the nutrient source is utilized as a nutrient source more efficiently by the engineered bacterial strain in the presence of the heterologous or engineered gene or gene set providing a competitive advantage than in the absence thereof. In other words, in an alternative embodiment, the engineered bacterial strain is able to use the nutrient source in the absence of the heterologous or engineered gene or gene set, but the presence of the heterologous or engineered gene or gene set enables the engineered bacterial strain to use the
nutrient source more efficiently, for example by providing a gene that can ensure the transport of the nutrient source before it is metabolized by the bacterial strain.
[0136] In a particular embodiment, the method further comprises administering the nutrient source, as defined above, to the subject, or providing the environment with the nutrient source, as defined above.
[0137] In a particular embodiment, said nutrient source is not used in its natural context. Typically, when the nutrient source is HMO as defined above, the subject is an adult. Indeed, as well-known from the skilled person, HMO are generally not eaten or drunk by adults.
[0138] In a particular embodiment, said engineered bacterial strain and said nutrient source are administered or provided either together or separately. For example, the nutrient source may be provided as a solution and the engineered bacterial strain may be provided in dry form or as an enteric-coated tablet or capsule. Alternatively, a composition comprising both the engineered bacterial strain and the nutrient source, for example in the form of a non-aqueous liquid or gel composition or in dry form or as an enteric-coated tablet or capsule, can be administered or provided. Alternatively, the nutrient source may be provided in dry form or as an enteric-coated tablet or capsule and the engineered bacterial strain may be provided in a separate dry form or as an enteric-coated tablet or capsule.
[0139] In a particular embodiment, the nutrient source can be administered or provided prior to the administration or provision of the engineered bacterial strain, or the nutrient source can be administered or provided contemporaneously with the administration or provision of the engineered bacterial strain, and/or the nutrient source can be administered or provided after the administration or provision of the engineered bacterial strain.
[0140] In a particular embodiment, the nutrient source is administered contemporaneously with the administration of the engineered bacterial strain and further administered after the administration of the engineered bacterial strain.
[0141] In a particular embodiment, said competitive advantage is or further includes an advantage in interference competition, in particular in intraspecies direct competition, wherein the engineered bacterial strain can typically produce antibacterials against other members of the microbiome, in particular against the target bacterial strain(s), as defined below, or wherein the engineered bacterial strain can typically be resistant to administered antibacterials to which other members of the microbiome, in particular the target bacterial strain(s), are sensitive.
[0142] In a more particular embodiment, said competitive advantage is provided or further provided by the production of one or more bacteriocins, as defined below, by said engineered bacterial strain.
[0143] In a particular embodiment, the engineered bacterial strain thus comprises or further comprises a heterologous or engineered gene or gene set involved in intraspecies direct
competition, more particularly a heterologous or engineered gene or gene set involved in the expression or synthesis of an antibacterial agent, in particular as defined in the section “Reduction of the level of a molecule produced by at least one target bacterial strain’’ below, more particularly an antibacterial agent to which the engineered bacterial strain is resistant and the target bacterial strain(s) is sensitive, more particularly a heterologous or engineered gene or gene set involved in the expression or synthesis of one or more bacteriocins.
[0144] In a particular embodiment, said engineered bacterial strain does not comprise any antibiotic-resistance gene or marker.
[0145] In a particular embodiment, said engineered bacterial strain is auxotrophic. In a more particular embodiment, said engineered bacterial strain comprises an auxotrophic selection marker such as air (alanine racemase), thyA (Thymidylate synthase), dapA (4-hydroxy- tetrahydrodipicolinate synthase). In a more particular embodiment, said engineered bacterial strain is auxotrophic to the nutrient source as defined above.
[0146] In a particular embodiment, said engineered bacterial strain further comprises a nucleic acid, in particular a heterologous or engineered nucleic acid, involved in the expression of a molecule of interest, in particular a molecule of interest having a beneficial effect, as defined above, for the subject or environment, or for the subject’s or environment’s microbiome.
[0147] In a particular embodiment, the method of the invention further includes administering to the subject or providing to the environment a prebiotic.
[0148] Prebiotics include, but are not limited to, amino acids, biotin, fructo-oligosaccharide, galacto-oligosaccharides, hemicelluloses (e.g., arabinoxylan, xylan, xyloglucan, and glucomannan), inulin, chitin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, gums (e.g., guar gum, gum arabic and carrageenan), oligofructose, oligodextrose, tagatose, resistant maltodextrins (e.g., resistant starch), trans- galactooligosaccharide, pectins (e.g., homogalacturonan, citrus pectin, apple pectin, and rhamnogalacturonan-l), dietary fibers (e.g., soy fiber, sugarbeet fiber, pea fiber, corn bran, and oat fiber) and xylooligosaccharides.
[0149] In a particular embodiment, said prebiotic is not the nutrient source as defined above.
Reduction of the level of a molecule produced by at least one target bacterial strain [0150] In the context of the invention, the level, in a subject, of a molecule produced by at least one target bacterial strain which is harmful and/or not beneficial to said subject, is reduced. [0151] By “molecule” is meant herein any type of molecule which can be directly or indirectly produced by a bacteria, such as nucleic acids, peptides, polypeptides, proteins, carbohydrates, lipids, small compounds, metabolites, organic acids, alcohols, etc.. In a particular embodiment, said molecule is a peptide, polypeptide or protein.
[0152] In the context of the invention, by “molecule which is harmful and/or not beneficial to a subject” is meant herein a molecule which (i) is directly or indirectly involved in the triggering and/or the maintenance of a disease, disorder, condition or unesthetic effect in any subject, (ii) is directly or indirectly involved in the triggering and/or the maintenance of a disease, disorder, condition, or unesthetic effect in a subject displaying specific features, (iii) directly or indirectly leads to the maintenance or growth of microorganisms that are associated with a disease, disorder, condition or unesthetic effect in a subject and/or (iv) does not directly or indirectly produce a beneficial effect to a subject compared to a mutant or variant thereof.
[0153] In the context of the invention, said beneficial effect can be of any type such as stimulating the immune system, breaking down potentially toxic compounds, synthesizing certain vitamins and/or amino acids, or protecting from pathogenic organisms.
[0154] Examples of molecules produced by target bacterial strain(s) which are harmful and/or not beneficial to a subject are disclosed in more detail in the section “Method of preventing or treating a disease, disorder or condition” below.
[0155] By “produced molecule” is meant herein a molecule which is expressed, secreted, displayed or produced by said target bacterial strain(s). In particular, said produced molecule can be expressed by a gene or set of genes comprised by said target bacterial strain(s), and then be secreted, membrane displayed or kept intracellularly by said target bacterial strain(s).
Target bacterial strain(s)
[0156] In the context of the invention, the target bacterial strain(s) is a bacterial strain as defined in the section “Bacterial strain” above, provided that said engineered bacterial strain and said target bacterial strain(s) are from the same species. In a particular embodiment, said target bacterial strain(s) is a commensal bacterial strain. In another particular embodiment, said target bacterial strain(s) is a pathogenic bacterial strain.
[0157] In a particular embodiment, the target bacterial strain(s) is a Bacteroides bacterial strain, in particular a Bacteroides thetaiotaomicron and/or a Bacteroides faecis strain. In one embodiment, the target bacterial strain(s) is a strain of a bacterial species selected from the group consisting of Escherichia coll, Bacteroides fragilis, Enterococcus faecalis, Yersinia pestis, Francisella tularensis, Bacillus anthracis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enterica Typhi, Fusobacterium nucleatum, Bacteroides fragilis, Cutibacterium acnes and Helicobacter pylori. In another embodiment, the target bacterial strain(s) is a Propionibacterium propionicum, Corynebacterium amycolatum, Actinomyces massiliensis or Bacteroides thetaiotaomicron strain. In another embodiment, the target bacterial strain(s) is a strain of a bacterial species from the Firmicutes phylum. In another embodiment, the target bacterial strain(s) is a Roseburia intestinalis strain. In another embodiment, the target bacterial strain(s) is a Prevotella copri strain. In another embodiment, the target bacterial strain(s) is a Eggerthella lenta strain. In another embodiment, the target bacterial strain(s) is a Enterococcus faecalis, Enterococcus faecium or Lactobacillus brevis strain. In another
embodiment, the target bacterial strain(s) is a Clostridium sporogenes strain. In another embodiment, the target bacterial strain(s) is a Escherichia coli strain or a strain of a Gammaproteobacteria. In another embodiment, the target bacterial strain(s) is a Prevotella copri or Bacteroides vulgatus strain. In another embodiment, the target bacterial strain(s) is a C. difficile strain.
Reduction of the level
[0158] By “level” is meant herein the amount or concentration of said specific produced molecule in the subject or in the environment. As will be understood by the skilled person, depending on the fact that said produced molecule is secreted, displayed or remained intracellular in said target bacterial strain(s), the level of said produced molecule will be determined either in the subject or environment, or in the subject’s or environment’s microbiome hosting the target bacterial strain(s).
[0159] By “reduction of the level of the produced molecule” is meant herein a decrease in the level of the produced molecule after the engineered bacterial strain is administered or provided, or engineered in-situ, compared to the level of said produced molecule in the absence of any administration or provision of said engineered bacterial strain. In a particular embodiment, the reduction of the level of the produced molecule refers to a decrease in the ratio of the level of the produced molecule to the level of a mutant or variant of said produced molecule.
[0160] In the context of the invention, the reduction of the level of the produced molecule applies to the specific molecule produced by the target bacterial strain(s), and does not encompass any mutant or variant of said produced molecule. However, in some embodiments the level of any mutant or variant of said produced molecule may further be reduced by the methods of the invention.
[0161] By “variant” or “mutant” of the produced molecule is meant herein a modified version of the produced molecule, compared to the version produced by the target bacterial strain(s). Preferably, said variant or mutant of the produced molecule does not have the same direct or indirect effect on the subject, the environment or other microorganisms present in the subject or environment, and/or the same activity as the version of the molecule produced by the target bacterial strain(s). Preferably, said variant or mutant of the produced molecule is not directly nor indirectly harmful to the subject or to the environment.
[0162] In a particular embodiment, the reduction of the level of the produced molecule is a statistically significant decrease in the level of the produced molecule or a statistically significant decrease in the ratio of the level of the produced molecule to the level of a mutant or variant of said produced molecule.
[0163] In a particular embodiment, said reduction of the level of the produced molecule is observed 30 min after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source, in particular 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3
weeks, or 1 month after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source.
[0164] In a particular embodiment, said reduction of the level of the produced molecule is maintained (not necessarily at the same level) for 30 min after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source, in particular for 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year after the first administration of the engineered bacterial strain and/or the first administration of the nutrient source.
[0165] In a particular embodiment, said reduction of the level of the produced molecule is maintained (not necessarily at the same level) for the whole period during which the engineered bacterial strain and/or the nutrient source is administered, in particular is regularly administered. [0166] The reduction of the level of the produced molecule by administration of the engineered bacterial strain is due to the transient or permanent, partial or total replacement of the target bacterial strain(s) producing said produced molecule, by the engineered bacterial strain which does not produce said molecule, thanks to the competitive advantage of the engineered bacterial strain over the target bacterial strain(s).
[0167] In a particular embodiment, the reduction of the level of the molecule produced by the target bacterial strain(s) is due only to the administration of said engineered bacterial strain. In other words, in that embodiment, the reduction of the level of molecule produced by the target bacterial strain(s) is not mediated by another administered additional element, such as an element degrading or sequestering said molecule, an element modifying the target bacterial strain(s) in such a way that the molecule is no longer produced or is produced in a mutant or variant version, or an element that kills or reduces the growth the target bacterial strain(s). In particular, in an embodiment, no antibacterial agent is administered to the subject.
[0168] By “antibacterial agent” is meant an agent that either kills or inhibits the growth of a bacteria.
[0169] Examples of antibacterial agents include antibiotics, bacteriocins, endolysins, bacteriolytic enzymes, phages (in particular prophages or filamentous phages), toxins, polypeptides having a/p-type SASP activity, nucleases, molecules involved in type Vl-secretion system (T6SS)-mediated effector translocation, molecules involved in type Ill-secretion system (T3SS), molecules involved in type IV-secretion system (T4SS), molecules involved in contactdependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz), molecules involved in microcin proximity-dependent inhibition (MccPDI) and any combination thereof.
[0170] In a particular embodiment, said antibacterial agent is a combination of a contactdependent antibacterial agent such as molecules involved in type Vl-secretion system (T6SS)- mediated effector translocation, molecules involved in type Ill-secretion system (T3SS),
molecules involved in type IV-secretion system (T4SS), molecules involved in contact-dependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz) or molecules involved in microcin proximity-dependent inhibition (MccPDI), and of a contact-independent antibacterial agent such as antibiotics or bacteriocins.
[0171] In some embodiments, the antibiotic is selected from the group consisting of penicillins such as penicillin G, penicillin K, penicillin N, penicillin O, penicillin V, methicillin, benzylpenicillin, nafcillin, oxacillin, cioxacillin, dicloxacillin, ampicillin, amoxicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, epicillin, carbenicillin, ticarcillin, temocillin, mezlocillin, and piperacillin; cephalosporins such as cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cefonicid, cefprozil, cefuroxime, cefuzonam, cefmetazole, cefotetan, cefoxitin, loracarbef, cefbuperazone, cefminox, cefotetan, cefoxitin, cefotiam, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefodizime, cefotaxime, cefovecin, cefpimizole, cefpodoxime, cefteram, ceftamere, ceftibuten, ceftiofur, ceftiolene, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, latamoxef, cefclidine, cefepime, cefluprenam, cefoselis, cefozopran, cefpirome, cefquinome, flomoxef, ceftobiprole, ceftaroline, ceftolozane, cefaloram, cefaparole, cefcanel, cefedrolor, cefempidone, cefetrizole, cefivitril, cefmatilen, cefmepidium, cefoxazole, cefrotil, cefsumide, ceftioxide, cefuracetime, and nitrocefin; polymyxins such as polysporin, neosporin, polymyxin B, and polymyxin E, rifampicins such as rifampicin, rifapentine, and rifaximin; Fidaxomicin; quinolones such as cinoxacin, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, grepafloxacin, levofloxacin, pazufloxacin, temafloxacin, tosufloxacin, clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin, sitafloxacin, trovafloxacin, prulifloxacin, delafloxacin, nemonoxacin, and zabofloxacin; sulfonamides such as sulfafurazole, sulfacetamide, sulfadiazine, sulfadimidine, sulfafurazole, sulfisomidine, sulfadoxine, sulfamethoxazole, sulfamoxole, sulfanitran, sulfadimethoxine, sulfametho-xypyridazine, sulfametoxydiazine, sulfadoxine, sulfametopyrazine, and terephtyl; macrolides such as azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin, carbomycin A, josamycin, kitasamycin, midecamycin, oleandomycin, solithromycin, spiramycin, troleandomycin, tylosin, and roxithromycin; ketolides such as telithromycin, and cethromycin; fluoroketolides such as solithromycin; lincosamides such as lincomycin, clindamycin, and pirlimycin; tetracyclines such as demeclocycline, doxycycline, minocycline, oxytetracycline, and tetracycline; aminoglycosides such as amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, sisomicin, tobramycin, paromomycin, and streptomycin; ansamycins such as geldanamycin, herbimycin, and rifaximin; carbacephems such as loracarbef; carbapenems such as ertapenem, doripenem, imipenem (or cilastatin), and meropenem; glycopeptides such as teicoplanin, vancomycin, telavancin, dalbavancin, and oritavancin; lincosamides such as clindamycin and lincomycin; lipopeptides such as daptomycin;
monobactams such as aztreonam; nitrofurans such as furazolidone, and nitrofurantoin; oxazolidinones such as linezolid, posizolid, radezolid, and torezolid; teixobactin, clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifabutin, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin (or dalfopristin), thiamphenicol, tigecycline, tinidazole, trimethoprim, alatrofloxacin, fidaxomycin, nalidixic acid, rifampin, derivatives and combination thereof.
[0172] Other examples of antibacterial agents include azaserine, bestatin, D-cycloserine, 1 ,10- phenanthroline, 6-diazo-5-oxo-L-norleucine, L-alanyl-L-1 -aminoethyl-phosphonic acid; aureolic acids such as chromomycin A3, mithramycin A and mitomycin C C; coumarin-glycosides such as novobiocin; diphenyl ether derivatives such as irgasan; epipolythiodixopiperazines such as gliotoxin from Gliocladium fimbriatum; cerulenin; glucosamines such as 1 -deoxymannojirimycin, 1 -deoxynojirimycin and N-methyl-1 -deoxynojirimycin; indole derivatives such as staurosporine; diaminopyrimidines such as iclaprim (AR-100); macrolactams such as ascomycin; statins such as mevastatin.; polyphenolic acids such as (+)-usnic acid; polyethers such as lasalocid A, lonomycin A, monensin, nigericin and salinomycin; picolinic acid derivatives such as fusaric acid; peptidyl nucleosides such as blasticidin S, nikkomycin, nourseothricin and puromycin; nucleosides such as adenine 9-p-D-arabinofuranoside, 5-azacytidine, cordycepin, formycin A, tubercidin and tunicamycin; pleuromutilins such as GSK-565154, GSK-275833 and tiamulin; peptide deformylase inhibitors such as LBM415 (NVP PDF-713) and BB 83698; methenamine (hexamine), doxorubicin, piericidin A, stigmatellin, actidione, anisomycin, apramycin, coumermycin A1 , L(+)-lactic acid, cytochalasins (e.g. cytochalasin B and cytochalasin D), emetine and ionomycin; antiseptic agents such as chlorhexidine, phenol derivatives (e.g. thymol and triclosan), quaternary ammonium compounds (e.g. benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, cetrimonium bromide, cetrimonium chloride and cetrimonium stearate), octenidine dihydrochloride, and terpenes (e.g. terpinen-4-ol).
[0173] In a particular embodiment, the level of the molecule produced by the target bacterial strain(s) may be reduced or further reduced by the administration of the engineered bacterial strain by using an engineered bacterial strain, as defined above, which is able or further able to kill or inhibit the growth of said target bacterial strain(s).
[0174] Therefore, in a particular embodiment, the engineered bacterial strain produces or further produces an antibacterial agent, as defined above, to which the engineered bacterial strain is resistant to, but to which the target bacterial strain(s) is sensitive to. In a more particular embodiment, the engineered bacterial strain produces or further produces an antibacterial agent, as defined above, to which the engineered bacterial strain is resistant, but to which the target bacterial strain(s) and other bacteria from the subject are sensitive.
[0175] In the particular embodiment where the engineered bacterial strain produces or further produces an antibacterial agent, the antibacterial agent can be for example a bacteriocin or an endolysin. Other examples of antibacterial agents include bacteriolytic enzymes, phages (in
particular prophages or filamentous phages), toxins, polypeptides having a/p-type SASP activity, nucleases, molecules involved in type Vl-secretion system (T6SS)-mediated effector translocation, molecules involved in type Ill-secretion system (T3SS), molecules involved in type IV-secretion system (T4SS), molecules involved in contact-dependent inhibition (CDI), molecules involved in contact-dependent inhibition mediated by glycine zipper proteins (Cdz), molecules involved in microcin proximity-dependent inhibition (MccPDI) and any combination thereof.
[0176] By “bacteriocin” is meant herein a proteinaceous or peptidic toxin produced by bacteria to inhibit the growth of other bacterial strain(s).
[0177] Bacteriocins are categorized in several ways, including producing strain, common resistance mechanisms, and mechanism of killing. Such bacteriocins have been described from gram negative bacteria (e.g. microcins, colicin-like bacteriocins and tailocins) and from gram positive bacteria (e.g. Class I, Class II, Class III or Class IV bacteriocins).
[0178] In one embodiment, said at least one bacteriocin is selected from the group consisting of microcins, colicin-like bacteriocins, tailocins, Class I, Class II, Class III and Class IV bacteriocins. [0179] By “microcins” is meant herein very small bacteriocins, composed of relatively few amino acids, and typically including microcin V (MccV) produced by Escherichia coli and subtilosin A produced by Bacillus subtilis. Examples of microcins include MccB17, MccC, MccD93, MccJ25, MccL, MccV, MccS, MccE492, MccM, MccH47, Mccl47, MccN and MccPDI.
[0180] By “colicin-like bacteriocin” or “CLBs" is meant herein bacteriocins found in Gramnegative bacteria, which are modular proteins between 20 and 90 kDa in size and often consist of a receptor binding domain, a translocation domain and a cytotoxic domain. Examples of CLBs typically include colicins, in particular colicins A, B, D, K, E1 , E2, E3, E4, E5, E6, E7, E8, E9, la, lb, M, N, S4, II, Y, 5, 10; klebicins, in particular klebicins A, B, C, CCL, D, KpneA, KaerA, KoxyY, Kvarla, Kpnela, KaerM, KpneM (or Kpne CHS1 10), KpneM2 (or Kpne e1602) and KvarM (or Kvar 6A2); alveicins, in particular alveicins A and B; marcescins, in particular marcescins A, B and 28B; S-type pyocins, in particular pyocins S1 , S2, S3, S5, S4, AP41 ; cloacins, in particular cloacin DF13; and pesticin.
[0181] By “tailocin” is meant herein a multisubunit bacteriocin that resembles bacteriophage tails. There are two classes of tailocin particles, the flexible noncontractile F-tailocins and the rigid contractile R-tailocins, which resemble and are evolutionarily related to Siphoviridae and Myoviridae phage tails, respectively. Examples of tailocins typically include F-type and R-type pyocins, carotovoricin, xenorhabdicin, and maltocin.
[0182] As used herein, the term “Class I bacteriocin” refers to small peptide inhibitors which include nisin and other lantibiotics. Examples of Class I bacteriocins typically include type A lantibiotics such as nisin A, nisin Z, bisin, subtilin, epidermin, gallidermin, mutacin II, mutacin I, mutacin III, pep5, epicidin 280, epilancin K7, lacticin 481 , lacticin 3147, cytolysin, staphylococcin C55, salvaricin A, lactocin S, streptococcin A-FF2, sublancin 168, carnocin U149, variacin 8 and
cypemycin; and type B lantibiotics such as mersacidin, actagardine, duramycin B, duramycin C, cinnamycin, ancovenin, and plantaricin C.
[0183] As used herein, the term “Class II bacteriocin” refers to small (<10 kDa) heat-stable bacteriocins, subdivided into five subclasses: the class Ila bacteriocins (pediocin-like bacteriocins), which correspond to the largest subgroup and contain an N-terminal consensus sequence across this group and a C-terminal region responsible for species-specific activity, causing cell-leakage by permeabilizing the target cell wall; the class lib bacteriocins (two-peptide bacteriocins) which require two different peptides for activity; the class lie bacteriocins which encompass cyclic peptides, in which the N-terminal and C-terminal regions are covalently linked; the class lid bacteriocins which cover single-peptide bacteriocins, which are not post- translationally modified and do not show the pediocin-like signature; and the class lie bacteriocins, which encompass those bacteriocins composed of three or four non-pediocin like peptides. Examples of class Ila bacteriocins typically include pediocin, pediocin A, pediocin AcH, pediocin PA-1 , pediocin PP-1 , pediocin SJ-1 , prepediocin AcH, prepediocin PA-1 , mesentericin Y105, mesentericin 52A, carnobacteriocin B2, carnobacteriocin BM1 , sakacin A, sakacin G, sakacin P, sakacin X, enterocin A, enterocin BC25, enterocin P, enterocin P-like, enterocin CRL35, enterocin HF, enterocin SE-K4, leucocin A, leucocin B-Ta11 a, leucocin C, leucocin C- TA33a, curvacin A, listeriocin 743A, avicin A, bavaricin A/SppA, curvaticin L442, mundticin, mundticin CRL35, mundticin KS, mundticin L, mundticin QLI2, pediocin ACCEL, piscicocin CS526, piscicolin 126, piscicolin 126, piscicocin Vi a, bifidocin B, CoaA/Coagulin/CoaA, mutacin F-59.1 , PapA, weissellin A, bacteriocin 602, bavaricin MN, divercin V41 , divergicin M35, duracin GL, bacteriocin 31 /BacA, bacteriocin 1580, bacteriocin 43, bacteriocin RC714, bacteriocin T8, hiracin JM79, penocin A/PenA, bacteriocin MC4-1 , carnocin CP52, plantaricin 423, plantaricin C19, prebacteriocin SkgA2, lactococcin MMFII, ubericin A, piscicocin V1 b, bacteriocin E50-52, bacteriocin L-1077, bacteriocin 37, acidocin A, and bacteriocin OR-7. Examples of class lib bacteriocins typically include enterocin C, enterocin 1071 , gassericin T, gassericin S, lactococcin G, lactococcin Q, plantaricin E/F, plantaricin J/K, plantaricin S, plantaricin NC8, lactacin F, brochocin-C, thermophilin 13, ABP-118, salivaricin P, mutacin IV and lactocin 705. Examples of class lie bacteriocins typically include enterocin AS-48, lactocyclicin Q, garvicin ML, gassericin A, acidocin B and butyrovibriocin AR10. Examples of class lid bacteriocins typically include aureocin A53, garvicin A, laterosporulinl O, lactococcin A, lactococcin 972, lacticin Q, carnobacteriocin XY, leucocin B, thuricin S, thuricin-17 and bactofensin A. Examples of class lie bacteriocins typically include aureocin A70.
[0184] As used herein, the term “Class III bacteriocin” refers to large (>10 kDa), heat-labile protein bacteriocins. This class is subdivided in two subclasses: subclass Illa (bacteriolysins) and subclass 11 lb. Subclass Illa comprises those peptides that kill bacterial cells by cell wall degradation, thus causing cell lysis, and typically include Lysostaphin. Subclass II lb, in contrast, comprises those peptides that do not cause cell lysis, killing the target cells by disrupting plasma
membrane potential. Examples of class III bacteriocins typically include Lysostaphin, enterolysin A, helveticin V-1829, helveticin J, caseicin 80, lactacin A, lactacin B, zoocin A, millericin B, linocin M18 and acidophilus A.
[0185] As used herein, the term “Class IV bacteriocin” refers to complex bacteriocins containing lipid or carbohydrate moieties. Examples of class IV bacteriocins typically include sublancin 168, glycocin F, ASM1 , enterocin 96 and enterocin F4-9.
[0186] In a particular embodiment, in particular when the target bacterial strain(s) is a Bacteroides strain, in particular a B. thetaiotaomicron strain, the bacteriocin is a bacteroidetocin, as disclosed for example in Coyne et al. (2019) Nat. Commun. 10:3460.
[0187] By “endolysin” or “lysin” is meant herein enzymes used by bacteriophages at the end of their replication cycle to degrade the peptidoglycan of the bacterial host from within, resulting in cell lysis and release of progeny virions. They are typically either P(1 ,4)-glycosylases (lysozymes), transglycosylases, amidases or endopeptidases. Examples of endolysins typically include PhiV10p30, STM0907.Fels0, epsilon15p25, YuA20, ORF23, BcepMu22, F1 16p62, STM2715.S.Fels2, gp76, SPSV3_gp23, phi32_17, HK022p54, HK97p58, HK620p36, VIP0007, Sf6p62, R (SfVp40), gp22, Nazgul38, K (P2p09), K (Wphi09), rv5_gp085, EpJS98_gp116, gp3.5 (from 13A phage), gp3.5 (from BAM phage), gp3.5 (from ECODS1 phage), CKV1 F_gp16, T3p18, gh-1 p12, gp3.5 (from K1 1 phage), ORF12, Bcep43-27, Bcep781 -27, Bcep1 -28, BcepNY3gene26, gp45, gp28, P27p30, RB49p102, phi1 -p102, lys (T5.040), Aeh1 p339, YYZgp45, cpSH2 lysin, lysin from STB12 phage, PlyP40, endolysin from phi11 phage, endolysins from the Pseudomonas aeruginosa phages DKZ and EL, endolysins of the Pseudomonas putida phage, endolysins of the E. coli phage N4, endolysins of the phage LUZ24, gp61 muramidase, STM0016 endolysin, PSP3 endolysin, phiKZgp144, ELgp188, Salmonella endolysin, Enterobacteria phage T4 endolysin, Acinetobacter baumanii endolysin, E. coli phage KIF endolysin, OBPgpLYS, PSP3 Salmonella endolysin (PSP3gp1 ), E. coli phage P2 endolysin (P2gp9), Salmonella typhimurium phage muramidase STMOO16, E. co// phage N4 muramidase N4-gp61 and KZ144. Examples of endolysins also include endolysins disclosed in Fernandez- Ruiz et al. (2018) Front. Microbiol. 9:1033.
[0188] In a particular embodiment, said antibacterial agent is produced from a gene or set of genes derived from a bacterium which is from the same species as the engineered bacterial strain. In another particular embodiment, said antibacterial agent is produced from a gene or set of genes derived from a bacterium which is from a different species than the engineered bacterial strain.
[0189] In a particular embodiment, said engineered bacterial strain produces several antibacterial agents targeting different bacterial strains or different bacterial species.
[0190] In a particular embodiment, said engineered bacterial strain produces at least one antibacterial agent targeting a bacterial strain from the same species as the engineered bacterial
strain, and at least one different antibacterial agent targeting a bacterial species from another species than the engineered bacterial strain.
[0191] In a particular embodiment, said engineered bacterial strain further comprises a gene or gene set conferring resistance to said antibacterial agent, in particular to said bacteriocin, type Vl-secretion system (T6SS) or antibiotic.
[0192] In a particular embodiment, in particular when said antibacterial agent is a nuclease or a toxin, said antibacterial agent is produced in the target bacterial strain after conjugation. In other words, in a particular embodiment, said engineered bacterial strain is able to transduce, in the target bacterial strain, a plasmid encoding an antibacterial agent, as defined above.
Non-production of the molecule by the engineered bacterial strain
[0193] In the context of the invention, the engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s). However, in a particular embodiment, the engineered bacterial strain may produce a variant or a mutant, as defined above, of the molecule produced by the target bacterial strain(s), in particular a non-harmful variant or mutant of the molecule produced by the target bacterial strain(s), thereby reducing the level, in the subject, of the molecule produced by the target bacterial strain(s), in particular reducing the ratio of the level, in the subject, of the molecule produced by the target bacterial strain(s) to the level, in the subject, of a mutant or variant of the molecule produced by the target bacterial strain(s). In an alternative embodiment, the engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s) and does not produce either any variant or any mutant thereof, thereby reducing the level, in the subject, of the molecule produced by the target bacterial strain(s).
[0194] In a particular embodiment, said engineered bacterial strain does not naturally produce the molecule produced by the target bacterial strain(s).
[0195] By “not naturally produce” is meant herein the engineered bacterial strain has not been engineered to not produce said molecule. In other words, the engineered bacterial strain is obtained from a bacterial strain, which, naturally, without any genetic engineering, does not produce said molecule. In that embodiment, the engineered bacterial strain can naturally produce a mutant or variant, as defined above, in particular a non-harmful mutant or variant, of the molecule produced by the target bacterial strain(s).
[0196] In an alternative embodiment, said engineered bacterial strain has been engineered to not produce the molecule produced by the target bacterial strain(s). In other words, the engineered bacterial strain is both engineered to comprise the heterologous or engineered gene or gene set providing a competitive advantage, and to not produce the molecule produced by the target bacterial strain(s). In that embodiment, the engineered bacterial strain can have been engineered to produce a mutant or variant, as defined above, in particular a non-harmful mutant or variant, of the molecule produced by the target bacterial strain(s). Alternatively, the engineered bacterial strain can have been engineered to not produce neither said molecule produced by the target bacterial strain(s) nor any variant or any mutant thereof.
[0197] In a particular aspect of the invention, the bacterial strain used in the context of the invention is engineered in situ. In other words, in all the methods of the invention, the method can alternatively comprise: administering to the subject or providing to the environment a bacterial delivery vehicle for delivery into a bacterial strain of interest, wherein said bacterial strain of interest and said target bacterial strain are from the same species, wherein said bacterial delivery vehicle comprises:
(A) (a1) a heterologous gene or gene set providing a competitive advantage, as defined above, to the bacterial strain of interest over the target bacterial strain, or
(a2) a nucleic acid encoding a gene editing enzyme/system designed to modify the genome of said bacterial strain of interest so that said bacterial strain of interest has a competitive advantage, as defined above, over the target bacterial strain, and
(B) optionally a nucleic acid encoding a gene editing enzyme/system designed to modify the genome of said bacterial strain of interest so that said bacterial strain of interest does not produce said molecule produced by the target bacterial strain, as defined above, wherein said gene editing enzyme/system does not lead to the death of the bacterial strain of interest, whereby said bacterial strain of interest is engineered in situ to not produce said molecule produced by the target bacterial strain and to have a competitive advantage over the target bacterial strain, and whereby said level of molecule produced by the target bacterial strain is reduced in the subject or environment.
[0198] By “bacterial delivery vehicle” is meant herein any mean that allows the transfer of a payload into a bacterium.
[0199] There are several types of delivery vehicle encompassed by the present invention including, without limitation, bacteriophage scaffold, virus scaffold, chemical based delivery vehicle (e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes), proteinbased or peptide-based delivery vehicle, lipid-based delivery vehicle, nanoparticle-based delivery vehicles, non-chemical-based delivery vehicles (e.g., transformation, electroporation, sonoporation, optical transfection), particle-based delivery vehicles (e.g., gene gun, magnetofection, impalefection, particle bombardment, cell-penetrating peptides) or donor bacteria (conjugation).
[0200] Any combination of delivery vehicles is also encompassed by the present invention.
[0201] The delivery vehicle can refer to a bacteriophage derived scaffold and can be obtained from a natural, evolved or engineered capsid.
[0202] In some embodiments, the delivery vehicle is the payload as bacteria are naturally competent to take up a payload from the environment on their own.
[0203] In a particular embodiment, said bacterial delivery vehicle is a packaged phagemid, said heterologous genes and/or nucleic acids being located on the phagemid.
Method of preventing or treating a disease, disorder or condition
[0204] The present invention also concerns a method for preventing and/or treating, in a subject, a disease, disorder or condition directly or indirectly associated to at least one target moleculeproducing bacterial strain, said method comprising administering to the subject a therapeutically efficient amount of an engineered bacterial strain, as defined above, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is involved directly or indirectly in said disease, disorder or condition, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the disease, disorder or condition is prevented and/or treated in the subject.
[0205] The present invention also concerns an engineered bacterial strain, as defined above, for use for preventing and/or treating, in a subject, a disease, disorder or condition directly or indirectly associated to at least one target molecule-producing bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is directly or indirectly involved in said disease, disorder or condition, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species.
[0206] The present invention further concerns the use of an engineered bacterial strain, as defined above, for the manufacture of a medicament intended for the prevention and/or the treatment of a disease, disorder or condition directly or indirectly associated to at least one target molecule-producing bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is directly or indirectly involved in said disease, disorder or
condition, and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species.
[0207] In the context of the invention, the term "treating" or "treatment" means reversing, alleviating, or inhibiting the progress of the disease, disorder or condition to which such term applies, or one or more symptoms of such disease, disorder or condition.
[0208] In the context of the invention, the term "prevention" refers to any indicia of success in protecting a subject or patient (e.g. a subject or patient at risk of developing a disease, disorder or condition) from developing, contracting, or having a disease, disorder or condition, including preventing one or more symptoms of a disease, disorder or condition or diminishing the occurrence, severity, or duration of any symptoms of a disease, disorder or condition following administration of the engineered bacterial strain as described herein.
[0209] By a "therapeutically effective amount" of an engineered bacterial strain of the invention is meant a sufficient amount of the engineered bacterial strain to treat or prevent a specific disease, disorder or condition, to contribute to the treatment of a specific disease, disorder or condition, or to avoid side effects of a treatment of a specific disease, disorder or condition, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the engineered bacterial strain of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disease, disorder or condition being treating and the severity of the disease, disorder or condition, activity of the specific engineered bacterial strain employed, the specific combinations employed, the age, body weight, general health, sex and diet of the subject, the time of administration, route of administration and rate of excretion of the specific engineered bacterial strains employed, the duration of the treatment, drugs used in combination or coincidental with the specific engineered bacterial strains employed, and like factors well known in the medical arts.
[0210] In the context of the invention, a “disease, disorder or condition directly or indirectly associated to at least one target molecule-producing bacterial strain” is disease, disorder or condition directly or indirectly associated to at least one bacterial strain because of the production by said bacterial strain(s) of at least one given molecule.
[0211] In a particular embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for the onset and/or the maintenance and/or the progression and/or the worsening of said disease, disorder or condition. In another particular embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for specific symptoms associated with said disease, disorder or condition.
[0212] In another particular embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for a lack of efficiency of therapeutic and/or prophylactic therapies against said disease, disorder or condition. In a more particular
embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for such a lack of efficiency by direct interaction with said therapeutic and/or prophylactic therapy, for example by quenching, binding, neutralizing, and/or degrading the active molecule of the therapy. In another more particular embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for such a lack of efficiency by indirect interaction with said therapeutic and/or prophylactic therapy, for example by interacting with the cells targeted by the therapy and making them non- or less responsive to the therapy.
[0213] In another particular embodiment, the molecule(s) produced by the target bacterial strain(s) is directly or indirectly responsible for specific side effects of therapeutic and/or prophylactic therapies against a disease, disorder or condition.
[0214] In a particular embodiment, said molecule(s) is a toxin. In particular, said molecule(s) may be an exotoxin or an endotoxin. Exotoxins are generated and actively secreted; endotoxins remain part of the bacteria. The response to a bacterial toxin can involve severe inflammation and can lead to sepsis.
[0215] Examples of toxins include Colibactin of E. coli, Toxin A and other enzymes (e.g., hemolysin, leukotoxin, exfoliative toxin, enterotoxin, and toxic-shock syndrome toxin-1 (TSST-1 )) from Staphylococcus aureus (typically as described in Tam and Torres, Microbiol Spectr. 2019 Mar; 7(2)) and fragilysin (Bft) from Enterotoxigenic (ETBF) strains of Bacteroides fragilis, Botulinum neurotoxin, Tetanus toxin, Diphteria toxin, Anthrax toxin, Alpha toxin, Pertussis toxin, Shiga toxin, Heat-stable enterotoxin (E. coli ST), or any toxin described in Henkel et al., (Toxins from Bacteria in EXS. 2010 ; 100: 1-29).
[0216] By “colibactin” is meant herein a secondary metabolite synthetized by the clbA-S genes present in the 54-kb pathogenicity pks island, a genetic island encoding a non-ribosomal peptide synthetase-polyketide synthase (NRPS-PKS) assembly line in Enterobacteriaceae. Colibactin is typically produced as a prodrug moiety that is exported in the periplasm by the efflux pump ClbM and then hydrolyzed by the periplasmic membrane-bound ClbP protein with a peptidase activity, which releases the active colibactin.
[0217] In a particular embodiment, said method is for treating and/or preventing colorectal cancer, and said molecule is fragilysin, in particular produced by Enterotoxigenic Bacteroides fragilis (ETBF).
[0218] In a particular embodiment, said method is for treating and/or preventing colorectal cancer, and said molecule is colibactin, in particular produced by Enterococcus faecalis and/or E. coli.
[0219] In a particular embodiment, said molecule(s) is a virulence factor.
[0220] A virulence factor can be any substance produced by a pathogen that alters hostpathogen interaction by increasing the degree of damage done to the host. Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche in the host, to evade the host's immune response, to facilitate entry to and egress from host
cells, to obtain nutrition from the host, or to inhibit other physiological processes in the host. Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, scavenging factors and factors that promote biofilm formation. [0221] Examples of virulence factors include virulence factors encoded by the following E. coli virulence factor genes EHEC-HlyA, fimA, fimF, fimH, neuC, kpsE, sfa, foe, iroN, aer, iha, papC, papGI, papGII, papGIII, hlyC, cnf1 , hra, sat, ireA, usp ompT, ibeA, malX, fyuA, irp2, traT, afaD, ipaH, eltB, estA, bfpA, eaeA, espA, aaiC, aatA, TEM, CTX, SHV, csgA, csgB, csgC, csgD, csgE, csgF, csgG, csgH, genes within T 1 SS, T2SS, T3SS, T4SS, T5SS, T6SS (secretion systems) and blc, virulence factors encoded by the Yersinia pestis virulence factor gene yscF, virulence factors encoded by the Francisella tularensis virulence factor gene fslA, virulence factors encoded by the Bacillus anthracis virulence factor gene pag, virulence factors encoded by the Vibrio cholera virulence factor genes ctxA, ctxB, tcpA and toxT, virulence factors encoded by the Pseudomonas aeruginosa virulence factor genes pyoverdine (e.g., sigma factor pvdS, biosynthetic genes pvdL, pvdl, pvdJ, pvdH, pvdA, pvdF, pvdQ, pvdN, pvdM, pvdO, pvdP, transporter genes pvdE, pvdR, pvdT, opmQ), siderophore pyochelin (e.g., pchD, pchC, pchB, pchA, pchE, pchF and pchG), and toxins (e.g., exoll, exoS and exoT), virulence factors encoded by the Klebsiella pneumoniae virulence factor genes fimA and cps, virulence factors encoded by the Acinetobacter baumannii virulence factor genes ptk and epsA, virulence factors encoded by the Salmonella enterica Typhi virulence factor genes MIA and ssrB, virulence factors encoded by the Fusobacterium nucleatum virulence factor genes FadA and TIG IT, and virulence factors encoded by the Bacteroides fragilis virulence factor gene bft.
[0222] In a particular embodiment, said molecule is a molecule encoded by a Cutibacterium acnes porphyrins gene, a CAMP-factor (CAMP1 , CAMP2, CAMP3, CAMP4), Hyaluronate lyase (HYL-IB/II, HYL-IA), Lipases (GehA, GehB), Haemolysins, Sialidases, Endoglycoceramidases, Endo-B-N-acetylglucosaminidase, Dermatan sulphate adhesin (DsA1 , DsA2), Proline-Threonine Repeats (PTRs) or in any virulence factors included on the acne associated genomic loci 1 , 2, 3(plasmid), 4 such as a tight adhesion locus (tad), Streptolysin S-associated genes (sag), nonribosomal peptide synthetases (NRPS) as described in Tomida etal. (2013) mBio 4, e00003- 13).
[0223] In a particular embodiment, in particular in a method for treating and/or preventing gastric cancer, said molecule is cytotoxin-associated antigen A (CagA) and/or vacuolating cytotoxin (VacA), preferably produced by Helicobacter pylori.
[0224] In a particular embodiment, said molecule(s) is a bacterial mimic peptide.
[0225] By “bacterial mimic peptide” is meant herein a peptide produced by a bacterium or part of a protein or polypeptide produced by a bacterium, which mimics the structure, sequence, and/or function of a subject’s peptide or of a part of a subject’s protein or polypeptide.
[0226] In a particular embodiment, the bacterial mimic peptide has homology, in particular 80% homology, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology, with a subject’s peptide or a part of a subject’s protein or polypeptide.
[0227] By “homology” is meant herein the amino acid sequence of two or more amino acid molecules is partially or completely identical. In certain embodiments the homologous amino acid sequence has 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% sequence similarity or identity to the amino acid sequence of reference.
[0228] As used herein, the percent homology between two sequences is equivalent to the percent identity, as defined above, between the two sequences.
[0229] In a particular embodiment, said bacterial mimic peptide is associated with an autoimmune disease. In a particular embodiment, said bacterial mimic peptide is one of those mentioned in Negi et al. (2017) PLoS ONE 12(7): e018051 , in particular one of those disclosed in S1 Table of Negi et al.
[0230] In a particular embodiment, said bacterial mimic peptide is produced by a target Proteobacteria or Firmicutes bacterial strain. In a particular embodiment, said bacterial mimic peptide is one of the 24 gut bacterial peptides identified by Negi et al. with homology to four human peptides from Low molecular weight phosphotyrosine protein phosphatase, Aldehyde dehydrogenase family 3 member B1 , Maleylacetoacetate isomerase and Uracil-DNA glycosylase.
[0231] In a particular embodiment, said molecule is the Ro60 protein produced by human commensal bacteria comprising a Ro60 ortholog gene, in particular by Propionibacterium propionicum, Corynebacterium amycolatum, Actinomyces massiliensis and/or Bacteroides thetaiotaomicron.
[0232] In a particular embodiment, said molecule(s) is a molecule able to induce or sustain or worsen an autoimmune reaction in the host.
[0233] In a particular embodiment, said molecule(s) is a peptide that mimics a human autoantigen.
[0234] In a particular embodiment, in particular in a method for treating and/or preventing acute inflammatory myocarditis, said molecule is a beta-galactosidase produced by Bacteroides faecis and/or Bacteroides thetaiotaomicron bacterial strains.
[0235] In a particular embodiment, in particular in a method for treating and/or preventing type 1 diabetes, said molecule is a peptide, produced by human commensal bacteria in particular by bacteria of the Firmicutes phylum, that mimics insulin B 9-25, a self-epitope involved in type 1 diabetes (Garcia et al. Peripheral tolerance to insulin is encoded by mimicry in the microbiome. Biorxiv 2019.12.18.881433 (2019) doi:10.1 101/2019.12.18.881433) and which is typically encoded by a gene which is part of the transketolase N superfamily.
[0236] In a particular embodiment, in particular in a method for treating and/or preventing antiphospholipid syndrome, said molecule is a peptide, produced by Roseburia intestinalis, that
mimics the epitope of the autoantigen p2-glycoprotein I (P2GPI), a self-epitope involved in antiphospholipid syndrome (APS) (Ruff et al. (2019) Cell Host Microbe 26, 100-1 13. e8).
[0237] In a particular embodiment, in particular in a method for treating and/or preventing rheumatoid arthritis, said molecule is a Prevotella cop/7-produced peptide exhibiting high homology with autoantigens of rheumatoid arthritis patients.
[0238] In a particular embodiment, said molecule(s) is a bacterial enzyme.
[0239] In a more particular embodiment, said molecule(s) is a bacterial enzyme targeting a drug administered to the subject to treat and/or prevent a disease, disorder or condition. In the context of the invention, a “bacterial enzyme targeting a drug” encompasses both an enzyme leading to the elimination of the drug and an enzyme involved in the more general evolution of the drug activity in the subject once administered to said subject.
[0240] Said given drug may be selected from the group consisting of Nicardipine- HCI, Risperidone, Tolcapone, Azathioprine, Entacapone, Exemestane, Nimodipine, Capsaicin, Dexamethasone, Ethacrynic Acid, Rifampin (Rifampicin), Sulindac, Vorinostat, Dolasetron, Mycophenolate Mofetil, Zidovudine (3'-Azido-3'-Deoxythymidine), Allopurinol, Betamethasone, Bisacodyl, Estradiol, Famciclovir, Flutamide, Hydrocortisone, Hydrocortisone Acetate, Methylprednisolone, Metronidazole, Nabumetone, Pantoprazole, Prednisolone, Progesterone, Prednisone, Spironolactone, Sulfasalazine, Tinidazole, Fluoxetine-HCI, Misoprostol, Megestrol Acetate, Capecitabine, Chenodiol (Chenodeoxycholic Acid), Clofazimine, Clonazepam, Cortisone Acetate, Dantrolene-Na, Duloxetine, Fludrocortisone Acetate, lloperidone, Lorazepam, Nilutamide, Nitisinone, Nitrofurantoin, Oxazepam, Paliperidone, Prasugrel, Probenecid, Rifabutin, Sulfamethoxazole, Ursodiol, Omeprazole, Tenatoprazole, Artemisinin, Danazol, Olmesartan medoxomil, Phenazopyridine, Nitrendipine, Racecadrotil, Fenofibrate, Fluphenazine, Telmisartan, Benzbromarone, Oxethazaine, Mefloquine, Quinacrine, Pimozide, Loxapine succinate, Cyclobenzaprine, Ethopropazine, Promethazine, Clemizole and Pyrimethamine.
[0241] Said given drug may further be selected from the group consisting of abacavir sulfate, acebutolol, acecainide, alfuzosin, almotriptan, alprenolol, amantadine, aminoglutethimide, amisulpride, anagrelide, anastrozole, antazoline phosphate, apomorphine, artemisinin, atenolol, atorvastatin calcium, azatadine maleate, bambuterol, Benazepril, benzbromarone, benzthiazide, betamethasone acetate, betamethasone valerate, betaxalol, bezafibrate, bicalutamide, biperiden, bisacodyl, bisoprolol fumarate, bromocriptine mesylate, budesonide, bupropion, buramate, buspirone, camylofine dihydrochloride, capecitabine, carbetapentane citrate, carbinoxamine maleate, carisoprodol, Carvedilol, celecoxib, cetirizine, chlormezanone, cimetidine, citalopram hydrobromide, clemastine fumarate, clemizole, clenbuterol, clidinium bromide, clonidine, clopidogrel sulfate, Clozapine, colchicine, cyclobenzaprine, cyclophosphamide, cyproterone acetate, dabigatran etexilate mesylate, danazol, darifenacin hydrobromide, dasatinib, deflazacort, desvenlafaxine succinate, dexamethasone,
dextromethorphan hydrobromide, diacetamate, Dicyclomine, diflorasone diacetate, digitoxin, digoxin, diltiazem, diperodon, diphenylpyraline, Dipyridamole, disopyramide phosphate, domperidone, doxazosin mesylate, doxepin, doxylamine succinate, drospirenone, duloxetine, eletriptan hydrobromide, enalapril maleate, Entacapone, ergonovine maleate, ergotamine tartrate, eszopiclone, ethopropazine, ethoxzolamide, ethynodiol diacetate, etodolac, ezetimibe, famciclovir, famprofazone, febuxostat, fenofibrate, fenspiride, fexofenadine, finasteride, fluconazole, fluoxetine, fluphenazine, fluvoxamine maleate, galantamine, gliclazide, glipizide, griseofulvin, guanfacine, haloperidol, hyoscyamine, idebenone, imatinib, indapamide, indomethacin, Irbesartan, irsogladine maleate, isradipine, itraconazole, ketorolac tromethamine, ketotifen fumarate, labetalol, lamotrigine, letrozole, levamisole, levonorgestrel, linagliptin, lofexidine, Loperamide, losartan, lovastatin, loxapine succinate, mebendazole, mebhydrolin naphthalenesulfonate, mefloquine, megestrol acetate, melphalan, memantine, metaxalone, Methocarbamol, methoxsalen, methsuximide, methylphenidate, methysergide maleate, meticrane, metitepine maleate, metoclopramide, metolazone, metoprolol tartrate, mevastatin, mianserin, mifepristone, milnacipran, mycophenolate mofetil, nadolol, nafronyl oxalate, naftopidil, naloxone, naproxen(+), nateglinide, nefazodone, nefopam, neostigmine bromide, nevirapine, nicergoline, nitrendipine, nizatidine, norethindrone acetate, Norgestimate, noscapine, olanzapine, olmesartan medoxomil, omeprazole, orphenadrine citrate, oxaprozin, oxcarbazepine, oxethazaine, oxybutynin chloride, Paclitaxel, paliperidone, pantoprazole, papaverine, paroxetine, penbutolol sulfate, pentoxifylline, pergolide mesylate, pericyazine, perindopril erbumine, phenacetin, Phenazopyridine, phenytoin sodium, pidotimod, pimozide, pitavastatin calcium, Pranoprofen, prazosin, prednisone, pridinol methanesulfonate, primaquine phosphate, Procarbazine, promethazine, pyrimethamine, quetiapine, quinacrine, quinapril, quinine sulfate, racecadotril, ramelteon, ramipril, ranitidine, ranolazine, rebamipide, repaglinide, Reserpine, riluzole, rimantadine, risperidone, ritonavir, rivastigmine tartrate, rizatriptan benzoate, ropinirole, rosiglitazone maleate, rosuvastatin calcium, roxatidine acetate, sertraline, sildenafil citrate, solifenacin succinate, sotalol, spiperone, sulfasalazine, sulfinpyrazone, sulindac, sulpiride, sumatriptan succinate, tacrine, tacrolimus, tadalafil, tamsulosin hydrchloride, tegaserod maleate, telmisartan, tenatoprazole, tenoxicam, terazosin, terbinafine, thiabendazole, thiothixene, tiapride, timolol maleate, tinidazole, Tolazamide, topotecan, trandolapril, tranilast, trazodone, trihexyphenidyl, trimebutine maleate, trimetazidine dihydrochloride, trimethobenzamide, trimipramine maleate, Triprolidine, tropisetron, trospium chloride, valsartan, venlafaxine, verapamil, vilazodone, Vinpocetine, voriconazole, warfarin, zaleplon, zidovudine [azt], ziprasidone mesylate and zolpidem.
[0242] In a particular embodiment, said molecule(s) is selected from the bacterial enzymes having oxidation, deamination, isomerization, esterification, condensation, reduction, hydrolysis and/or rearrangement activities. In a particular embodiment, said molecule(s) is selected from - glucuronidases, nitroreductases and sulfoxide reductases.
[0243] In a particular embodiment, when said given drug is dantrolene, clonazepam, and/or nicardipine, said molecule is an enzyme having nitro-reduction activity.
[0244] In an alternative embodiment, when said given drug is risperidone, said molecule is an enzyme having hydrolysis activity, in particular an enzyme hydrolysing the isoxazole moiety of risperidone.
[0245] In an alternative embodiment, when said given drug is sulfasalazine, said molecule is an enzyme having azoreduction activity.
[0246] In an alternative embodiment, when said given drug is digoxin, and said molecule is cytochrome glycoside reductase, said target bacterial strain producing said molecule being preferably Eggerthella lenta.
[0247] In an alternative embodiment, when said given drug is levodopa (L-DOPA), in particular in a subject suffering from Parkinson’s disease, said molecule is tyrosine decarboxylase, preferably produced by Enterococcus faecalis, Enterococcus faecium and/or Lactobacillus brevis and/or dopamine dehydrolase, preferably produced by Eggerthella lenta.
[0248] In another embodiment, when said given drug is levodopa (L-DOPA), in particular in a subject suffering from Parkinson’s disease, said molecule is DHPAA synthase, preferably produced by Clostridium sporogenes.
[0249] In an alternative embodiment, when said given drug is gemcitabine, said molecule is a cytidine deaminase, said target bacterial strain producing said molecule being preferably Escherichia coll and/or Gammaproteobacteria.
[0250] In an alternative embodiment, when said given drug is prontosil, said molecule is an enzyme converting prontosil into p-aminobenzenesulfonamide by azo-reduction.
[0251] In an alternative embodiment, when said given drug is selected from sulfasalazine, ipsalazide and balsalazide, said molecule is an enzyme converting said drug into 5-aminosalicylic acid.
[0252] In an alternative embodiment, when said given drug is a non-steroidal anti-inflammatory drug, said molecule is a p-glucuronidase.
[0253] In a particular embodiment, in particular in a method for treating and/or preventing type 2 diabetes, said molecule is a bacterial enzyme involved in amino acid metabolism, preferably produced by Prevotella copri and/or Bacteroides vulgates.
[0254] In a particular embodiment, said molecule is a bacterial adhesin.
[0255] In a more particular embodiment, said molecule is a bacterial adhesin involved in the adsorption of a given drug, administered to the subject to treat and/or prevent a disease, disorder or condition, to the target bacterial strain.
[0256] In a particular embodiment, when said given drug is L-DOPA, typically in a subject suffering from Parkinson’s disease, said molecule is a molecule involved in the adsorption of L- DOPA by Helicobacter pylori, typically a bacterial adhesin from H. pylori involved in said adsorption.
[0257] In a particular embodiment, said molecule(s) is a bacterial molecule competing with a given drug for a receptor of the subject’s cells.
[0258] In a particular embodiment, when said given drug is acetaminophen, said molecule is p- cresol produced by C. difficile or an enzyme involved in the production and/or secretion of p- cresol by C. difficile.
[0259] In a particular embodiment, said molecule(s) is a bacterial metabolite.
[0260] In a particular embodiment, said method is for preventing and/or treating liver disease, and said molecule(s) is selected from the group consisting of ethanol, ammonia and acetaldehyde.
[0261] In a particular embodiment, said method is for preventing and/or treating NAFLD and/or cardiovascular disease, and said molecule is a choline metabolite.
[0262] In a particular embodiment, said molecule is a bacterial antigen, and said method is for treating and/or preventing a disease selected from liver cirrhosis, hepatic encephalopathy, renal failure, autoimmune hepatitis, NAFLD and NASH.
[0263] In a particular embodiment, said molecule is not oxalate.
[0264] In a particular embodiment, said engineered bacterial strain does not naturally produce, as defined above, said molecule(s). In a particular embodiment, said engineered bacterial strain naturally produces a non-harmful mutant or variant of said molecule(s).
[0265] In an alternative embodiment, said engineered bacterial strain has been engineered to not produce said molecule(s), as defined above. In an alternative embodiment, said engineered bacterial strain has been engineered to produce a non-harmful mutant or variant of said molecule(s).
[0266] In a particular embodiment, when said molecule is a peptide that mimics a human autoantigen, said engineered bacterial strain does not produce said peptide, or produces a variant or mutant of said peptide which does not show any homology or show less homology with said human autoantigen.
[0267] In the context of the invention, examples of diseases, disorders or conditions to be treated or prevented by the method of the invention include a neurodegenerative disease or condition; a brain disease or condition; a CNS disease or condition; memory loss or impairment; a heart or cardiovascular disease or condition, such as heart attack, stroke or atrial fibrillation; a liver disease or condition; a kidney disease or condition, such as chronic kidney disease (CKD); a pancreas disease or condition; a lung disease or condition, such as cystic fibrosis or COPD; a gastrointestinal disease or condition; a throat or oral cavity disease or condition; an ocular disease or condition; a genital disease or condition, such as a vaginal, labial, penile or scrotal disease or condition; a sexually-transmissible disease or condition, such as gonorrhea, HIV infection, syphilis or chlamydia infection; an ear disease or condition; a skin disease or condition; a heart disease or condition; a nasal disease or condition; a haematological disease or condition, such as anaemia, in particular anaemia of chronic disease or cancer; a viral infection; a
pathogenic bacterial infection; a cancer; an autoimmune disease or condition, such as SLE; an inflammatory disease or condition, such as rheumatoid arthritis, psoriasis, eczema, asthma, ulcerative colitis, colitis, Crohn’s disease or IBD; autism; ADHD; bipolar disorder; ALS (Amyotrophic Lateral Sclerosis); osteoarthritis; a congenital or development defect or condition; miscarriage; a blood clotting condition; bronchitis; dry or wet AMD; neovascularisation (for example of a tumour or in the eye); common cold; epilepsy; fibrosis, such as, liver or lung fibrosis; a fungal disease or condition, such as thrush; a metabolic disease or condition, such as obesity, anorexia, diabetes, Type I or Type II diabetes; ulcer(s), such as gastric ulceration or skin ulceration; dry skin; Sjogren’s syndrome; cytokine storm; deafness, hearing loss or impairment; slow or fast metabolism (ie, slower or faster than average for the weight, sex and age of the subject); conception disorder, such as infertility or low fertility; jaundice; skin rash; Kawasaki disease; Lyme disease; an allergy, such as a nut, grass, pollen, dust mite, cat or dog fur or dander allergy; malaria, typhoid fever, tuberculosis or cholera; depression; mental retardation; microcephaly; malnutrition; conjunctivitis; pneumonia; pulmonary embolism; pulmonary hypertension; a bone disorder; sepsis or septic shock; sinusitus; stress (such as occupational stress); thalassaemia, anaemia, von Willebrand Disease, or haemophilia; Shingles or cold sore; menstruation; and low sperm count.
[0268] In an example, the neurodegenerative or CNS disease, disorder or condition is selected from the group consisting of Alzheimer disease, geriopsychosis, Down syndrome, Parkinson's disease, Creutzfeldt-Jakob disease, diabetic neuropathy, Parkinson syndrome, Huntington's disease, Machado-Joseph disease, amyotrophic lateral sclerosis and diabetic neuropathy.
[0269] Autoimmune diseases that may be treated or prevented include Acute Disseminated Encephalomyelitis (ADEM), acute necrotizing hemorrhagic leukoencephalitis, Addison’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome (APS), autoimmune angioedema, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus (SLE), Lyme disease, Meniere’s disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic’s), neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonage-Turner syndrome, Pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, Tolosa-Hunt syndrome, transverse myelitis, Type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vesiculobullous dermatosis, vitiligo, and Wegener’s granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).
[0270] Inflammatory diseases that may be treated or prevented include Alzheimer disease, ankylosing spondylitis, arthritis (osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), asthma, atherosclerosis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), nephritis, Parkinson's disease, and ulcerative colitis.
[0271] The present invention also concerns a method for the cosmetic caring of a subject presenting unesthetic manifestation due to at least one target molecule-producing bacterial strain(s), said method comprising administering to the subject a cosmetically efficient amount of an engineered bacterial strain, as defined above, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set, as defined above, providing a competitive advantage, as defined above, over the target molecule-producing bacterial strain(s), wherein said engineered bacterial strain does not produce, as defined above, the molecule(s) produced by the target bacterial strain(s) which is involved in said unesthetic manifestation, wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species.
[0272] By “unesthetic manifestation” is meant herein a non-pathological manifestation on a subject, in particular on the skin of a subject, of the effect of a molecule produced by a target bacterial strain(s) on the subject. Examples of unesthetic manifestation include redness, feeling of heat or warmth, tension, tingling, stinging, tightness, pigment spots, burning sensation, itching sensation, tautness, visible squama, thickening of the skin, wrinkles, sagging skin, localized resistant fat, and/or cellulite appearance.
[0273] In particular embodiments, the engineered bacterial strain of the invention is in a pharmaceutical, veterinary or cosmetic composition.
[0274] The pharmaceutical or veterinary composition according to the invention may further comprise a pharmaceutically acceptable excipient.
[0275] By “pharmaceutically acceptable excipient” is meant herein a non-pharmaceutically active additive used in the manufacture of a pharmaceutical composition, which allows the pharmaceutically active ingredient to be manufactured into a pharmaceutical formulation or a galenic formulation providing the necessary bioavailability of the medicament to the patient upon the administration of the pharmaceutical composition. The excipient is preferably compatible with the other ingredients of the composition and produces no adverse effect, allergic reaction or other undesirable reaction when it is administered to a human or an animal.
[0276] The cosmetic composition according to the invention may further comprise a cosmetically acceptable excipient.
[0277] By “cosmetically acceptable excipient” is meant herein a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a cosmetic composition or otherwise used as a vehicle, carrier, or diluents to facilitate administration of a cosmetically active ingredient and that is compatible therewith.
[0278] A solid pharmaceutically or cosmetically acceptable vehicle or excipient may include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet- disintegrating agents. Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.
[0279] The pharmaceutical, veterinary or cosmetic composition may be prepared as a sterile solid composition that may be suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. The pharmaceutical, veterinary or cosmetic compositions of the invention may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monooleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like. The engineered bacterial strains according to the invention can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for enteral administration include sterile solutions, emulsions, and suspensions.
[0280] The engineered bacterial strains according to the invention may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable pharmaceutical or cosmetic additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and enteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration. The liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
[0281] In some embodiments, the invention encompasses pharmaceutical, veterinary or cosmetic composition formulated for delayed or gradual enteric release. In preferred
embodiments, formulations or pharmaceutical preparations of the invention are formulated for delivery of the engineered bacterial strain into the distal small bowel and/or the colon. The formulation can allow the engineered bacterial strain to pass through stomach acid and pancreatic enzymes and bile, and reach undamaged to be viable in the distal small bowel and colon.
[0282] In some embodiments, the pharmaceutical, veterinary or cosmetic composition is micro- encapsulated, formed into tablets and/or placed into capsules, preferably enteric-coated capsules.
[0283] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release, using cellulose acetate (CA) and polyethylene glycol (PEG). In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using a hydroxypropylmethylcellulose (HPMC), a microcrystalline cellulose (MCC) and magnesium stearate. In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using e.g., a poly(meth)acrylate, e.g. a methacrylic acid copolymer B, a methyl methacrylate and/or a methacrylic acid ester, or a polyvinylpyrrolidone (PVP).
[0284] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release using a release-retarding matrix material such as: an acrylic polymer, a cellulose, a wax, a fatty acid, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, polyvinylpyrrolidone, a vinyl acetate copolymer, a vinyl alcohol copolymer, polyethylene oxide, an acrylic acid and methacrylic acid copolymer, a methyl methacrylate copolymer, an ethoxyethyl methacrylate polymer, a cyanoethyl methacrylate polymer, an aminoalkyl methacrylate copolymer, a poly(acrylic acid), a poly(methacrylic acid), a methacrylic acid alkylamide copolymer, a poly(methyl methacrylate), a poly(methacrylic acid anhydride), a methyl methacrylate polymer, a polymethacrylate, a poly(methyl methacrylate) copolymer, a polyacrylamide, an aminoalkyl methacrylate copolymer, a glycidyl methacrylate copolymer, a methyl cellulose, an ethylcellulose, a carboxymethylcellulose, a hydroxypropylmethylcellulose, a hydroxymethyl cellulose, a hydroxyethyl cellulose, a hydroxypropyl cellulose, a crosslinked sodium carboxymethylcellulose, a crosslinked hydroxypropylcellulose, a natural wax, a synthetic wax, a fatty alcohol, a fatty acid, a fatty acid ester, a fatty acid glyceride, a hydrogenated fat, a hydrocarbon wax, stearic acid, stearyl alcohol, beeswax, glycowax, castor wax, carnauba wax, a polylactic acid, polyglycolic acid, a co-polymer of lactic and glycolic acid, carboxymethyl starch, potassium methacrylate/divinylbenzene copolymer, crosslinked polyvinylpyrrolidone, polyvinylalcohols, polyvinylalcohol copolymers, polyethylene glycols, non-crosslinked polyvinylpyrrolidone, polyvinyl acetates, polyvinylacetate copolymers or any combination thereof.
[0285] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are formulated for delayed or gradual enteric release as described in U.S. Pat. App. Pub.
20110218216, which describes an extended release pharmaceutical composition for oral administration, and uses a hydrophilic polymer, a hydrophobic material and a hydrophobic polymer or a mixture thereof, with a microenvironment pH modifier. The hydrophobic polymer can be ethylcellulose, cellulose acetate, cellulose propionate, cellulose butyrate, methacrylic acid-acrylic acid copolymers or a mixture thereof. The hydrophilic polymer can be polyvinylpyrrolidone, hydroxypropylcellulose, methylcellulose, hydroxypropylmethyl cellulose, polyethylene oxide, acrylic acid copolymers or a mixture thereof. The hydrophobic material can be a hydrogenated vegetable oil, hydrogenated castor oil, carnauba wax, candelilla wax, beeswax, paraffin wax, stearic acid, glyceryl behenate, cetyl alcohol, cetostearyl alcohol or and a mixture thereof. The microenvironment pH modifier can be an inorganic acid, an amino acid, an organic acid or a mixture thereof. Alternatively, the microenvironment pH modifier can be lauric acid, myristic acid, acetic acid, benzoic acid, palmitic acid, stearic acid, oxalic acid, malonic acid, succinic acid, adipic acid, sebacic acid, fumaric acid, maleic acid; glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, sodium dihydrogen citrate, gluconic acid, a salicylic acid, tosylic acid, mesylic acid or malic acid or a mixture thereof.
[0286] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions are a powder that can be included into a tablet or a suppository. In alternative embodiments, a formulation or pharmaceutical preparation of the invention can be a “powder for reconstitution” as a liquid to be drunk or otherwise administered.
[0287] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions can be administered in a cream, gel, lotion, liquid, feed, or aerosol spray. Engineered bacterial strains may be immobilized onto appropriately sized polymeric beads so that the coated beads may be added to aerosols, creams, gels or liquids. The size of the polymeric beads may be from about 0.1 pm to 500 pm, for example 50 pm to 100 pm. The coated polymeric beads may be incorporated into animal feed, including pelleted feed and feed in any other format, incorporated into any other edible device used to present phage to the animals, added to water offered to animals in a bowl, presented to animals through water feeding systems. In some embodiments, the compositions are used for treatment of surface wounds and other surface infections using creams, gels, aerosol sprays and the like.
[0288] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions can be administered by inhalation, in the form of a suppository or pessary, topically (e.g., in the form of a lotion, solution, cream, ointment or dusting powder), epi- or transdermally (e.g., by use of a skin patch), orally (e.g., as a tablet, which may contain excipients such as starch or lactose), as a capsule, ovule, elixirs, solutions, or suspensions (each optionally containing flavoring, coloring agents and/or excipients), or they can be injected parenterally (e.g., intravenously, intramuscularly or subcutaneously). For parenteral administration, the compositions may be used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual
administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
[0289] In some embodiments, the pharmaceutical, veterinary or cosmetic compositions can also be dermally or transdermally administered. For topical application to the skin, the pharmaceutical, veterinary or cosmetic composition can be combined with one or a combination of carriers, which can include but are not limited to, an aqueous liquid, an alcohol base liquid, a water soluble gel, a lotion, an ointment, a nonaqueous liquid base, a mineral oil base, a blend of mineral oil and petrolatum, lanolin, liposomes, proteins carriers such as serum albumin or gelatin, powdered cellulose carmel, and combinations thereof. A topical mode of delivery may include a smear, a spray, a bandage, a time-release patch, a liquid-absorbed wipe, and combinations thereof. The pharmaceutical, veterinary or cosmetic composition can be applied to a patch, wipe, bandage, etc., either directly or in a carrier(s). The patches, wipes, bandages, etc., may be damp or dry, wherein the engineered bacterial strain is in a lyophilized form on the patch. The carriers of topical compositions may comprise semi-solid and gel-like vehicles that include a polymer thickener, water, preservatives, active surfactants, or emulsifiers, antioxidants, sun screens, and a solvent or mixed solvent system. U.S. Pat. No. 5,863,560 discloses a number of different carrier combinations that can aid in the exposure of skin to a medicament, and its contents are incorporated herein.
[0290] For intranasal or administration by inhalation, the pharmaceutical, veterinary or cosmetic composition is conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, or nebuliser with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3-heptafluoropropane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container, pump, spray, or nebuliser may contain a solution or suspension of the active compound, e.g., using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g., sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the engineered bacterial strain of the invention and a suitable powder base such as lactose or starch.
[0291] For administration in the form of a suppository or pessary, the pharmaceutical, veterinary or cosmetic composition can be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment, or dusting powder. Compositions of the invention may also be administered by the ocular route. For ophthalmic use, the compositions of the invention can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.
[0292] Dosages and desired drug concentrations of the pharmaceutical and veterinary composition compositions of the present invention may vary depending on the particular use. The determination of the appropriate dosage or route of administration is within the skill of an ordinary physician. Animal experiments can provide reliable guidance for the determination of effective doses in human therapy.
[0293] For transdermal administration, the pharmaceutical, veterinary or cosmetic composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.
[0294] For transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used. The active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.
[0295] In a particular embodiment of the methods of treatment and/or prevention or the methods of cosmetic treatment disclosed herein, when the heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source, as defined above, the method further comprises administering said nutrient source to the subject.
[0296] The methods of the invention of reducing the level of a molecule can also be applied to the environment.
[0297] For example, the method of the invention can be applied to soil or water to eliminate a toxin or environmental contamination, such as in an industrial chemical spill or waste product. The method of the invention can also be applied to waste water or industrial waste or byproduct to decontaminate or detoxify the waste. In yet other embodiments, the method of the invention can be applied to industrial or environmental material such as but not limited to agricultural or food production waste to produce or improve the production of a metabolic product.
Subject, regimen and administration
[0298] The subject according to the invention is an animal, preferably a mammal, even more preferably a human. However, the term "subject" can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheep, donkeys, rabbits, ferrets, gerbils, hamsters, chinchillas, rats, mice, guinea pigs and non-human primates, among others, or non-mammals such as poultry, that are in need of treatment.
[0299] The human subject according to the invention may be a human at the prenatal stage, a new-born, a child, an infant, an adolescent or an adult at any age.
[0300] In a preferred embodiment, the subject has been diagnosed with, or is at risk of developing an infection, a disorder and/or a disease preferably due to or associated with a bacterium. Diagnostic methods of such infection, disorder and/or disease are well known by the man skilled in the art.
[0301] In a particular embodiment, the infection, disorder and/or disease presents a resistance to treatment, preferably the infection, disorder or disease presents an antibiotic resistance.
[0302] In a particular embodiment, the subject has never received any treatment prior to the administration of the engineered bacterial strain according to the invention.
[0303] In a particular embodiment, the subject has already received at least one line of treatment, preferably several lines of treatment, prior to the administration of the engineered bacterial strain according to the invention.
[0304] Preferably, the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day. In a particular embodiment, the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day.
[0305] The duration of treatment according to the invention is preferably comprised between 1 day and 20 weeks, more preferably between 1 day and 10 weeks, still more preferably between 1 day and 4 weeks, even more preferably between 1 day and 2 weeks. In a particular embodiment, the duration of the treatment is about 1 week. Alternatively, the treatment may last as long as the infection, disorder and/or disease persists.
[0306] In a particular embodiment, the duration of treatment according to the invention is comprised between 2 days and 20 weeks and involves (i) several successive administrations of the engineered bacterial strain and of the nutrient source, or (ii) a single administration of the engineered bacterial strain and several successive administrations of the nutrient source, or (iii) several successive administrations of the engineered bacterial strain and several successive administrations of the nutrient source, the administrations of the nutrient source being continued at least once after stopping administrations of the engineered bacterial strain.
[0307] The form of the pharmaceutical or veterinary compositions comprising the engineered bacterial strain of the invention and/or the nutrient source, the route of administration and the dose of administration thereof can be adjusted by the man skilled in the art according to the type and severity of the infection, disease or disorder (e.g. depending on the bacteria species involved in the disease, disorder and/or infection and its localization in the patient’s or subject’s body), and to the patient or subject, in particular its age, weight, sex, and general physical condition.
[0308] Particularly, the amount of engineered bacterial strains according to the invention and/or the amount of nutrient source to be administered has to be determined by standard procedure well known by those of ordinary skills in the art. Physiological data of the patient or subject (e.g. age, size, and weight) and the routes of administration have to be taken into account to determine
the appropriate dosage, so as a therapeutically effective amount will be administered to the patient or subject.
[0309] For example, the total amount of engineered bacterial strain, for each administration may be comprised between 1 billion and 100 billion cfu of engineered bacteria, from 5 billion to 50 billion cfu, or from 10 billion to 25 billion cfu of engineered bacteria.
[0310] For example, when the nutrient source is milk oligosaccharide, the total amount of milk oligosaccharide, for each administration, may be comprised between 4.5 and 18 g of milk oligosaccharide per day, in particular between 9 and 18 g of milk oligosaccharide per day.
[0311] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0312] All publications mentioned herein are incorporated herein by reference. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.
[0313] It must be noted that as used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells (e.g., a population of such cells). Similarly, reference to “a nucleic acid” includes one or more of such nucleic acids.
Examples
Example 1 - Method to prevent colorectal cancer by decreasing the abundance of a toxinproducing bacterial population
[0314] A personalized method to prevent colorectal cancer (CRC) initiation or progression associated with the presence of colibactin-producing E. coli by in-situ reduction or replacement of the resident colibactin-producing E. coli with an engineered and non toxigenic version of the patient’s E. co// strain is disclosed.
[0315] It has been shown that E. coli are more frequently found in CRC biopsies than in healthy mucosa. Furthermore, the majority of mucosa-associated E. coli isolated from CRC harbors the pks genomic island (pks-i- E. coli) that is responsible for the synthesis of colibactin, a genotoxic compound. It has also been reported that transient contact of a few malignant cells with colibactin-producing E. co// increases tumor growth in a xenograft mouse model. In the present method, patients are screened for the presence of pks-i- E. coli. For positive patients, the pks+ strain is isolated and grown. The strain is engineered to contain both an operon encoding for the internalization and metabolism of 2’FL and a very targeted genetic mutation in the ClbP gene leading to the inactivation of the genotoxic activity of the Colibactin toxin, but maintaining the antagonistic activity of the toxin. The single-amino acid mutations of the ClbP gene in pks-i- E. coli are a genetic modification selected from the group consisting of S95A, S95R and K98T. The engineered E. coli is grown in fermenters at high titers and a pharmaceutical composition comprising the engineered E. coli is prepared. The pharmaceutical composition is administered to human patients together with 2’FL to replace the resident E. coli pks+ strain from the patient, strain that has been isolated to start with. The administration results in colonization of the patient gut by the engineered E. co// strain in which the genotoxic activity of the Colibactin toxin has been inactivated, but the antagonistic activity of the toxin is maintained, leading to significant reduction or even total replacement of the resident population of pks-i- E. coli in the patient, which translates into a decrease of the genotoxic Colibactin toxin levels in the patients gut. Additional administrations over time further result in a diminution, in the patient, of the percentage of E. coli having a Colibactin toxin with genotoxic activity, while increasing, in the patient, the percentage
of E. co// producing a Colibactin toxin without genotoxic activity. In this way, the exposure of the patient to the negative effects of the genotoxic activity of the Colibactin toxin is minimized as the level of the genotoxic version of the Colibactin is reduced and the initiation or progression of the colorectal cancer is therefore prevented.
Example 2 - Method to stop the progression of myocarditis by replacement of an immunogenic-peptide producing bacterial population
[0316] It is herein disclosed a method to stop the progression of myocarditis towards debilitating cardiomyopathy, with significant mortality, by in-situ reduction or replacement of the resident Bacteroides faecis and/or Bacteroides thetaiotaomicron strains with a cocktail of one Bacteroides faecis strain and one Bacteroides thetaiotaomicron strain, both engineered to express a betagalactosidase with decreased homology to human MYH6 cardiac peptide and therefore reduced immunogenic potential.
[0317] In the present method, patients diagnosed with Acute Inflammatory Myocarditis (AIM) are screened for the presence of Bacteroides thetaiotaomicron and/or Bacteroides faecis in their stool and the presence of antibodies against these strains in their serum.
[0318] For patients colonized with B. thetaiotaomicron, a strain of B. thetaiotaomicron with an engineered version of beta-galactosidase genes that leads to the expression of an active betagalactosidase with reduced homology to human MYH6 cardiac peptide, wherein said strain has further been engineered to be able to internalize and metabolize either 2’FL or LNT, or both, is administered to the patient, together with either 2’FL or LNT, or both.
[0319] For patients colonized with B. faecis, a strain of B. faecis with an engineered version of beta-galactosidase genes that leads to the expression of an active beta-galactosidase with reduced homology to human MYH6 cardiac peptide, wherein said strain has further been engineered to be able to internalize and metabolize either 2’FL or LNT, or both, is administered to the patient, together with either 2’FL or LNT, or both.
[0320] For patients colonized with both B. thetaiotaomicron and B. faecis, (i) a strain of B. thetaiotaomicron with an engineered version of beta-galactosidase genes that leads to the expression of an active beta-galactosidase with reduced homology to human MYH6 cardiac peptide, wherein said strain has further been engineered to be able to internalize and metabolize either 2’FL or LNT, or both, and (ii) a strain of B. faecis with an engineered version of betagalactosidase genes that leads to the expression of an active beta-galactosidase with reduced homology to human MYH6 cardiac peptide, wherein said strain has further been engineered to be able to internalize and metabolize either 2’FL or LNT, or both, are administered to the patient, together with either 2’FL or LNT, or both.
[0321] The preparation of the administered pharmaceutical composition is achieved by growing both strains separately in fermenters at high titers, followed by formulation into a single stable drug product or two separate stable drug products.
[0322] The administration results in colonization of the patient gut by the engineered B. thetaiotaomicron and/or B. faecis strains in which the immunogenicity of a peptidic sequence within the beta-galactosidase is reduced, leading to significant reduction or even total replacement of the resident population of B. thetaiotaomicron, or B. faecis, or both in the patient, which translates into a decrease of the level of highly immunogenic beta-galactosidase proteins with strong homology with human MYH6 cardiac peptide in the patient gut. Additional administrations over time further result in a diminution, in the patient, of the percentage of Bacteroides having a peptidic sequence of Bacteroides beta-galactosidase with high homology with human MYH6 cardiac peptide, while increasing, in the patient, the percentage of Bacteroides having a peptidic sequence of Bacteroides beta-galactosidase with low homology with human MYH6 cardiac peptide. In this way, the exposure of the patient to the negative auto-immune effects caused by the immune cross-reactivity of the Bacteroides thetaiotaomicron and/or Bacteroides faecis beta-galactosidase protein and the human MYH6 cardiac peptide is minimized.
Example 3 - Replacement, in mice gut, of a B. thetaiotaomicron strain expressing a betagalactosidase protein with high homology to human MYH6 cardiac peptide by an engineered B. thetaiotaomicron strain expressing a beta-galactosidase protein with low homology to human MYH6 cardiac peptide and a competitive advantage
[0323] Mice comprising, in their gut, a B. thetaiotaomicron strain expressing a beta-galactosidase protein with high homology to human MYH6 cardiac peptide are used.
[0324] An engineered B. thetaiotaomicron strain wherein the gene encoding beta-galactosidase has been inactivated is produced. Said strain is further engineered to be resistant to a specific antibiotic, which confers to this strain a competitive advantage over the B. thetaiotaomicron strain present in the mice gut.
[0325] The engineered B. thetaiotaomicron strain is orally administered to the mice, together with the antibiotic, prior to or after the antibiotic.
[0326] This administration results in a diminution, in the mice gut, of the percentage of B. thetaiotaomicron expressing a beta-galactosidase protein with high homology to human MYH6 cardiac peptide, while increasing, in the mice gut, the percentage of B. thetaiotaomicron expressing a beta-galactosidase protein with low homology to human MYH6 cardiac peptide. This leads to the replacement, in the mice gut, of the B. thetaiotaomicron strain expressing a beta-galactosidase protein with high homology to human MYH6 cardiac peptide by a B. thetaiotaomicron strain expressing a beta-galactosidase protein with low homology to human MYH6 cardiac peptide.
Example 4 - Method to improve Levodopa therapy against Parkinson’s disease by decreasing the abundance of a drug-modifying bacterial population
[0327] Herein is disclosed a method to improve L-dopa therapy of patients suffering from Parkinson’s disease by in-situ reduction or replacement of the resident Enterococcus faecalis (E. faecalis) and/or Enterococcus faecium (E. faecium) strains that metabolize Levodopa (L-dopa) using a PLP-dependent tyrosine decarboxylase, with an engineered E. faecalis strain and/or E. faecium strain that cannot metabolize L-dopa.
[0328] The primary treatment for Parkinson’s disease is L-dopa, which is prescribed to manage motor symptoms that result from dopaminergic neuron loss in the substantia nigra. It has been shown that E. faecalis and E. faecium from the gut microbiome can metabolize L-dopa, reducing its availability and leading to side effects (Maini Rekdal et al. (2019) Science 364:eaau6323).
[0329] Patients suffering from Parkinson’s disease are screened for the presence of E. faecium and/or E. faecalis. For positive patients, a pharmaceutical composition is prepared that contain a strain of either E. faecalis or E. faecium or both, that have been engineered to contain both an operon encoding for the internalization and metabolism of 2’FL and a very targeted genetic mutation in the tyrDC gene or another gene from the highly conserved tyrDC operon, leading to the prevention of the L-dopa decarboxylation in the gut.
[0330] The engineered E. faecium and/or E. faecalis are grown in fermenters at high titers and a pharmaceutical composition comprising the engineered E. faecium and/or E. faecalis is prepared. The pharmaceutical composition is administered to human patients together with 2’FL to reduce the colonization level of resident E. faecium or E. faecalis or both strains from the patient. The administration results in colonization of the patient gut by the engineered E. faecalis and/or E. faecium strain in which the catalytic activity of at least one of the four genes from the TyrDC operon has been inactivated, leading to significant reduction or even total replacement of the resident population of E. faecalis and/or E. faecium in the patient, which translates into a decrease metabolism of administered L-dopa. Additional administrations over time further result in a diminution, in the patient, of the percentage of E. faecalis and/or E. faecium having an L- dopa metabolism activity, while increasing, in the patient, the percentage of E. faecalis and/or E. faecium that cannot metabolize L-dopa. In this way, the exposure of the patient to the negative effects of the L-dopa metabolism by the gut microbiome is minimized and the availability of L- dopa is therefore not reduced by the gut microbiome, which does not impair L-dopa treatment in patients suffering from Parkinson's disease.
Claims
1. A method for reducing in a subject the level of a molecule produced by at least one target bacterial strain which is harmful and/or not beneficial to said subject, comprising: administering to the subject an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target bacterial strain, wherein said engineered bacterial strain does not produce said molecule produced by the target bacterial strain, and wherein said engineered bacterial strain and said target bacterial strain are from the same species, whereby said level of molecule produced by the target bacterial strain is reduced in the subject.
2. The method according to claim 1 , wherein said heterologous gene or gene set providing a competitive advantage is from another species than the engineered bacterial strain.
3. The method according to claim 1 or 2, wherein said heterologous or engineered gene or gene set providing a competitive advantage is a gene or gene set involved in the import and/or metabolism of a nutrient source.
4. The method according to any one of claims 1 to 3, wherein said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene encoding a transporter of a nutrient source.
5. The method according to claim 3 or 4, wherein said nutrient source is a rare carbohydrate.
6. The method according to claim 5, wherein less than 50% of other bacterial cells in the subject utilize the rare carbohydrate as a nutrient source.
7. The method according to claim 5 or 6, wherein the rare carbohydrate is a polysaccharide.
8. The method according to claim 5 or 6, wherein the rare carbohydrate is a sulfated carbohydrate.
9. The method according to claim 5 or 6, wherein the rare carbohydrate is selected from the group consisting of alginate, fucoidan, laminarin, xylan, galactans and any combination thereof.
10. The method according to claim 9, wherein the rare carbohydrate is selected from the group consisting of porphyran, agarose, carrageenan, ulvan, xylan and any combination thereof.
11. The method according to claim 5 or 6, wherein the rare carbohydrate is a carbohydrate cleaved by a glycoside hydrolase belonging to glycoside hydrolase family GH86.
12. The method according to claim 5 or 6, wherein the rare carbohydrate is a sulfated polygalactan.
13. The method according to any one of claims 5 to 12, wherein said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene selected from the group consisting of genes encoding porphyranase, glycoside hydrolase, sulfatase, galactosidase and any combination thereof.
14. The method according to any one of claims 5 to 12, wherein said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a nucleic acid encoding a protein which sequence is at least 80% identical to at least one of BACPLE 1683-1706 from the Bacteroides plebeius genome.
15. The method according to any one of claims 5 to 14, wherein said heterologous or engineered gene set providing a competitive advantage comprises at least six genes.
16. The method according to claim 5 or 6, wherein the rare carbohydrate is a milk oligosaccharide.
17. The method according to claim 16, wherein the rare carbohydrate is a human milk oligosaccharide.
18. The method according to claim 16 or 17, wherein said milk oligosaccharide consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.
19. The method according to any one of claims 16 to 18, wherein said milk oligosaccharide is selected from the group consisting of lacto-N-biose, lacto-N-triose, N-acetyllactosamime, lacto- N-neotriose, lacto-N-tetraose, lacto-N-neotetraose, fucosyllactose, lacto-N-fucopentose, lactodifucotetrose, sialyllactose, disialyllactone-N-tetrose, 2’-fucosyllactose, 3’-sialyllactosamine, 3’-fucosyllactose, 3’-sialyl-3-fucosyllactose, 3’-sialyllactose, 6’-sialyllactosamine, 6’-sialyllactose,
difucosyllactoase, lacto-N-fucosylpentose I, lacto-N-fucosylpentose II, lacto-N-fucosylpentose III, lacto-N-fucosylpentose V, sialyllacto-N-tetraose, their derivatives and combinations thereof.
20. The method according to any one of claims 16 to 19, wherein said heterologous or engineered gene or gene set providing a competitive advantage is or comprises a gene of the H5 gene cluster from Bifidobacterium longum subsp. infantis.
21. The method according to any one of claims 2 to 20, wherein the nutrient source cannot be utilized as a nutrient source by the engineered bacterial strain in the absence of the heterologous or engineered gene or gene set providing a competitive advantage.
22. The method according to any one of claims 2 to 21 , said method further comprising administering said nutrient source to the subject.
23. The method according to any one of claims 1 to 22, wherein the reduction of the level of the molecule produced by the at least one target bacterial strain is only due to the administration of said engineered bacterial strain.
24. The method according to claim 23, wherein no antibacterial agent is administered to the subject.
25. The method according to claim 23, wherein said engineered bacterial strain further produces an antibacterial agent to which the engineered bacterial strain is resistant, but to which the target bacterial strain is sensitive.
26. The method according to claim 25, wherein said engineered bacterial strain further produces one or more antibacterial agents to which the engineered bacterial strain is resistant, but to which said target bacterial strain and other bacteria from the subject are sensitive.
27. The method according to claim 25 or 26, wherein the antibacterial agent is a bacteriocin.
28. The method according to any one of claims 1 to 27, wherein said produced molecule is expressed, secreted, and/or displayed by said at least one target bacterial strain.
29. The method according to any one of claims 1 to 28, wherein said engineered bacterial strain does not naturally produce the molecule produced by said at least one target bacterial strain.
30. The method according to any one of claims 1 to 28, wherein said engineered bacterial strain has been engineered to not produce the molecule produced by said at least one target bacterial strain.
31. The method according to any one of claims 1 to 30, wherein said engineered bacterial strain produces a variant or mutant of the molecule produced by the at least one target bacterial strain, thereby reducing the level of the molecule produced by the at least one target bacterial strain.
32. The method according to any one of claims 1 to 30, wherein said engineered bacterial strain does not produce any variant or any mutant of the molecule produced by the at least one target bacterial strain.
33. A method for preventing or treating, in a subject, a disease, disorder or condition associated to a target molecule-producing bacterial strain, said method comprising: administering to the subject a therapeutically efficient amount of an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target molecule-producing commensal bacterial strain, wherein said engineered bacterial strain does not produce the molecule produced by the target bacterial strain which is involved in said disease, disorder or condition, and wherein said engineered bacterial strain and said target commensal bacterial strain are from the same species, whereby the disease, disorder or condition is prevented or treated in the subject
34. The method according to claim 33, wherein said disease, disorder or condition associated to said target bacterial strain is an autoimmune disease.
35. The method according to claim 33, wherein said molecule is a molecule able to induce or sustain an autoimmune reaction in the host.
36. The method according to claim 33, wherein said molecule is a peptide that mimics a human autoantigen.
37. The method according to any one of claims 33 to 36, wherein said engineered bacterial strain does not naturally produce said molecule.
38. The method according to any one of claims 33 to 36, wherein said engineered bacterial strain has been engineered to not produce said molecule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163253239P | 2021-10-07 | 2021-10-07 | |
US63/253,239 | 2021-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023057598A1 true WO2023057598A1 (en) | 2023-04-13 |
Family
ID=84332370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/077865 WO2023057598A1 (en) | 2021-10-07 | 2022-10-06 | Methods involving bacterial strain replacement |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023057598A1 (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
WO2015197082A1 (en) | 2014-06-27 | 2015-12-30 | Glycom A/S | Oligosaccharide production |
WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
EP3445857A1 (en) * | 2016-04-20 | 2019-02-27 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for nucleic acid expression and protein secretion in bacteroides |
WO2019232284A1 (en) * | 2018-05-30 | 2019-12-05 | Evolve Biosystems, Inc. | Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis |
EP3620510A1 (en) * | 2018-09-06 | 2020-03-11 | Jennewein Biotechnologie GmbH | Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock |
WO2020146888A1 (en) * | 2019-01-11 | 2020-07-16 | The Trustees Of Columbia University In The City Of New York | Microbiome engineering through engineered mobile genetic elements |
WO2020252370A1 (en) * | 2019-06-13 | 2020-12-17 | Novome Biotechnologies, Inc. | Biologically contained bacteria and uses thereof |
WO2021160854A1 (en) | 2020-02-13 | 2021-08-19 | Danmarks Tekniske Universitet | Burden-addicted production strains |
WO2022013269A1 (en) * | 2020-07-15 | 2022-01-20 | Danmarks Tekniske Universitet | Engineered probiotic bacteria for prebiotic-responsive control of colonization |
US20220135984A1 (en) * | 2019-12-30 | 2022-05-05 | Eligo Bioscience | Microbiome modulation of a host by delivery of dna payloads with minimized spread |
-
2022
- 2022-10-06 WO PCT/EP2022/077865 patent/WO2023057598A1/en not_active Application Discontinuation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
WO2015197082A1 (en) | 2014-06-27 | 2015-12-30 | Glycom A/S | Oligosaccharide production |
EP3445857A1 (en) * | 2016-04-20 | 2019-02-27 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for nucleic acid expression and protein secretion in bacteroides |
WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
WO2019232284A1 (en) * | 2018-05-30 | 2019-12-05 | Evolve Biosystems, Inc. | Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis |
EP3620510A1 (en) * | 2018-09-06 | 2020-03-11 | Jennewein Biotechnologie GmbH | Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock |
WO2020146888A1 (en) * | 2019-01-11 | 2020-07-16 | The Trustees Of Columbia University In The City Of New York | Microbiome engineering through engineered mobile genetic elements |
WO2020252370A1 (en) * | 2019-06-13 | 2020-12-17 | Novome Biotechnologies, Inc. | Biologically contained bacteria and uses thereof |
US20220135984A1 (en) * | 2019-12-30 | 2022-05-05 | Eligo Bioscience | Microbiome modulation of a host by delivery of dna payloads with minimized spread |
WO2021160854A1 (en) | 2020-02-13 | 2021-08-19 | Danmarks Tekniske Universitet | Burden-addicted production strains |
WO2022013269A1 (en) * | 2020-07-15 | 2022-01-20 | Danmarks Tekniske Universitet | Engineered probiotic bacteria for prebiotic-responsive control of colonization |
Non-Patent Citations (39)
Title |
---|
AGGARWAL NIKHIL ET AL: "Engineering probiotics for therapeutic applications: recent examples and translational outlook", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 65, 15 April 2020 (2020-04-15), pages 171 - 179, XP086318313, ISSN: 0958-1669, [retrieved on 20200415], DOI: 10.1016/J.COPBIO.2020.02.016 * |
ANGELIN J ET AL: "Exopolysaccharides from probiotic bacteria and their health potential", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 162, 22 June 2020 (2020-06-22), pages 853 - 865, XP086280635, ISSN: 0141-8130, [retrieved on 20200622], DOI: 10.1016/J.IJBIOMAC.2020.06.190 * |
BANDARA ET AL., ORG BIOMOL CHEM, vol. 18, no. 9, 2020, pages 1747 - 1753 |
BELKAID ET AL., SCIENCE, vol. 346, 2014, pages 954 - 959 |
BOBER JOSEF R. ET AL: "Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications", ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, vol. 20, no. 1, 4 June 2018 (2018-06-04), US, pages 277 - 300, XP093020099, ISSN: 1523-9829, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100750/pdf/nihms-985062.pdf> DOI: 10.1146/annurev-bioeng-062117-121019 * |
CANFOR, NAT. REV. ENDOCRINOL., vol. 11, 2015, pages 577 - 591 |
CAROLINE B KURTZ ET AL: "An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans", SCI. TRANSL. MED, 16 January 2019 (2019-01-16), XP055609142, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/11/475/eaau7975.full.pdf> [retrieved on 20190726], DOI: 10.1126/scitranslmed.aau7975 * |
CHARBONNEAU MARK R. ET AL: "Developing a new class of engineered live bacterial therapeutics to treat human diseases", NATURE COMMUNICATIONS, vol. 11, no. 1, 8 April 2020 (2020-04-08), XP093020049, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-020-15508-1.pdf> DOI: 10.1038/s41467-020-15508-1 * |
CHEN ZHEJIE ET AL: "Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 176, 16 July 2021 (2021-07-16), XP086773928, ISSN: 0169-409X, [retrieved on 20210716], DOI: 10.1016/J.ADDR.2021.113870 * |
COINES JOAN ET AL: "Computer Simulation to Rationalize "Rational" Engineering of Glycoside Hydrolases and Glycosyltransferases", JOURNAL OF PHYSICAL CHEMISTRY PART B, vol. 126, no. 4, 24 January 2022 (2022-01-24), US, pages 802 - 812, XP093019745, ISSN: 1520-6106, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jpcb.1c09536> DOI: 10.1021/acs.jpcb.1c09536 * |
COYNE ET AL., NAT. COMMUN., vol. 10, 2019, pages 3460 |
DEVLIN ET AL., NAT. CHEM. BIOL., vol. 11, 2015, pages 685 - 690 |
E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17 |
FERNANDEZ-RUIZ ET AL., FRONT. MICROBIOL., vol. 9, 2018, pages 1033 |
FULDE ET AL., IMMUNOL. REV., vol. 260, 2014, pages 21 - 34 |
GARCIA ET AL.: "Peripheral tolerance to insulin is encoded by mimicry in the microbiome", BIORXIV, 2019 |
GENG ALEI ET AL: "New Insights into the Co-Occurrences of Glycoside Hydrolase Genes among Prokaryotic Genomes through Network Analysis", MICROORGANISMS, vol. 9, no. 2, 19 February 2021 (2021-02-19), pages 427, XP093020284, DOI: 10.3390/microorganisms9020427 * |
GRICE, GENOME RES, vol. 25, 2015, pages 1514 - 1520 |
HAISER ET AL., SCIENCE, vol. 341, 2013, pages 295 - 8 |
HENKEL ET AL., TOXINS FROM BACTERIA IN EXS, vol. 100, 2010, pages 1 - 29 |
IJSSENNAGGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 112, 2015, pages 10038 - 43 |
JIN YERIN ET AL: "Characterization of Neoagarooligosaccharide Hydrolase BpGH117 from a Human Gut Bacterium Bacteroides plebeius", MARINE DRUGS, vol. 19, no. 5, 13 May 2021 (2021-05-13), pages 271, XP093020757, DOI: 10.3390/md19050271 * |
KIRMIZ ET AL., ANNU REV FOOD SCI TECHNOL, vol. 9, 2018, pages 429 |
MA JUNHENG ET AL: "Engineered probiotics", MICROBIAL CELL FACTORIES, vol. 21, no. 1, 27 April 2022 (2022-04-27), XP093020046, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s12934-022-01799-0/fulltext.html> DOI: 10.1186/s12934-022-01799-0 * |
MAINI REKDAL ET AL., SCIENCE, vol. 364, 2019 |
NAT. IMMUNOL, vol. 14, 2013, pages 685 - 690 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453 |
NEUMAN ET AL., FEMS MIICROBIOL. REV., vol. 39, 2015, pages 509 - 521 |
NINONUEVO ET AL., J AGRIC FOOD CHEM, vol. 54, 2006, pages 7471 - 7480 |
PAN MEICHEN ET AL: "Combining omics technologies with CRISPR-based genome editing to study food microbes", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 61, 1 February 2020 (2020-02-01), pages 198 - 208, XP086096201, ISSN: 0958-1669, [retrieved on 20200205], DOI: 10.1016/J.COPBIO.2019.12.027 * |
PICHLER ET AL., NAT COMMUN, vol. 11, 2020, pages 3285 |
RUFF ET AL., CELL HOST MICROBE, vol. 26, 2019, pages 100 - 113 |
SCHARSCHMIDT ET AL., DRUG DISCOV. TODAY DIS. MECH., vol. 10, 2013, pages e83 - e89 |
SUISSA RONIT ET AL: "Molecular genetics for probiotic engineering: dissecting lactic acid bacteria", TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 30, no. 3, 24 August 2021 (2021-08-24), pages 293 - 306, XP086961610, ISSN: 0966-842X, [retrieved on 20210824], DOI: 10.1016/J.TIM.2021.07.007 * |
TAMTORRES, MICROBIOL SPECTR., vol. 7, no. 2, March 2019 (2019-03-01) |
VINCENT M ISABELLA ET AL: "Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria", NATURE BIOTECHNOLOGY, vol. 36, no. 9, 1 January 2018 (2018-01-01), New York, pages 857 - 864, XP055532308, ISSN: 1087-0156, DOI: 10.1038/nbt.4222 * |
YANO ET AL., CELL, vol. 161, 2015, pages 264 - 76 |
YATSUENKO ET AL., NATURE, vol. 486, 2012, pages 222 - 631 |
ZHOU ZHAO ET AL: "Engineering probiotics as living diagnostics and therapeutics for improving human health", MICROBIAL CELL FACTORIES, vol. 19, no. 1, 4 March 2020 (2020-03-04), XP093020038, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12934-020-01318-z/fulltext.html> DOI: 10.1186/s12934-020-01318-z * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11224621B2 (en) | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | |
US20220395521A1 (en) | Microbiome regulators and related uses thereof | |
US10869903B2 (en) | Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease | |
US20230285475A1 (en) | Probiotic formulations and methods for use | |
TW202014519A (en) | Methods and compositions for killing a target bacterium | |
US20220162270A1 (en) | Methods, uses & compositions | |
WO2020028871A1 (en) | Prenatal probiotic formulations | |
US11939592B2 (en) | Host bacterium specific nanoparticle | |
US20170333493A1 (en) | Probiotic bacteria for the prevention and treatment of salmonella | |
WO2023057598A1 (en) | Methods involving bacterial strain replacement | |
US20230201316A1 (en) | Atp-hydrolyzing enzyme useful for treating dysbiosis | |
US20230126159A1 (en) | Engineered bacterial strains comprising a transgene | |
WO2023057599A1 (en) | Methods involving bacteroides strain replacement | |
US20230114520A1 (en) | Engineered bifidobacterium strains comprising a transgene | |
Langlete | Isolation of bacterial vesicles and characterisation of their genetic cargo | |
Wei et al. | Single-Cell Oral Delivery Platform for Enhanced Acid Resistance and Intestinal Adhesion | |
Tsai et al. | The study of candidate sialometabolism genes and sialometabolism gene regulation in Haemophilus influenzae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22802029 Country of ref document: EP Kind code of ref document: A1 |
|
WA | Withdrawal of international application |